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A B S T R A C T
Background
Intermediate hyperglycaemia (IH) is characterised by one or more measurements of elevated blood glucose concentrations, such as
impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and elevated glycosylated haemoglobin A1c (HbA1c). These levels
are higher than normal but below the diagnostic threshold for type 2 diabetes mellitus (T2DM). The reduced threshold of 5.6 mmol/
L (100 mg/dL) fasting plasma glucose (FPG) for defining IFG, introduced by the American Diabetes Association (ADA) in 2003,
substantially increased the prevalence of IFG. Likewise, the lowering of the HbA1c threshold from 6.0% to 5.7% by the ADA in 2010
could potentially have significant medical, public health and socioeconomic impacts.
Objectives
To assess the overall prognosis of people with IH for developing T2DM, regression from IH to normoglycaemia and the difference in
T2DM incidence in people with IH versus people with normoglycaemia.
Search methods
We searched MEDLINE, Embase, ClincialTrials.gov and the International Clinical Trials Registry Platform (ICTRP) Search Portal up
to December 2016 and updated the MEDLINE search in February 2018. We used several complementary search methods in addition
to a Boolean search based on analytical text mining.
Selection criteria
We included prospective cohort studies investigating the development of T2DM in people with IH. We used standard definitions of
IH as described by the ADA or World Health Organization (WHO). We excluded intervention trials and studies on cohorts with
additional comorbidities at baseline, studies with missing data on the transition from IH to T2DM, and studies where T2DM incidence
was evaluated by documents or self-report only.
Data collection and analysis
One review author extracted study characteristics, and a second author checked the extracted data. We used a tailored version of the
Quality In Prognosis Studies (QUIPS) tool for assessing risk of bias. We pooled incidence and incidence rate ratios (IRR) using a
random-effects model to account for between-study heterogeneity. To meta-analyse incidence data, we used a method for pooling
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proportions. For hazard ratios (HR) and odds ratios (OR) of IH versus normoglycaemia, reported with 95% confidence intervals (CI),
we obtained standard errors from these CIs and performed random-effects meta-analyses using the generic inverse-variance method.
We used multivariable HRs and the model with the greatest number of covariates. We evaluated the certainty of the evidence with an
adapted version of the GRADE framework.
Main results
We included 103 prospective cohort studies. The studies mainly defined IH by IFG5.6 (FPG mmol/L 5.6 to 6.9 mmol/L or 100 mg/
dL to 125 mg/dL), IFG6.1 (FPG 6.1 mmol/L to 6.9 mmol/L or 110 mg/dL to 125 mg/dL), IGT (plasma glucose 7.8 mmol/L to 11.1
mmol/L or 140 mg/dL to 199 mg/dL two hours after a 75 g glucose load on the oral glucose tolerance test, combined IFG and IGT
(IFG/IGT), and elevated HbA1c (HbA1c5.7 : HbA1c 5.7% to 6.4% or 39 mmol/mol to 46 mmol/mol; HbA1c6.0 : HbA1c 6.0% to
6.4% or 42 mmol/mol to 46 mmol/mol). The follow-up period ranged from 1 to 24 years. Ninety-three studies evaluated the overall
prognosis of people with IHmeasured by cumulative T2DM incidence, and 52 studies evaluated glycaemic status as a prognostic factor
for T2DM by comparing a cohort with IH to a cohort with normoglycaemia. Participants were of Australian, European or North
American origin in 41 studies; Latin American in 7; Asian or Middle Eastern in 50; and Islanders or American Indians in 5. Six studies
included children and/or adolescents.
Cumulative incidence of T2DM associated with IFG5.6, IFG6.1, IGT and the combination of IFG/IGT increased with length of follow-
up. Cumulative incidence was highest with IFG/IGT, followed by IGT, IFG6.1 and IFG5.6. Limited data showed a higher T2DM
incidence associated withHbA1c6.0 compared toHbA1c5.7 .We rated the evidence for overall prognosis as of moderate certainty because
of imprecision (wide CIs in most studies). In the 47 studies reporting restitution of normoglycaemia, regression ranged from 33% to
59% within one to five years follow-up, and from 17% to 42% for 6 to 11 years of follow-up (moderate-certainty evidence).
Studies evaluating the prognostic effect of IH versus normoglycaemia reported different effect measures (HRs, IRRs and ORs). Overall,
the effect measures all indicated an elevated risk of T2DM at 1 to 24 years of follow-up. Taking into account the long-term follow-
up of cohort studies, estimation of HRs for time-dependent events like T2DM incidence appeared most reliable. The pooled HR and
the number of studies and participants for different IH definitions as compared to normoglycaemia were: IFG5.6: HR 4.32 (95% CI
2.61 to 7.12), 8 studies, 9017 participants; IFG6.1: HR 5.47 (95% CI 3.50 to 8.54), 9 studies, 2818 participants; IGT: HR 3.61
(95% CI 2.31 to 5.64), 5 studies, 4010 participants; IFG and IGT: HR 6.90 (95% CI 4.15 to 11.45), 5 studies, 1038 participants;
HbA1c5.7 : HR 5.55 (95% CI 2.77 to 11.12), 4 studies, 5223 participants; HbA1c6.0 : HR 10.10 (95% CI 3.59 to 28.43), 6 studies,
4532 participants. In subgroup analyses, there was no clear pattern of differences between geographic regions. We downgraded the
evidence for the prognostic effect of IH versus normoglycaemia to low-certainty evidence due to study limitations because many studies
did not adequately adjust for confounders. Imprecision and inconsistency required further downgrading due to wide 95% CIs and
wide 95% prediction intervals (sometimes ranging from negative to positive prognostic factor to outcome associations), respectively.
This evidence is up to date as of 26 February 2018.
Authors’ conclusions
Overall prognosis of people with IH worsened over time. T2DM cumulative incidence generally increased over the course of follow-
up but varied with IH definition. Regression from IH to normoglycaemia decreased over time but was observed even after 11 years of
follow-up. The risk of developing T2DM when comparing IH with normoglycaemia at baseline varied by IH definition. Taking into
consideration the uncertainty of the available evidence, as well as the fluctuating stages of normoglycaemia, IH and T2DM, which may
transition from one stage to another in both directions even after years of follow-up, practitioners should be careful about the potential
implications of any active intervention for people ’diagnosed’ with IH.
P L A I N L A N G U A G E S U M M A R Y
Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (’prediabetes’)
Review question
We wanted to find out whether raised blood sugar (’prediabetes’) increases the risk of developing type 2 diabetes and how many of these
people return to having normal blood sugar levels (normoglycaemia). We also investigated the difference in type 2 diabetes development
in people with prediabetes compared to people with normoglycaemia.
Background
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Type 2 diabetes is often diagnosed by blood sugar measurements. These include fasting blood glucose, which is a measurement of
the sugar in blood after an oral glucose tolerance test (drinking 75 g of glucose on an empty stomach) or by measuring glycosylated
haemoglobin A1c (HbA1c), a long-term marker of blood glucose levels. Type 2 diabetes can have bad effects on health in the long term
(diabetic complications), like severe eye or kidney disease or diabetic feet, eventually resulting in foot ulcers.
Raised blood glucose levels (hyperglycaemia), which are above normal ranges but below the limit of diagnosing type 2 diabetes,
indicate prediabetes, or intermediate hyperglycaemia. The way prediabetes is defined has important effects on public health because
some physicians treat people with prediabetes with medications that can be harmful. For example, reducing the threshold for defining
impaired fasting glucose (after an overnight fast) from 6.1 mmol/L or 110 mg/dL to 5.6 mmol/L or 100 mg/dL, as done by the
American Diabetes Association (ADA), dramatically increased the number of people diagnosed with prediabetes worldwide.
Study characteristics
We searched for observational studies (studies where no intervention takes place but people are observed over prolonged periods of time)
that investigated how many people with prediabetes at the beginning of the study developed type 2 diabetes. We also evaluated studies
comparing people with prediabetes to people with normoglycaemia. Prediabetes was defined by different blood glucose measurements.
We found 103 studies, monitoring people over 1 to 24 years. More than 250,000 participants began the studies. In 41 studies the
participants were of Australian, European or North American origin, in 7 studies participants were primarily of Latin American origin
and in 50 studies participants were of Asian or Middle Eastern origin. Three studies had American Indians as participants, and one
study each invited people from Mauritius and Nauru. Six studies included children, adolescents or both as participants.
This evidence is up to date as of 26 February 2018.
Key results
Generally, the development of new type 2 diabetes (diabetes incidence) in people with prediabetes increased over time. However, many
participants also reverted from prediabetes back to normal blood glucose levels. Compared to people with normoglycaemia, those with
prediabetes (any definition) showed an increased risk of developing type 2 diabetes, but results showed wide differences and depended
on how prediabetes was measured. There were no clear differences with regard to several regions in the world or different populations.
Because people with prediabetes may develop diabetes but may also change back to normoglycaemia almost any time, doctors should
be careful about treating prediabetes because we are not sure whether this will result in more benefit than harm, especially when done
on a global scale affecting many people worldwide.
Certainty of the evidence
The certainty of the evidence for overall prognosis was moderate because results varied widely. The certainty of evidence for studies
comparing prediabetic with normoglycaemic people was low because the results were not precise and varied widely. In our included
observational studies the researchers often did not investigate well enough whether factors like physical inactivity, age or increased body
weight also influenced the development of type 2 diabetes, thus making the relationship between prediabetes and the development of
type 2 diabetes less clear.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Outcome: development of T2DM
Prognosis of people with intermediate hyperglycaemia
Follow-up
(years)
Cumulative T2DM incidence % (95% CI)
[no of studies; no of participants with intermediate hyperglycaemia]
Regression from
intermediate hy-
pergly-
caemia to normo-
glycaemia %(95%
CI)
[no of studies;
no of participants
with intermediate
hyperglycaemia]
Overall certainty
of the evidence
(GRADE)a
IFG5.6 IFG6.1 IGT IFG + IGT HbA1c5.7 HbA1c6.0
1 - - 13 (5-23)
[3; 671]
29 (23-36)
[1; 207]
- - 59 (54-64)
[2; 375]
⊕⊕⊕©
Moderateb
2 2 (1-2)
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11 (8-14)
[2; 549]
16 (9-26)
[9; 1998]
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9 (2-20)
[3; 927]
22 (18-27)
[3; 417]
34 (28-41)
[1; 209]-
- 7 (5-10)
[1; 370]
41 (24-69)
[7; 1356]
4 17 (13-22)
[3; 800]
30 (17-44)
[2; 1567]
22 (12-34)
[5; 1042]
- 14 (7-23)
[3; 5352]
44 (40-48)
[2; 627]
33 (26-40)
[3; 807]
5 18 (10-27)
[7; 3530]
26 (19-33)
[11; 3837]
39 (25-53)
[12; 3444]
50 (37-63)
[5; 478]
25 (18-32)
[4; 3524]
38 (26-51)
[3; 1462]
34 (27-42)
[9; 2603]
6 22 (15-31)
[4; 738]
37 (31-43)
[5; 279]
29 (25-34)
[7; 775]
58 (48-67)
[4; 106]
17 (14-20)
[1; 675]
- 23 (3-53)
[5; 1328]
7 18 (8-30)
[5; 980]
15 (0-45)
[4; 434]
19 (13-26)
[5; 835]
32 (20-45)
[4; 753]
21 (16-27)
[1; 207]
- 41 (37-45)
[4; 679]
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48 (31-66)
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- - 39 (33-44)
[2; 328]
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CI: conf idence interval; HbA1c5.7: glycosylated haemoglobin A1c, 5.7% threshold; HbA1c6.0: glycosylated haemoglobin A1c, 6.0% threshold; IFG5.6: impaired fast ing glucose,
5.6 mmol/ L threshold; IFG6.1: impaired fast ing glucose, 6.1 mmol/ L threshold; IGT : impaired glucose tolerance; T2DM : type 2 diabetes mellitus.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aWith phase 2 explanatory studies aim ing to conf irm independent associat ions between the prognost ic factor and the
outcome, GRADE starts with ’high quality’ (Huguet 2013). We assumed the GRADE factor publicat ion bias was inherent with
this type of research (phase 2 design), so we did not use it as a potent ial downgrading factor
bDowngraded by one level because of imprecision (wide CIs for most intermediate hyperglycaemia def init ions and the
associat ion with T2DM incidence and regression f rom intermediate hyperglycaemia)
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B A C K G R O U N D
For a glossary of terms please see Appendix 1.
’Prediabetes’, ’borderline diabetes’, ’prediabetic stage’, ’high risk
of diabetes’, ’dysglycaemia’ or ’intermediate hyperglycaemia’ (IH)
are terms used to characterise various measurements of elevated
blood glucose concentrations, such as impaired fasting glucose
(IFG), impaired glucose tolerance (IGT), elevated glycosylated
haemoglobin A1c (HbA1c) or combinations of these conditions
(WHO/IDF 2006). Elevated blood glucose levels that indicate
hyperglycaemia are too high to be considered normal, but they
are below the diagnostic threshold for type 2 diabetes mellitus
(T2DM). Therefore, due to the continuous glycaemic spectrum
from normal to the diabetic stage, a sound evidence base is needed
to define glycaemic thresholds for people at high risk of T2DM, es-
pecially because dysglycaemia is commonly an asymptomatic con-
dition, so naturally it often remains undiagnosed (CDC 2015).
The various terms used to describe stages of hyperglycaemia may
cause people to havemarked emotional reactions. For example, the
term prediabetes may imply (at least for non-experts) that diabetes
is unavoidable, whereas (high) risk of diabetes gives people the
impression that they can possibly avoid the disease altogether. In
addition to the disputable construct of intermediate health states
termed ’predisease’ (Viera 2011), many people may associate the
label ’prediabetes’ with dire consequences. Alternatively, any diag-
nosis of prediabetes may be an opportunity to reassess, for exam-
ple, eating habits and physical activity levels, thus enabling affected
individuals to actively change their health-related behaviours.
Several institutional bodies like the American Diabetes Associa-
tion (ADA) and the World Health Organization (WHO) have
established commonly used criteria to define people who are at a
high risk of developing T2DM.
• In 1979, the National Diabetes Data Group (NDDG)
described glucose intolerance as an intermediate metabolic state
between normoglycaemia and diabetes (NDDG 1979). NDDG
defined this IGT as an elevated plasma glucose concentration
(7.8 mmol/L to 11.1 mmol/L or 140 mg/dL to 199 mg/dL) two
hours after a 75 g glucose load on the oral glucose tolerance test
(OGTT).
• In 1997, the Expert Committe on the Diagnosis and
Classification of Diabetes Mellitus and later the WHO defined
two intermediate states of glucose regulation existing between
regular glucose homeostasis and diabetes: IGT was diagnosed
two hours after a 75 g OGTT by a plasma glucose level of 7.8
mmol/L to 11.1 mmol/L (140 mg/dL to 199 mg/dL) or by the
concept of IFG (ADA 1997; WHO 1999). The initial definition
of IFG was a fasting plasma glucose (FPG) level of 6.1 mmol/L
to 6.9 mmol/L (110 mg/dL to 125 mg/dL). In 2003, the ADA
reduced the lower threshold to 5.6 mmol/L (100 mg/dL) (ADA
2003). However, the WHO did not endorse this lower cut-off
point for IFG (WHO/IDF 2006).
• More recently, an elevated HbA1c has been introduced to
identify people at high risk of developing T2DM. In 2009, the
International Expert Committee (IEC) proposed HbA1c
measurements of 6.0% to 6.4% (42 mmol/mol to 46 mmol/
mol) to identify people at a high risk of T2DM (IEC 2009). In
2010, the ADA re-defined this HbA1c level as 5.7% to 6.4% (39
mmol/mol to 46 mmol/mol) (ADA 2010), a decision not
endorsed by WHO, IEC or other organisations.
The various glycaemic tests do not identify the same people
at risk, as there is an imperfect overlap among the glycaemic
modalities available to define IH (Cheng 2006; Gosmanov 2014;
Morris 2013; Selvin 2011). Unlike IFG and IGT, HbA1c re-
flects longer-term glycaemic control, that is, how a person’s blood
glucose concentrations have been during the preceding two to
three months (Inzucchi 2012). Compared with IFG and IGT
measurements, HbA1c assessments have less intrapersonal vari-
ability when repeated. However, haemoglobin variants, genetic
haemoglobinopathies, thalassemias and iron deficiency anaemia
substantially influence HbA1c measurements (Mostafa 2011).
The FPG thresholds of defining IFG and the question whether
HbA1c is an adequate tool to diagnose IH are still a subject of
debate (Buysschaert 2011; Buysschaert 2016). In studies investi-
gating the risk of IH as measured by HbA1c, the association is
probably underestimated if time-dependent effects are not taken
into account (Lind 2009). On the other hand, some investigators
question whether HbA1c as such is the right outcome measure for
studies of diabetes (Lipska 2017).
Also, IFGand IGTdiffer in their age and sex distribution, andboth
increase with advancing age (Nathan 2007), as glucose tolerance
deteriorates with age (Gale 2013). ’Ethnicity’ and geography are
additional important features: the prevalence of elevated HbA1c
in black people is twice as high as in non-Hispanic white people,
but the opposite is true for IGT (Selvin 2011; Ziemer 2010). The
number of people with IH identified in South Asian compared
with European cohorts and the associated cardiovascular disease
(CVD) risk depend on how prediabetes is diagnosed (Eastwood
2016).
The increase in T2DM results from an interaction between ge-
netic and environmental factors, reflecting behavioural changes
over time such as decreased physical activity levels and increased
body weight (DeFronzo 2011; Nathan 2007). Both IFG and IGT
are insulin-resistant states, and insulin resistance is thought to be
the core defect in T2DM: people with (isolated) IFG predom-
inantly have β-cell dysfunction with impaired insulin secretion
(DeFronzo 1989), plus moderate hepatic insulin resistance, but
near-normal muscle insulin sensitivity. The consequence is exces-
sive fasting hepatic glucose production followed by elevated FPG.
During an OGTT the early insulin response (0 to 30/60 min) is
impaired, resulting in an excessive early rise in postload glucose
(PG). The late insulin response (60 min to 120 min) appears in-
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tact and the two-hour PG returns to its approximately starting
FPG level (DeFronzo 2011; Nathan 2007). People with (isolated)
IGT have normal to slightly reduced hepatic insulin sensitivity
and moderate to severe muscle insulin resistance (Abdul-Ghani
2006; Jensen 2002). During an OGTT both the early and the late
insulin response are impaired. Hyperglycaemia is progressive and
prolonged after the glucose load, and the two-hour PG remains
above its starting FPG level (DeFronzo 2011; Nathan 2007).
There are some known risk indicators for the development of
T2DM, including a positive family history, gestational diabetes
mellitus, obesity, ’ethnicity’ (e.g. the risk of diabetes is thought
to be higher among Asians, Hispanics, and ’black’ people), poly-
cystic ovarian syndrome, impaired insulin secretion and insulin
resistance, abnormal coagulation factors and endothelial dysfunc-
tion. However, the evidence base for the weight of a single risk
indicator and the interplay of various factors is still under inves-
tigation. Type 2 diabetes mellitus is a rather complex metabolic
state and could be described as an asymptomatic risk factor for a
future disease (Yudkin 2016), and hence prediabetes a risk factor
for another risk factor (Nathan 2007).
Diabetes is a category, whereas IFG and IGT reflect a continuous
variable with more or less arbitrarily chosen cut-off points (Yudkin
1990; Yudkin 2014). The reduced lower threshold of 5.6 mmol/
L (100 mg/dL) to define IFG by the ADA in 2003 substantially
increased the prevalence of IFG with potentially significant public
health and socioeconomic implications (Davidson 2003; Yudkin
2014; Yudkin 2016). Some authors have argued that substantial
benefits might ensue even if it were only possible to delay the onset
of diabetes by detecting and treating prediabetes (Cefalu 2016).
Interestingly, some people with IH will not develop T2DM, and
some people will return or ’regress’ to normoglycaemia. In the Di-
abetes Prevention Program (DPP), the hazard ratio of developing
T2DMwas 0.44 (95% confidence interval 0.37 to 0.55) in people
having at least one normal OGTT during theDPP compared with
people who never regressed to normoglycaemia during the DPP
(Perreault 2012; Perreault 2014). The ADA associated regression
with remission and defined it as a partial or complete diabetes re-
mission of glycaemic measurements for at least one year without
pharmacological or surgical interventions (Buse 2009). This could
have significant impact on “the therapeutic strategy from diabetes
prevention and lifelong glucose-lowering treatment to induction
of regression and monitoring for relapse” (Yakubovich 2012).
O B J E C T I V E S
Objective 1: to assess the overall prognosis of people with IH for
the development of T2DM and to assess how many people with
IH revert back to normoglycaemia (regression).
With regard to objective 1 we established the following ’Popula-
tion, Intervention, Outcome, Timing, Setting’ (PICOTS) table
(adapted according to the PICOTS system presented in Debray
2017).
Item Definition
Population People with intermediate hyperglycaemia (defined by IFG, IGT or elevated HbA1c)
Intervention None
Comparator None
Outcome Development of type 2 diabetes
Regression to normoglycaemia
Timing At least 1 year follow-up
Setting Outpatients
IFG: impaired fasting glucose; IGT: impaired glucose tolerance; HbA1c: glycosylated haemoglobin A1c
Objective 2: to assess the difference in T2DM incidence in people
with IH versus people with normoglycaemia.
With regard to objective 2 we established the following PICOTS
table (adapted according to the PICOTS system presented in
Debray 2017).
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Item Definition
Population People with intermediate hyperglycaemia (defined by IFG, IGT or elevated HbA1c)
Intervention Intermediate hyperglycaemia as a prognostic factor
Comparator Normoglycaemia
Outcome Development of type 2 diabetes
Timing At least one year follow-up
Setting Outpatients
IFG: impaired fasting glucose; IGT: impaired glucose tolerance; HbA1c: glycosylated haemoglobin A1c
M E T H O D S
Criteria for considering studies for this review
Study design
Prospective cohort studies investigating either the overall progno-
sis of people with IH for developing T2DM or IH versus normo-
glycaemia as a prognostic factor for developing T2DM (Altman
2001).
Inclusion criteria
Types of participants
To study the overall prognosis of people with IH and regression
from IH to normoglycaemia, we included cohort studies in people
with IH at baseline, defined by impaired fasting glucose (IFG), im-
paired glucose tolerance (IGT), elevated glycosylated haemoglo-
bin A1c (HbA1c) or any combination of these. IH had to be estab-
lished by standard cut-off values for IFG, IGT or elevatedHbA1c,
as defined by ADA orWHO (ADA 1997; ADA 2003; ADA 2010;
ICH 1997; IEC 2009; WHO 1998; WHO/IDF 2006).
To study whether IH compared to normoglycaemia is a prognostic
factor for developingT2DM,we included cohort studies in people
with IH and normoglycaemia at baseline.
Definition of IH
We defined IH according to ADA and WHO descriptions.
• IFG5.6 threshold, usually defined as a fasting plasma
glucose level between 5.6 mmol/L and 6.9 mmol/L at baseline.
• IFG6.1 threshold, usually defined as a fasting plasma
glucose level between 6.1 mmol/L and 6.9 mmol/L at baseline.
• IGT, usually defined as a plasma glucose level between 7.8
mmol/L and 11.1 mmol/L two hours after a 75 g OGTT at
baseline.
• Isolated IFG was defined as IFG5.6 or IFG6.1 only (without
IGT), and isolated IGT was defined as IGT only (without
IFG5.6 or IFG6.1).
• HbA1c5.7 threshold, usually defined as HbA1c
measurement between 5.7% and 6.4% at baseline.
• HbA1c6.0 threshold, usually defined as HbA1c
measurement between 6.0% and 6.4% at baseline.
Types of outcome measures
Our outcome of primary interest was the diagnosis of newly devel-
oped T2DM (T2DM incidence). T2DM incidence should have
been diagnosed by blood glucose measurements such as fasting
plasma glucose (FPG), two-hour postload glucose (PG) orHbA1c.
Diagnosis could have been combined with self-reported diabetes,
physician-diagnosed diabetes or use of antihyperglycaemic medi-
cations such as oral hypoglycaemic drugs, insulin or both.
Exclusion criteria
• Intervention trials and study designs other than prospective
cohort studies.
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• People with comorbidities at baseline (e.g. people with
coronary heart disease and IGT).
• Missing data on transition from IH to T2DM.
• Follow-up period after baseline assessment not specified
(not possible to associate T2DM incidence with length of
follow-up).
• T2DM incidence evaluated by documents (e.g. hospital
records, retrospective use of registers) or self-report only.
Search methods for identification of studies
The fundamental challenge of this review question was to define
the population of interest, that is, people with IH. We expected a
great number of terms describing this population, such as people
with prediabetes, mentions of IFG, IGT or HbA1c somewhere
in the title or abstract of relevant publications, and terms like
risk factors, predictors, prevalence, incidence and several other
concepts which cannot be foreseen when developing a Boolean
search strategy in a conceptual way.
One option to address this problem would have been to design
a highly sensitive search strategy, which would have resulted in
a yield of more than 15,000 references, which was unfeasible for
fast human screening but could be addressed in the future with
robust automated classification algorithms. Instead, we designed a
more specific Boolean search approach based on text analysis and
augmented by the following complementary search methods.
1. Identification of systematic reviews addressing our review
question.
2. Careful checking of reference lists and Discussion sections
of relevant studies.
3. A non-human skill dependent search method based on
PubMed’s ’similar articles’ algorithm.
Boolean search
We developed the search strategy using analytical text mining of
44 relevant publications (range of publication years 2008 to 2015,
from31 journals) already known to review author BR.We used the
tools PubReMiner, TerMine and AntConc and applied the prog-
nosis filters by the Hedges Team (Wilczynski 2004; Wilczynski
2005).
We searched the following sources from database inception to the
specified date.
• MEDLINE Ovid Epub Ahead of Print, In-Process & Other
Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid
MEDLINE(R) (1946 to 15 December 2016 and then updated
to 26 February 2018).
• Embase Ovid (1974 to 2016 Week 50, last searched 15
December 2016).
• ClinicalTrials.gov (searched 15 December 2016).
• WHO International Clinical Trials Registry Platform
(ICTRP) Search Portal ( apps.who.int/trialsearch; searched 15
December 2016).
Before publication, we updated theMEDLINE search as reflected
above. We restricted the update to MEDLINE because 98% of
the publications of included studies identified up to the point of
updating (on 26 February 2018) were indexed in MEDLINE.
The search strategy consisted of two tiers.
1. Prediabetes as predictor for cardiovascular disease (CVD),
mortality, stroke, cancer, micro- and macrovascular
complications.
2. Prediabetes as predictor for diabetes incidence.
We combined both strategies with the conjunction ’OR’ because
it was likely that search results for prediabetes as a predictor for
complications also contained data on diabetes incidence. For de-
tails of all search strategies see Appendix 2.
Study extraction of relevant systematic reviews
In addition, we extracted relevant publications from 16 identified
systematic reviews (Echouffo-Tcheugui 2016; Erqou 2013; Ford
2010;Hope 2016;Huang 2014b;Huang 2014a;Huang 2016; Lee
2012;Morris 2013; Santos-Oliveira 2011; Sarwar 2010; Schottker
2016; Twito 2015; Xu 2015; Zhang 2012a; Zhong 2016).
Reference checking of included studies
We extracted relevant publications after handsearching the full
texts of included studies (Methods section, Discussion section,
reference lists).
’Similar articles’-based search method
On 15 March 2018 we ran PubMed’s ’similar articles’ algorithm
with the 224 publications of included studies identified by our
search methods so far (’seed publications’ in Appendix 2). When
using the ’similar articles’ algorithm, search results in PubMed are
retrieved and ranked according to pre-calculated similarities of the
seed publications.Wedownloaded the first 500 results (of 24,124),
deduplicated them against the already identified seed publications
and screened the resulting set.
Selection of studies
Two review authors (BR and BH) independently scanned the title,
abstract, or both, of every record retrieved in the literature searches
to determine which studies to assess further. We investigated the
full text of all potentially relevant articles, resolving discrepancies
through consensus or by recourse to a third review author (MIM).
We prepared a flow diagram of the number of studies identified
and excluded at each stage in accordance with the PRISMA flow
diagram of study selection (Liberati 2009).
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Data extraction and management
For studies that fulfilled our inclusion criteria, one review author
(BR) extracted key study characteristics, inclusion and exclusion
criteria of study participants, stated aim of the study, definitions
of prognosis, prognostic factor and outcome (normoglycaemia,
intermediate glycaemia and T2DM incidence), baseline charac-
teristics of study participants and data on transition from IH (as
defined by IFG, IGT, elevated HbA1c or combinations thereof )
to T2DM. Another author (MIM) checked these data extractions,
and we resolved any disagreements by discussion or, if required, by
consultation with a third review author (BH).We used parts of the
checklist for critical appraisal and data extraction for systematic
reviews of predictionmodelling studies (CHARMS), which helps
to evaluate prediction modelling studies (Moons 2014), and we
established our own context-specific data extraction sheets after
piloting data extraction for 15 studies.
Dealing with companion publications
In the event of companion publications or multiple reports of a
prospective cohort study (e.g. because of different time points in-
vestigated) we focused on the analysis of the publication describ-
ing the longest follow-up from baseline and extracted data from
shorter follow-ups in case some measures were not reported in the
publication on the longest follow-up (e.g. the most recent paper
might have described the association between elevatedHbA1c and
T2DM incidence, but an older publication might have described
the association between IGT and T2DM incidence). Companion
publications or multiple reports of a primary study were listed as
secondary references under the primary reference of the included,
ongoing or excluded study.
Assessment of risk of bias in included studies
One review author (BR) assessed the risk of bias of each included
study and another review author (MIM) checked the accuracy of
this assessment. We resolved any disagreements by consensus, or
by consultation with a third review author (BH). We used a tai-
lored version of the Quality In Prognosis Studies (QUIPS) tool
for assessing risk of bias in studies of the prognostic factor IH ver-
sus normoglycaemia (Dretzke 2014; Hayden 2013; see Appendix
3). Our tool consisted of six risk of bias domains: study partic-
ipation, study attrition, glycaemic status measurement, outcome
measurement, study confounding; and statistical analysis and re-
porting. The study participation domain consisted of five items:
description of the source population or population of interest, de-
scription of the baseline study sample, adequate description of the
sampling frame and recruitment, adequate description of the pe-
riod and place of recruitment, and adequate description of inclu-
sion and exclusion criteria. The study attrition domain consisted
of four items: description of attempts to collect information on
participants who dropped out, reasons for loss to follow-up pro-
vided, adequate description of participants lost to follow-up, and
no important differences between participants who completed the
study and those who did not. The glycaemic status measurement
domain consisted of four items: provision of clear definition or
description of the glycaemic status, adequately valid and reliable
method of measuring glycaemic status, reporting of continuous
variables or use of appropriate cut points, and use of same method
and setting of measurement of glycaemic status in all study par-
ticipants. The outcome measurement domain consisted of three
items: provision of clear definition of the outcome, use of ade-
quately valid and reliable method of outcome measurement, and
use of same method and setting of outcome measurement in all
study participants. The study confounding domain consisted of
the seven items: measurement of all important confounders, pro-
vision of clear definitions of the important confounders measured,
adequately valid and reliable measurement of all important con-
founders, use of same method and setting of confounding mea-
surement in all study participants, appropriate imputation meth-
ods used formissing confounders (if applicable), important poten-
tial confounders accounted for in the study design, and important
potential confounders accounted for in the analysis. The statistical
analysis and reporting domain consisted of two items: sufficient
presentation of data to assess the adequacy of the analytic strategy,
and adequate statistical model for the design of the study. There is
no recommended tool for assessing risk of bias in studies of overall
prognosis. Therefore, we applied the tailored QUIPS tool to these
studies as well but without the domains for study confounding
and statistical analysis and reporting because these were not suit-
able to basic calculations of cumulative incidence. We planned to
investigate the influence of low risk of bias (low risk of bias in all
domains) versus unclear/high risk of bias (unclear or high risk of
bias in at least one of these domains).
Measures of T2DM incidence and unit of analyses
issues
If more than one group from the same cohort study was eligible for
inclusion in the samemeta-analysis, we included the groups only if
separate information was available (e.g. data on T2DM incidence
for female and male participants). If more than one time point of
T2DM was available for a study (e.g. cumulative incidence data)
we included data in the appropriate meta-analysis for each time
point separately and did not pool data across different follow-up
periods.
Data synthesis
Our primary aim for overall prognosis in people with IH was to
provide a transparent overview of the whole data matrix describ-
ing a wide variety of possible associations between various isolated
and combined definitions of IH and incident T2DM in dissim-
ilar populations covering diverse time periods. We also evaluated
whether IH compared to normoglycaemia is a prognostic factor
for developing T2DM.
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First, we grouped studies on IH definitions, i.e. isolated IFG 5.6
mmol/L to 6.9 mmol/L (IFG5.6 threshold), isolated IFG 6.1
mmol/L to 6.9mmol/L (IFG6.1 threshold), isolated IGT (glucose
concentration 7.8 mmol/L to 11.1 mmol/L two hours after a 75
g glucose load on the OGTT), IFG and IGT combined, HbA1c
6.0% to 6.4% (HbA1c6.0 threshold), and HbA1c 5.7% to 6.4%
(HbA1c5.7 threshold). Then we evaluated subgroups of different
geographic locations/’ethnicities’ for each IH definition.
We expected the following outcome measures.
• Cases (cumulative incidence at follow-up; e.g. 20 new
diabetes cases out of 400 people with IFG at baseline (5%)) and
cumulative incidence rates (cases per 1000 person-years) for
overall prognosis of people with IH.
• Odds ratios (ORs), incidence rate ratios (IRRs), and hazard
ratios (HRs) for IH versus normoglycaemia as a prognostic factor
for developing T2DM.
We pooled incidence and incidence rate ratios (IRR) using a ran-
dom-effects model to account for between-study heterogeneity.
For meta-analysis of incidence data, we used a method for pool-
ing proportions which uses the Freeman-Tukey Double Arcsine
Transformation to stabilise the variances (Freeman 1950). The
meta-analysis was performed using the Stata software user writ-
ten programme metaprop (Stata 2015). For the confidence in-
tervals (CI) for individual studies shown on the forest plots for
incidence, we used the Wilson approach (Newcombe 1998). For
meta-analysis of IRRs, we first computed the log IRRs and their
approximate standard errors and then used an inverse variance
weighted random-effects model to pool the log IRRs (Hasselblad
1994; Higgins 2011b). We exponentiated the pooled log IRR to
obtain the pooled IRR. The meta-analysis of log IRRs was per-
formed using the Stata user written programme metan.
If publications reported HRs with associated 95% CIs, we ob-
tained standard errors from these CIs as described in chapter
7.7.7.3 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011a), and we performed meta-analysis using
the generic inverse-variance method (RevMan 2014). When pos-
sible, we reported both adjusted and unadjusted HRs, but we pri-
marily used adjusted HRs from multivariable models of studies
incorporating similar covariates (Dretzke 2014).
Assessment of heterogeneity
We expected substantial clinical heterogeneity between studies be-
cause of geographical/’ethnic’ and methodological diversity. We
did not intend to address statistical heterogeneity (inconsistency)
using the I2 statistic because this statistic does not indicate how
much the effect size varies, which is what people want to know
when asking about the implications of heterogeneity (Borenstein
2017a). Also, the I2 statistic is problematic in the context of prog-
nosis studies because individual studies often have large sample
sizes resulting in narrow CIs, which can result in high I2 values
even if inconsistency between studies is moderate (Iorio 2015). In-
stead, when there were at least three studies, we reported the range
of the effects of the random-effects meta-analyses using predic-
tion intervals (Borenstein 2017b; Higgins 2009; IntHout 2016;
Riley 2011; Riley 2015). In a random-effects meta-analysis, the
prediction interval reflects the whole distribution of effects across
study populations, including the effect expected in a future study
(IntHout 2016; Riley 2015).
Certainty of the evidence
We created a ’Summary of findings’ table using Review Manager
5 (RevMan 2014). We used an adapted version of the GRADE
framework for prognostic factor research for describing the influ-
ence of IFG, IGT, elevated HbA1c and both IFG and IGT on
the development of T2DM (Huguet 2013). We justified all de-
cisions to downgrade the certainty of evidence using footnotes,
and we made comments to aid the reader’s understanding of this
Cochrane Review where necessary.
Sensitivity analysis
We planned to perform sensitivity analyses to explore the influ-
ence of the following factors (when applicable) on effect sizes by
excluding:
• studies at high or unclear risk of bias;
• very long or large studies to establish the extent to which
they dominate the results.
Subgroup analysis
Because we stratified the analyses by IH definition and geographi-
cal locations/’ethnicity’, which we thought were the main sources
of heterogeneity, we did not plan to perform subgroup analyses.
However, if at least 10 studies specifying diabetes incidence data
were included, we would have investigated age and sex by testing
for interactions between subgroups.
If T2DM incidence data were available for children and adoles-
cents, we reported the results separately.
R E S U L T S
Description of studies
Results of the search
We identified a total of 8354 records through database search-
ing and an additional 259 records from 16 systematic reviews.
After excluding duplicates and non-relevant records based on ti-
tle and abstract screening, we assessed 450 full-text records. Of
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these we excluded 213 full-text articles; the remaining 237 articles
were reports of 110 studies. Of the 110 studies, 4 were poten-
tially relevant ongoing trials (NCT00786890; NCT02838693;
NCT02958579; Vilanova 2017), and 3 are awaiting classification
(Li 2001; Misnikova 2011; NCT00816608). Therefore, we in-
cluded 103 studies. We added 86 new publications after hand-
searching the full texts of included studies, but these were all sec-
ondary publications of the included studies.
The complementary ’similar articles’ algorithm search using our set
of known publications yielded 263 publications for screening after
deduplication.This resulted in 24newpublications after excluding
irrelevant articles based on title and abstract screening. We did
not identify new studies but found 13 secondary publications of
studies we had already included.
Altogether, we included 103 prospective cohort studies (329 pub-
lications) in the review. After the initial search in four databases
(in December 2016), we observed that 98% of all included publi-
cations were indexed in Ovid MEDLINE. Therefore, we decided
to restrict the pre-publication update search in February 2018 to
Ovid MEDLINE.
For full details of search results see Figure 1.
Figure 1. Study flow diagram
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Included studies
For a detailed description of the characteristics of the included
studies, see Characteristics of included studies; Appendix 4;
Appendix 5; Appendix 6; Appendix 7; Appendix 8; Appendix 9;
Appendix 10; Appendix 11; Appendix 12; Appendix 13; Appendix
14; Appendix 15; Appendix 16; and Appendix 17. The following
is a succinct overview.
Source of data
The 103 studies took place in the following regions of the world.
• Australia: 3 studies.
• Latin America: 7 studies (Chile, 1 study; Columbia, 1
study; Mexico, 5 studies (2 studies with primarily Mexican
Americans took place in the USA (Garcia 2016; Lorenzo 2003)).
• North America: 12 studies (USA ,12 studies, with 4 studies
in particular populations: Pima Indians/Native Americans, 3
studies (Vijayakumar 2017; Wang 2011; Wheelock 2016); and
Japanese Americans, 1 study (McNeely 2003)).
• Africa: 1 study (performed in South Africa but with a
population consisting of South African Indians (Motala 2003)).
• Middle East: 7 studies (Iran, 5 studies; Israel, 1 study;
Jordan, 1 study).
• Asia: 42 studies (China, 11 studies; India, 5 studies; Japan,
8 studies; Korea, 11 studies; Singapore, 2 studies; Taiwan, 2
studies; Thailand, 3 studies).
• Islands: 2 studies (Mauritius, 1 study; Micronesia (Nauru),
1 study).
• Europe: 29 studies (Denmark, 1 study; Finland, 5 studies;
France, 3 studies; Germany, 3 studies; Greece, 1 study; Italy, 3
studies; Malta, 1 study; Spain, 3 studies; Sweden, 3 studies;
Netherlands, 4 studies; UK, 2 studies). One study in the
Netherlands included a mixed population of South-Asian
Surinamese participants, African Surinamese participants and
“Ethnic Dutch” participants (Admiraal 2014).
Fifty-eight studies contributed most of the data (Appendix 4).
Measurements of overall prognosis of people with IH and of
the prognostic factor IH versus normoglycaemia
Of the 103 included studies, 17 evaluated the overall prognosis
of people with IH for the development of type 2 diabetes melli-
tus without a normoglycaemic comparison group. Of these stud-
ies, six recruited participants with IFG at baseline (Baena-Diez
2011; Gautier 2010; Lecomte 2007; Leiva 2014; Levitzky 2008;
Sharifi 2013), six recruited participants with IGT at baseline
(Kleber 2010; Kleber 2011; Ko 1999;Marshall 1994; Rajala 2000;
Ramachandran 1986), two recruited a mixed IFG/IGT cohort
(Rasmussen 2008; Toshihiro 2008), and three recruited partici-
pants with various definitions of IH (Kim 2014; Lee 2016; Song
2016a). In addition, 76 studies with a normoglycaemic compar-
ison group contributed data to evaluate the overall prognosis of
people with IH by means of cumulative incidence. Therefore,
analysis of overall prognosis is based on 93 studies.
Fifty-two studies assessed the prognostic effect of IH versus nor-
moglycaemia for the development of type 2 diabetes mellitus
and provided outcome measures as ratios (hazard ratio (HR), in-
cidence rate ratio (IRR) and/or odds ratio (OR)). Forty-seven
studies explicitly defined normoglycaemia, often by a combina-
tion of FPG thresholds and two hour post-load glucose thresh-
olds (Anjana 2015; Baena-Diez 2011; Bergman 2016; Chen
2003;Chen2017;Coronado-Malagon 2009;DenBiggelaar 2016;
Derakhshan 2016;Dowse 1991; Forouhi 2007;Guerrero-Romero
2006; Heianza 2012; Janghorbani 2015; Jaruratanasirikul 2016;
Kim2005;Ko1999;Ko2001; Larsson 2000; Lecomte 2007; Leiva
2014; Li 2003; Ligthart 2016; Lipska 2013; Liu 2014; Liu 2017;
Lyssenko 2005; Magliano 2008; Man 2017; Meigs 2003; Motala
2003; Motta 2010; Mykkänen 1993; Nakanishi 2004; Peterson
2017; Qian 2012; Rajala 2000; Rathmann 2009; Rijkelijkhuizen
2007; Sasaki 1982; Soriguer 2008; Toshihiro 2008; Vaccaro 1999;
Valdes 2008; Viswanathan 2007; Wang 2011; Wat 2001; Weiss
2005; Yeboah 2011). In the remaining studies, it was evident
that normoglycaemia reflected the population with neither IH nor
T2DM at baseline.
IH was commonly defined by the IFG5.6 threshold (FPG level
5.6 mmol/L to 6.9 mmol/L or 100 mg/dL to 125 mg/dL),
IFG6.1threshold (FPG level 6.1 mmol/L to 6.9 mmol/L or 110
mg/dL to 125 mg/dL), IGT (plasma glucose concentration 7.8
mmol/L to 11.1 mmol/L or 140 mg/dL to 199 mg/dL two hours
after a 75 g glucose load on the OGTT), or combinations of
these criteria (Appendix 5; Appendix 6). Sixty-six studies used an
OGTT at baseline as part of the strategy to assess glycaemic status,
and 46 studies used OGTT at baseline and follow-up (Appendix
5).
Twelve studies defined IH by applying the HbA1c5.7 thresh-
old (HbA1c 5.7% to 6.4% or 39 mmol/mol to 46 mmol/mol)
(Bae 2011; Cederberg 2010; Han 2017; Heianza 2012; Kim
2014; Kim 2016a; Lee 2016; Lipska 2013; Man 2017; Nakagami
2016; Vijayakumar 2017; Warren 2017), and 10 studies used the
HbA1c6.0 threshold (HbA1c 6.0% to 6.4% or 42 mmol/mol to
46 mmol/mol) (Bae 2011; Bonora 2011; Chamnan 2011; Han
2017; Heianza 2012; Kim 2016a; Nakagami 2016; Sato 2009;
Wang 2011; Warren 2017).
Overview of study populations
Sixty-nine studies (67%) started recruitment after 1990 (see
Characteristics of included studies), and overall follow-up ranged
from 1 year in Bai 1999, Coronado-Malagon 2009 and Kleber
2010 to 24 years in Bergman 2016 (see Characteristics of included
studies; Appendix 7).
Depending on the phase of the study, the number of participants
differed. The first phase of every study often constituted a large
epidemiological investigation of, for example, the importance of
various risk factors for cardiovascular health; in total, more than
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250,000 participants began the studies (Appendix 8). The number
of participants with IH depended on how the studies defined this
condition at baseline and the way they measured the development
of T2DM.
The overall prognosis of participants with IH at baseline and across
all follow-up times (1 to 20 years) was based on the following data
(Table 1).
• IFG5.6: 13,692 participants.
• IFG6.1: 9943 participants.
• IGT: 13,728 participants.
• Both IFG and IGT: 2434 participants.
• HbA1c5.7 : 9758 participants.
• HbA1c6.0 : 2529 participants.
Follow-up time across all measures of IH at baseline had the fol-
lowing number of participants per year of follow-up (in parenthe-
ses, number of people with IH who regressed to normoglycaemia);
see Table 1.
• 1 year: 878 (375) participants.
• 2 years: 3882 (2852) participants.
• 3 years: 3014 (1356) participants.
• 4 years: 9388 (807) participants.
• 5 years: 16,275 (2603) participants.
• 6 years: 2573 (1328) participants.
• 7 years: 3209 (679) participants.
• 8 years: 3293 (328) participants.
• 9 years: 1588 (299) participants.
• 10 years: 5425 (894) participants.
• 11 years: 1655 (736) participants.
• 12 years: 3574 (no data) participants.
• 15 years: 70 (no data) participants.
• 20 years: 114 (no data) participants.
Data on the prognostic factor IH versus normoglycaemia for the
development of T2DM were based on the following number of
participants with IH at baseline (Table 2). Data were reported by
ratio measures (HR, IRR, OR).
• IFG5.6: 42,694 participants.
• IFG6.1: 12,507 participants.
• IGT: 25,617 participants.
• Both IFG and IGT: 6160 participants.
• HbA1c5.7 : 8094 participants.
• HbA1c6.0 : 6126 participants.
• Both HbA1c5.7 and IFG5.6: 3761 participants.
Themean age of adult participants at baseline ranged from30years
to 77 years (Appendix 9). In two studies all the participants were
female (De Abreu 2015; Larsson 2000), and in eight studies all the
participants were male (Charles 1997; Lecomte 2007; Nakanishi
2004; Park 2006; Sato 2009; Stengard 1992; Toshihiro 2008;
Zethelius 2004). The bodymass index (BMI) of the participants at
baseline ranged from 23.2 kg/m2 to 39.1 kg/m2. A family history
of diabetes was reported in 3% to 100% of the study participants.
At baseline, 60 studies (58%) reported diastolic and systolic blood
pressure; 43 studies (22%), smoking status; 66 studies (64%),
FPG; 24 studies (23%), HbA1c; 44 studies (43%), two-hour
glucose measurements; 7 studies (7%), medications; 26 studies
(25%), comorbidities; 20 studies (19%), hypertension; and 5 stud-
ies (5%), dyslipidaemia (Appendix 10).
Categorisation of studies
In order to address the complexity of our dataset with regard to
factors potentially influencing the definition, detection and de-
velopment of T2DM, such as genetics, environmental and social
conditions, the way risk factors and T2DM incidence were mea-
sured, and access to health care (Avilés-Santa 2016; De Rekeneire
2007; Herman 2012; Likhari 2010; Maruthur 2011; Parrinello
2016) - with all of these features interacting to some degree - we
choose to provide the reader with a broad overview mainly focus-
ing on geographic regions in the following way.
Groups consisted of participants from studies taking place in Aus-
tralia, Europe or North America; people from Latin America; in-
dividuals from Asia or the Middle East; and American (Pima) In-
dians and Pacific/Indian Ocean islanders (’American Indians/Is-
lands’ group). The logic of grouping participants in the last cohort
together resided in the fact that they shared some characteristics
relevant to T2DM, including a considerable genetic background
risk, historic isolation from outside communities with substan-
tial influence from Western diets, or both (Hanson 2014; Jowett
2009; Nair 2015; Serjeantson 1983).
For 41 studies, we categorised the origin of participants as
’Australia/Europe/North America’ (Admiraal 2014; Baena-Diez
2011; Bonora 2011; Cederberg 2010; Chamnan 2011; Charles
1997; Cugati 2007; De Abreu 2015; Den Biggelaar 2016;
Filippatos 2016; Forouhi 2007; Gautier 2010; Hanley 2005;
Kleber 2010; Kleber 2011; Larsson 2000; Lecomte 2007; Levitzky
2008; Ligthart 2016; Lipska 2013; Lyssenko 2005; Magliano
2008; Marshall 1994; McNeely 2003; Meigs 2003; Motta 2010;
Mykkänen 1993; Peterson 2017; Rajala 2000; Rasmussen 2008;
Rathmann 2009; Rijkelijkhuizen 2007; Schranz 1989; Soriguer
2008; Stengard 1992; Vaccaro 1999; Valdes 2008; Warren 2017;
Weiss 2005; Yeboah 2011; Zethelius 2004).
For seven studies, we categorised the origin of participants as
’Latin America’ (Coronado-Malagon 2009; Ferrannini 2009;
Garcia 2016; Gomez-Arbelaez 2015; Guerrero-Romero 2006;
Leiva 2014; Lorenzo 2003). Although Garcia 2016 and Lorenzo
2003 took place in the USA, they included primarily Mexican
Americans, hence the rationale for this categorisation.
We categorised 50 studies as ’Asia/Middle East’ (Aekplakorn 2006;
Ammari 1998; Anjana 2015; Bae 2011; Bai 1999; Bergman 2016;
Chen 2003; Chen 2017; Derakhshan 2016; Han 2017; Heianza
2012; Inoue 1996; Janghorbani 2015; Jaruratanasirikul 2016;
Jeong 2010; Jiamjarasrangsi 2008a; Kim 2005; Kim 2008; Kim
2014; Kim 2016a; Ko 1999; Ko 2001; Latifi 2016; Lee 2016;
Li 2003; Liu 2008; Liu 2014; Liu 2016; Liu 2017; Man 2017;
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Mohan 2008; Motala 2003; Nakagami 2016; Nakanishi 2004;
Noda 2010; Park 2006;Qian 2012; Ramachandran 1986; Sadeghi
2015; Sasaki 1982; Sato 2009; Sharifi 2013; Shin 1997; Song
2015; Song 2016a; Toshihiro 2008; Viswanathan 2007; Wang
2007; Wat 2001; Wong 2003). Of these, 37 studies recruited
participants from China, Japan, South Korea, Singapore, Taiwan
and Thailand (Aekplakorn 2006; Bae 2011; Chen 2003; Chen
2017; Han 2017; Heianza 2012; Inoue 1996; Jaruratanasirikul
2016; Jeong 2010; Jiamjarasrangsi 2008a; Kim 2005; Kim 2008;
Kim 2014; Kim 2016a; Ko 1999; Ko 2001; Lee 2016; Li 2003;
Liu 2008; Liu 2014; Liu 2016; Liu 2017; Man 2017; Nakagami
2016; Nakanishi 2004; Noda 2010; Park 2006; Qian 2012; Sasaki
1982; Sato 2009; Shin 1997; Song 2015; Song 2016a; Toshihiro
2008; Wang 2007; Wat 2001; Wong 2003), 5 studies recruited
participants from India (Anjana 2015; Bai 1999; Mohan 2008;
Ramachandran 1986; Viswanathan 2007), 1 study involved In-
dian-South African participants (Motala 2003), and 7 studies re-
cruited participants from Iran, Israel and Jordan (Ammari 1998;
Bergman 2016;Derakhshan 2016; Janghorbani 2015; Latifi 2016;
Sadeghi 2015; Sharifi 2013).
We categorised the origin of participants as ’American Indians/
Islands’ in five studies. Three of the five studies had American In-
dians as participants (Vijayakumar 2017; Wang 2011; Wheelock
2016), one included Mauritians (Söderberg 2004), and the re-
maining study included Nauruans (Dowse 1991).
Six studies included black participants (Admiraal 2014; Bergman
2016; Hanley 2005; Söderberg 2004; Warren 2017; Yeboah
2011), representing 25% to 47% of all participants in these stud-
ies.
Six studies included children, adolescents or both as participants
(Jaruratanasirikul 2016; Kleber 2010; Kleber 2011; Vijayakumar
2017; Weiss 2005; Wheelock 2016).
Measurement of the development of T2DM
Almost all studies combined criteria to define incident T2DM,
using indicators such as FPG of 7.0 mmol/L or more, two-hour
postload glucose level of 11.1 mmol/L or more, HbA1c of 6.5%
or more, receipt of antidiabetic medication, physician diagnosis
or self-report.
Of the 103 included studies, 64 included FPG of 7.0 mmol/L or
more, and 52, two-hour postload glucose level of 11.1 mmol/L or
more, in their definition of incident T2DM. Eighteen studies used
HbA1c as part of the definition of T2DM, typically an HbA1c
level of 6.5% or more. One study defined T2DM incidence based
only on anHbA1c level of 6.5% ormore (Lee 2016). In 34 studies,
antidiabetic treatment comprised part of the definition of T2DM,
and in 15 studies physician diagnosis or self-report was part of the
T2DM incidence definition.
Risk of bias in included studies
For details on the QUIPS tool and the risk of bias of the included
studies see Appendix 3 andCharacteristics of included studies. The
results are summarised below separately for studies that provided
data on overall prognosis for people with IH and on IH versus
normoglycaemia as a prognostic factor.
a) Overall prognosis of people with IH for the development
of T2DM and b) regression from IH to normoglycaemia
There were 93 studies providing data on cumulative incidence.
Figure 2 summarises the risk of bias results across all studies, while
the results for each study are shown in Figure 3 and Figure 4 (split
into two figures because of the large number of studies). We eval-
uated the first four risk of bias domains (i.e. study participation,
study attrition, glycaemic status measurement, outcome measure-
ment) of the QUIPS tool.
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Figure 2. Risk of bias graph for studies of overall prognosis of people with intermediate hyperglycaemia for
developing type 2 diabetes: review authors’ judgements about each risk of bias item presented as percentages
across all included studies
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Figure 3. ’Risk of bias’ summary for studies of overall prognosis in people with intermediate hyperglycaemia
for developing type 2 diabetes: review authors’ judgements about each risk of bias item for each included study
(part 1). The summary was split into part 1 (Figure 3) and part 2 (Figure 4) for better legibility
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Figure 4. Risk of bias summary for studies of overall prognosis of people with intermediate hyperglycaemia
for developing type 2 diabetes: review authors’ judgements about each risk of bias item for each included study
(part 2)
18Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Study participation
Study authors described the five items in this domain sufficiently
in most (65 studies; 70%) included studies. Eleven studies did
not adequately characterise the sampling frame and/or recruit-
ment procedures (Bae 2011; Baena-Diez 2011; Gautier 2010;
Guerrero-Romero 2006; Inoue 1996; Ko 1999; McNeely 2003;
Ramachandran 1986; Schranz 1989; Viswanathan 2007; Weiss
2005). One study was at high risk of bias for the item ’description
of the source population or population of interest’ (Ramachandran
1986).
Study attrition
Forty-eight studies attempted to collect information on partici-
pants who were lost to follow-up, while 40 studies were at unclear
risk of bias and five studies were at high risk of bias (Ammari 1998;
Bai 1999; Charles 1997; Gautier 2010; Meigs 2003).
In most (61 studies; 66%) of the studies we could not identify
the reasons for loss to follow-up or adequate descriptions of these
participants. Five studies were at high risk of bias for one or both
of the items (Anjana 2015; Bai 1999; Bonora 2011; Charles 1997;
Jaruratanasirikul 2016).
Only 23 studies (25%) provided information on potentially im-
portant differences between participants who completed the stud-
ies and those who did not.
Glycaemic status measurement
Study authors described these items sufficiently in 85 studies
(91%). One study did not describe three of the four items (’clear
definition of the outcome provided’, ’adequately valid and reliable
method of measurement’, and ’continuous variables reported or
appropriate cut points used’) in enough detail (Shin 1997).
Outcome measurement
Study authors described the three items sufficiently in 89 studies
(96%). One study was at high risk of bias for the item ’provision
of clear definition of the outcome’ (Hanley 2005).
c) Development of T2DM in people with IH as compared to
people with normoglycaemia
There were 52 studies comparing IH with normoglycaemia as a
prognostic factor for T2DM. Figure 5 shows the results for the six
domains summarised across studies, and the result for each study
is shown in Figure 6.
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Figure 5. Risk of bias graph for studies of intermediate hyperglycaemia versus normoglycaemia as a
prognostic factor for developing type 2 diabetes: review authors’ judgements about each risk of bias item
presented as percentages across all included studies
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Figure 6. Risk of bias summary for studies of intermediate hyperglycaemia versus normoglycaemia as a
prognostic factor for developing type 2 diabetes: review authors’ judgements about each risk of bias item for
each included study
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Fourteen studies provided data on multivariable HRs of T2DM
incidence, adjusted for 2 to 13 covariates (Bae 2011; Bonora 2011;
Forouhi 2007; Han 2017; Heianza 2012; Janghorbani 2015; Kim
2005; Li 2003; Liu 2016; Lyssenko 2005; Nakagami 2016; Wang
2011; Warren 2017; Yeboah 2011). Whenever possible, we used
the reported model with the greatest number of covariates.
Study participation
Study authors described the items of this domain sufficiently in
most (42 studies; 82%) of the included studies. Two studies did
not adequately characterise the sampling frame and/or recruitment
procedures (Bae 2011; Viswanathan 2007).
Study attrition
Study authors usually described these items sufficiently and at-
tempted to collect information on participants who were lost to
follow-up. However, in most (32 studies; 63%) of the included
studies we could not identify the reasons for losses to follow-up
or adequate descriptions of these participants. Only 10 studies
(20%) provided information on potentially important differences
between participants who completed the studies and those who
did not. Two studies were at high risk of bias on one of the four
items (Bonora 2011; Jeong 2010).
Glycaemic status measurement
Study authors described the items sufficiently in 40 (78%) studies.
Outcome measurement
Study authors described these items sufficiently in 46 studies
(90%). One study had a high risk of bias for the item ’clear defi-
nition of the outcome provided’ (Hanley 2005).
Study confounding
Only one study described all items sufficiently (Derakhshan2016).
It was difficult to judge study confounding because the number of
important covariatesmeasuredwas limited. If studies analysed data
by means of multivariable regression models, they often adjusted
these analyses taking into account several covariates: age (43 out of
52 studies), anthropometric measures such as BMI (33 out of 52
studies), sex (31 out of 52 studies), family history of diabetes (24
out of 52 studies), smoking status (24 out of 52 studies), blood
pressure/hypertension (19 out of 52 studies), triglycerides (18 out
of 52 studies), cholesterol (17 out of 52 studies), physical activity
(14 out of 52 studies), drinking status (12 out of 52 studies),
socioeconomic status (8 out of 52 studies), ’ethnicity’ (5 out 52
studies), medications (3 out of 52 studies) and renal function (1
study); for details see Appendix 16 and Appendix 17.
Twenty studies (39%) adjusted their analyses for age, sex and
anthropometric measures (e.g. BMI or waist circumference)
(Admiraal 2014; Bergman 2016; Bonora 2011; Chamnan 2011;
Chen 2003;Derakhshan 2016; Forouhi 2007;Han 2017;Heianza
2012; Janghorbani 2015; Kim 2005; Kim 2016a; Li 2003; Man
2017; Sadeghi 2015; Soriguer 2008; Valdes 2008; Wang 2011;
Warren 2017; Yeboah 2011). Six studies (12%) adjusted for
age, sex, anthropometric measures and physical activity (Bonora
2011; Derakhshan 2016; Forouhi 2007; Han 2017; Kim 2016a;
Yeboah 2011), and five studies (10%) also included smoking sta-
tus (Bonora 2011; Derakhshan 2016; Forouhi 2007; Han 2017;
Kim 2016a). When used, covariates were usually clearly defined
and measured. However, only two studies reported an imputa-
tion method for missing confounders (Derakhshan 2016; Sadeghi
2015).
Statistical analysis and reporting
Study authors addressed this domain sufficiently in 44 studies
(86%).
Development of T2DM in people with IH
In the following we report the results of the analyses for the overall
prognosis of people with IH as well as regression from IH to
normoglycaemia, and the effects of glycaemic status (IH versus
normoglycaemia) as a prognostic factor for T2DM.
Definition of IH at baseline
Studies defined IH as follows.
• IFG5.6 threshold, usually defined as a fasting plasma
glucose level of 5.6 mmol/L to 6.9 mmol/L.
• IFG6.1 threshold, usually defined as a fasting plasma
glucose level of 6.1 mmol/L to 6.9 mmol/L.
• IGT, usually defined as a plasma glucose level of 7.8 mmol/
L to 11.1 mmol/L two hours after a 75 g OGTT.
• Isolated IFG was defined as IFG5.6 or IFG6.1 alone,
without IGT, and isolated IGT was defined as IGT alone,
without IFG5.6 or IFG6.1.
• HbA1c5.7 threshold, usually defined as HbA1c
measurement of 5.7% to 6.4%.
• HbA1c6.0 threshold, usually defined as HbA1c
measurement of 6.0% to 6.4%.
Depending onhow investigatorsmeasured IH, the followingnum-
ber of study cohorts provided information on T2DM incidence
associated with glycaemic status at baseline (one study might
have investigated several associations between glycaemic status and
T2DM incidence within the same study, for example, one cohort
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with IFG5.6, another cohort with IFG6.1 and a third cohort with
IGT).
• IFG5.6/isolated IFG5.6: 27/10 study cohorts.
• IFG6.1/isolated IFG6.1: 22/9 study cohorts.
• IGT/isolated IGT: 39/18 study cohorts.
• Combined IFG and IGT: 15 study cohorts.
• HbA1c5.7 : 7 study cohorts.
• HbA1c6.0 : 10 study cohorts.
• Combined HbA1c5.7 and IFG5.6: 3 study cohorts.
a) Overall prognosis of people with IH for developing T2DM
Irrespective of the definition of IH at baseline, the cumulative
incidence of T2DM seemed to increase with length of follow-
up, though there was no obvious linear trend. There was no clear
pattern of differences between geographic regions.
IH defined by IFG5.6 mmol/L threshold
Diabetes incidence associated with IFG5.6 at baseline and follow-
up periods from 2 to 12 years showed pooled cumulative inci-
dences of 2% to 38% (Figure 7; Figure 8).
Figure 7. Impaired fasting glucose 5.6 mmol/L (IFG5.6) threshold: association with cumulative type 2
diabetes mellitus (T2DM) incidence over 2-5 years
*Isolated IFG5.6
CI: confidence interval; M: men; n/N: events/number of participants; W: women
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Figure 8. Impaired fasting glucose 5.6 mmol/L (IFG5.6) threshold: association with cumulative type 2
diabetes mellitus (T2DM) incidence over 6-12 years
*Isolated IFG5.6
**’Africa’: African Surinamese cohort, ’Asia’: Asian Surinamese cohort, ’Australia/Europe/North America’:
’ethnic Dutch’ cohort.
CI: confidence interval; M: men; n/N: events/number of participants; W: women
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The number of studies and participants, and the cumulative in-
cidence of T2DM (pooled if more than one study) according to
follow-up period were as follows.
• 2 years’ follow-up: 1 study, 1335 participants, cumulative
incidence 2% (95% confidence interval (CI) 1 to 2).
• 3 years’ follow-up: 3 studies, 1091 participants, cumulative
incidence 17% (95% CI 6 to 32).
• 4 years’ follow-up: 3 studies, 800 participants, cumulative
incidence 17% (95% CI 13 to 22).
• 5 years’ follow-up: 7 studies, 3530 participants, cumulative
incidence 18% (95% CI 10 to 27).
• 6 years’ follow-up: 4 studies, 783 participants, cumulative
incidence 22% (95% CI 15 to 31).
• 7 years’ follow-up: 5 studies, 980 participants, cumulative
incidence 18% (95% CI 8 to 30).
• 8 years’ follow-up: 2 studies, 1887 participants, cumulative
incidence 34% (95% CI 27 to 40).
• 9 years’ follow-up: 3 studies, 1356 participants, cumulative
incidence 38% (95% CI 10 to 70).
• 10 years’ follow-up: 6 studies, 1542 participants,
cumulative incidence 23% (95% CI 14 to 33).
• 12 years’ follow-up: 3 studies, 433 participants, cumulative
incidence 31% (95% CI 19 to 34).
IH defined by IFG6.1 mmol/L threshold
Diabetes incidence, as associated with IFG6.1 at baseline and a
follow-up period of 2 to 15 years, showed pooled cumulative in-
cidences of 9% to 48% (Figure 9; Figure 10).
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Figure 9. Impaired fasting glucose 6.1 mmol/L (IFG6.1) threshold: association with cumulative type 2
diabetes mellitus (T2DM) incidence over 2-5 years
*Isolated IFG6.1
CI: confidence interval; M: men; n/N: events/number of participants; W: women
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Figure 10. Impaired fasting glucose 6.1 mmol/L (IFG6.1) threshold: association with cumulative type 2
diabetes mellitus (T2DM) incidence over 6-15 years
*Isolated IFG6.1
CI: confidence interval; n/N: events/number of participants
The number of studies and participants, and the cumulative in-
cidence of T2DM (pooled if more than one study) according to
follow-up period were as follows.
• 2 years’ follow-up: 2 studies, 549 participants, cumulative
incidence 11% (95% CI 8 to 14).
• 3 years’ follow-up: 3 studies, 927 participants, cumulative
incidence 9% (95% CI 2 to 20).
• 4 years’ follow-up: 2 studies, 1567 participants, cumulative
incidence 30% (95% CI 17 to 44).
• 5 years’ follow-up: 11 studies, 3837 participants,
cumulative incidence 26% (95% CI 19 to 33).
• 6 years’ follow-up: 5 studies, 279 participants, cumulative
incidence 37% (95% CI 31 to 43).
• 7 years’ follow-up: 4 studies, 434 participants, cumulative
incidence 15% (95% CI 0 to 45).
• 8 years’ follow-up: 1 study, 29 participants, cumulative
incidence 48% (95% CI 31 to 66).
• 10 years’ follow-up: 6 studies, 537 participants, cumulative
incidence 29% (95% CI 17 to 43).
• 11 years’ follow-up: 1 study, 402 participants, cumulative
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incidence 38% (95% CI 33 to 43).
• 15 years’ follow-up: 1 study, 1382 participants, cumulative
incidence 31% (95% CI 28 to 33).
IH defined by IGT
Diabetes incidence associated with IGT at baseline showed pooled
cumulative incidences of 13% to 60% after a follow-up period of
1 to 20 years (Figure 11; Figure 12).
Figure 11. Impaired glucose tolerance (IGT): association with cumulative type 2 diabetes mellitus (T2DM)
incidence over 1-5 years
*Isolated IGT
CI: confidence interval; n/N: events/number of participants
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Figure 12. Impaired glucose tolerance (IGT): association with cumulative type 2 diabetes mellitus (T2DM)
incidence over 6-20 years *Isolated IGT
CI: confidence interval; M: men; n/N: events/number of participants; W: women
The number of studies and participants, and the cumulative in-
cidence of T2DM (pooled if more than one study) according to
follow-up period were as follows.
• 1 year’s follow-up: 3 studies, 671 participants, cumulative
incidence 13% (95% CI 5 to 23).
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• 2 years’ follow-up: 9 studies, 1998 participants, cumulative
incidence 16% (95% CI 9 to 26).
• 3 years’ follow-up: 3 studies, 417 participants, cumulative
incidence 22% (95% CI 18 to 27).
• 4 years’ follow-up: 5 studies, 1042 participants, cumulative
incidence 22% (95% CI 12 to 34).
• 5 years’ follow-up: 12 studies, 3444 participants,
cumulative incidence 39% (95% CI 25 to 53).
• 6 years’ follow-up: 7 studies, 775 participants, cumulative
incidence 29% (95% CI 25 to 34).
• 7 years’ follow-up: 5 studies, 835 participants, cumulative
incidence 19% (95% CI 13 to 26).
• 8 years’ follow-up: 4 studies, 1021 participants, cumulative
incidence 43% (95% CI 37 to 49).
• 9 years’ follow-up: 1 study, 163 participants, cumulative
incidence 53% (95% CI 45 to 60).
• 10 years’ follow-up: 6 studies, 443 participants, cumulative
incidence 26% (95% CI 17 to 37).
• 11 years’ follow-up: 1 study, 1253 participants, cumulative
incidence 46% (95% CI 43 to 49).
• 12 years’ follow-up: 2 studies, 1552 participants,
cumulative incidence 41% (95% CI 38 to 43).
• 20 years’ follow-up: 1 study, 114 participants, cumulative
incidence 60% (95% CI 50 to 68).
IH defined by combined IFG and IGT
Diabetes incidence associated with the combination of both IFG
and IGT at baseline showed pooled cumulative incidences of 29%
to 84% at 1 to 12 years (Figure 13).
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Figure 13. Combined impaired glucose tolerance (IGT) and impaired fasting glucose (IFG): association with
cumulative type 2 diabetes mellitus (T2DM) incidence over 1-12 years
CI: confidence interval; M: men; n/N: events/number of participants; W: women
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The number of studies and participants, and the cumulative in-
cidence of T2DM (pooled if more than one study) according to
follow-up period were as follows.
• 1 year’s follow-up: 1 study, 207 participants, cumulative
incidence 29% (95% CI 23 to 36).
• 3 years’ follow-up: 1 study, 209 participants, cumulative
incidence 34% (95% CI 28 to 41).
• 5 years’ follow-up: 5 studies, 478 participants, cumulative
incidence 50% (95% CI 37 to 63).
• 6 years’ follow-up: 4 studies, 106 participants, cumulative
incidence 58% (95% CI 48 to 67).
• 7 years’ follow-up: 4 studies, 753 participants, cumulative
incidence 32% (95% CI 20 to 45).
• 8 years’ follow-up: 1 study, 356 participants, cumulative
incidence 52% (95% CI 47 to 57).
• 9 years’ follow-up: 1 study, 69 participants, cumulative
incidence 84% (95% CI 74 to 91).
• 10 years’ follow-up: 2 studies, 49 participants, cumulative
incidence 30% (95% CI 17 to 44).
• 12 years’ follow-up: 2 studies, 207 participants, cumulative
incidence 70% (95% CI 63 to 76).
IH defined by HbA1c5.7 threshold
Diabetes incidence associated with HbA1c5.7 at baseline and a
follow-up period of 4 to 10 years showed pooled cumulative inci-
dences of 14% to 31% (Figure 14).
Figure 14. Elevated glycosylated haemoglobin A1c (HbA1c) 5.7% threshold: association with cumulative
type 2 diabetes mellitus (T2DM) incidence over 4-10 years
CI: confidence interval; n/N: events/number of participants
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The number of studies and participants, and the cumulative in-
cidence of T2DM (pooled if more than one study) according to
follow-up period were as follows.
• 4 years’ follow-up: 3 studies, 5352 participants, cumulative
incidence 14% (95% CI 7 to 23).
• 5 years’ follow-up: 4 studies, 3524 participants, cumulative
incidence 25% (95% CI 18 to 32).
• 6 years’ follow-up: 1 study, 675 participants, cumulative
incidence 17% (95% CI 14 to 20).
• 7 years’ follow-up: 1 study, 207 participants, cumulative
incidence 21% (95% CI 16 to 27).
• 10 years’ follow-up: 2 studies, 2854 participants,
cumulative incidence 31% (95% CI 29 to 33).
IH defined by HbA1c6.0 threshold
Most studies were undertaken in Asia. Diabetes incidence associ-
ated with HbA1c6.0 at baseline and a follow-up period of 3 to 15
years showed pooled cumulative incidences of 7% to 44% (Figure
15).
Figure 15. Elevated glycosylated haemoglobin A1c (HbA1c) 6.0% threshold: association with cumulative
type 2 diabetes mellitus (T2DM) incidence over 3-15 years
CI: confidence interval; n/N: events/number of participants
The number of studies and participants, and the cumulative in-
cidence of T2DM (pooled if more than one study) according to
follow-up period were as follows.
• 3 years’ follow-up: 1 study, 370 participants, cumulative
incidence 7% (95% CI 5 to 10).
• 4 years’ follow-up: 2 studies, 627 participants, cumulative
incidence 44% (95% CI 40 to 48).
• 5 years’ follow-up: 3 studies, 1462 participants, cumulative
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incidence 38% (95% CI 26 to 51).
• 15 years’ follow-up: 1 study, 70 participants, cumulative
incidence 29% (95% CI 19 to 40).
Children and adolescents with IH (mostly IGT)
Diabetes incidence in children and adolescents, usually associated
with IGT at baseline and with follow-up of 1 to 10 years, showed
pooled cumulative incidences of 1% to 56% (Figure 16). We did
not observe any distinct pattern between T2DM incidence and
geography.
Figure 16. Cumulative type 2 diabetes mellitus (T2DM) incidence in children/adolescents over 1-10 years
CI: confidence interval; HbA1c 5.7: glycosylated haemoglobin A1c 5.7% threshold; (i-)IGT: (isolated) impaired
glucose tolerance; n/N: events/number of participants; NO: non-overweight; OV: overweight
The number of studies and participants, and the cumulative in-
cidence of T2DM (pooled if more than one study) according to
follow-up period were as follows.
• 1 year’s follow-up: 1 study, 79 participants, cumulative
incidence 1% (95% CI 0 to 7).
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• 2 years’ follow-up: 1 study, 33 participants, cumulative
incidence 24% (95% CI 13 to 41).
• 4 years’ follow-up: 1 study, 119 participants, cumulative
incidence 3% (95% CI 1 to 7).
• 5 years’ follow-up: 3 studies, 264 participants, pooled
cumulative incidence 32% (95% CI 26 to 38).
• 10 years’ follow-up: 1 study (2 subpopulations), 169
participants, cumulative incidence 56% (95% CI 49 to 64).
Special populations with IH
Studies involving black populations were scarce: one study re-
ported a cumulative T2DM incidence of 35% in African Suri-
namese after 10 years of follow-up in association with IFG5.6
at baseline (Admiraal 2014). Another study, which used IFG5.6
at baseline, reported a T2DM cumulative incidence of 33% in
African Americans after 7.5 years of follow-up (Yeboah 2011).
b) Regression from IH to normoglycaemia
Adults
In the 47 studies reporting data on regression from IH to normo-
glycaemia in adults within a follow-up period of 1 to 11 years,
pooled percentages ranged from 17% to 59% (Figure 17; Figure
18). Regression to normoglycaemia varied widely and showed nei-
ther a clear linear reduction or increase nor a distinct pattern as-
sociated with geography. Regression rates were often reported in
association with IGT at baseline; however, there were no distinct
differences in regression rates when compared with IFG5.6, IFG6.1
or HbA1c5.7 as IH risk factors.
Figure 17. Regression from intermediate hyperglycaemia to normoglycaemia in adults over 1-5 years
CI: confidence interval; HbA1c5.7: glycosylated haemoglobin A1c 5.7%; i-IFG5.6/6.1: (isolated) impaired fasting
glucose 5.6/6.1 mmol/L threshold;IGT: impaired glucose tolerance; n/N: events/number of participants
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Figure 18. Regression from intermediate hyperglycaemia to normoglycaemia in adults over 6-11 years
CI: confidence interval; i-IFG5.6/6.1: (isolated) impaired fasting glucose 5.6/6.1 mmol/L threshold; i-IGT:
(isolated) impaired glucose tolerance; n/N: events/number of participants
The number of studies and participants, and the proportion re-
gressing from IH to normoglycaemia (pooled if more than one
study) according to follow-up period were as follows.
• 1 year’s follow-up: 2 studies, 375 participants, regression to
normoglycaemia 59% (95% CI 54 to 64).
• 2 years’ follow-up: 9 studies, 2852 participants, regression
to normoglycaemia 46% (95% CI 36 to 55).
• 3 years’ follow-up: 7 studies, 1356 participants, regression
to normoglycaemia 41% (95% CI 24 to 59).
• 4 years’ follow-up: 3 studies, 807 participants, regression to
normoglycaemia 33% (95% CI 26 to 40).
• 5 years’ follow-up: nine studies, 2603 participants,
regression to normoglycaemia 34% (95% CI 27 to 42).
• 6 years’ follow-up: 5 studies, 1328 participants, regression
to normoglycaemia 23% (95% CI 3 to 53).
• 7 years’ follow-up: 4 studies, 679 participants, regression to
normoglycaemia 41% (95% CI 37 to 45).
• 8 years’ follow-up: 2 studies, 328 participants, regression to
normoglycaemia 39% (95% CI 33 to 44).
• 9 years’ follow-up: 1 study, 299 participants, regression to
normoglycaemia 17% (95% CI 14 to 22)
• 10 years’ follow-up: 7 studies, 894 participants, regression
to normoglycaemia 42% (95% CI 22 to 63).
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• 11 years’ follow-up: 2 studies, 736 participants, regression
to normoglycaemia 28% (95% CI 17 to 39).
Children and adolescents
Regression from IH to normoglycaemia in children and adoles-
cents within a follow-up period of one to four years showed per-
centages from 45% to 81% (Figure 19). There were no distinct
patterns with regard to geography. IGT at baseline was often in-
vestigated as the IH risk factor.
Figure 19. Regression from intermediate hyperglycaemia to normoglycaemia in children/adolescents over
1-4 years
CI: confidence interval; IGT: impaired glucose tolerance; n/N: events/number of participants
The number of studies and participants, and the proportion re-
gressing from IH to normoglycaemia according to follow-up pe-
riod were as follows.
• 1 year’s follow-up: 1 study, 79 participants, regression to
normoglycaemia 66% (95% CI 55 to 75).
• 2 years’ follow-up: 1 study, 33 participants, regression to
normoglycaemia 45% (95% CI 30 to 62).
• 4 years’ follow-up: 1 study, 119 participants, regression to
normoglycaemia 81% (95% CI 73 to 87).
c) IH versus normoglycaemia as a prognostic factor for
developing T2DM
Prognostic factor studies used various definitions for IH and dif-
ferent effect measures (IRR, OR and HR) to express the effect
of glycaemic status on development of T2DM. The findings are
presented below according to IH definition and effect measure.
No data were available on the prognostic factor IH versus normo-
glycaemia for children or adolescents.
HR as the effect measure
IFG 5.6 mmol/L threshold
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Eight studies reported HRs and the IFG5.6 threshold for IH at
baseline (Analysis 1.1). The length of follow-up ranged from 4 to
22 years (studies are ordered with ascending length of follow-up
in Analysis 1.1). The studies included 9017 participants with IH
and 25,850 participants with normoglycaemia. The overall HR
was 4.32 (95% CI 2.61 to 7.12). The 95% prediction interval
ranged from 0.75 to 25.01
The comparison of geographic regions showed the following re-
sults (Analysis 1.1).
• Asia/Middle East (4 studies, 2385 participants with IH and
12,418 participants with normoglycaemia, 5 to 12 years’ follow-
up): the pooled HR was 5.07 (95% CI 3.41 to 7.53). The 95%
prediction interval ranged from 1.07 to 24.02.
• Australia/Europe/North America (3 studies, 5685
participants with IH and 12,837 participants with
normoglycaemia, 8 to 22 years’ follow-up): the pooled HR was
4.15 (95% CI 1.24 to 13.87). Calculation of the 95% prediction
interval did not provide a meaningful estimate.
• American Indians/Islands (1 study, 947 participants with
IH and 595 participants with normoglycaemia, 4 years’ follow-
up): the HR was 2.38 (95% CI 1.85 to 3.06).
IFG 6.1 mmol/L threshold
Nine studies reported HRs and the IFG6.1 threshold for IH at
baseline (Analysis 1.2). The length of follow-up ranged from 5 to
22 years (studies are ordered by ascending length of follow-up in
Analysis 1.2). The studies included 2818 participants with IH and
18,591 participants with normoglycaemia. The overall HR was
5.47 (95% CI 3.50 to 8.54). The 95% prediction interval ranged
from 1.09 to 27.56
The comparison of geographic regions showed the following re-
sults (Analysis 1.2).
• Asia/Middle East (5 studies, 1054 participants with IH and
9756 participants with normoglycaemia, 5 to 11 years’ follow-
up): the pooled HR was 10.55 (95% CI 3.61 to 30.81).
Calculation of the 95% prediction interval did not provide a
meaningful estimate.
• Australia/Europe/North America (4 studies, 1736
participants with IH and 8835 participants with
normoglycaemia, 6 to 22 years’ follow-up): the pooled HR was
3.30 (95% CI 2.32 to 4.67). The 95% prediction interval
ranged from 0.84 to 12.99.
• Latin America (1 study, 28 participants with IH and 66
participants with normoglycaemia, 6 years’ follow-up): the HR
was 2.06 (95% CI 1.76 to 2.41).
IGT
Five studies reported HRs and IGT for IH at baseline (Analysis
1.3). The length of follow-up ranged from 5 to 16 years (studies
are ordered by ascending length of follow-up in Analysis 1.3).
These studies included 4010 participants with IH and 12,566
participants with normoglycaemia. The overall HRwas 3.61 (95%
CI 2.31 to 5.64). The 95% prediction interval ranged from 0.69
to 18.97.
The comparison of geographic regions showed the following re-
sults (Analysis 1.3).
• Asia/Middle East (3 studies, 1780 participants with IH and
6695 participants with normoglycaemia, 5 to 12 years’ follow-
up): the pooled HR was 4.48 (95% CI 2.81 to 7.15).
Calculation of the 95% prediction interval did not provide a
meaningful estimate.
• Australia/Europe/North America (2 studies, 2230
participants with IH and 5871 participants with
normoglycaemia, 6 to 16 years’ follow-up): the pooled HR was
2.53 (95% CI 1.52 to 4.19).
Combined IFG and IGT
Five studies reportedHRs andused both IFGand IGT for defining
IH at baseline (Analysis 1.4). The length of follow-up ranged from
4 to 12 years (studies are ordered by ascending length of follow-
up in Analysis 1.4). These studies included 1038 participants with
IH and 8719 participants with normoglycaemia. The overall HR
was 6.90 (95% CI 4.15 to 11.45). The 95% prediction interval
ranged from 1.06 to 44.95.
The comparison of geographic regions showed the following re-
sults (Analysis 1.4).
• Asia/Middle East (3 studies, 461 participants with IH and
6695 participants with normoglycaemia, 5 to 12 years’ follow-
up): the pooled HR was 10.20 (95% CI 5.45 to 19.09).
Calculation of the 95% prediction interval did not provide a
meaningful estimate.
• Australia/Europe/North America (1 study, 221 participants
with IH and 1429 participants with normoglycaemia, 6 years’
follow-up): the HR was 3.80 (95% CI 2.30 to 6.28).
• American Indians/Islands (1 study, 356 participants with
both IFG and IGT and 595 participants with normoglycaemia,
4 years’ follow-up): the HR was 4.06 (95% CI 3.05 to 5.40).
HbA1c 5.7% threshold
Four studies reported HRs and the HbA1c5.7 threshold for IH at
baseline (Analysis 1.5). The length of follow-up ranged from 4
to 22 years (studies are ordered by ascending length of follow-up
in Analysis 1.5). The studies included 5223 participants with IH
and 19,824 participants with normoglycaemia. The overall HR
was 5.55 (95% CI 2.77 to 11.12). The 95% prediction interval
ranged from 0.23 to 141.18.
The comparison of geographic regions showed the following re-
sults (Analysis 1.5).
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• Asia/Middle East (3 studies, 3196 participants with IH and
13,609 participants with normoglycaemia, 4 to 5 years’ follow-
up): the pooled HR was 7.21 (95% CI 5.14 to 10.11). The 95%
prediction interval ranged from 0.81 to 64.52.
• Australia/Europe/North America (1 study, 2027
participants with IH and 6215 participants with
normoglycaemia, 22 years’ follow-up): the HR was 2.71 (95%
CI 2.48 to 2.96).
HbA1c 6.0% threshold
Six studies reported HRs and the HbA1c6.0 threshold for IH at
baseline (Analysis 1.6). The length of follow-up ranged from 4 to
22 years (studies are ordered by ascending length of follow-up in
Analysis 1.6). The studies included 4532 participants with IH and
26,167 participants with normoglycaemia. The overall HR was
10.10 (95% CI 3.59 to 28.43). Calculation of the 95% prediction
interval did not provide a meaningful estimate.
The comparison of geographic regions showed the following re-
sults (Analysis 1.6).
• Asia/Middle East (4 studies, 3492 participants with IH and
19,242 participants with normoglycaemia, 4 to 12 years’ follow-
up): the pooled HR was 13.12 (95% CI 4.10 to 41.96).
Calculation of the 95% prediction interval did not provide a
meaningful estimate.
• Australia/Europe/North America (2 studies, 1040
participants with IH and 6925 participants with
normoglycaemia, 15 to 22 years’ follow-up): the pooled HR was
5.09 (95% CI 1.69 to 15.37).
Both elevated HbA1c and IFG
One study in Japanese participants provided data on elevated
HbA1c and IFG for defining IH at baseline and estimated the ef-
fect of IHversus normoglycaemia using theHR(Analysis 1.7). The
combination of HbA1c5.7 plus IFG5.6 (410 participants) when
compared with normoglycaemia (4149 participants) showed an
HR of 32.50 (95% CI 23.00 to 45.92). The combination of
HbA1c5.7 plus IFG6.1 (159 participants) when compared with
normoglycaemia (5198 participants) showed an HR of 37.90
(95% CI 28.10 to 51.12). The combination of HbA1c6.0 plus
IFG5.6 (135 participants) when compared with normoglycaemia
(4493 participants) showed an HR of 53.70 (95% CI 38.40 to
75.09). The combination of HbA1c6.0 plus IFG6.1 (72 partici-
pants) when compared with normoglycaemia (5730 participants)
showed an HR of 52.30 (95% CI 37.80 to 72.37).
IH in special populations
Data on black populations were scarce: one study in African Suri-
namese reported an adjusted OR of 5.1 (95% CI 2.0 to 13.3) for
the association between IFG5.6 at baseline and T2DM incidence
at 7.5 years’ follow-up (Admiraal 2014). Another study including
a subgroup of African Americans reported the association of var-
ious measures of IH at baseline with the development of T2DM
using HRs (Warren 2017): after 16 years of follow-up the HR for
IFG5.6 was 2.65 (95% CI 2.11 to 3.32); for IFG6.1, the HR was
3.16 (95% CI 2.47 to 4.06); and for IGT, the HR was 2.55 (95%
CI 2.01 to 3.22). After 22 years’ follow-up, the HR for IFG5.6 was
2.05 (95% CI 1.75 to 2.40); for IFG6.1, the HR was 2.66 (95%
CI 2.26 to 3.13); for HbA1c5.7 , the HR was 2.24 (95% CI 1.92
to 2.61); and for HbA1c6.0, the HR was 2.60 (95% CI 2.21 to
3.05).
Incidence rate ratio as the effect measure
IFG 5.6 mmol/L threshold
Ten studies reported incidence rate ratios (IRRs) and used the
IFG5.6 threshold for IH. The studies included 24,357 participants
with IH and 155,272 participants with normoglycaemia (Figure
20). Of those with IH, 661 (2.7%) developed T2DM compared
with 1270 (0.8%) in participants with normoglycaemia. The over-
all IRR was 4.81 (95% CI 3.67 to 6.30) with a 95% prediction
interval ranging from 1.95 to 11.83.
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Figure 20. IFG: impaired fasting glucose; IRR: incidence rate ratio; n: number of cases; T: person-time in
years
The results for the geographic regions were as follows.
• Asia/Middle East (6 studies): T2DM developed in 434/
15,661 (2.8%) participants with IH and in 1204/145,597
(0.8%) participants with normoglycaemia. The pooled IRR was
5.23 (95% CI 3.77 to 7.25) with a 95% prediction interval
ranging from 1.72 to 15.89.
• Australia/Europe/North America (3 studies): T2DM
developed in 90/6322 (1.4%) participants with IH and in 32/
8062 (0.4%) participants with normoglycaemia. The pooled
IRR was 4.96 (95% CI 3.25 to 7.57) with a 95% prediction
interval ranging from 0.32 to 77.24.
• American Indians/Islands (1 study): T2DM developed in
137/2374 (5.8%) participants with IH and in 34/1613 (2.1%)
participants with normoglycaemia. The IRR was 2.74 (95% CI
1.88 to 3.99).
IFG 6.1 mmol/L threshold
Six studies reported IRRs and used an IFG6.1 threshold for IH.
Thee studies included 5115 participants with IH, of whom 127
(2.5%) developed T2DM, plus 56,580 participants with normo-
glycaemia, of whom 188 (0.3%) developed T2DM (Figure 21).
The overall IRR was 6.82 (95% CI 4.53 to 10.25) with a 95%
prediction interval ranging from 2.03 to 22.87.
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Figure 21. IFG: impaired fasting glucose; IRR: incidence rate ratio; n: number of cases; T: person-time in
years
The comparison of geographic regions showed a lower IRR for
Asia/Middle East as follows.
• Asia/Middle East (2 studies): T2DM developed in 21/1677
(1.3%) participants with IH and in 89/36,334 (0.2%)
participants with normoglycaemia. The pooled IRR was 3.62
(95% CI 1.67 to 7.83).
• Australia/Europe/North America (4 studies): T2DM
developed in 106/3438 (3.1%) participants with IH and in 99/
20,246 (0.5%) participants with normoglycaemia. The pooled
IRR was 8.55 (95% CI 6.37 to 11.48) with a 95% prediction
interval ranging from 4.37 to 16.73.
IGT threshold
Twelve studies reported IRRs and defined IH using IGT. The
studies included 18,468 participants with IH and 98,409 partici-
pants with normoglycaemia (Figure 22). T2DM developed in 947
(5.1%) participants with IH compared to 1147 (1.2%) in partic-
ipants with normoglycaemia. The overall IRR was 4.48 (95% CI
3.69 to 5.44) with a 95% prediction interval ranging from 2.60
to 7.70.
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Figure 22. IGT: impaired glucose tolerance; IRR: incidence rate ratio; n: number of cases; T: person-time in
years
The findings according to geographic regions were as follows.
• Asia/Middle East (5 studies): T2DM developed in 766/
14,809 (5.2%) participants with IH and in 390/73,128 (0.5%)
participants with normoglycaemia. The pooled IRR was 3.93
(95% CI 3.03 to 5.10) with a 95% prediction interval ranging
from 1.71 to 9.02.
• Australia/Europe/North America (5 studies): T2DM
developed in 75/2572 participants with IH and in 117/22,329
(0.5%) participants with normoglycaemia. The pooled IRR was
5.93 (95% CI 4.11 to 8.57) with a 95% prediction interval
ranging from 2.38 to 14.81.
• American Indians/Islands (2 studies): T2DM developed in
88/1087 (8.1%) participants with IH and in 48/2952 (1.6%)
participants with normoglycaemia. The pooled IRR was 4.46
(95% CI 3.12 to 6.38).
Combined IFG and IGT
Nine studies used both IFG and IGT to define IH and reported
IRRs. Of the 4470 participants with IH included in the stud-
ies, 551 (12.3%) developed T2DM compared with 1091 of the
90,072 (1.2%) participants with normoglycaemia (Figure 23).
The overall IRR was 10.94 (95% CI 7.22 to 16.58) with 95%
prediction interval ranging from 2.58 to 46.46.
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Figure 23. IFG: impaired fasting glucose; IGT: impaired glucose tolerance; IRR: incidence rate ratio; n:
number of cases; T: person-time in years
A lower pooled IRRwas observed for theAmerican Indians/Islands
cohort compared to other cohorts as shown below.
• Asia/Middle East (4 studies): T2DM developed in 430/
3166 (13.6%) participants with IH and in 918/69,463 (1.3%)
participants with normoglycaemia. The pooled IRR was 11.20
(95% CI 5.59 to 22.43). Calculation of the 95% prediction
interval did not provide a meaningful estimate.
• Australia/Europe/North America (4 studies): T2DM
developed in 55/699 (7.9%) participants with IH and in 109/
18,966 (0.6%) participants with normoglycaemia. The pooled
IRR was 13.92 (95% CI 9.99 to 19.40) with a 95% prediction
interval ranging from 6.71 to 28.85.
• American Indians/Islands (1 study): T2DM developed in
66/605 (10.9%) participants with IH and in 34/1613 (2.1%)
participants with normoglycaemia. The pooled IRR was 5.18
(95% CI 3.42 to 7.83).
HbA1c 5.7% threshold only and the combination of HbA1c
5.7% threshold with IFG 5.6 mmol/L threshold
One study, Heianza 2012, reported using HbA1c5.7 only or the
combination of IFG5.6 plus HbA1c5.7 to define IH at baseline
(Figure 24).
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Figure 24. IFG: impaired fasting glucose; HbA1c: glycosylated haemoglobin A1c; IRR: incidence rate ratio; n:
number of cases; T: person-time in years
T2DM developed in 30/1965 (1.5%) participants with IH de-
fined using HbA1c5.7 only compared with 46/19,961 (0.2%) in
participants with normoglycaemia. The IRR was 6.62 (4.18 to
10.49).
In the cohort with both HbA1c5.7 and IFG5.6, T2DM developed
in 154/1641 (9.4%)participants comparedwith 46/19961 (0.2%)
in participants with normoglycaemia. The IRR was 40.72 (95%
CI 29.30 to 56.61).
Odds ratio as the effect measure
IFG 5.6 mmol/L threshold
Twenty-one studies reportedORs and the IFG5.6 threshold for IH
(Analysis 2.1). The length of follow-up ranged from 4 to 24 years
(studies are ordered by ascending length of follow-up in Analysis
2.1). The studies included 9320 participants with IH and 38,327
participants with normoglycaemia. The overall ORwas 4.15 (95%
CI 2.75 to 6.28). The 95% prediction interval ranged from 0.54
to 32.00.
The comparison of geographic regions showed the following re-
sults (Analysis 2.1).
• Asia/Middle East (10 studies, 6359 participants with IH
and 28,218 participants with normoglycaemia, 4 to 24 years’
follow-up): the pooled OR was 2.94 (95% CI 1.77 to 4.86). The
95% prediction interval ranged from 0.43 to 19.93.
• Australia/Europe/North America (9 studies, 1949
participants with IH and 7920 participants with
normoglycaemia, 4 to 12 years’ follow-up): the pooled OR was
6.47 (95% CI 3.81 to 11.00). The 95% prediction interval
ranged from 0.99 to 42.32.
• Latin America (1 study, 65 participants with IH and 1594
participants with normoglycaemia, 7 years’ follow-up): the OR
was 4.28 (95% CI 3.21 to 5.71).
• American Indians/Islands (1 study, 947 participants with
IH and 595 participants with normoglycaemia, 4 years’ follow-
up): the OR was 3.12 (95% CI 2.31 to 4.21).
The test for subgroup differences did not indicate a significant
subgroup effect (P = 0.07). However, two of the four subgroups
had only one study each, so the validity of the analysis is uncertain.
Furthermore, there is substantial heterogeneity between studies
(Tau2 = 0.65 and 0.59) within each of the other two subgroups,
and the subgroup analysis does not appear to have explained het-
erogeneity.
IFG 6.1 mmol/L threshold
Fifteen studies reported ORs and the IFG6.1 threshold for IH at
baseline (Analysis 2.2). The length of follow-up ranged from 3
to 24 years (studies are ordered by ascending length of follow-
up in Analysis 2.2). The studies included 4574 participants with
threshold for IH and 32,292 participants with normoglycaemia.
The overall OR was 6.60 (95% CI 4.18 to 10.43). The 95%
prediction interval ranged from 0.93 to 46.82.
The comparison between geographic regions showed the following
results (Analysis 2.2).
• Asia/Middle East (7 studies, 3317 participants with IH and
25,604 participants with normoglycaemia, 3 to 24 years’ follow-
up): the pooled OR was 5.18 (95% CI 2.32 to 11.53). The 95%
prediction interval ranged from 0.29 to 91.37.
• Australia/Europe/North America (7 studies, 1240
participants with IH and 5094 participants with
normoglycaemia, 4 to 15 years’ follow-up): the pooled OR was
8.69 (95% CI 4.95 to 15.24). The 95% prediction interval
ranged from 1.20 to 62.69.
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• Latin America (1 study, 17 participants with IH and 1594
participants with normoglycaemia, 7 years’ follow-up): the OR
was 3.73 (95% CI 2.18 to 6.38).
The test for subgroup differences did not indicate a significant
subgroup effect (P = 0.10). However, one of the three subgroups
had only one study, and there is substantial heterogeneity between
studies (Tau2 = 1.08 and 0.57) within each of the other two sub-
groups.
IGT
Twenty studies reported adjusted ORs and IGT for IH at baseline
(Analysis 2.3). The length of follow-up ranged from 5 to 24 years
(studies are ordered by ascending length of follow-up in Analysis
2.3). The studies included 3139 participants with IH and 18,413
participants with normoglycaemia. The overall ORwas 4.61 (95%
CI 3.76 to 5.64). The 95% prediction interval ranged from 2.10
to 10.13.
The comparison of geographic regions showed the following re-
sults (Analysis 2.3).
• Asia/Middle East (6 studies, 1226 participants with IH and
7417 participants with normoglycaemia, 5 to 24 years’ follow-
up): the pooled OR was 3.74 (95% CI 2.83 to 4.94). The 95%
prediction interval ranged from 1.70 to 8.21.
• Australia/Europe/North America (11 studies, 1481
participants with IH and 7684 participants with
normoglycaemia, 4 to 12 years’ follow-up): the pooled OR was
5.20 (95% CI 3.62 to 7.45). The 95% prediction interval
ranged from 1.50 to 18.09.
• Latin America (2 studies, 381 participants with IH and
3097 participants with normoglycaemia, 7 to 8 years’ follow-up):
the pooled OR was 4.94 (95% CI 3.15 to 7.76).
• American Indians/Islands (1 study, 51 participants with IH
and 215 participants with normoglycaemia, 5 to 8 years’ follow-
up): the OR was 3.60 (95% CI 1.40 to 9.26).
The test for subgroup differences did not indicate a significant
subgroup effect (P = 0.47). However, two of the four subgroups
had only one or two studies, so the validity of the analysis is un-
certain.
Combined IFG and IGT
Nine studies reported ORs and used both IFG and IGT for defin-
ing IH at baseline (Analysis 2.4). The length of follow-up ranged
from 5 to 24 years (studies are ordered by ascending length of
follow-up in Analysis 2.4). The studies included 652 participants
with IH and 9004 participants with normoglycaemia. The over-
all OR was 13.14 (95% CI 7.41 to 23.30). The 95% prediction
interval ranged from 1.84 to 93.66.
The comparison of geographic regions showed the following re-
sults (Analysis 2.4).
• Asia/Middle East (3 studies, 498 participants with IHT and
3704 participants with normoglycaemia, 5 to 24 years’ follow-
up): the pooled OR was 6.99 (95% CI 3.09 to 15.83).
Calculation of the 95% prediction interval did not provide a
meaningful estimate.
• Australia/Europe/North America (6 studies, 154
participants with IH and 5300 participants with
normoglycaemia, 6 to 12 years’ follow-up): the pooled OR was
20.95 (95% CI 12.40 to 35.40). The 95% prediction interval
ranged from 4.93 to 89.05.
TheOR for the Australia/Europe/North America cohort of studies
appeared to be higher comparedwith the Asia/Middle East cohort.
HbA1c 5.7% threshold
Three studies reported ORs and HbA1c5.7 threshold for IH at
baseline (Analysis 2.5). The length of follow-up ranged from 6 to
10 years (studies are ordered with ascending length of follow-up
in Analysis 2.5). The studies included 906 participants with IH
and 2562 participants with normoglycaemia. The overall OR was
4.43 (95% CI 2.20 to 8.88). Calculation of the 95% prediction
interval did not provide a meaningful estimate.
The results by geographic region are as follows (Analysis 2.5).
• Asia/Middle East (1 study, 675 participants with IH and
462 participants with normoglycaemia, 6 years’ follow-up): the
OR was 4.54 (95% CI 2.65 to 7.78).
• Australia/Europe/North America (2 studies, 231
participants with IH and 2100 participants with
normoglycaemia, 7 to 10 years’ follow-up): the pooled OR was
4.38 (95% CI 1.36 to 14.15).
HbA1c 6.0% threshold
Three studies reported ORs and the HbA1c6.0 threshold for IH at
baseline (Analysis 2.6). The length of follow-up ranged from three
to five years. The studies included 1594 participants with IH and
16,723 participants with normoglycaemia. The overall OR was
12.79 (95% CI 4.56 to 35.85). Calculation of the 95% prediction
interval did not provide a meaningful estimate.
The comparison of geographic regions showed the following re-
sults (Analysis 2.6).
• Asia/Middle East (1 study, 1103 participants with IH and
10,763 participants with normoglycaemia, 5 years’ follow-up):
the OR was 23.20 (95% CI 18.70 to 28.78).
• Australia/Europe/North America (1 study, 370 participants
with IH and 5365 participants with normoglycaemia, 3 years’
follow-up): the OR was 15.60 (95% CI 6.90 to 35.27).
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• American Indians/Islands (1 study, 121 participants with
IH and 595 participants with normoglycaemia, 4 years’ follow-
up): the OR was 5.89 (95% CI 4.23 to 8.20).
The OR for the Asia/Middle East and Australia/Europe/North
America studies appeared higher compared with the American
Indians/Islands study.
Combination of HbA1c 5.7% threshold with IFG 5.6 mmol/L
threshold
Two studies defined IH using a combination of HbA1c5.7 and
IFG5.6 at baseline and reported ORs (Analysis 2.7). The length
of follow-up ranged from five to seven years (studies are ordered
by ascending length of follow-up in Analysis 2.7).The studies in-
cluded 2120 participants with IH and 11,886 participants with
normoglycaemia. The pooled OR was 35.91 (95% CI 20.43 to
63.12).
The findings for each geographic region are as follows (Analysis
2.7).
• Asia/Middle East (1 study, 1951 participants with IH and
10,761 participants with normoglycaemia, 5 years’ follow-up):
the OR was 46.70 (95% CI 33.60 to 64.91).
• Australia/Europe/North America (1 study, 169 participants
with IH and 1125 participants with normoglycaemia, 7 years’
follow-up): the OR was 26.20 (95% CI 16.30 to 42.11).
Subgroup and sensitivity analyses
There were not enough data to perform subgroup analyses by age
or sex. The special group of children and adolescents is reported
under the headings corresponding to the association between IH
and T2DM incidence and regression to normoglycaemia.
Sensitivity analyses for risk of bias were not meaningful because of
the diversity in measurement of T2DM incidence, definitions of
IH, and follow-up periods. The analysis of adequate adjustment
for confounding factors in studies reporting HRs may have pro-
vided interesting information, but there were not enough data to
analyse the impact of at least four or five well-known covariates in-
fluencing the relationship between prognostic factor and T2DM
incidence. There were no very large studies including participants
with IH at baseline.
Overview of complete data set and certainty of
the evidence
Table 1 provides a succinct overview of the overall prognosis of
people with IH as well as regression from IH to normoglycaemia
over 1 to 20 years of follow-up.
Table 2 provides a succinct overview of IH compared with normo-
glycaemia as a prognostic factor for developing T2DM according
to geographic regions/special populations and type of outcome
measurement.
Figure 25 shows the overall prognosis of IH as measured by cu-
mulative incidence over different follow-up periods and across all
populations, as well as regression from IH to normoglycaemia.
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Figure 25. Overall prognosis of people with intermediate hyperglycaemia (cumulative type 2 diabetes
incidence and regression to normoglycaemia) associated with measures of intermediate hyperglycaemia
HbA1c5.7/HbA1c6.0: glycosylated haemoglobin A1c 5.7%/6.0% threshold; IFG5.6/6.1: impaired fasting glucose
5.6/6.1 mmol/L threshold; IGT: impaired glucose tolerance
Figure 26 shows IH versus normoglycaemia as a prognostic factor
for developing T2DM measured by IRR, OR or HR across all
populations.
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Figure 26. Intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for developing type 2
diabetes (associated with different measures and relative risks of intermediate hyperglycaemia)
HbA1c5.7/HbA1c6.0: glycosylated haemoglobin A1c 5.7%/6.0% threshold; IFG5.6/6.1: impaired fasting glucose
5.6/6.1 mmol/L threshold; IGT: impaired glucose tolerance; IRR: incidence rate ratio; OR: odds ratio; HR:
hazard ratio
Taking into account all follow-up times and all populations, the
percentages of people with IH not developing T2DM over time
(i.e. either regressing to normoglycaemia or remaining ’predia-
betic’) were as follows (see Appendix 11): IFG5.6 cohorts, 79.2%;
IFG6.1 cohorts, 75.4%; IGT cohorts, 66.7%; combined IFG and
IGT cohorts, 57.2%; HbA1c5.7 cohorts, 79.7%; and HbA1c6.0
cohorts, 69.0%.
For overall prognosis, we started with high-certainty evidence be-
cause prospective cohort studies represent an adequate study de-
sign to investigate overall prognosis. However, we downgraded the
certainty of the evidence to moderate because of imprecise results
for most definitions of IH (Summary of findings for the main
comparison).
We considered the overall certainty of the evidence for the prognos-
tic factor IH versus normoglycaemia as low (Summary of findings
2; Summary of findings 3; Summary of findings 4; Summary of
findings 5; Summary of findings 6; Summary of findings 7). We
started with a high level of evidence because most included studies
were phase 2 explanatory studies, defined as studies that aimed to
confirm independent associations between the prognostic factor
and the outcome (Huguet 2013). We downgraded the evidence
for all IH measurements to low, first one level due to study lim-
itations because many studies did not adequately adjust for con-
founders (only six studies used the covariate core set of age, sex,
anthropometric measures and physical activity for adjustments
in multivariable regression analyses - Bonora 2011; Derakhshan
2016; Forouhi 2007; Han 2017; Kim 2016a; Yeboah 2011). Fur-
thermore, we downgraded one level for imprecision/inconsistency
(wide 95% CIs/wide 95% prediction intervals, sometimes rang-
ing from negative to positive prognostic factor to outcome associ-
ations).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Outcome: development of T2DM
Prognostic factor: intermediate hyperglycaemia versus normoglycaemia as measured by IFG5.6
No of studies No of participants with interme-
diate hyperglycaemia
Geographic region/special popu-
lation
Estimated effect (95% CI)
[95% prediction interval]
Overall certainty of the evidence
(GRADE)a
HR: 4
IRR: 6
OR: 10
HR: 2385
IRR: 15,661
OR: 6359
Asia/ M iddle East HR: 5.07 (3.41-4.86) [1.07-24.02]
IRR: 5.23 (3.77-7.25) [1.72-15.
89]
OR: 2.94 (1.77-4.86) [0.43-19.93]
⊕⊕©©
Lowb
HR: 3
IRR: 3
OR: 9
HR: 5685
IRR: 6322
OR: 1949
Australia/ Europe/ North America HR: 4.15 (1.24-13.9) [N/ M]
IRR: 4.96 (3.25-7.57) [0.32-77.
24]
OR: 6.47 (3.81-11.00) [0.99-42.
32]
HR: 0
IRR: 0
OR: 1
HR: 0
IRR: 0
OR: 65
Lat in America HR: NA
IRR: NA
OR: 4.28 (3.21-5.71)
HR: 1
IRR: 1
OR: 1
HR: 947
IRR: 2374
OR: 947
American Indians/ Islands HR: 2.38 (1.85-3.06)
IRR: 2.74 (1.88-3.99)
OR: 3.12 (2.31-4.21)
HR: 8
IRR: 10
OR: 21
HR: 9017
IRR: 24,357
OR: 9320
Overall HR: 4.32 (2.61-7.12) [0.75-25.0]
IRR: 4.81 (3.67-6.30) [1.95-11.
83]
OR: 4.15 (2.75-6.28) [0.53-32.4]
CI: conf idence interval; HR: hazard rat io;IFG5.6: impaired fast ing glucose 5.6 mmol/ L threshold; IRR: incidence rate rat io; NA: not applicable; N/M : f ewer than 3 studies or
calculat ion of the 95% predict ion interval did not provide a meaningful est imate; OR: odds rat io; T2DM : type 2 diabetes mellitus.
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GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aWith phase 2 explanatory studies aim ing to conf irm independent associat ions between the prognost ic factor and the
outcome, GRADE starts with ’high quality’ (Huguet 2013). We assumed the GRADE factor publicat ion bias was inherent with
this type of research (phase 2 design), so we did not use it as a potent ial downgrading factor
bDowngraded by one level because of study lim itat ions (many studies did not adequately adjust for confounders, if at all) and
by one level because of imprecision (CIs were wide) and inconsistency (wide 95% predict ion intervals sometimes ranging
f rom negative to posit ive prognost ic factor to outcome associat ions)
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Outcome: development of T2DM
Prognostic factor: intermediate hyperglycaemia as measured by IFG6.1
No of studies No of participants with interme-
diate hyperglycaemia
Geographic region/special popu-
lation
Estimated effect (95% CI)
[95% prediction interval]
Overall certainty of
the evidence (GRADE)a
HR: 5
IRR: 2
OR: 7
HR: 1054
IRR: 1677
OR: 3317
Asia/ M iddle East HR: 10.55 (3.61-30.81) [N/ M]
IRR: 3.62 (1.67-7.83) [N/ M]
OR: 5.18 (2.32-11.53) [0.29-91.
37]
⊕⊕©©
Lowb
HR: 4
IRR: 4
OR: 7
HR: 1736
IRR: 3438
OR: 1240
Australia/ Europe/ North America HR: 3.30 (2.32-4.67) [0.84-12.99]
IRR: 8.55 (6.37-11.48) [4.37-16.
73]
OR: 8.69 (4.95-15.24) [1.20-62.
69]
HR: 0
IRR: 0
OR: 1
HR: 0
IRR: 0
OR: 17
Lat in America HR: NA
IRR: NA
OR: 3.73 (2.18-6.38)
HR: 0
IRR: 0
OR: 0
HR: 0
IRR: 0
OR: 0
American Indians/ Islands HR: NA
IRR: NA
OR: NA
HR: 9
IRR: 6
OR: 15
HR: 2818
IRR: 5115
OR: 4574
Overall HR: 5.47 (3.50-8.54) [1.09-27.56]
IRR: 6.82 (4.53-10.25) [2.03-22.
87]
OR: 6.60 (4.18-10.43) [0.93-46.
82]
CI: conf idence interval; HR: hazard rat io;IFG6.1: impaired fast ing glucose 6.1 mmol/ L threshold; IRR: incidence rate rat io; NA: not applicable; N/M : f ewer than 3 studies or
calculat ion of the 95% predict ion interval did not provide a meaningful est imate; OR: odds rat io; T2DM : type 2 diabetes mellitus.
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GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aWith phase 2 explanatory studies aim ing to conf irm independent associat ions between the prognost ic factor and the
outcome, GRADE starts with ’high quality’ (Huguet 2013). We assumed the GRADE factor publicat ion bias was inherent with
this type of research (phase 2 design), so we did not use it as a potent ial downgrading factor
bDowngraded by one level because of study lim itat ions (many studies did not adequately adjust for confounders, if at all) and
by one level because of imprecision (CIs were wide) and inconsistency (wide 95% predict ion intervals sometimes ranging
f rom negative to posit ive prognost ic factor to outcome associat ions)
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Outcome: development of T2DM
Prognostic factor: intermediate hyperglycaemia as measured by IGT
No of studies No of participants with interme-
diate hyperglycaemia
Geographic region/special popu-
lation
Estimated effect (95% CI)
[95% prediction interval]
Overall certainty of the evidence
(GRADE)a
HR: 3
IRR: 5
OR: 6
HR: 1780
IRR: 14,809
OR: 1226
Asia/ M iddle East HR: 4.48 (2.81-7.15) [N/ M]
IRR: 3.93 (3.03-5.10) [1.71-9.02]
OR: 3.74 (2.83-4.94) [1.70-8.21]
⊕⊕©©
Lowb
HR: 2
IRR: 5
OR: 11
HR: 2230
IRR: 2572
OR: 1481
Australia/ Europe/ North America HR: 2.53 (1.52-4.19) [N/ M]
IRR: 5.93 (4.11-8.57) [2.38-14.
81]
OR: 5.20 (3.62-7.45) [1.50-18.09]
HR: 0
IRR: 0
OR: 2
HR: 0
IRR: 0
OR: 381
Lat in America HR: NA
IRR: NA
OR: 4.94 (3.15-7.76) [N/ M]
IRR: 2
OR: 1
HR: 0
IRR: 1087
OR: 51
HR: 0
American Indians/ Islands IRR: 4.46 (3.12-6.38) [N/ M]
OR: 3.60 (1.40-9.26)
HR: NA
HR: 5
IRR: 12
OR: 20
HR: 4010
IRR: 18,468
OR: 3139
Overall HR: 3.61 (2.31-5.64) [0.69-18.97]
IRR: 4.48 (3.59-5.44) [2.60-7.70]
OR: 4.61 (3.76-5.64) [2.10-10.13]
CI: conf idence interval; HR: hazard rat io;IGT : impaired glucose tolerance; IRR: incidence rate rat io; NA: not applicable; N/M : f ewer than 3 studies or calculat ion of the 95%
predict ion interval did not provide a meaningful est imate; T2DM : type 2 diabetes mellitus.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
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aWith phase 2 explanatory studies aim ing to conf irm independent associat ions between the prognost ic factor and the
outcome, GRADE starts with ’high quality’ (Huguet 2013). We assumed the GRADE factor publicat ion bias was inherent with
this type of research (phase 2 design), so we did not use it as a potent ial downgrading factor
bDowngraded by one level because of study lim itat ions (many studies did not adequately adjust for confounders, if at all) and
by one level because of imprecision (CIs were wide) and inconsistency (wide 95% predict ion intervals sometimes ranging
f rom negative to posit ive prognost ic factor to outcome associat ions)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
5
4
D
e
v
e
lo
p
m
e
n
t
o
f
ty
p
e
2
d
ia
b
e
te
s
m
e
llitu
s
in
p
e
o
p
le
w
ith
in
te
rm
e
d
ia
te
h
y
p
e
rg
ly
c
a
e
m
ia
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Outcome: development of T2DM
Prognostic factor: intermediate hyperglycaemia as measured by combined IFG and IGT
No of studies No of participants with interme-
diate hyperglycaemia
Geographic region/special popu-
lation
Estimated effect (95% CI)
[95% prediction interval]
Overall certainty of the evidence
(GRADE)a
HR: 3
IRR: 4
OR: 3
HR: 461
IRR: 3166
OR: 498
Asia/ M iddle East HR: 10.20 (5.45-19.09) [N/ M]
IRR: 11.20 (5.59-22.43) [N/ M]
OR: 6.99 (3.09-15.83) [N/ M]
⊕⊕©©
Lowb
HR: 1
IRR: 4
OR: 6
HR: 221
IRR: 699
OR: 154
Australia/ Europe/ North America HR: 3.80 (2.30-6.28) [N/ M]
IRR: 13.92 (9.99-19.40) [6.71-28.
85]
OR: 20.95 (12.40-35.40) [4.93-
89.05]
HR: 0
IRR: 0
OR: 0
HR: 0
IRR: 0
OR: 0
Lat in America HR: NA
IRR: NA
OR: NA
HR: 1
IRR: 1
OR: 0
HR: 356
IRR: 605
OR: 0
American Indians/ Islands HR: 4.06 (3.05-5.40)
IRR: 5.18 (3.42-7.83)
OR: NA
HR: 5
IRR: 9
OR: 9
HR: 1038
IRR: 4470
OR: 652
Overall HR: 6.90 (4.15-11.45) [1.06-44.
95]
IRR: 10.94 (7.22-16.58) [2.58-46.
46]
OR: 13.14 (7.41-23.30) [1.84-93.
66]
CI: conf idence interval; HR: hazard rat io;IFG: impaired fast ing glucose; IGT : impaired glucose tolerance; IRR: incidence rate rat io; NA: not applicable; N/M : f ewer than 3 studies
or calculat ion of the 95% predict ion interval did not provide a meaningful est imate; OR: odds rat io; T2DM : type 2 diabetes mellitus.
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GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aWith phase 2 explanatory studies aim ing to conf irm independent associat ions between the prognost ic factor and the
outcome, GRADE starts with ’high quality’ (Huguet 2013). We assumed the GRADE factor publicat ion bias was inherent with
this type of research (phase 2 design), so we did not use it as a potent ial downgrading factor
bDowngraded by one level because of study lim itat ions (many studies did not adequately adjust for confounders, if at all) and
by one level because of imprecision (CIs were wide) and inconsistency (wide 95% predict ion intervals)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Outcome: development of T2DM
Prognostic factor: intermediate hyperglycaemia as measured by HbA1c5.7
No of studies No of participants with interme-
diate hyperglycaemia
Geographic region/special popu-
lation
Estimated effect (95% CI)
[95% prediction interval]
Overall certainty of the evidence
(GRADE)a
HR: 3
IRR: 1
OR: 1
HR: 3196
IRR: 1965
OR: 675
Asia/ M iddle East HR: 7.21 (5.14-10.11) [0.81-64.
52]
IRR: 6.62 (4.18-10.49) [N/ M]
OR: 4.54 (2.65-7.78) [N/ M]
⊕⊕©©
Lowb
HR: 1
IRR: 0
OR: 2
HR: 2027
IRR: 0
OR: 231
Australia/ Europe/ North America HR: 2.71 (2.48-2.96) [N/ M]
IRR: NA
OR: 4.38 (1.36-14.15) [N/ M]
HR: 0
IRR: 0
OR: 0
HR: 0
IRR: 0
OR: 0
Lat in America HR: NA
IRR: NA
OR: NA
HR: 0
IRR: 0
OR: 0
HR: 0
IRR: 0
OR: 0
American Indians/ Islands HR: NA
IRR: NA
OR: NA
HR: 4
IRR: 1
OR: 3
HR: 5223
IRR: 1965
OR: 906
Overall HR: 5.55 (2.77-11.12) [0.23-141.
18]
IRR: 6.62 (4.18-10.49) [N/ M]
OR: 4.43 (2.20-8.88) [N/ M]
CI: conf idence interval; HbA1c5.7: glycosylated haemoglobin A1c 5.7% threshold; HR: hazard rat io;IRR: incidence rate rat io; NA: not applicable; N/M : f ewer than 3 studies or
calculat ion of the 95% predict ion interval did not provide a meaningful est imate; OR: odds rat io; T2DM : type 2 diabetes mellitus.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
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aWith phase 2 explanatory studies aim ing to conf irm independent associat ions between the prognost ic factor and the
outcome, GRADE starts with ’high quality’ (Huguet 2013). We assumed the GRADE factor publicat ion bias was inherent with
this type of research (phase 2 design), so we did not use it as a potent ial downgrading factor
bDowngraded by one level because of study lim itat ions (many studies did not adequately adjust for confounders, if at all) and
by one level because of imprecision (CIs were wide) and inconsistency (95% predict ion intervals sometimes ranging f rom
negative to posit ive prognost ic factor to outcome associat ions)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Outcome: development of T2DM
Prognostic factor: intermediate hyperglycaemia as measured by HbA1c6.0
No of studies No of participants with interme-
diate hyperglycaemia
Geographic region/special popu-
lation
Estimated effect (95% CI)
[95% prediction interval]
Overall certainty of the evidence
(GRADE)a
HR: 2
IRR: 0
OR: 1
HR: 1040
IRR: 0
OR: 370
Australia/ Europe/ North America HR: 5.09 (1.69-15.37) [N/ M]
IRR: NA
OR: 15.60 (6.90-35.27) [N/ M]
⊕⊕©©
Lowb
HR: 4
IRR: 0
OR: 1
HR: 3492
IRR: 0
OR: 1103
Asia/ M iddle East HR: 13.12 (4.10-41.96) [N/ M]
IRR: NA
OR: 23.20 (18.70-28.78) [N/ M]
HR: 0
IRR: 0
OR: 0
HR: 0
IRR: 0
OR: 0
Lat in America HR: NA
IRR: NA
OR: NA
IRR: 0
OR: 1
HR: 0
IRR: 0
OR: 121
HR: 0
American Indians/ Islands IRR: NA
OR: 5.89 (4.23-8.20) [N/ M]
HR: NA
HR: 6
IRR: 0
OR: 3
HR: 4532
IRR: 0
OR: 1594
Overall HR: 10.10 (3.59-28.43) [N/ M]
IRR: NA
OR: 12.79 [4.56-35.85] [N/ M]
CI: conf idence interval; HbA1c6.0: glycosylated haemoglobin A1c 6.0% threshold; HR: hazard rat io;IRR: incidence rate rat io; NA: not applicable; N/M : f ewer than 3 studies or
calculat ion of the 95% predict ion interval did not provide a meaningful est imate; OR: odds rat io; T2DM : type 2 diabetes mellitus.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
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aWith phase 2 explanatory studies aim ing to conf irm independent associat ions between the prognost ic factor and the
outcome, GRADE starts with ’high quality’ (Huguet 2013). We assumed the GRADE factor publicat ion bias was inherent with
this type of research (phase 2 design), so we did not use it as a potent ial downgrading factor
bDowngraded by one level because of study lim itat ions (many studies did not adequately adjust for confounders, if at all) and
by one level because of imprecision (most CIs were wide)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
6
0
D
e
v
e
lo
p
m
e
n
t
o
f
ty
p
e
2
d
ia
b
e
te
s
m
e
llitu
s
in
p
e
o
p
le
w
ith
in
te
rm
e
d
ia
te
h
y
p
e
rg
ly
c
a
e
m
ia
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
D I S C U S S I O N
Summary of main results
We included103prospective cohort studies frommanyparts of the
world evaluating people with IH, usually defined using the IFG5.6
or IFG6.1 threshold, IGT, combined IFG/IGTor elevatedHbA1c.
However, we did not identify studies involving black Africans or
Eastern Europeans. Participants were of Australian, European or
North American origin in 41 studies; primarily of Latin American
origin in 7 studies; Asian or Middle Eastern origin in 50 studies;
American Indians in 3 studies; Mauritians in 1 study; and Nauru-
ans in 1 study. Six studies included children, adolescents or both.
Ninety-three studies contributed data to estimate the overall prog-
nosis of people with IH, and 52 studies evaluated baseline gly-
caemic status as a prognostic factor by comparing an IH cohort
with a normoglycaemic cohort.
Cumulative incidence of T2DM for the IFG5.6 threshold, the
IFG6.1 threshold, IGT, combined IFG/IGT and elevated HbA1c,
showed increasing percentages over follow-up time; however, there
was no clear linear increase over time. Regression rates to nor-
moglycaemia, though decreasing over follow-up, showed fluctua-
tions and no clear linear decrease over time. The estimates of the
prognostic effect of IH versus normoglycaemia were comparable
when using HR, IRR or OR across the different definitions of IH.
There was no clear pattern of risk differences between geographic
regions.
Overall completeness and applicability of
evidence
A limiting factor of our review was that most studies took place
in Asia, the Middle East, Australia, Western Europe and North
America, affecting the generalisability of findings to other popu-
lations residing in Africa and Eastern Europe. We are also aware
that categorising the included studies based on region or ’ethnic-
ity’ has deficiencies with regard to clearly delineating study par-
ticipants. The complicated interplay of factors like genetics, diets,
and changing environmental and social conditions, among others,
makes it virtually impossible to achieve a generally accepted cate-
gorisation. We chose an approach based primarily on geographic
location because we thought that most readers would be inter-
ested in having a broad overview of any potential differences in
T2DM incidence based on this characteristic. At the same time,
we tried not to overload the reader with too much information
by fragmenting our dataset into all the different countries or into
more precisely defined ’ethnicities’, since some investigators even
reported several ’ethnic’ subgroups within a single study cohort.
However, we do provide detailed information, when available, in
our appendices to enable the interested reader to identify studies
according to whatever combination of factors seems of value to
generate hypotheses of potential differences between the diverse
study groups.
Only six studies addressed the overall prognosis of IH in 495 chil-
dren or adolescents, with approximately 50% originating from
high-risk American Indian cohorts, also affecting the applicabil-
ity of findings to other populations. No data were available on
the prognostic factor of IH versus normoglycaemia for children
or adolescents. Most studies determined the glycaemic status of
participants at baseline and follow-up on the basis of a single FPG,
glucose tolerance test or HbA1c. Therefore, participants may have
been misclassified at baseline, follow-up or both in either direc-
tion. Interestingly, 93 studies provided data on overall prognosis
of IH, but only 49 studies published information on regression
from IH to normoglycaemia.
Certainty of the evidence
To our knowledge there is no validated risk of bias tool for stud-
ies addressing overall prognosis. Moreover, information on some
applicable risk of bias domains of the QUIPS tools were limited.
However, as illustrated in Figure 25, there was a wide fluctuation
between the various definitions of IH as well as no linear increase
in T2DM incidence over time of follow-up. Of note, regression
rates to normoglycaemia were also high, even after more than five
years of follow-up, emphasising that transition from IH to T2DM
might be an intermediate state (Taylor 2017).
The certainty of the evidence for the overall prognosis of IH was
moderate due to imprecise results for most IH definitions. The
certainty of the evidence for the prognostic factor of IH versus
normoglycaemia was low, mainly because most studies did not ad-
just for confounders known to be independently associated with
T2DM incidence and due to substantial imprecision (wide 95%
CIs) and inconsistency (wide 95% prediction intervals). However,
the results of the six studies that adjusted for sex, anthropomet-
ric measures and physical activity were similar to the rest of the
prospective cohort studies.
Limitations in the review process
As described in the Methods section, it was difficult to define a
reliable search strategy, which probably holds true for many sys-
tematic reviews of prognostic studies. We noted that when check-
ing other systematic reviews on the topic and the references of the
included studies, around one third of our included studies were
identified through reference checking. However, using PubMed’s
’similar articles’ algorithm did not yield new studies but did help
us identify 13 secondary publications of studies we had already
included. The 103 prospective cohort studies included in this re-
view represent by far the largest amount of data synthesised on
the overall prognosis of IH and the impact of IH versus normo-
glycaemia as a prognostic factor for T2DM development. We did
not contact study authors for additional information, mainly for
logistical reasons but also because we anticipated poor response,
since many studies were published long ago. Moreover, retrieval
of additional information, often demanding recalculations, would
61Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
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have imposed a considerable burden on study authors.
During the review process, the need to establish a database of co-
hort studies specifying details on prognostic factors and outcomes,
amongst other things, became clear. Many large cohort studies
investigate the association of a great number of prognostic factors
with yet another large number of outcomes. These data may only
be detected through a detailed analysis of the full text (especially
tables and figures). It is evident that screening titles and abstracts
will miss this information.
We did not include participants of randomised controlled trials.
Though potentially some trialswith longer time of follow-up could
provide additional data, we decided not to include information
from intervention trials at this stage on theoretical grounds, as
any intervention will interfere with peoples’ lives, as opposed to
demonstrating the natural progression of a disorder. In addition,
we are conducting a series of Cochrane Reviews on interventions
for people with IH and may integrate these data in a later up-
date of this review (Hemmingsen 2016a; Hemmingsen 2016b;
Hemmingsen 2016c).
Agreements and disagreements with other
reviews
Gerstein 2007 is a widely cited review including 21 cohort stud-
ies and nine randomised controlled trials published between 1979
and 2004. The review authors annualised T2DM incidence rates,
which varied from 5% to 10%. Their relative risks for T2DM
incidence of 6.35 in people with IGT, 4.66 in people with IFG
and 12.1 with both IFG and IGT were higher but comparable to
our HR data. We did not annualise incidence rates because with
pronounced fluctuations between regression and development of
T2DM, assumptions to establish a model for annualising inci-
dence data over prolonged period of times appeared too strong.
Zhang 2010 examined ranges of HbA1c and also associated these
with annualised diabetes incidences. The results of seven included
studies reporting HbA1c categories showed an increase in T2DM
incidence across an HbA1c range from 5.0% to 6.5%. No meta-
analysis was performed. Our results also showed increased T2DM
incidence when the threshold of the HbA1c value at baseline was
raised from 5.7% to 6.0%. Morris et al. performed a meta-analy-
sis of prospective observational studies in which participants had
IH at baseline (Morris 2013). The review included 70 studies and
estimated pooled incidence rates using IFG (35.5 incident cases
per 1000 person-years as defined by ADA and 47.4 incident cases
per 1000 person-years as defined by WHO, 11 and 34 studies,
respectively), IGT (45.5 incident cases per 1000 person-years, 46
studies) and IFG/IGT (70.4 incident cases per 1000 person-years,
15 studies) definitions for IH. ElevatedHbA1cwas associatedwith
a pooled incidence rate of 35.6 per 1000 person-years. Similar
to our results, the review found that progression rates to T2DM
differed by definition of IH.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our systematic review on the development of type 2 diabetes mel-
litus (T2DM) in people with intermediate hyperglycaemia (IH)
or ’prediabetes’ identified several uncertainties: glycaemic status
can be measured in various ways, with IH usually defined by im-
paired fasting glucose (IFG) with cut-off levels of 5.6 mmol/L
or 6.1 mmol/L, by impaired glucose tolerance (IGT) or by ele-
vated HbA1c levels with thresholds of 5.7% or 6.0%. These def-
initions imply specific settings and demands on resources. It is
likely that the accuracy of information provided by the tests will
need to be balanced against the time, effort and cost required to
capture them. IFG measurement is cumbersome because of the
need for overnight fasting. HbA1c measurement is resource in-
tensive and must be standardised, taking into account potential
interference factors like anaemia, haemoglobinopathy or renal in-
sufficiency. IGT measurement is cumbersome and also resource
intensive. Overall, the certainty of the evidence was low for IH
versus normoglycaemia, mainly because many of the prospective
cohort studies did not adequately investigate other factors or co-
variates which could have confounded or modified the prognos-
tic effect of glycaemic status on T2DM incidence. Moreover, re-
sults varied widely, making it difficult to specify the best definition
for IH. The certainty of the evidence for the overall prognosis of
people with IH as well as regression from IH to normoglycaemia
was moderate because of imprecise results for most intermediate
hyperglycaemia definitions. With increasing years of follow-up,
T2DM incidence increased, but regression from IH to normogly-
caemia was also high. There was no clear pattern of geographical
differences; again, studies showedwide variation depending on the
definition of IH, mode of measurement and length of follow-up.
Due to the fluctuating stages of normoglycaemia, IH and T2DM,
which might show transition from one stage to another in both
directions and even after years of follow-up, practitioners should
be careful about the potential implications of any active interven-
tion for people ’diagnosed’ with IH.
Implications for research
Future prospective cohort studies should address the consequences
of IH to minimise secondary analyses of cohort studies where in-
vestigators synthetically form a subgroup of people with predia-
betes, as such analyses are suboptimal. There is an urgent need
for data from Eastern Europe and Africa to enable assessment of
the prognostic value of IH in these regions, and for prospective
cohort studies designed to examine the relationship between IH
and normoglycaemia, T2DM incidence and the development of
diabetic complications. The studies should adjust for confound-
ing using important, well-defined factors such as age, sex, ’ethnic-
ity’, anthropometric measures and physical activity. Also, studies
62Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
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should be adequately powered and analysed using suitable statisti-
cal techniques such as time-dependent regression methods. There
is a need for a database of cohort studies with details on all analysed
prognostic factor to outcome associations because many cohort
studies start with general questions like the influence of various
risk factors on cardiovascular disease, and specific factors may only
be identified by investigating the full text. The nature of these
investigations means that search strategies basing their retrieval
on titles and abstracts only will not be sufficient to identify these
studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Admiraal 2014
Name of study Surinamese in the Netherlands: study on health and ethnicity/healthy life in an urban
setting (SUNSET/HELIUS)
Inclusion criteria Participants of 2 studies (SUNSET andHELIUS), Surinamese and ethnicDutch, south-
east Amsterdam, aged 35-60 years with completed interviews and medical examinations
at baseline and follow-up
Exclusion criteria Missing FPG data, diabetes
Notes Baseline data for total cohort included in the analyses (N =456): South-Asian Surinamese
(N = 90), African Surinamese (N = 190), ethnic Dutch (N = 176)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Surinamese in the Netherlands study
Study participation: description of gly-
caemic status at baseline
Low risk 456 participants available for analysis; table
1 specifies people with IFG5.7
Study participation: adequate description
of sampling frame & recruitment
Low risk Random sample of 2975 Surinamese and
ethnic Dutch individuals, aged 35-60,
drawn from the population register of 2
neighbourhoods in southeast Amsterdam
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria specified
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Those who were lost to follow-up were
younger, had a higher BMI and greater
waist circumference, a higher FPG and
more often had baseline IFG than those
with follow-up data available after 10 years
Study attrition: reasons for loss to follow-
up provided
Low risk 777/1444 lost to follow-up (moved out-
side of Amsterdam, declined to participate,
died, non-response); figure S1
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Admiraal 2014 (Continued)
Study attrition: adequate description of
participants lost to follow-up
Low risk Reported in Table S2
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk See above
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IFG
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk FPG measurement by G6PD test
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 5.7-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; HbA1c ≥ 6.5; self-reported
T2DM
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Reliable measurement
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Limited number of confounders measured
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
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Admiraal 2014 (Continued)
Study confounding: important potential
confounders accounted for in study design
Low risk Adjustment for sex, age, BMI and change
in BMI after 10 years
Study confounding: important potential
confounders accounted for in the analysis
Low risk Unadjusted and adjusted analyses
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariate logistic regression
Aekplakorn 2006
Name of study None
Inclusion criteria Eymployees of the Electric Generation Authority Bangkok, Thailand aged ≥ 35 years
(’exploratory cohort’); middle-income social class
Exclusion criteria Diabetes at baseline
Notes Baseline data for cohort becoming diabetic (N = 361)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Cohort study of employees of the Electric Generation Authority
of Bangkok, Thailand
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk 3499 employees aged≥ 35 years; mostly urban dwellers of mid-
dle-income social class
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria specified
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Of 3254 participants without diabetes at baseline, 2667 took
part in the 1997 survey
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Aekplakorn 2006 (Continued)
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Individuals lost to follow-up were slightly older
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Unclear, limited data only
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk 2-h OGTT after 75-g glucose load
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Glucose oxidase method
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG ≥ 5.6 to < 7.0; IGT: 2-h PG ≥ 7.8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0 or 2-h glucose ≥ 11.1; development of T2DM
during the follow-up period until 1997 according to FPG or
diagnosis and/or receipt of diabetes medication during follow-
up
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Limited number of confounders
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
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Aekplakorn 2006 (Continued)
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Age, sex, BMI, waist circumference, smoking status, drinking
status, family history, hypertension
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes; IFG status (model 2) and IGT status (model 3)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariable logistic regression
Ammari 1998
Name of study None
Inclusion criteria Community-based survey of cardiovascular risk factors in 4 Jordanian towns, individuals
aged≥ 25 years; follow-up on one of the town (Sikhra) and matched control group with
non-IGT (normal) individuals from initial survey
Exclusion criteria Diabetes
Notes Few baseline data reported for total study population (N = 212)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk 4 community-based survey of cardiovascular risk factors in 4
Jordanian towns
Study participation: description of gly-
caemic status at baseline
Low risk Community-based survey of cardiovascular risk factors in 4 Jor-
danian towns
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
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Ammari 1998 (Continued)
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
High risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not described (some comparison of participants with non-par-
ticipants)
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not described
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IGT
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk FPG and 2-h 75 g OGTT
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 2-h PG 7.8 to < 11.1 (WHO 1985)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk 2-h PG ≥ 11.1 (WHO 1985)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes (probably FPG and 2-h OGTTwas also measured at follow-
up)
Study confounding: important
confounders measured
Unclear risk Some baseline parameters were investigated (hypercholestero-
laemia, hypertriglyceridaemia, obesity, hypertension, family his-
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Ammari 1998 (Continued)
tory of diabetes)
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Scarce data
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Scarce data
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Not reported
Anjana 2015
Name of study Chennai Urban Rural Epidemiology Study (CURES)
Inclusion criteria Representative sample from Chennai, ≥ 20 years of age
Exclusion criteria Diabetes at baseline, unknown glycaemic status
Notes Baseline data for cohort becoming diabetic at follow-up (N = 176)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Chennai Urban Rural Epidemiology Study
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Anjana 2015 (Continued)
Study participation: description of gly-
caemic status at baseline
Low risk 299 with ’prediabetes’
Study participation: adequate description
of sampling frame & recruitment
Low risk Representative sample fromChennai,≥ 20
years
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria specified
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
High risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk i-IFG, i-IGT, IFG/IGT
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk i-IGT: 2-h PG 7.8-11.0 and FPG > 5.6; i-
IFG: FPG 5.6-6.9 and 2-h PG < 7.8; pre-
diabetes: FPG 5.6-6.9 or 2-h PG 7.8-11.0
(i-IGT or i-IFG or IFG/IGT)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1; diagnosed;
antihyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
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Anjana 2015 (Continued)
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk For IFG/IGT, several confounders mea-
sured as predictors for incident diabetes
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cox proportional hazards model for vari-
ous single factors
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Univariate analyses
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Cox proportional hazards model, univari-
ate analyses for single variables
Bae 2011
Name of study None
Inclusion criteria Individuals who participated in comprehensive health check-ups annually for 5 years
Exclusion criteria Anaemiawith a haemoglobin level < 7.4mmol/L; self-reported diabetes and undiagnosed
diabetes (FPG concentration 7.0 mmol/l or HbA1c 6.5%; absence of HbA1c data at
any visit
Notes Baseline data for total cohort
Risk of bias
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Bae 2011 (Continued)
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Participants partially undergoing annual or biannual health
check-ups (Kangbuk Samsung Hospital Total,Healthcare Cen-
ter)
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Unclear risk Scarce data
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk HbA1c5.7 and HbA1c6.0
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Unclear risk Normal reference for HbA1c: < 5
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
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Bae 2011 (Continued)
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; HbA1c ≥ 6.5; history of diabetes; antihypergly-
caemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk 2 covariates measured: age and sex
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk 2 covariates included: age and sex
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk 2 covariates analysed: age and sex
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, hazard ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Kaplan-Meier method, Cox proportional hazard analysis (2 co-
variates), ROC analysis
Baena-Diez 2011
Name of study None
Inclusion criteria Participants aged > 18 years visiting a healthcare centre with impaired fasting glucose
measured twice
Exclusion criteria Corticosteroid therapy, terminal illness, life expectancy of 1 year or less, diabetes
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Baena-Diez 2011 (Continued)
Notes Baseline data for cohort with intermediate hyperglycaemia (N = 115)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Healthcare centre in Barcelona, Spain, “Cohorta Zona Franca”
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Unclear risk Scarce data
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria specified
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Quote: “no significant differences”
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IFG
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk FPG measured twice
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: 6.1-6.9
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Baena-Diez 2011 (Continued)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0 (measured twice)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk FPG
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some variables (univariate analyses) associated with progression
to diabetes
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some confounders measured
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Univariate analyses for single variables
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Cox regression for other risk factors (e.g. obesity) associated with
progression to diabetes
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Bai 1999
Name of study None
Inclusion criteria Staff of the Indian Institute of Technology of Chennai, along with their family members,
aged 20 years and over
Exclusion criteria Treatment for diabetes
Notes Baseline data for the IGT cohort (N = 252)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Staff of the Indian Institute of Technology of Chennai, along
with their family members, aged 20 years and over
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
High risk Not reported
Study attrition: reasons for loss to follow-
up provided
High risk Not reported
Study attrition: adequate description of
participants lost to follow-up
High risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IGT
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
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Bai 1999 (Continued)
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 7.8 to < 11.1 (WHO 1985)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk 2-h PG ≥ 11.1 (WHO 1985)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Not reported, cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Not reported
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Not reported
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Bergman 2016
Name of study Israel study of glucose intolerance, obesity and hypertension (Israel GOH study)
Inclusion criteria Survival until follow-up with fasting blood glucose < 126 mg/dL (7.0 mmol/L) and 1-
and 2-h postload glucose values available at baseline
Exclusion criteria Individuals with diabetes
Notes Baseline data for IGT cohort (N = 24)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Israeli general population registry sample
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Comment: “no differences” between non-
participants and participants
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Comment: IGT
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
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Bergman 2016 (Continued)
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk Comment: FPG 5.6-7.8; 2-h BG 7.8-11.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Unclear risk Comment: FPG ≥ 7.8, 2-h BG ≥ 11.1;
reported diabetes
Outcome measurement: method of out-
come measurement used valid & reliable
Unclear risk Non-standard FPG thresholds
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Comment: some confounders were mea-
sured
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Comment: scarce data
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Comment: scarce data
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple multinomial logistic regression
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Bonora 2011
Name of study Bruneck Study
Inclusion criteria White men and women, aged 40-79 years
Exclusion criteria Not reported
Notes No baseline data (except white participants aged > 40 years, N = 919)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Bruneck study, a long-term prospective population-based study
of atherosclerosis and its risk factors
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
High risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Unclear risk HbA1c categories, IFG (additional analyses)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
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Bonora 2011 (Continued)
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk HbA1: 6.0-6.49; IFG: not defined, probably FPG 5.6-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; HbA1c ≥ 6.5; diabetes treatment
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Yes
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, hazard ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazards models; additional models were run
with updates variables (HbA1c and other variables were assessed
every 5 years during follow-up)
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Cederberg 2010
Name of study None
Inclusion criteria All inhabitants of the city of Oulo, Finland, born in 1935
Exclusion criteria Diabetes at baseline
Notes Baseline data for the total cohort (N = 553), men (N = 223), women (N = 330)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Part of a longer follow-up study assessing type 2 diabetes and
IGT
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IFG, IGT, IFG/IGT
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
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Cederberg 2010 (Continued)
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: 6.1-6.9; 2-h PG < 7.8; IGT: FPG > 7.0; 2-h PG 7.8 to <
11.1; elevated HbA1c: 5.7-6.4
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk Confirmed by 2 diabetic 75 g OGTTs (2-h PG ≥ 11.1) and/or
fasting values
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some confounders measured
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, risk ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Log-binomial regression
114Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chamnan 2011
Name of study European Prospective Investigation of Cancer (EPIC)-Norfolk cohort
Inclusion criteria Participants aged 40-74 years from the Norfolk region, UK; individuals with HbA1c
measurements at baseline and the second health assessment
Exclusion criteria Diabetes at baseline, missing data
Notes Baseline data for HbA1c 6.0-6.4 cohort (N = 370)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Population-based study monitoring indi-
viduals recruited from general practice in
the Norfolk region, UK
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Scarce data
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk HbA1c (50% of all participants had infor-
mation on this measure at baseline); analy-
ses were limited to these individuals
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Chamnan 2011 (Continued)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk HbA1c 6.0-6.4
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk HbA1c ≥ 6.5; reported physician-diag-
nosed diabetes or diabetes medications;
antihyperglycaemic medication; diagnosis
through medical records, registers or death
certificates; results for clinically and/or bio-
chemically diagnosed diabetes were used
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Yes
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
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Chamnan 2011 (Continued)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression (for every 0.5% increase
in HbA1c as well as for different categories
of HbA1c)
Charles 1997
Name of study Paris Prospective Study
Inclusion criteria Longitudinal epidemiologic study of cardiovascular risk factors in male employees of the
Paris police, born in France between 1917-28
Exclusion criteria No diabetes or cardiovascular disease
Notes Baseline data for individuals with IGT converting to T2DM (N = 32)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Longitudinal epidemiologic study of cardiovascular risk fac-
tors in male employees of the Paris
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
High risk Not reported
Study attrition: reasons for loss to follow-
up provided
High risk Not reported
Study attrition: adequate description of
participants lost to follow-up
High risk Not reported
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Charles 1997 (Continued)
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IGT
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 2-h PG ≥ 7.8 to < 11.1 (WHO 1985)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk 2-h PG ≥ 11.1 (WHO 1985); physician diagnosed diabetes
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes (see below)
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Charles 1997 (Continued)
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariate logistic regression (odds ratio for an increase of 1
SD in the population of participants with NGT or IGT)
Chen 2003
Name of study None
Inclusion criteria Residents of Penghu, Taiwan aged 40-79 years were selected for a baseline diabetes
prevalence study
Exclusion criteria Diabetes at baseline
Notes Baseline data for cohort converting to T2DM (N = 26)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Random sample of residents of Penghu, Taipei were selected for
a baseline diabetes prevalence survey
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
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Chen 2003 (Continued)
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Quote: “the 600 persons who were re-examined did not signif-
icantly differ from the others”
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IFG
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 6.1-7.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some confounders measured
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
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Chen 2003 (Continued)
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Age-sex adjusted odds ratio
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression (selected risk factors)
Chen 2017
Name of study None
Inclusion criteria Participants with complete 3 year follow-up and non-pharmacological interventions
Exclusion criteria Participants aged 0-60 years, incomplete baseline data, diabetes at baseline
Notes Baseline data for i-IFG/i-IGTand IFG/IGT across age groups < 40 years + > 60 years
(data indicate range across groups) (i-IFG < 40 years: N = 51 and > 60 years: N = 278;
i-IGT < 40 years: N = 41 and > 60 years: N = 151; IFG/IGT: < 40 years: N = 34 and >
60 years: N = 175)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Permanent participants of Fujian province (China), part of the
baseline survey from the REACTION study investigating the
association between diabetes and cancer
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
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Chen 2017 (Continued)
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IFG, IGT, IFG/IGT
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 5.6-6.9 + 2-h PG ≤ 7.8; IGT: FPG < 5.6 + 2-h PG
7.8 to ≤ 11.0; IFG/IGT: FPG 5.6-6.9 + 2-h PG 7.8 to ≤ 11.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1; previously diagnosed diabetes
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Confounder adjustment for HOMA-IR and HOMA-B
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
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Chen 2017 (Continued)
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes (HOMA-IR, HOMA-B)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Stepwise multiple regression analysis (for HOMA-IR or
HOMA-B)
Coronado-Malagon 2009
Name of study None
Inclusion criteria Healthy Mexicans
Exclusion criteria Previous diabetes diagnosis, various diseases and medications affecting glucose
metabolism
Notes Baseline characteristics for the prediabetic cohort (N = 217)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Personnel working for Petróleos Mexicanos with annual health-
checkups living in the metropolitan area of Mexico City
Study participation: description of gly-
caemic status at baseline
Unclear risk Quote: “prediabetes”
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
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Coronado-Malagon 2009 (Continued)
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Unclear risk IFG and IGT (ADA 2007), vague definition
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Unclear risk IFG and IGT: 5.6-6.9 and 7.8 to < 11.1 (ADA 2007), vague
definition
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Unclear risk FPG ≥ 7.0 or 2-h PG ≥ 11.1 (ADA 2007), vague definition
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Scarce data
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Scarce data
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Coronado-Malagon 2009 (Continued)
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Scarce data
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Scarce data
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Scarce data
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, relative risk
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression
Cugati 2007
Name of study Blue Mountains Eye Study (BMES)
Inclusion criteria Survey of vision and common eye diseases in 2 postcode areas west of Sydney; all per-
manent non-institutionalised residents with birth date prior to January 1943 (aged 49+
at baseline) were invited to attend a detailed eye examination at a local clinic
Exclusion criteria Nursing home residents, diabetes at baseline, missing data
Notes Baseline data for BMES I study, people without diabetes (N = 3437/3654)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Older community within the geographically de-
fined area west of Sydney, Australia; population-
based survey of vision and common eye diseases
Study participation: description of gly-
caemic status at baseline
Low risk Yes
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Cugati 2007 (Continued)
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes, for most variables
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IFG
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 5.6 -6.9 (originally FPG ≥ 6.1 to < 7.
0)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; self-reported diabetes history; anti-
hyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
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Cugati 2007 (Continued)
Study confounding: important
confounders measured
Unclear risk Few variables (adjustment for age and sex)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Few variables
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Few variables
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariate-adjusted discrete logistic models,
few variables
De Abreu 2015
Name of study Geelong Osteoporosis Study (GOS)
Inclusion criteria Female arm of the GOS
Exclusion criteria No FPG level or self-report of antihyperglycaemic medication or diabetes status
Notes Baseline data for IFG cohort at baseline (N = 187)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Utilised data from the female arm of the Geelong
Osteoporosis Study, Australia
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De Abreu 2015 (Continued)
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IFG
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: 5.5-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; self-reported; antihyperglycaemic
medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
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De Abreu 2015 (Continued)
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Yes, also age-standardised incidence rate and
additional covariates reported (metabolic syn-
drome, fasting glucose at baseline) (see Appendix
16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression
Den Biggelaar 2016
Name of study Cohort on Diabetes and Atherosclerosis Maastricht (CODAM)
Inclusion criteria Individuals with an elevated risk of type 2 diabetes and cardiovascular disease
Exclusion criteria Previously diagnosed type 2 diabetes at baseline, who did not undergo an OGTT and
incomplete OGTT data
Notes Baseline data for prediabetic group (N = 122)
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Den Biggelaar 2016 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Participants of the Cohort on Diabetes
and AtherosclerosisMasstricht (CODAM)
study on natural progression of glucose tol-
erance
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Analyses restricted individuals without
T2DM who participated in the follow-up
measurements
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Scarce data
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IFG and IGT
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk FPG 6.1-6.9; 2-h PG 7.8-11.1
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Den Biggelaar 2016 (Continued)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Not reported, cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Not reported
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Discriminatory ability of beta-cell func-
tions indices to predict ’prediabetes’ and
T2DM by means of ROC curves
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Derakhshan 2016
Name of study Tehran Lipid and Glucose Study (TLGS)
Inclusion criteria 3 separate analyses to investigate incidence of type 2 diabetes, hypertension and chronic
kidney disease
Exclusion criteria Individuals aged < 20 years, type 2 diabetes at baseline, missing data, no follow-ups
Notes Baseline data for ’prediabetes’ group with normal blood pressure (IFG and/or IGT, N =
523)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Population-based study on a representative
sample of the populationofTehran todeter-
mine the prevalence and incidence of non-
communicable diseases and their risk fac-
tors
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Unclear risk Quote: “prediabetes” (IFG and IGT)
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Derakhshan 2016 (Continued)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk 5.55 ≤ FPG < 7.0; 7.77 ≤ 2-h PG ≤ 11.1;
no antihyperglycaemic medication
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1; antihypergly-
caemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Yes
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Low risk Multiple imputation
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Incidence rate, hazard ratio
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Derakhshan 2016 (Continued)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazard models
Dowse 1991
Name of study Nauru Study
Inclusion criteria All Nauruans aged 20 years and over; this survey included 266 individuals who were not
diabetic in the combined 1975/76 survey; individuals who had previously attended either
or both the 1975/76 and 1982 surveys; individuals with at least one parent identified as
being of Nauruan heritage
Exclusion criteria Diabetes
Notes No baseline data
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Nauruan population, persons of Micronesian ancestry
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Description of inclusion and exclusion criteria
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Some reasons provided
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
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Dowse 1991 (Continued)
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Scarce data
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IGT
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: FPG < 7.8 and 2-h PG ≥ 7.8 - < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk 2-h PG ≥ 11.1 (WHO 1985); FPG ≥ 7.8
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some confounders were measured
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Yes
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Yes
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Dowse 1991 (Continued)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression models
Ferrannini 2009
Name of study Mexico City Diabetes Study
Inclusion criteria Population-based study of diabetes and cardiovascular risk factors in low-income neigh-
bourhoods in Mexico City, participants aged 35-64 years
Exclusion criteria Type 2 diabetes, type 1 diabetes, pregnant women
Notes Baseline characteristics provided for a range across different definitions of ’prediabetes’
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Data were collected as part of the Mexico City Diabetes
Study
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Description of inclusion and exclusion criteria
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
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Ferrannini 2009 (Continued)
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Unclear, limited data
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk (i)IFG, (i)IGT
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 6.1-6.9; IGT: FPG < 7.0 and 2-h PG 7.8-11.
1; i-IFG6.1/i-IFG5.6: 2-h PG < 7.8 and FPG 6.1-6.9/5.
6-6.1; i-IGT/i-IGT6.1/i-IGT5.6
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Not for transition data (intermediate hyperglycaemia to
T2DM)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
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Ferrannini 2009 (Continued)
Study confounding: important potential
confounders accounted for in study design
Unclear risk Scarce data
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Scarce data
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, relative risk (multiplemodel odds
ratios were calculated for 1 SD of the population value of
that variable, in order to compare the relative importance
of the variables (sex, familial diabetes, age, BMI, FPG,
2-h PG)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Logistic regression (for calculation of odds ratios, see
above)
Filippatos 2016
Name of study ATTICA (province of Attica, Greece)
Inclusion criteria 1 participant per household, inhabitants from the Attica province
Exclusion criteria People living in institutions; people with CVD and of those with chronic viral infections
Notes Baseline data for IFG5.6 cohort
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk ATTICA study
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described (par-
ticipants with no diabetes and no CVD at base-
line)
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Filippatos 2016 (Continued)
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes (85% participation rate)
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IFG5.6
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk FBG 5.6-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FBG > 6.9; use of antidiabetic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some confounders measured
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
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Filippatos 2016 (Continued)
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some confounders included
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some confounders analysed
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression models
Forouhi 2007
Name of study Ely Study (Cambridgeshire, UK)
Inclusion criteria All adults free of known diabetes registered with a single practice serving Ely, adults aged
40-69 years
Exclusion criteria Diabetes
Notes Baseline data for the IFG6.1 cohort (N = 257)
Cumulative incidence increased across increasing age groups and was higher in men than
in women
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk The Ely Study (Cambridgeshire, UK)was a prospec-
tive study of the aetiology of T2DM
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
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Forouhi 2007 (Continued)
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Scarce data
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IFG
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG6.1: FPG 6.1-6.9 (FPG < 7.0 and 2-h PG < 11.
1) and IFG5.6: FPG 5.6-6.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1; physician diagnosis or
treatment for diabetes
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some confounders measured
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Forouhi 2007 (Continued)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, hazard ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox regression (cumulative hazard curves by glucose
status)
Garcia 2016
Name of study Sacramento Area Latino Study on Aging (SALSA)
Inclusion criteria Older Mexican Americans residing in the Sacramento metropolitan statistical area
Exclusion criteria Missing baseline diabetes status, certain neighbourhoods
Notes Baseline data for the IFG cohort (N = 310)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Participants were from the Sacramento
Area Latino Study on Aging (SALSA),
a longitudinal cohort study of physical
and cognitive impairment and cardiovas-
cular diseases in community-dwelling older
Mexican Americans residing in the Sacra-
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Garcia 2016 (Continued)
mento Metropolltan Statistical Area
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Not reported but only 12/1789 partici-
pants were excluded
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IFG
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk FBG 5.6-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; self-reported; antihypergly-
caemic medication; diabetes comedication
at death
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Garcia 2016 (Continued)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some confounders measured
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Multistate Markov models
Study confounding: important potential
confounders accounted for in the analysis
Low risk Multistate Markov models
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence (hazard ratio was
calculated for the association between
neighbourhood scocioeconomic position
(NSEP) scores and transitions between var-
ious (pre)diabetic stages)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multistate Markov models
Gautier 2010
Name of study Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR)
cohort
Inclusion criteria Men and women aged 30-64 years recruited from volunteers who were offered periodic
health examinations free of charge by the French Social Security at 10 health centres in
western France
144Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gautier 2010 (Continued)
Exclusion criteria Diabetes at baseline, individuals with unknown diabetes status at the 9-year examination
Notes No baseline data for cohort with intermediate hyperglycaemia
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Participants of theData from anEpidemio-
logical Study on the InsulinResistance Syn-
drome (DESIR) cohort who had IFG at
baseline
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Unclear risk Key characteristics unclear
Study participation: adequate description
of period & recruitment place
Unclear risk Time frame unclear
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
High risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IFG
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
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Gautier 2010 (Continued)
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 5.6-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; treatment for diabetes (at 1 of
the 3-yearly examinations)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Some confounders measured
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes (see below)
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes (see below)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence (odds ratios for 9-
year incident diabetes per 1 SD change in
waist circumference and weight in IFG)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic models (for increases in waist cir-
cumference and weight)
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Gomez-Arbelaez 2015
Name of study None
Inclusion criteria Adults ≥ 35 years attending a general practitioner for any reason
Exclusion criteria Known diabetes, acute illness, pregnancy, use of antihyperglycaemic medication
Notes Baseline data for the total cohort (N = 772)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Longitudinal observational study conducted in a healthcare cen-
tre in Floridablanca, Colombia
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk The sub-sample of people with intermediate hyperglycaemiawas
followed for diabetes incidence
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
High risk Not reported
Study attrition: reasons for loss to follow-
up provided
High risk Not reported
Study attrition: adequate description of
participants lost to follow-up
High risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Intermediate hyperglycaemia as measured by FPG, OGTT,
HbA1c; FINDRISC score
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
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Gomez-Arbelaez 2015 (Continued)
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: ≥ 5.6 to < 7.0; IGT: ≥ 7.8 to < 11.1; HbA1c ≥ 5.7 to ≤
6.4
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; OGTT ≥ 11.1; HbA1c ≥ 6.5
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Age and sex-adjusted odds ratios for FINDRISC score
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk For FINDRISC score
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Age and sex-adjusted odds ratios
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariate logistic regression for the association between the
FINDRISC score and incident T2DM
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Guerrero-Romero 2006
Name of study None
Inclusion criteria Men and non-pregnant women, aged 20-64 years, were recruited from the city of Du-
rango, northern Mexico; with NGT or IGT
Exclusion criteria Participants who failed to attend 2 or more visits
Notes Baseline data for IGT cohort at baseline progressing to T2DM (N = 20); all individuals
were counselled on the importance of diet and physical exercise (standard care for the
whole cohort)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Cohort study in healthy Mexicans to determine predictors for
the development of metabolic disorders
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Unclear risk Time frame unclear
Study participation: adequate description
of period & recruitment place
Unclear risk Period of recruitment unclear
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IGT
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Guerrero-Romero 2006 (Continued)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 2-h PG ≥ 7.8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk 2-h PG: ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (for association between beta-cell
function and IGT/T2DM) (see Appendix 16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk For beta-cell function and IGT/T2DM
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some confounders measured
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate
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Guerrero-Romero 2006 (Continued)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariate logistic regression on relative risk of IGT or T2DM
associated with beta-cell function
Han 2017
Name of study Ansung-Ansan cohort study, part of the Korean Genome and Epidemiology Study (Ko-
GES), to investigate the trends in diabetes and associated risk factors
Inclusion criteria Urban (Ansan) and rural (Ansung) communities (within 60 km of Seoul)
Exclusion criteria Unknown glucose status, individuals with known diabetes, participants who were newly
diagnosed with type 2 diabetes at baseline examination; persons with a history of malig-
nant diseases,
liver failure, end-stage renal disease, rheumatological diseases and acute or chronic infec-
tious diseases, individuals who had taken steroids in the previous 3 months; individuals
who did not undergo any follow-up examination after the baseline examination
Notes Baseline data for i-IFG, i-IGT and IFG/IGT
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Ansung-Ansan Cohort Study, part of the
Korean Genome and Epidemiology Study
(KoGES)
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes (follow-up rate at 12 years 60.6%)
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Han 2017 (Continued)
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 5.6-6.9 and no diagnosis of dia-
betes; IGT: 2-h PG 7.8 to < 11.1; i-IFG5.6:
IFG without IGT; i-IGT: IGT without
IFG; IGT/IGT: IFG+IGT; ’prediabetes’:
IFG or IGT
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1; HbA1c ≥ 6.
5; current antihyperglycaemic treatment
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Yes
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
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Han 2017 (Continued)
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, haz-
ard ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariate Cox proportional hazard
model
Hanley 2005
Name of study Insulin Resistance Atherosclerosis Study (IRAS)
Inclusion criteria 4 clinical centres (Oakland, Los Angeles - non-Hispanic whites and blacks recruited
from Kaiser Permanente) and San Antonio, San Luis Valley (non-Hispanic whites and
Hispanics): from 2 population-based studies (San Antonio Heart Study and the San Luis
Valley Diabetes study)
Exclusion criteria Participants with inflammatory diseases; diabetes; no information on metabolic variables
of interest and follow-up glucose tolerance status
Notes Baseline data for diabetic cohort at follow-up (N = 131); participants were recruited
from 2 population-based studies: the San Antonio Heart Study and the San Luis Valley
diabetes study
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Observational study of the relationship be-
tween insulin resistance, cardiovascular dis-
ease and its known risk factors in differ-
ent ethnic groups and varying states of glu-
cose tolerance; the study was conducted
at 4 clinical centres; report on individu-
als who were nondiabetic at baseline and
for whom information was available on
metabolic variables of interest and follow-
up glucose tolerance status
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Hanley 2005 (Continued)
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Response rate 81%
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Unclear risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG, IGT (WHO 1999)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
High risk Not specified
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
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Hanley 2005 (Continued)
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix
16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates measured (see Appendix
16 and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates (age, sex, clinical centre,
ethnicity) (see Appendix 16 and Appendix
17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression
Heianza 2012
Name of study Toranomon Hospital Health Management Center Study (TOPICS)
Inclusion criteria Participants from the TOPICS: apparently healthy Japanese government employees who
underwent annual multiphasic health screening examinations; the study attempted to
elucidate the incidence of and risk factors for various diseases among the Japanese pop-
ulation
Exclusion criteria Diabetes at baseline, missing data at baseline
Notes Baseline data for the total cohort (N = 6241)
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Heianza 2012 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Healthy Japanese government employees
who underwent annual examinations for
health screening
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 5.6-6.9 or FPG 6.1-6.9; HbA1c
5.7 -6.4 or 6.0-6.4; IFG/HbA1c = ’predia-
betes’
Glycaemic status measurement: same
method and setting of measurement of the
Low risk Yes
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Heianza 2012 (Continued)
glycaemic status for all study participants
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; HbA1c ≥ 6.5%; self-reported
clinician-diagnosed diabetes
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Yes
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, haz-
ard ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox regression, multivariate model
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Inoue 1996
Name of study None
Inclusion criteria Non-obese participants with IGT and 22 normal control persons were selected from the
participants of a health screening programme
Exclusion criteria People with liver or kidney diseases
Notes Baseline data for the IGT cohort (N = 37)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Unclear risk Participants of a health screening programme
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Unclear risk Scarce data
Study participation: adequate description
of period & recruitment place
Unclear risk Scarce data
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IGT
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
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Inoue 1996 (Continued)
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: ≥ 7.8 to < 11.1 (presumed WHO 1985)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk IGT: ≥ 11.1 (presumed WHO 1985)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Not reported, cumulative incidence data
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Not reported
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Not reported, cumulative incidence data
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Kruskal-Wallis test
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Janghorbani 2015
Name of study Isfahan Diabetes Prevention Study (IDPS)
Inclusion criteria Participants with a family history of type 2 diabetes, being non-diabetic
Exclusion criteria Type 1 diabetes, pregnancy
Notes Baseline data for i-IFG, i-IGT and IFG/IGT cohort (N = 770); first-degree relatives of
people with T2DM; data on the cohort without hypertension at baseline
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Ongoing cohort in central Iran to assess the
various potential risk factors for diabetes in
people with a family history of T2DM
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Description of inclusion and exclusion cri-
teria
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
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Janghorbani 2015 (Continued)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk i-IGT: FPG < 5.6 and 2-h PG 7.8-11.1; i-
IFG: 5.6-6.9 and 2-h PG < 7.8; IFG/IGT:
5.6-6.9 and 2-h PG 7.8-11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 11.1; antihyperglycaemic medica-
tion; 2nd FPG ≥ 7.0; 2-h PG ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix
16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates measured (age, sex,
BMI, triglycerides, total cholesterol) (see
Appendix 16 and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates measured (age, sex,
BMI, triglycerides, total cholesterol) (see
Appendix 16 and Appendix 17)
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Janghorbani 2015 (Continued)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, haz-
ard ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazards model
Jaruratanasirikul 2016
Name of study None
Inclusion criteria Obese Thai children and adolescents aged 8-15 years, Pediatric Endocrine Clinic at
Songklanagarind Hospital (Hat Yai, Songkhia Thailand)
Exclusion criteria No clinical findings of secondary obesity, not on corticosteroids
Notes Baseline data for IGT cohort (N = 27)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
Study attrition: reasons for loss to follow-
up provided
High risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
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Jaruratanasirikul 2016 (Continued)
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk (i)-IGT: FPG < 5.6 and 2-h PG 7.8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG > 7.0; 2-h PG ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Not reported
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Not reported
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Jaruratanasirikul 2016 (Continued)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox regression analysis for ROC curves (cut-off FPG levels)
Jeong 2010
Name of study None
Inclusion criteria People older 20 years living in the rural area of Dalseong County near Daegu visiting
community health centres
Exclusion criteria Not reported
Notes 1287 participants were re-evaluated in 2008 and 187 new participants “added to the
study”; baseline data for participants with incident diabetes (N = 135)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Population-based survey to determine the prevalence and inci-
dence of ’prediabetes’ and diabetes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
High risk Several surveys plus new recruitment; follow-up rate 80.5%; no
description of dropouts
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Jeong 2010 (Continued)
Study attrition: reasons for loss to follow-
up provided
High risk Not reported
Study attrition: adequate description of
participants lost to follow-up
High risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG ≥ 5.6 to < 7.0; IGT: 2-h PG ≥ 7.8 to < 11.1; ’pre-
diabetes’: IFG or IGT
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Several covariates were measured (see Appendix 16 and
Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
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Jeong 2010 (Continued)
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Unclear risk Odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression models
Jiamjarasrangsi 2008a
Name of study None
Inclusion criteria Individuals 35 years or older participating in the annual physical checkup at least twice
during the years 2001-2005
Exclusion criteria People with diabetes
Notes Baseline data for total cohort becoming diabetic at follow-up (N = 48)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk University hospital employees
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
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Jiamjarasrangsi 2008a (Continued)
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG ≥ 5.6 to < 7.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Logistic regression on hepatic enzymes; incidence rate: few co-
variates (see Appendix 16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Logistic regression on hepatic enzymes
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Logistic regression on hepatic enzymes
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Jiamjarasrangsi 2008a (Continued)
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Logistic regression on hepatic enzymes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Logistic regression on hepatic enzymes
Study confounding: important potential
confounders accounted for in study design
Unclear risk lLogistic regression on hepatic enzymes
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Logistic regression on hepatic enzymes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression (independent variables: hepatic enzymes) and
Poisson regression analyses
Kim 2005
Name of study None
Inclusion criteria People visiting the Health Promotion Centre of Samsung Medical Center for a physical
health check-up
Exclusion criteria Diabetes
Notes Baseline data for FPG group 4 (6.1-7.0) with baseline and follow-up (N = 276)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes (FPG categories)
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
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Kim 2005 (Continued)
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Participation rate 20.9% in group 4; scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 6.1 to < 7.0 (group 4)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; antihyperglycaemic treatment
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Several covariates measured (see Appendix 16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Scarce data
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Kim 2005 (Continued)
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Scarce data
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, hazard ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox regression analysis
Kim 2008
Name of study None
Inclusion criteria Individuals undergoing a medical examination at Inha University Hospital with a follow-
up medical examination 2 years later
Exclusion criteria Individuals diagnosed with diabetes at baseline
Notes Baseline data for IFG5.6/IFG6.1 cohort (N = 1335/N = 494)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Participants who underwent amedical examination at Inha Uni-
versity Hospital and had either NGT or IFG
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
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Kim 2008 (Continued)
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Participants diagnosed with diabetes in 2002 were excluded
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG5.6: FPG 5.6-7.0; IFG6.1: FPG 6.1-7.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Measurement of cumulative incidence
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Kim 2008 (Continued)
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Not reported
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Measurement of cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk ROC curves for predicting the future onset of diabetes
Kim 2014
Name of study None
Inclusion criteria Pre-screened individuals with ’prediabetes’ visiting the diabetes clinic at Seoul National
University Bundang Hospital (SNUB) in 2005/06 after they were diagnosed with pre-
diabetes at their health check-up or primary clinic
Exclusion criteria Taking oral hypoglycaemic agents or insulin
Notes Baseline data for i-IFG (N = 158)/i-IGT (N = 65)/IFG/IGT (N = 119)/i-HbA1c (N =
64); total: N = 406
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Pres-screened individuals with ’prediabetes’
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Kim 2014 (Continued)
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Pre-defined participants with intermediate hyperglycaemia
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk i-IFG: FPG 5.6-6.9 and 2-h PG < 7.8; i-IGT: 2-h PG 7.8-
11.1 and FPG < 5.6; IFG/IGT: combined glucose intolerance;
HbA1c: 5.7-6.4
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1; HbA1c ≥ 6.5
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
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Kim 2014 (Continued)
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk For C-peptide
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk For C-peptide
Study confounding: measurement of con-
founders valid & reliable
Unclear risk For C-peptide
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk For C-peptide
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk For C-peptide
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk For C-peptide
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression for association of T2DM develop-
ment and C-peptide levels
Kim 2016a
Name of study None
Inclusion criteria Medical examinations at the Health Screening and Promotion Center at Asan Medical
Center (Seoul, Korea)
Exclusion criteria History of diabetes mellitus, taking antihyperglycaemic medications, FPG ≥ 7.0 mmol/
L or HbA1c ≥ 6.5% at baseline
Notes 2 baseline data cohorts: ’prediabetes’ by FPG and HbA1c (N = 3544 and N = 1713)
Risk of bias
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Kim 2016a (Continued)
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Unclear risk Participants who underwent medical examinations in a health
screening and promotion centre
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk FPG 5.6-6.9; HbA1c 5.7-6.4
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk FPG ≥ 7.0; HbA1c ≥ 6.5; antihyperglycaemic medications
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Kim 2016a (Continued)
Outcome measurement: clear definition of
the outcome provided
Low risk Yes
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Several covariates measured (see Appendix 16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariate logistic regression
Kleber 2010
Name of study None
Inclusion criteria Obese children and adolescents aged 10-17 years with IGT attending the outpatient
centre (Department of Paediatric Nutrition Medicine, Witten/Herdecke Germany)
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Kleber 2010 (Continued)
Exclusion criteria Not reported
Notes Baseline data for IGT cohort (N = 79)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Obese white children and adolescents with IGT attending an
outpatient centre
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Unclear risk Time of recruitment unclear
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk No exclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Probably no dropouts
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 2-h PG > 7.7: IFG: FPG ≥ 5.5
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Kleber 2010 (Continued)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk T2DM by ADA 2000 guidelines
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Not reported
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple linear regression
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Kleber 2011
Name of study None
Inclusion criteria Obese white children with IGT without medication or endocrine/syndromal disorders,
aged 10-17 years not participating in the intervention part of the study
Exclusion criteria Children in the intervention part of the study
Notes Baseline data for IFG cohort (N = 128)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Obese children and adolescents with IGT not attending an in-
tervention trial
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Unclear risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
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Kleber 2011 (Continued)
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: not reported (presumed 7.8-11.1)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk “ADA” (2000 criteria - 2-h PG ≥ 11.1)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Measurement of cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Npt reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Not reported
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple linear regression
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Ko 1999
Name of study None
Inclusion criteria Chinese participants with IGT
Exclusion criteria Not reported
Notes Letter to the editor
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Chinese participants with IGT
Study participation: description of gly-
caemic status at baseline
Low risk WHO/NDGG 1979
Study participation: adequate description
of sampling frame & recruitment
Unclear risk Scarce data
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported (IGT cohort)
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported (IGT cohort)
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported (IGT cohort)
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not applicable (IGT cohort)
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk IGT (WHO/NDDG 1979 definition)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
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Ko 1999 (Continued)
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk Yes
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk Assumed WHO/NDDG 1979 definition
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Cox regression analysis (to predict the progression to diabetes
with age, sex, BMI, blood pressure, HbA1c, FPG, 1-h PG and
2-h PG as predictor variables)
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Ko 2001
Name of study None
Inclusion criteria The Diabetes and Endocrine Centre of the prince of Wales Hospital in Hong Kong
screened individuals with risk factors for glucose intolerance (family history of diabetes,
history of gestational diabetes, overweight, hypertension) by OGTT
Exclusion criteria Diabetes at baseline
Notes Baseline data for IFG cohort (N = 55)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Individuals with risk factors for glucose intolerance undergoing
screening for diabetes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
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Ko 2001 (Continued)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 6.1-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Measurement of cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk No ratios reported
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk No ratios reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
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Ko 2001 (Continued)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Kaplan-Meier analysis, Cox regression analysis (to predict the
progression to diabetes with age, sex, BMI, blood pressure, FPG,
gestational diabetes, HbA1c, smoking habit and IFG status be-
ing independent variables - no hazard ratios provided)
Larsson 2000
Name of study None
Inclusion criteria Postmenopausal women aged 55-57 years in a health screening programme; random
sample of 265/1843 invited for follow-up (new OGTT); 1843 women were grouped
according to WHO and ADA glucose tolerance criteria
Exclusion criteria Not reported
Notes Baseline data for (i)-IGT (N = 66)/(i)-IFG (N = 42)/IFG/IGT (N = 30); 265 follow-up
participants were randomly sampled from each glucose tolerance group of the original
cohort and invited for follow-up; NGT at baseline vs follow-up: FPG < 5.3 vs < 6.1;
FPG 5.3: 15% conversion factor as recommended by theWHO (blood glucose > plasma
glucose)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Unclear risk Postmenopausal women participating in a health screening pro-
gramme; follow-up: a random sample of the original cohort
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk No exclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
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Larsson 2000 (Continued)
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk (i)-IFG: BG 5.3-5.9 and 2-h BG < 7.8; (i)-IGT: FPG < 5.3 and
2-h BG 7.8-11.0; IFG/IGT: BG 5.3-5.9 and 2-h BG 7.8-11.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Measurement of cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Not reported
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
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Larsson 2000 (Continued)
Study confounding: important potential
confounders accounted for in study design
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Chi-squared test
Latifi 2016
Name of study None
Inclusion criteria Residents aged over 20 years
Exclusion criteria Not reported
Notes Baseline for prediabetic cohort becoming diabetic at follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk First phase of prevalence study of the metabolic syndrome and
its related factors in Ahvaz Diabetes Research Centre, Iran
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk No exclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
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Latifi 2016 (Continued)
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk 5.6 ≤ FPG < 7.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; antihyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Several covariates measured (see Appendix 16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
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Latifi 2016 (Continued)
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates (see Appendix 16 and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates (see Appendix 16 and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Unclear risk Cumulative incidence, incidence rate
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Multiple logistic regression of factors affecting the incidence
of diabetes and prediabetes among healthy people in phase 1
(baseline)
Lecomte 2007
Name of study None
Inclusion criteria People with IFG recruited from medical check-ups by the French social security system
in the 9 preventive health centres of IRSA (Institut Interrégional pur la Santé)
Exclusion criteria No personal history of diabetes, no hypoglycaemic drug treatment
Notes Baseline data for IFG cohort attending both examinations (N = 743)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Yes
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Lecomte 2007 (Continued)
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 6.1-6.9; no personal history of diabetes; no hypogly-
caemic treatment
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; personal history of diabetes; antihyperglycaemic
treatment
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Measurement of cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
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Lecomte 2007 (Continued)
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Univariate analyses, some covariates measured (see Appendix 16
and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates, univariate analyses (see Appendix 16 and
Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression, univariate analyses on risk factors for devel-
oping diabetes
Lee 2016
Name of study None
Inclusion criteria Individuals undergoinghealth checkups at a singlemedical institution (GangneungAsian
Hospital)
Exclusion criteria Previously diagnosed with diabetes, history of diabetes medication use, only 1 measure-
ment
Notes Baseline data for the total cohort (N = 3497)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
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Lee 2016 (Continued)
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk HbA1c 5.7-6.4
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk HbA1c ≥ 6.5
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Measurement of cumulative incidence
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Lee 2016 (Continued)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes for coffee consumption
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk 1 covariate
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk No ratios reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Unclear risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Kaplan-Meier survival analysis for progression to diabetes ac-
cording to coffee consumption
Leiva 2014
Name of study Programa de Investigación de Factores de Riesgo de Enfermedad Cardiovascular
(PIFRECV)
Inclusion criteria Study participants were recruited in 2005 by the ’Programa de Investigación de Factores
de Riesgo de Enfermedad Cardiovascular’ (PIFRECV); participants had to have an FPG
5.6-6.9 mmol/L
Exclusion criteria Diabetes, individuals on corticosteroid treatment, pregnant women, individuals with
cardiovascular complications
Notes Most baseline data for cohort becoming diabetic at follow-up (N = 94 with IFG)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
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Leiva 2014 (Continued)
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: 5.6-7.0 (low range: 5.6-6.1; high
range: 6.1-6.9)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG≥ 7.0 (on 2 consecutive days);HbA1c
≥ 6.5
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
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Leiva 2014 (Continued)
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates were measured (see
Appendix 16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates planned (see Appendix 16
and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16
and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox regression analysis (comparing ’high
range’ glycaemia (> 6.1 mmol/L) with ’low
range’ glycaemia (< 6.1 mmol/L)
Levitzky 2008
Name of study Framingham Heart Study
Inclusion criteria Participants were drawn from the Framingham Offspring cohort; participants who at-
tended examinations (referred to as index examinations)
Exclusion criteria Participants with CHD or diabetes
Notes Baseline data for individuals on first exam, free of CVD (N = 4058)
Risk of bias
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Levitzky 2008 (Continued)
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG5.6: FPG 5.6-6.9; IFG6.1: FPG 6.1-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
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Levitzky 2008 (Continued)
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; antihyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix 16 and Appendix
17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16 and Appendix
17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16 and Appendix
17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Pooled logistic regression, multivariable models
Li 2003
Name of study Kinmen Study (study in Kin-Chen, Kinmen, Taiwan)
Inclusion criteria Individuals aged ≥ 30 years in Kin-Chen; FPG 5.6-7.0 and 2-h PG < 11.1
Exclusion criteria Diabetes
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Li 2003 (Continued)
Notes Baseline data for i-IGT (N = 118)/i-IFG (N = 42)/IFG/IGT (N = 49) cohorts
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes, series of community-based epidemio-
logical surveys of diabetes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk i-iFG: FPG 6.1-7.0 and 2-h PG < 7.8; i-
IGT: FPG<6.1 and2-h PG7.8-11.1; IFG/
IGT: FPG 6.1-7.0 and 2-h PG 7.8-11.1
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Li 2003 (Continued)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.0; antihypergly-
caemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix
16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16
and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16
and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, haz-
ard ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazard model (hazard ra-
tios ofT2DMfor relative insulin resistance,
beta-cell dysfunction and varying degrees
of glucose intolerance)
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Ligthart 2016
Name of study Rotterdam study, targeting cardiovascular, endocrine, hepatic, neurological, ophthalmic,
psychiatric, dermatological, oncological and respiratory diseases
Inclusion criteria Community dwelling population aged 45/55 years and older in Rotterdam, no diabetes
at baseline
Exclusion criteria No valid baseline fasting glucose measurement, no informed consent
Notes Baseline data for prediabetic cohort (N = 1382)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
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Ligthart 2016 (Continued)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk FBG > 6.0 and < 7.0; non-fasting BG > 7.
7 and < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FBG ≥ 7.0; non-fasting BG ≥ 11.1; anti-
hyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates for lifetime risk of diabetes
(see Appendix 16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk For lifetime risk of diabetes
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk For lifetime risk of diabetes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Incidence rate
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Ligthart 2016 (Continued)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Modified version of survival analysis to cal-
culate the lifetime risk of diabetes
Lipska 2013
Name of study Health, Aging, and Body Composition study (Health ABC)
Inclusion criteria Aged 70-79 years from Pittsburgh (PA) and Memphis (TN); no difficulty performing
activities of daily living, walking 0.25 mile (402 m) or climbing 10 steps without resting;
no reported need of assistive devices (e.g. cane, walker); no active treatment for cancer
in the prior 3 years; no life-threatening illness; and no plans to leave the area for 3 years
Exclusion criteria Not surviving baseline, diagnosed diabetes, missing HbA1c or FPG values at baseline,
without adequate follow-up after baseline
Notes Baseline data for i-IFG (N = 189)/i-HbA1c5.7 (N = 207)/IFG/HbA1c (N = 169) cohorts
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
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Lipska 2013 (Continued)
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk i-IFG: FPG 5.6-6.9 and HbA1c < 5.7; i-
HbA1c: 5.7-6.4 and FPG > 5.6; IFG and
HbA1c: FPG 5.6-6.9 and HbA1c 5.7-6.4
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk Single HbA1c ≥ 6.5 (years 2,6,7); self-re-
port of physician diagnosis (annually); an-
tihyperglycaemic medication (years 1,2,4,
6,7)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Multiple covariates measured (see
Appendix 16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
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Lipska 2013 (Continued)
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariable logistic regression
Liu 2008
Name of study None
Inclusion criteria Individuals from the JiangSu province of China, aged 35-74 years, to trace the incidence
of CVD and diabetes; individuals participating twice in the study
Exclusion criteria Individuals suffering from cancer, severe disability, severe psychiatric disturbances; indi-
viduals with diabetes, missing data
Notes Baseline data for non-diabetic participants (N = 1844); men (N = 788)/women (N =
1056)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
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Liu 2008 (Continued)
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG 5.6-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.0; antihyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix 16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
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Liu 2008 (Continued)
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16 and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16 and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, relative risk
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazards regression
Liu 2014
Name of study None
Inclusion criteria Shanghai residents
Exclusion criteria Not reported
Notes Baseline data for the prediabetic cohort converting to T2DM (N = 78)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
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Liu 2014 (Continued)
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Unclear risk “WHO criteria”
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Unclear risk Scarce data
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Unclear risk Scarce data; IFG or GT
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Unclear risk “WHO criteria”
Outcome measurement: method of out-
come measurement used valid & reliable
Unclear risk Scarce data
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
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Liu 2014 (Continued)
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Not reported
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Analysis of variance
Liu 2016
Name of study Beijing Longitudinal Study on Aging (BLSA)
Inclusion criteria Chinese elders free of diabetes at baseline
Exclusion criteria Diabetes at baseline
Notes Baseline data for participants without diabetes at baseline (N = 1857)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
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Liu 2016 (Continued)
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk FPG 6.1-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; self-reported; antihypergly-
caemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix
16 and Appendix 17)
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Liu 2016 (Continued)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16
and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16
and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Hazard ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Subdistribution hazards model
Liu 2017
Name of study ChinaMulticenter Collaborative Study of Cardiovascular Epidemiology (ChinaMUCA)
Inclusion criteria 2 studies: ChinaMulticenter Collaborative Study of Cardiovascular Epidemiology (Chi-
naMUCA) study and the China Cardiovascular Health Study
Exclusion criteria Individualswithmissing baseline glucose information, individuals fromDeyang, Sichuan
(earthquake) and individuals with ASCVD at baseline
Notes Baseline data for IFG cohort at baseline (N = 3607)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
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Liu 2017 (Continued)
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Participants lost to follow-up e.g. were
younger, had lower BMI levels and higher
physical activity levels
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk FBG 5.6-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FBG ≥ 7.0; using insulin/antihypergly-
caemic medications; self-reported
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
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Liu 2017 (Continued)
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix
16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16
and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16
and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazard regression
Lorenzo 2003
Name of study San Antonio Heart Study (SAHS)
Inclusion criteria Mexican-Americans and non-Hispanic whites participating in a study of type 2 diabetes
and cardiovascular disease
Exclusion criteria Phase 1 participants (waist circumference was not measured), and those in phase 2 with
diabetes at baseline
Notes Baseline data for cohort converting to T2DM (N = 195)
Risk of bias
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Lorenzo 2003 (Continued)
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 6.1-6.9; IGT: 2-h PG 7.8 to < 11.1
(WHO 1999)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
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Lorenzo 2003 (Continued)
Outcome measurement: clear definition of
the outcome provided
Low risk FPG:≥ 7.0; 2-h PHG:≥ 11.1 (WHO1999/1985)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix 16 and
Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16 and
Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16 and
Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression (diabetes risk of the
metabolic syndrome and components of the
metabolic syndrome)
Lyssenko 2005
Name of study Botnia Study
Inclusion criteria People with type 2 diabetes in western Finland were invited to participate together with
their familymembers; nondiabetic individuals were invited (familymembers or ’controls’
(spouses), aged 18-73 years; prospective visits every 2-3 years; at least 2 OGTTs
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Lyssenko 2005 (Continued)
Exclusion criteria MODY, individuals with missing data
Notes Baseline data for IFG-IGT individuals who converted to T2DM (N = 86)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Description of inclusion and exclusion criteria
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG ≥ 6.1 (WHO 1999 criteria)
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Lyssenko 2005 (Continued)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk WHO 1999 criteria
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Univariate analyses
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Univariate analyses
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Univariate analyses
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, hazard ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Univariate Cox proportional hazards model (adjusted for BMI)
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Magliano 2008
Name of study Australian Diabetes, Obesity and Lifestyle Study (AusDiab)
Inclusion criteria National population-based survey in adults aged ≥ 25 years
Exclusion criteria Participants refusing further contact, deceased, moved overseas or into a nursing facility
classified for high care, had a terminal illness
Notes Baseline data for cohort becoming diabetic at follow-up (N = 224/5842)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
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Magliano 2008 (Continued)
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 6.1-6.9 and 2-h PG < 7.8; IGT:
FPG < 7.0 and 2-h PG ≤ 7.8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1; current anti-
hyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Multiple covariates included (see Appendix
16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk ORs per SD changes in FPG and HbA1c
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate per
year, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariate logistic regression (logFRPG
and logHbA1c)
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Man 2017
Name of study Singapore Malay Eye Study (SIMES)
Inclusion criteria Malay adults in Singapore aged 40-80 years; SIMES aims to assess the prevalence, inci-
dence, progression, associated factors and impact of major eye disease as well as access
to eye care by Asian Malays
Exclusion criteria Diabetes, missing data
Notes Baseline data for incident diabetes cohort (N = 127)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
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Man 2017 (Continued)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk HbA1c 5.7-6.4; no self-reported diabetes or an-
tihyperglycaemic medication
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk Random glucose ≥ 11.1 or HbA1c > 6.4; self-
reported history or antihyperglycaemic medica-
tion
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariatesmeasured (see Appendix 16 and
Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16 and
Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, risk ratio
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Man 2017 (Continued)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariate analyses using modified Poission
regressionmodels to estimate adjusted risk ratios
Marshall 1994
Name of study San Luis Valley Diabetes Study
Inclusion criteria The SanLuis ValleyDiabetes Study determined the prevalence and incidence ofNIDDM
amongHispanic and non-Hispanic white adults; sample without prior diabetes diagnosis
aged 30-74 years; IGT at the initial visit
Exclusion criteria Unavailability of complete data
Notes Baseline data for IGT cohort converting to T2DM (N = 20)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
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Marshall 1994 (Continued)
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 2-h PG ≥ 7.8 to < 11.1 (WHO 1985)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk 2-h PG ≥ 11.1 (WHO 1985)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
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Marshall 1994 (Continued)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression (baseline dietary risk fac-
tors to predict the development of diabetes; glucose
levels as continuous variables)
McNeely 2003
Name of study Japanese American Community Diabetes Study
Inclusion criteria Second-generation (Nisei) and third-generation (Sansei) Japanese-American participants
residing in Kong County, Washington
Exclusion criteria Individuals with diabetes at baseline
Notes Baseline data for cohort converting to T2DM at 5-6 years (N = 50)/10 years (N = 74)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Unclear risk Scarce data
Study participation: adequate description
of period & recruitment place
Unclear risk Scarce data
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
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McNeely 2003 (Continued)
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Some difference reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG ≥ 6.1 to < 7.0; IGT: 2-h PG ≥
7.8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1; antihypergly-
caemic medication prescribed by a physi-
cian
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence
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McNeely 2003 (Continued)
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression (ROC-curves, clinical
model)
Meigs 2003
Name of study Baltimore Longitudinal Study of Aging (BLSA)
Inclusion criteria Community dwelling volunteers, largely from the Baltimore (MD) and Washington,
D.C. areas; primarily white middle- and upper-middle socioeconomic class aged 21-96
years, being examined approximately every 2 years; open cohort design with dropouts
replaced (around 1000 persons at each study cycle); attending at least 3 examinations
and an OGTT within an 8-year period
Exclusion criteria 2 or fewer OGTTs or > 4 years elapsed between any 2 OGTTs
Notes Baseline data for the IFG-IGT cohort (N = 265); follow-up time: at least 6 years 77%,
at least 10 years 44%, at least 16 years 16%, at least 20 years 4.5%
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
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Meigs 2003 (Continued)
Study attrition: description of attempts to
collect information on participants who
dropped out
High risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 6.1-6.9 and 2-h PG≤ 7.8; IGT:
FPG < 6.1 and 2-h PG 7.8-11.0; IFG/IGT
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1 (IFG-IGT: di-
abetes defined by OGTT)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence, incidence rates
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence, incidence rates
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence, incidence rates
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Meigs 2003 (Continued)
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence, incidence rates
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence, incidence rates
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence, incidence rates
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence, incidence rates
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Kaplan-Meier product limit estimates
Mohan 2008
Name of study Chennai Urban Population Study-19 (CUPS-19)
Inclusion criteria Participants of 2 residential colonies in Chennai, India, representing the middle and
lower income groups ≥ 20 years of age
Exclusion criteria Individuals with diabetes
Notes Baseline data for cohort becoming diabetic at follow-up (N = 64/476)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
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Mohan 2008 (Continued)
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG ≥ 6.1 to < 7; IGT: 2-h PG ≥ 7.
8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7; 2-h PG ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence, incidence rate
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence, incidence rate
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Mohan 2008 (Continued)
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence, incidence rate
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence, incidence rate
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence, incidence rate
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence, incidence rate
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence, incidence rate
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox regression analysis (effects of various
risk factors but not intermediate hypergly-
caemia on diabetes)
Motala 2003
Name of study None
Inclusion criteria South African Indians, mainly living in Durban (1984); survey to determine the preva-
lence of NIDDM among South African Indians; non-pregnant participants > 15 years
of age
Exclusion criteria Not reported
Notes Baseline data for responders (both baseline and follow-up examination) (N = 563)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
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Motala 2003 (Continued)
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: FPG < 7.8 and 2-h PG 7.8 to < 11.1 (WHO 1985)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.8; 2-h PG ≥ 11.1 (WHO 1985)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
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Motala 2003 (Continued)
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression (to evaluate the effect of various pre-
dictor variables for type 2 diabetes)
Motta 2010
Name of study Italian Longitudinal Study on Aging (ILSA)
Inclusion criteria Elderly participants aged 65-84 years involved in ILSA studies
Exclusion criteria Not reported
Notes No baseline characteristics provided
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
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Motta 2010 (Continued)
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: 6.1 to < 7.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
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Motta 2010 (Continued)
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk t-test
Mykkänen 1993
Name of study None
Inclusion criteria Participants from Kuopio, Finland
Exclusion criteria Diabetes at baseline, incomplete OGTT at the follow-up examination
Notes Baseline data for cohort developing T2DM (N = 69)
Risk of bias
Bias Authors’ judgement Support for judgement
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Mykkänen 1993 (Continued)
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: FPG < 7.8 and 2-h PG 7.8-11.1 (WHO 1985)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.8; 2-h PG ≥ 11.1 (WHO 1985)
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Mykkänen 1993 (Continued)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk ANCOVA, odds ratios (risk of developing diabetes associated
with various risk factors)
Nakagami 2016
Name of study Kurihashi Lifestyle Cohort Study
Inclusion criteria Baseline health check-ups at Kurihashi Hospital
Exclusion criteria People < 30 years or≥ 80 years, diabetes at baseline, people with chronic diseases, missing
covariate data
Notes Baseline data for cohort converting to T2DM (N = 99)
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Nakagami 2016 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Scarce data
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk FPG 5.5-6.9; HbA1c 5.7-6.4
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
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Nakagami 2016 (Continued)
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0, HbA1c ≥ 6.5; physician diagnosis of
diabetes
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix 16 and
Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates measured (see Appendix 16 and
Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates measured (see Appendix 16 and
Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, hazard ratio (associated with
a 1 SD increase in the levels of FPG or HbA1c)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazards models
Nakanishi 2004
Name of study None
Inclusion criteria Employees of Company A, one of the largest building contractors in Japan (in major
cities around Japan); Japanese men aged 35-59 years with no prior history of coronary
heart disease or stroke
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Nakanishi 2004 (Continued)
Exclusion criteria Not participating in all the consecutive annual health examinations
Notes Baseline characteristics for IFG cohort (N = 246)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 6.1-6.9
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Nakanishi 2004 (Continued)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; antihyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix 16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates measured (see Appendix 16 and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates measured (see Appendix 16 and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, relative risk (adjusted
for all other components and clustering of components of the
metabolic syndrome at study entry)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazards model
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Noda 2010
Name of study Japanese Public-Health Center-based prospective (Diabetes) Study (JPHC Study)
Inclusion criteria All registered Japanese inhabitants in 11 public health center areas aged 40-59 years old
in cohort I and 40-69 years old in cohort II; inhabitants who received annual health-
checkups; authors included those who were 51-70 years of age at the time of the baseline
survey of diabetes
Exclusion criteria Missing data, casual blood samples in any of the 2 health check-ups; known diabetes or
an FPG of 125 mg/dL or more at baseline
Notes Baseline characteristics for the total cohort (N = 2207)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Scarce data
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
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Noda 2010 (Continued)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk Taken from table 2: FPG levels: IFG 5.6
and 6.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; HbA1c ≥ 6.1%; self-reported
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
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Noda 2010 (Continued)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Crude incidence, ROC curves
Park 2006
Name of study None
Inclusion criteria Korean men employed at a semiconductor manufacturing facility in Korea participating
in an annual health examination at a university hospital
Exclusion criteria Diabetes, failing to undergo subsequent examinations within 2 years; missing data
Notes Baseline data for incident diabetic participants with IFG at baseline (N = 40)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Scarce data
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Park 2006 (Continued)
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG ≥ 5.6
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence, incidence rate
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence, incidence rate
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence, incidence rate
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Park 2006 (Continued)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazardsmodels (for sequential changes in FPG
levels)
Peterson 2017
Name of study Follow-up of a cohort originally from the population-based Västerbotten Intervention
Program (VIP), a strategy to reach all middle-aged persons individually at ages 40, 50
and 60 years, by inviting them to participate in systematic risk factor screening and
individual counselling about healthy lifestyle habits; neuropathy study part of the VIP
Inclusion criteria All individuals who became 40, 50 or 60 years and who belonged to the list for a specific
primary care centre or lived within the area for that centre
Exclusion criteria People not participating in the neuropathy study
Notes Baseline data for IGT cohort (N = 29)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
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Peterson 2017 (Continued)
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: FPG < 7.0 and 2-h PG≥ 7.8 to < 11.
1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk Yes
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence
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Peterson 2017 (Continued)
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk ANOVA, regression analyses
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Cumulative incidence
Qian 2012
Name of study None
Inclusion criteria Shanghai residents
Exclusion criteria Not reported
Notes Baseline data for cohort progressing to T2DM (N = 377)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
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Qian 2012 (Continued)
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk i-IFG: 6.1-6.9 and 2-h PG < 7.8; i-IGT: < 6.1 and 2-h PG 7.8-
11.0; IFG/IGT: 6.1-6.9 and 2-h PG 7.8-11.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
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Qian 2012 (Continued)
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression (to assess the potential contributing factors
to diabetes incidence)
Rajala 2000
Name of study None
Inclusion criteria Inhabitants in Oulu (northern Finland) recruited from the official population register
to investigate the prevalence of diabetes and IGT, reasons for early retirement and the
prevalence of depression
Exclusion criteria Previoulsy diagnosed diabetic people
Notes Only few baseline data for IGT cohort (N = 171); new cases identified by OGTTs in
1994 and 1996-8
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
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Rajala 2000 (Continued)
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Prevalence of hypertension was higher among people lost to
follow-up
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 2-h PG 7.8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk 2-h PG ≥ 11.1; 2 × FPG ≥ 6.7
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence, incidence rate
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
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Rajala 2000 (Continued)
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence, incidence rate
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence, incidence rate
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence, incidence rate
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression (for effects of hypertension and an-
tihypertensive medications)
Ramachandran 1986
Name of study None
Inclusion criteria Indian individuals with IGT
Exclusion criteria Not reported
Notes Baseline data for the diabetic cohort at follow-up (N = 39)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
High risk Not reported
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Unclear risk Scarce data
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Ramachandran 1986 (Continued)
Study participation: adequate description
of period & recruitment place
Unclear risk Scarce data
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 7.8-11.0 (presumed NDDG 1979)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk 2-h PG > 11.0 (presumed NDDG 1979)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
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Ramachandran 1986 (Continued)
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Not reported
Rasmussen 2008
Name of study Anglo-Danish-Dutch study of Intensive Treatment in People with Screen Detected Di-
abetes in Primary Care (ADDITION)
Inclusion criteria Population-based high-risk screening and intervention study for type 2 diabetes; persons
aged 40-69 years registered with the participating practices in 5 counties in Denmark
with a risk score of 5 points or more; measurement of fasting capillary blood glucose
and OGTT; annual glucose measurement recommended for individuals with IFG and
IGT; individuals with 2 diabetic glucose values on separate days were included in the
intervention programme
Exclusion criteria Severe concurrent illness, alcohol abuse or subsequently treated by general practitioners
not in the addition study; individuals with diabetes
Notes Baseline data for IFG (N = 607)/IGT cohort (N = 903)
Risk of bias
Bias Authors’ judgement Support for judgement
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Rasmussen 2008 (Continued)
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Unclear risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG (i-IFG): FBG 5.6 to < 6.1 and 2-h BG
< 7.8; IGT (i-IGT): FBG < 6.1 and 2-h BG
7.8 to < 11.1; IFG/IGT
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Unclear risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FBG ≥ 6.1 or 2-h BG ≥ 11.1
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Rasmussen 2008 (Continued)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence, incidence rate
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence, incidence rate
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence, incidence rate
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Regression models (for sequential changes
in some covariates)
Rathmann 2009
Name of study Kooperative Gesundheitsforschung in der Region Augsburg (KORA S4/F4)
Inclusion criteria People living in Augsburg and surroundings; KORAwas follow-up ofMONICAWHO-
Project (Monitoring Trends and determinants in Cardiovascular Disease); S1: 25-64
years, S2/S3/S4: 25-74 years
Exclusion criteria People with known diabetes
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Rathmann 2009 (Continued)
Notes Baseline characteristics for total cohort (participants of the follow-up; age-group 55-74
years; N = 887)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Some differences reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 6.1-6.9; IGT: 2-h PG 7.8 to <
11.1; ’prediabetes’: i-IFG, i-IGT and IFG/
IGT
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Rathmann 2009 (Continued)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1; validated
physician diagnosis
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix
16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16
and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analyses (see Appendix 16
and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, odds
ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression models
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Rijkelijkhuizen 2007
Name of study Hoorn Study
Inclusion criteria General Dutch population (Hoorn) aged 50-75 years at baseline; participants completing
both measurements in 1989 and 1996
Exclusion criteria People using antihyperglycaemic medications or diet for diabetes were marked as known
diabetes mellitus; missing information of plasma glucose values
Notes Baseline data for IFG6.1 (N = 149)/IFG5.6 (N = 488)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk No substantial differences
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
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Rijkelijkhuizen 2007 (Continued)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG5.6: FPG 5.6-7.0; IFG6.1: FPG 6.1-7.0; IGT: 2-h PG 7.8 to
< 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG: ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix 16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16 and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16 and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, odds ratio
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Rijkelijkhuizen 2007 (Continued)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazards models
Sadeghi 2015
Name of study Isfahan Cohort Study (ICS), baseline survey of the Isfahan Healthy Heart Program
(IHHP)
Inclusion criteria Participants of the baseline survey of the Isfahan Healthy Heart Program, a community
trial for prevention and control of CVD
Exclusion criteria Diabetes at baseline
Notes Baseline data for prediabetic cohort at baseline becoming diabetic at follow-up (N = 131)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
Low risk Yes
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Sadeghi 2015 (Continued)
study and those who did not
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG ≥ 5.5 and < 7.0; IGT: 2-h
OGTT ≥ 7.8 and < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG > 7.0; 2-h OGTT > 11.1; IFG/IGT;
antihyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix
16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Low risk Stochastic regression methods
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16
and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16
and Appendix 17)
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Sadeghi 2015 (Continued)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, odds
ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariate logistic regression
Sasaki 1982
Name of study None
Inclusion criteria Epidemiological survey on diabetes mellitus in Osaka, Japan and follow-up study
Exclusion criteria Not reported
Notes Baseline data for the IGT cohort (N = 13)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
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Sasaki 1982 (Continued)
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: FPG < 7.8 and 2-h PG 7.8-11.1 (WHO 1980)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.8 or 2-h PG ≥ 11.1 (WHO 1980)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Scarce data
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Scarce data
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Scarce data
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
262Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sasaki 1982 (Continued)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence, incidence rate
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Multiple logistic regression (standardised regression coefficients
for single covariates)
Sato 2009
Name of study Kansai Healthcare Study
Inclusion criteria Japanese male employees of a company in the area of Kansai, aged 40-55 years, not taking
an oral antihyperglycaemic or insulin at study entry and considered to be involved in
sedentary jobs
Exclusion criteria Not reported
Notes Baseline data for cohort becoming diabetic at follow-up (N = 659/6804); non-standard
categories for elevated HbA1c values were used (Table 1, p 645 of the publication)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
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Sato 2009 (Continued)
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk Table 1: IFG: FPG group 6.1-6.9; HbA1c-group: 6.0-6.4
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; antihyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Yes
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
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Sato 2009 (Continued)
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression (FPG, HbA1c categories)
Schranz 1989
Name of study Study within the WHO-assisted National Diabetes Programme
Inclusion criteria Within the framework of the WHO-assisted National Diabetes Programme a cohort of
Maltese people was investigated
Exclusion criteria Known diabetic persons
Notes Baseline data for diabetic cohort at follow-up (N = 166)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Unclear risk Scarce data
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Yes
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Schranz 1989 (Continued)
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 2-h PG≥ 7.8 to < 11.1 (WHO1985)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk 2-h PG ≥ 11.1 (WHO 1985)
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence
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Schranz 1989 (Continued)
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Not reported
Sharifi 2013
Name of study Zanjan Healthy Heart Study
Inclusion criteria Participants from the Zanjan Healthy Heart Study, aged 21-75 years, individuals with
IFG
Exclusion criteria Not reported
Notes Baseline data for active participants (N = 123) of the IFG cohort
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
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Sharifi 2013 (Continued)
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Unclear risk High attrition rate (> 50%)
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk FPG 5.6-7.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG > 7.0 (2 measurements); diabetes diagnosis based
on documents
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
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Sharifi 2013 (Continued)
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Logistic regression (BMI and physical activity for pre-
diction of diabetes)
Shin 1997
Name of study Yonchon study
Inclusion criteria Individuals living in Yonchon County (South Korea), free of diabetes aged ≥ 30 years
Exclusion criteria Diabetes
Notes Baseline data for individuals converting to T2DM (N = 67)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
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Shin 1997 (Continued)
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Unclear risk Scarce data
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Unclear risk Scarce data
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Unclear risk Assumed WHO 1985 criteria
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Unclear risk Scarce data
Outcome measurement: clear definition of
the outcome provided
Low risk “WHO criteria”; antihyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Unclear risk Scarce data
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Unclear risk Scarce data
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
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Shin 1997 (Continued)
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression (1 mmol/L difference for FPG and
2-h plasma glucose)
Song 2015
Name of study Korean Genome Epidemiology Study-Kangwha Study (KoGES)
Inclusion criteria People aged ≥ 40 years
Exclusion criteria Missing key variables, history of stroke, angina pectoris ormyocardial infarction, diabetes
Notes Baseline data for prediabetic cohort (men: N = 154; women: N = 167; total: N = 321);
ranges for men - women
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
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Song 2015 (Continued)
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Responders had relatively low FPG and
HbA1c at baseline compared to non-re-
sponders
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 5.6-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; HbA1c ≥ 6.5; antihypergly-
caemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
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Song 2015 (Continued)
Study confounding: important
confounders measured
Low risk Yes
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Unclear risk Cumulative incidence, relative risk
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Generalised linear models
Song 2016a
Name of study None
Inclusion criteria Survey of the prevalence of T2DM in an urban community; eligible permanent inhabi-
tants 15-74 years
Exclusion criteria Not reported
Notes Baseline data for prediabetic cohort (N = 334)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
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Song 2016a (Continued)
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FG 5.6-6.9; IGT: 2-h G 7.8-11.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk IFG ≥ 7.0; 2-h G ≥ 11.0; HbA1c ≥ 6.5; self-reported
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
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Song 2016a (Continued)
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression models (sex-related risk factors associated
with the development of diabetes)
Soriguer 2008
Name of study Pizarra study, evaluating the prevalence of latent autoimmune diabetes of adults (LADA)
in the context of the overall prevalence of diabetes in Southern Spain
Inclusion criteria People aged 18-65 years from Pizarra, Malaga
Exclusion criteria Institutionalised persons, pregnant women, severe clinical or psychological disorder
Notes Baseline data for final sample of follow-up (N = 714); diabetes diagnosis according to
capillary blood glucose levels > 6.1 mmol/L or post OGTT BG > 11.1 mmol/L
Risk of bias
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Soriguer 2008 (Continued)
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Scarce data
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Unclear risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: BG 5.6-6.1 and 2-h BG < 7.8; IGT:
BG < 5.6 and 2-h BG 7.8-11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
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Soriguer 2008 (Continued)
Outcome measurement: clear definition of
the outcome provided
Low risk BG > 6.1 or 2-h BG > 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix
16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16
and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16
and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, rel-
ative risk
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariate logistic regression
Stengard 1992
Name of study Finnish Cohorts of the Seven Countries Study
Inclusion criteria Elderly Finnish men, survivors of the Finnish cohorts of the Seven-Countries Study
(studying mortality, morbidity and risk factor levels of cardiovascular diseases in different
countries), aged 65-84 years at baseline
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Stengard 1992 (Continued)
Exclusion criteria Not reported
Notes Baseline data for IGT cohort converting to T2DM (N = 17)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 2-h PG 7.8-11.1
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Stengard 1992 (Continued)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk 2-h PG ≥ 11.1 (WHO 1985); antihyper-
glycaemic medications
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix
16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16
and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16
and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression
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Söderberg 2004
Name of study None
Inclusion criteria Population based survey in Mauritius, 3 cohorts of nonpregnant participants aged 25-
79 years with classifiable data from 2 separate surveys
Exclusion criteria Not reported
Notes Baseline data for cohort 1987-1998 (N = 2631), 10 years follow-up; 3 cohorts 1987-
1992 (N = 3680), 1992-1998 (N = 4178), 1987-1998 (N = 2631)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
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Söderberg 2004 (Continued)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG ≥ 6.1 to < 7.0 and 2-h PG < 7.8; IGT: FPF < 7.0
and 2-h PG ≥ 7.8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence, incidence rate
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence, incidence rate
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence, incidence rate
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence, incidence rate
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence, incidence rate
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence, incidence rate
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence, incidence rate
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate
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Söderberg 2004 (Continued)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Calculation of incidence rate ratios, Poisson regression analysis
to estimate sex effects between 1987 and 1998 allowing for ad-
justments
Toshihiro 2008
Name of study None
Inclusion criteria Japanese mal workers of a railroad company receiving a health-check at Nishimatsuzono
Clinic, IFG and/or IGT cohort
Exclusion criteria People with type B or C hepatitis virus infections
Notes Baseline data for cohort becoming diabetic at follow-up (N = 36/128);participants with
IFG and/or IGT were given advice about lifestyle modifications once or twice a year
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
Unclear risk Not reported
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Toshihiro 2008 (Continued)
study and those who did not
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 6.1-6.9 and 2-h PG < 7.8; IGT: FPG < 7.0 and 2-h
PG 7.8-11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG > 11.1; non-fasting PG > 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
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Toshihiro 2008 (Continued)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazards model (multivariate analysis of inde-
pendent risk factors and recovery factors)
Vaccaro 1999
Name of study None
Inclusion criteria Telephone company employees in the age range 40-59 years were screened in the province
of Naples for major cardiovascular risk factors
Exclusion criteria Taking antihyperglycaemic medication, previous diabetes diagnosis
Notes Baseline data for total cohort (follow-up examination; N = 560)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
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Vaccaro 1999 (Continued)
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Those lost to follow-up were older and more frequently women
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Unclear risk Unusual thresholds
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Unclear risk IFG: FPG 5.6-6.0; IGT: 2-h PG 6.7-9.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; antihyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Not reported
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Not reported
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Not reported
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Vaccaro 1999 (Continued)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio (probably unadjusted)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Unclear risk Quote: “standard methods”
Valdes 2008
Name of study Asturias Study (Asturias)
Inclusion criteria Survey of diabetes and cardiovascular risk factors in the principality of Asturias, northern
Spain; participants from basic health area
Exclusion criteria Type 1 diabetes, pregnancy, severe disease, hospitalisation, use of diabetogenic drugs,
missing data; diabetes
Notes Baseline data for IFG 5.6-6.1 (N = 114)/IFG 6.1-6.9 (N = 52)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
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Valdes 2008 (Continued)
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG5.6: 5.6-6.1; IFG6.1: 6.1-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1; clinical diabetes diagnosis; an-
tihyperglycaemic medication, diet
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix 16 and Appendix
17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
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Valdes 2008 (Continued)
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16 and Appendix
17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16 and Appendix
17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multivariate logistic regression
Vijayakumar 2017
Name of study None
Inclusion criteria Participants were 10-19 years of age at first examination without diabetes, and at least 1
follow-up examination before the 40th birthday
Exclusion criteria History of possibly taking metformin at baseline
Notes Baseline data for adults (A)/children (C ) with HbA1c 5.7-6.4 (children: N = 62, adults:
N = 168)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
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Vijayakumar 2017 (Continued)
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk FPG 5.6-6.9; 2-h PG 7.8-11.9; HbA1c 5.7-6.4
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1; previous clinical diagnosis
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence, incidence rate
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence, incidence rate
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence, incidence rate
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Vijayakumar 2017 (Continued)
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence, incidence rate
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence, incidence rate
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence, incidence rate
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence, incidence rate
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, incidence rate
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk ROC curves, increments in HbA1c and FPG or 2-h PG to cal-
culate 10-year cumulative incidence
Viswanathan 2007
Name of study None
Inclusion criteria Programme on primary prevention of diabetes in the population and in high risk people
(positive family history of diabetes); individuals with at least 2 follow-up visits; partici-
pants were given advice on preventive measures such as dietary modifications and regular
exercise
Exclusion criteria Known history of diabetes, newly diagnosed diabetes during screening
Notes Baseline data for IGT group (N = 619); participants were given advice on preventive
measures such as dietary modifications and regular exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Unclear risk Scarce data
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Viswanathan 2007 (Continued)
Study participation: adequate description
of period & recruitment place
Unclear risk Scarce data
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 2-h PG 7.8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Unclear risk Not defined, presumably by OGTT
Outcome measurement: method of out-
come measurement used valid & reliable
Unclear risk Scarce data
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Unclear risk Scarce data
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix 16 and Appendix 17)
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Viswanathan 2007 (Continued)
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Not reported
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Not reported
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16 and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16 and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression, Cox regression analysis
Wang 2007
Name of study Beijing Project as part of the National Diabetes Survey
Inclusion criteria Inhabitants of Beijing aged 25 years or older
Exclusion criteria Newly diagnosed diabetes or CHD at baseline, known diabetes
Notes Baseline data for cohort with incident diabetes and no CHD (N = 67)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
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Wang 2007 (Continued)
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Low risk Yes
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk Yes
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 6.1-6.9; IGT: 2-h PG 7.8-11.0
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
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Wang 2007 (Continued)
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix
16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16
and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16
and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, risk ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Multiple logistic regression
Wang 2011
Name of study Strong Heart Study (SHS)
Inclusion criteria Data collected from American Indians at the baseline and second exams from those
participants who had HbA1c and FPG measured
Exclusion criteria Antihyperglycaemic medications, renal dialysis, kidney transplant
Notes No baseline data reported
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
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Wang 2011 (Continued)
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Those lost to follow-up had lower BMI
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: 5.6 to < 7.0; HbA1c 6.0 to < 6.5
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG≥ 7.0; HbA1c ≥ 6.5; FPG/HbA1c: ≥ 6.5 or FPG≥
7.0; antihyperglycaemic medication
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
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Wang 2011 (Continued)
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix 16 and Appendix
17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16 and Appendix
17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16 and Appendix
17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression
Warren 2017
Name of study Atherosclerosis Risk in Communities study (ARIC)
Inclusion criteria Adults aged 45-64 years from the communities of Jackson, MS; Forsyth County, NC;
suburban Minneapolis, MN; and Washington County, MD, USA
Exclusion criteria Participants with prevalent diabetes, chronic kidney disease, atherosclerotic cardiovascu-
lar disease, or peripheral arterial disease, those who were missing variables of interest, or
those who fasted for < 10 h
Notes 2 different baseline cohorts; 4 prediabetes definitions (visit 2: IFG 5.6-6.9: N = 4112;
HbA1c 5.7-6.4: N = 2027; visit 4: IFG 5.6-6.9: N = 2142; IGT: N = 2009)
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Warren 2017 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk FPG 5.6-6.9 (ADA); FG 6.1-6.9 (WHO)
; 2-h 7.8-11.0 (ADA); HbA1c 5.7-6.4
(ADA); 6.0-6.4 (IEC)
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
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Warren 2017 (Continued)
Outcome measurement: clear definition of
the outcome provided
Unclear risk Self-report of physician diagnosis; antihy-
perglycaemicmedication reported during a
study visit or annual telephone call
Outcome measurement: method of out-
come measurement used valid & reliable
Unclear risk Missing lab measurements
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix
16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16
and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Low risk Some covariates analysed (see Appendix 16
and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Hazard ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazards models
298Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wat 2001
Name of study Hong Kong Cardiovascular Risk Factor Prevalence Study
Inclusion criteria Follow-up of the Hong Kong Cardiovascular Risk Factor Prevalence Study in Hong
Kong Chinese aged 25-74 years; persons with IGT (matched controls from the same
population with normal glucose tolerance), investigation of the development of appro-
priate population-wide coronary heart disease prevention strategies andmonitoring their
long-term impact
Exclusion criteria Diabetes at baseline
Notes Baseline data for IGT cohort (N = 322)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Scarce data
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
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Wat 2001 (Continued)
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: FPG < 7.8 and 2-h PG 7.8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.8; 2-h PG ≥ 11.1
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
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Wat 2001 (Continued)
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression (per unit increase for
some covariates)
Weiss 2005
Name of study None
Inclusion criteria Obese children and adolescents aged 4-18 years were recruited from the Yale Pediatric
Obesity Clinic (New Haven, Conneticut, USA)
Exclusion criteria Participants with medical conditions, using medications that may affect glucose
metabolism before their first OGTT
Notes Baseline data for IGT cohort (N = 33)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Unclear risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Unclear risk Scarce data
Study participation: adequate description
of period & recruitment place
Unclear risk Scarce data
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria reported
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk No dropouts
Study attrition: reasons for loss to follow-
up provided
Low risk No dropouts
Study attrition: adequate description of
participants lost to follow-up
Low risk No dropouts
Study attrition: no important differences
between participants who completed the
study and those who did not
Low risk No dropouts
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Weiss 2005 (Continued)
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: FPG < 5.6 and 2-h PG 7.8-11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG > 11.1; presentation of hyperglycaemia
(more than 2 random glucose measurements > 11.1), glucosuria,
polydipsia, and polyuria
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
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Weiss 2005 (Continued)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Mann-Whitney U test and linear regression (to identify predic-
tors of 2-h glucose on the second OGTT)
Wheelock 2016
Name of study Pima Indian Study (Gila River Indian Community - near Phoenix, Arizona)
Inclusion criteria Gila River Indian Community in Arizona (mostly Pima or Tohono Indians); children
and adolescents 5-19 years who were nondiabetic at baseline and had at least 1 follow-
up examination
Exclusion criteria Not reported
Notes Baseline data for the full cohort (N = 5532); prediabetic cohort = non-overweight (N
= 37) + IGT group and overweight + IGT group (N = 132); 5-11 years/12-19 years);
age-stratified incidence data on overweight participants + IGT or overweight and either
hypertension or hypercholesterolaemia + IGT (metabolic set (MSet))
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Unclear risk Only inclusion criteria described
Study attrition: description of attempts to
collect information on participants who
Unclear risk Scarce data
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Wheelock 2016 (Continued)
dropped out
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 2-h PG ≥ 7.8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG≥ 7.0; 2-h PG≥ 11.1; previous diag-
nosis
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
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Wheelock 2016 (Continued)
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Cumulative incidence
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox regression model using eachmetabolic
risk factor as a continuous variable; viola-
tion of the proportionality assumption was
noted, therefore cumulative incidence rates
were calculated from a Poisson regression
model
Wong 2003
Name of study Singapore Impaired Glucose Tolerance Follow-up Study
Inclusion criteria Representative sample of the Singapore population aged 18-69 years; persons with IGT
and matched controls
Exclusion criteria Antihyperglycaemic medication, venepuncture failure; persons with IFG
Notes Baseline data for IGT group (N = 291)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
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Wong 2003 (Continued)
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Unclear risk Scarce data
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Scarce data
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 2-h PG ≥ 7.8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; 2-h PG ≥ 11.1; physician di-
agnosed diabetes
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Cumulative incidence
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Wong 2003 (Continued)
Study confounding: clear definitions of im-
portant confounders provided
Unclear risk Cumulative incidence
Study confounding: measurement of con-
founders valid & reliable
Unclear risk Cumulative incidence
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Unclear risk Cumulative incidence
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in study design
Unclear risk Cumulative incidence
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Not reported
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk ANCOVA using general linear models
(comparisons between continuous vari-
ables)
Yeboah 2011
Name of study Multi-Ethnic Study of Atherosclerosis (MESA)
Inclusion criteria Persons without known CVD at baseline from 6 US communities aged 45-84 years
Exclusion criteria Personswith a history of physician-diagnosedmyocardial infarction, angina, heart failure,
stroke, or transient ischaemic attack, or who had undergone an invasive procedure for
CVD (coronary artery bypass graft surgery, angioplasty, valve replacement, pacemaker
placement, or other vascular surgeries)
Notes Baseline data for IFG cohort (N = 940)
Risk of bias
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
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Yeboah 2011 (Continued)
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Low risk Yes
Study attrition: reasons for loss to follow-
up provided
Low risk Yes
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Scarce data
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Scarce data
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IFG: FPG 5.6-6.9
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Low risk Yes
Outcome measurement: clear definition of
the outcome provided
Low risk FPG > 6.9; antihyperglycaemicmedication
during examinations 2,3,4
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
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Yeboah 2011 (Continued)
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Low risk Yes
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Low risk Yes
Study confounding: important potential
confounders accounted for in the analysis
Low risk Yes
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Cumulative incidence, hazard ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Cox proportional hazards model
Zethelius 2004
Name of study None
Inclusion criteria All men residing in Uppsala were invited to a health survey in 1970; reinvestigation 20
years later (= baseline) at 70 years of age
Exclusion criteria Diabetes, antihyperglycaemic medications
Notes Baseline data for cohort converting to T2DM (N = 26)
Risk of bias
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Zethelius 2004 (Continued)
Bias Authors’ judgement Support for judgement
Study participation: description of source
population or population of interest
Low risk Yes
Study participation: description of gly-
caemic status at baseline
Low risk Yes
Study participation: adequate description
of sampling frame & recruitment
Low risk Yes
Study participation: adequate description
of period & recruitment place
Low risk Yes
Study participation: adequate description
of inclusion & exclusion criteria
Low risk Inclusion and exclusion criteria described
Study attrition: description of attempts to
collect information on participants who
dropped out
Unclear risk Not reported
Study attrition: reasons for loss to follow-
up provided
Unclear risk Not reported
Study attrition: adequate description of
participants lost to follow-up
Unclear risk Not reported
Study attrition: no important differences
between participants who completed the
study and those who did not
Unclear risk Not reported
Glycaemic status measurement: provision
of clear definition or description of gly-
caemic status
Low risk Yes
Glycaemic status measurement: valid and
reliable method of glycaemic status mea-
surement
Low risk Yes
Glycaemic status measurement: continu-
ous variables reported or appropriate cut
points used
Low risk IGT: 2-h PG 7.8 to < 11.1
Glycaemic status measurement: same
method and setting of measurement of the
glycaemic status for all study participants
Unclear risk Yes
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Zethelius 2004 (Continued)
Outcome measurement: clear definition of
the outcome provided
Low risk FPG ≥ 7.0; antihyperglycaemic medications
Outcome measurement: method of out-
come measurement used valid & reliable
Low risk Yes
Outcome measurement: same method &
setting of outcome measurement for all
study participants
Low risk Yes
Study confounding: important
confounders measured
Unclear risk Some covariates measured (see Appendix 16 and Appendix 17)
Study confounding: clear definitions of im-
portant confounders provided
Low risk Yes
Study confounding: measurement of con-
founders valid & reliable
Low risk Yes
Study confounding: same method & set-
ting for measurements of confounders for
all study participants
Low risk Yes
Study confounding: appropriate methods
used if missing confounder data imputed
Unclear risk Not reported
Study confounding: important potential
confounders accounted for in study design
Unclear risk Some covariates included (see Appendix 16 and Appendix 17)
Study confounding: important potential
confounders accounted for in the analysis
Unclear risk Some covariates analysed (see Appendix 16 and Appendix 17)
Statistical analysis & reporting: sufficient
presentation of data to assess adequacy of
the analytic strategy
Low risk Odds ratio
Statistical analysis & reporting: the statisti-
cal model is adequate for the design of the
study
Low risk Logistic regression, multivariate models (adjusted for BMI, age
at baseline and length of follow-up)
Note: for better readability all IFG/IGT andHbA1c measurements are reported in numerical format only (IFG and IGT weremeasured
in mmol/L, HbA1c was measured in %)
ADA: American Diabetes Association; ANOVA: analysis of variance; BG: blood glucose; BMI: body mass index; CHD: coronary heart
disease; CI: confidence interval; CVD: cardiovascular disease; FG: fasting glucose; FBG: fasting blood glucose; FINDRISC: Finnish
Diabetes Risk Score; FPG: fasting plasma glucose; G6PD: glucose-6-P-dehydrogenase test; HbA1c: glycosylated haemoglobin A1c;
HbA1c5.7: intermediate hyperglycaemia with HbA1c 5.7% as lower threshold (usually reflecting 5.7%-6.4%);HbA1c6.0: intermediate
hyperglycaemia with HbA1c 6.0% as lower threshold (usually reflecting 6.0%-6.4%); HOMA-B: homeostatic model assessment
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beta-cell function; HOMA-IR: homeostatic model assessment for insulin resistance; HR: hazard ratio; IEC: International Expert
Committee; IFG: impaired fasting glucose; IFG5.6: impaired fasting glucose with 5.6 mmol/L as lower threshold; IFG6.1: impaired
fasting glucose with 6.1 mmol/L as lower threshold; IFG/IGT: both IFG and IGT; i-IFG: isolated IFG; IGT: impaired glucose
tolerance; i-IGT: isolated IGT; JDS: Japanese Diabetes Society;MSet: metabolic set;NDDG: National Diabetes Data Group; NGSP:
National Glycohemoglobin Standardization Program; NGT: normal glucose tolerance; OGTT: oral glucose tolerance test; OR: odds
ratio; PG: postload glucose; ROC: receiver operating characteristics; RR: risk ratio, relative risk; T2DM: type 2 diabetes mellitus;
WHO: World Health Organization.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdul-Ghani 2011 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Alvarsson 2009 Intervention study
Alyass 2015 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Amoah 2002 Not a prospective cohort study
Andreou 2017 No data on transition from intermediate hyperglycaemia to type 2 diabetes
(prevalence data)
Bancks 2015 Only self-reported diabetes, frequency matched population
Birmingham Diabetes Survey Working Party 1976 Non-standard thresholds for intermediate hyperglycaemia
Bjornholt 2000 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Bodicoat 2017 Long-term follow-up of an interventional study
Boned 2016 Hypertensive cohort
Boucher 2015 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Brantsma 2005 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Brateanu 2017 Retrospective cohort study
Braun 1996 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Burchfiel 1995 No cohort with intermediate hyperglycaemia
Chamukuttan 2016 Intervention trial
Chang 2017 Investigation of the association between thyroid function and the development
of intermediate hyperglycaemia/diabetes
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(Continued)
Chen 1995 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Cheng 2011 Not a prospective cohort study
Cheung 2007 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Choi 2002 Not a prospective cohort study
Cicero 2005 No valid data on transition from intermediate hyperglycaemia to type 2 diabetes
Cosson 2011 Not a prospective cohort study
Costa 2005 Study design paper
Cree-Green 2013 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Cropano 2017 Investigation of the association between gene variants and development of in-
termediate hyperglycaemia/diabetes
Dagogo-Jack 2011 Evaluation of the transition from normoglycaemia to intermediate hypergly-
caemia
Daniel 1999 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Decode 2003 Aggregate data of 22 cohorts; no data on transition from intermediate hyper-
glycaemia to type 2 diabetes
Deedwania 2013 No data on diabetes incidence
DeFina 2012 Not a prospective cohort study
DeJesus 2016 Not a prospective cohort study
Deschenes 2016 Cohort with depressive symptoms
Dinneen 1998 Not a prospective cohort study
Doi 2007 No cohort with intermediate hyperglycaemia
Du 2016 Cross-sectional study, no cohort with intermediate hyperglycaemia
Edelman 2004 Non-standard thresholds for intermediate hyperglycaemia
Edelstein 1997 Aggregated data on 6 prospective studies, no reliable additional data on transi-
tion from intermediate hyperglycaemia to type 2 diabetes
Engberg 2010 Intervention trial
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(Continued)
Eskesen 2013 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Feizi 2017 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Feskens 1989 No cohort with intermediate hyperglycaemia
Festa 2003 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Folsom 2000 No cohort with intermediate hyperglycaemia
Gil-Montalban 2015 Diagnosis of type 2 diabetes incidence by database only
Giraldez-Garcia 2015 No data on type 2 diabetes incidence
Glauber 2018 Incidence established by register data
Gonzalez-Villalpando 2014 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Gopinath 2013 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Gu 2015 No data on transition from intermediate hyperglycaemia to type 2 diabetes
(database)
Gupta 2011 Intervention trial, hypertensive cohort
Hackett 2014 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Haffner 1997 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Haffner 2000 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Hajat 2012 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Hanai 2005 No data on transition from intermediate hyperglycaemia to type 2 diabetes,
OGTTs were unit of analysis
He 2018 Investigation of the association of glycaemic index diets and glycaemic load
diets with development of type 2 diabetes
Helmrich 1991 No cohort with intermediate hyperglycaemia
Henninger 2015 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Holbrook 1990 No cohort with intermediate hyperglycaemia
Hong 2016 Not a prospective cohort study
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Huang 2014c Not a prospective cohort study (database)
Hulman 2017 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Inoue 2008 Retrospective cohort study
Invitti 2006 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Jallut 1990 Not a prospective cohort study
James 1998 No cohort with intermediate hyperglycaemia
Jansson 2015 No cohort with intermediate hyperglycaemia
Jarrett 1979 Intervention trial
Jarrett 1982 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Jeanne 2018 No cohort with intermediate hyperglycaemia, investigation of the association
between birth weight and physical activity and cardiometabolic health
Jiamjarasrangsi 2008b No data on transition from intermediate hyperglycaemia to type 2 diabetes
Joshipura 2017 Diabetes incidence data for ’prediabetes’ group only
Kadowaki 1984 Non-standard thresholds for intermediate hyperglycaemia
Kametani 2002 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Kanauchi 2003 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Kanaya 2005 Investigation of a prediction model for development of diabetes
Kawahara 2015 Not a prospective cohort study
Khan 2017 Diabetes incidence defined by register data
Khang 2010 Not a prospective cohort study
Kieboom 2017 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Kim 2012a Not a prospective cohort study
Kim 2012b Not a prospective cohort study
Kim 2013 No data on transition from intermediate hyperglycaemia to type 2 diabetes
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Kim 2016b No data on transition from intermediate hyperglycaemia to type 2 diabetes
Kim 2017a Investigation of the association between sleep duration and development of
type 2 diabetes
Kim 2017b No data on transition from intermediate hyperglycaemia to type 2 diabetes
Ko 2000 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Kosaka 1996 Non-standard thresholds, no numerical data on transition from intermediate
hyperglycaemia to type 2 diabetes
Kowall 2013 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Krabbe 2017 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Le Boudec 2016 Withdrawn publication
Lee 2014 No cohort with intermediate hyperglycaemia
Lee 2017 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Leite 2009 Intervention trial
Li 2011 Evaluation of a diabetes risk tool
Liatis 2014 Participants of a diabetes prevention programme
Libman 2008 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Liu 2017a No data on transition from intermediate hyperglycaemia to type 2 diabetes
Liu 2017b Investigation of the association between the bone resorption marker CTX and
incident intermediate hyperglycaemia/diabetes
Malmstrom 2018 Type 2 diabetes incidence measured mainly through registers; nested case-con-
trol study; no transition data
Manson 1992 No cohort with intermediate hyperglycaemia
McNeill 2006 No data on transition from intermediate hyperglycaemia to type 2 diabetes
McPhillips 1990 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Medalie 1975 No data on transition from intermediate hyperglycaemia to type 2 diabetes; no
common thresholds for diagnosis of intermediate hyperglycaemia and type 2
diabetes
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Metcalf 2017 No cohort with intermediate hyperglycaemia
Miranda 2017 Investigationof the associationbetween advanced glycation endproducts (AGE)
and their receptor (RAGE) and type 2 diabetes incidence
Mirbolouk 2016 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Monesi 2012 No cohort with intermediate hyperglycaemia
Morrison 2012 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Nakagami 2017 No cohort with intermediate hyperglycaemia
Nakasone 2017 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Nano 2017 Investigation of the association between liver transaminases and development
of intermediate hyperglycaemia/type 2 diabetes
Nguyen 2014 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Nichols 2007 Not a prospective cohort study
Nichols 2010 Not a prospective cohort study
Nichols 2015 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Njolstad 1998 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Norberg 2006 Not a prospective cohort study
Nowicka 2011 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Ohlson 1987 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Oizumi 2011 Non-standard thresholds for intermediate hyperglycaemia
Okada 2017 Diabetes incidence data for prediabetic cohort only (FPG 5.6-6.9 or HbA1c 5.
7%-6.4%)
Onat 2007 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Onat 2013a Non-standard IFG/IGT definition
Onat 2013b Non-standard IFG/IGT definition
Osei 2004 No data on transition from intermediate hyperglycaemia to type 2 diabetes
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Paddock 2017 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Perry 1995 Type 2 diabetes mellitus incidence not established by glucose measurements
(questionnaires, reviews of primary care records, reviews of death certificates)
Pinelli 2011 Cross-sectional study
Polakowska 2011 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Pradhan 2007 Intervention trial (Women’s Health Study)
Priya 2013 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Qiao 2003 Not a prospective cohort study
Qiu 2015 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Ramachandran 2012 Not a prospective cohort study
Rauh 2017 Development of a prediction model for HbA1c levels after 6 years in the non-
diabetic general population
Reynolds 2006 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Rimm 1995 No cohort with intermediate hyperglycaemia
Sacks 2017 Investigation of patient activation to predict the course of type 2 diabetes
Sai 2017 No cohort with intermediate hyperglycaemia
Samaras 2015 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Schmitz 2016 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Schottker 2011 Diabetes incidence by self-report only
Schulze 2008 Evaluation of a diabetes risk score
Schwarz 2007 No individuals with intermediate hyperglycaemia at baseline
Serrano 2013 Study design paper
Shimazaki 2007 Not a prospective cohort study
Song 2007 Mix of old an new participants in 2 study phases, participants with with both
IFG and IGT were combined into an IFG group
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Song 2016b Not a prospective cohort study
Sorgjerd 2015 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Soria 2009 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Stampfer 1988 No cohort with intermediate hyperglycaemia
Strauss 1974 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Suvitaival 2018 Evaluation of a new biomarker (’plasma lipidome’) model
Tabak 2009 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Tai 2004 Aggregated data from several prevalence and incidence studies
Takkunen 2016 Cohort from intervention trial, no data on cohort with intermediate hypergly-
caemia
Tanabe 2009 Not a prospective cohort study
Vaccaro 2005 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Vaidya 2016 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Vazquez 2000 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Vega-Vázquez 2017 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Von Eckardstein 2000 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Wang 2010 New diabetes cases were identified through hospital records only
Warram 1996 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Wei 1999 Investigation of the association between cardiorespiratory fitness and interme-
diate hyperglycaemia/type 2 diabetes mellitus
Welborn 1979 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Wheeler 2017 Investigation of genetic determinants of HbA1c on the development of type 2
diabetes
Wingard 1993 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Woo 2015 No data on transition from intermediate hyperglycaemia to type 2 diabetes
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Wu 2017a No data on transition from intermediate hyperglycaemia to type 2 diabetes
Wu 2017b Intermediate hyperglycaemia determined through register data, retrospective
study
Wu 2018 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Xu 2014 Investigation of a prediction model for development of diabetes
Yang 2016 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Ye 2014 No data on people with intermediate hyperglycaemia
Yi 2017 No data on type 2 diabetes incidence
Yokota 2017 Retrospective cohort study
Yoshinaga 1996 Non-standard thresholds for intermediate hyperglycaemia
Yoshinaga 1999 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Zargar 2001 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Zethelius 2008 No data on transition from intermediate hyperglycaemia to type 2 diabetes,
establishment of a predictive model
Zhang 2012b No data on transition from intermediate hyperglycaemia to type 2 diabetes
Zhang 2016 No data on transition from intermediate hyperglycaemia to type 2 diabetes
Zimmet 1992 No data on transition from intermediate hyperglycaemia to type 2 diabetes
FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; IFG: impaired fasting glucose; IGT: impaired glucose tolerance.
Characteristics of studies awaiting assessment [ordered by study ID]
Li 2001
Study name Model development of diabetes in adult Chinese
Starting date 1986, follow-up 6 years
Contact information Guangwei Li, Department of Endocrinology, China-Japan Friendship Hospital, Beijing 100029 China
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Li 2001 (Continued)
Notes Establishment of a model for type 2 diabetes and the roles of insulin resistance and insulin secretion impair-
ment; needs translation
Misnikova 2011
Study name Risk of diabetes and cardiovascular events in persons with early glucose metabolism impairments
Starting date 2006, follow-up 3 years
Contact information Misnikova IV, Endocrinology, Moscow Regional Research Clinical Institute, Russian Federation
Notes Conference abstract, no publication available
NCT00816608
Study name The effect of maximum body weight in lifetime on the development of type 2 diabetes (MAXWEL)
Starting date August 2006
Contact information Professor Soo Lim, Seoul National University Bundang Hospital
Notes Study completion date: September 2013; no publication available
Characteristics of ongoing studies [ordered by study ID]
NCT00786890
Trial name or title A survey to evaluate the cardiovascular risk status of subjects with pre-diabetes in Hong Kong (JADE-HK2)
Starting date November 2008
Contact information Juliana Chan, Professor, Chinese University of Hong Kong
Notes Estimated study completion date: December 2018
NCT02838693
Trial name or title Assessing progression to type-2 diabetes (APT-2D): a prospective cohort study expanded from BRITE-SPOT
(Bio-bank and Registry for StratIfication and Targeted intErventions in the Spectrum Of Type 2 Diabetes)
(APT-2D)
Starting date March 2016
Contact information Sue-Anne Toh, MBBChir, MSc, MA; +65 67722195; mdcsates@nus.edu.sg
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NCT02838693 (Continued)
Notes Estimated study completion date: December 2021
NCT02958579
Trial name or title A population based study on metabolic syndrome complications, and mortality (MetSCoM)
Starting date January 2005
Contact information Alireza Esteghamati, MD (esteghamati@tums.ac.ir); Zahra Aryan, MD, MPH (aryanzahra@yahoo.com)
Notes Estimated study completion date: January 2020
Vilanova 2017
Trial name or title Prevalence, clinical features and risk assessment of pre-diabetes in Spain: the prospective Mollerussa cohort
study
Starting date August 2011
Contact information Dr Didac Mauricio, MD; didacmauricio@gmail.com
Notes TheMollerussa study completed its recruitment phase in July 2014 and the 12 month follow-up in July 2015.
Participants will be followed up long-term through annual extraction of data included in the individual’s
electronic medical records
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D A T A A N D A N A L Y S E S
Comparison 1. Hazard ratio as the effect measure for the development of T2DM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 T2DM incidence (IFG5.6) 8 34867 Hazard Ratio (Random, 95% CI) 4.32 [2.61, 7.12]
1.1 Asia/Middle East 4 14803 Hazard Ratio (Random, 95% CI) 5.07 [3.41, 7.53]
1.2 Australia/Europe/North
America
3 18522 Hazard Ratio (Random, 95% CI) 4.15 [1.24, 13.87]
1.3 American Indians/Islands 1 1542 Hazard Ratio (Random, 95% CI) 2.38 [1.85, 3.06]
2 T2DM incidence (IFG6.1) 10 21475 Hazard Ratio (Random, 95% CI) 5.47 [3.50, 8.54]
2.1 Asia/Middle East 5 10810 Hazard Ratio (Random, 95% CI) 10.55 [3.61, 30.81]
2.2 Australia/Europe/North
America
4 10571 Hazard Ratio (Random, 95% CI) 3.30 [2.32, 4.67]
2.3 Latin America 1 94 Hazard Ratio (Random, 95% CI) 2.06 [1.76, 2.41]
3 T2DM incidence (IGT) 5 16576 Hazard Ratio (Random, 95% CI) 3.61 [2.31, 5.64]
3.1 Asia/Middle East 3 8475 Hazard Ratio (Random, 95% CI) 4.48 [2.81, 7.15]
3.2 Australia/Europe/North
America
2 8101 Hazard Ratio (Random, 95% CI) 2.53 [1.52, 4.19]
4 T2DM incidence (IFG + IGT) 5 9757 Hazard Ratio (Random, 95% CI) 6.90 [4.15, 11.45]
4.1 Asia/Middle East 3 7156 Hazard Ratio (Random, 95% CI) 10.20 [5.45, 19.09]
4.2 Australia/Europe/North
America
1 1650 Hazard Ratio (Random, 95% CI) 3.80 [2.30, 6.28]
4.3 American Indians/Islands 1 951 Hazard Ratio (Random, 95% CI) 4.06 [3.05, 5.40]
5 T2DM incidence (HbA1c5.7) 4 25047 Hazard Ratio (Random, 95% CI) 5.55 [2.77, 11.12]
5.1 Asia 3 16805 Hazard Ratio (Random, 95% CI) 7.21 [5.14, 10.11]
5.2 Australia/Europe/North
America
1 8242 Hazard Ratio (Random, 95% CI) 2.71 [2.48, 2.96]
6 T2DM incidence (HbA1c6.0) 6 30699 Hazard Ratio (Random, 95% CI) 10.10 [3.59, 28.43]
6.1 Asia/Middle East 4 22734 Hazard Ratio (Random, 95% CI) 13.12 [4.10, 41.96]
6.2 Australia/Europe/North
America
2 7965 Hazard Ratio (Random, 95% CI) 5.09 [1.69, 15.37]
7 T2DM incidence (HbA1c +
IFG)
1 Hazard Ratio (Fixed, 95% CI) Subtotals only
7.1 HbA1c5.7 + IFG5.6 1 4559 Hazard Ratio (Fixed, 95% CI) 32.50 [23.00, 45.92]
7.2 HbA1c5.7 + IFG6.1 1 5357 Hazard Ratio (Fixed, 95% CI) 37.90 [28.10, 51.12]
7.3 HbA1c6.0 + IFG5.6 1 4628 Hazard Ratio (Fixed, 95% CI) 53.70 [38.40, 75.09]
7.4 HbA1c6.0 + IFG6.1 1 5802 Hazard Ratio (Fixed, 95% CI) 52.30 [37.80, 72.37]
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Comparison 2. Odds ratio as the effect measure for the development of T2DM
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 T2DM incidence (IFG5.6) 21 47647 Odds Ratio (Random, 95% CI) 4.15 [2.75, 6.28]
1.1 Asia/Middle East 10 34577 Odds Ratio (Random, 95% CI) 2.94 [1.77, 4.86]
1.2 Australia/Europe/North
America
9 9869 Odds Ratio (Random, 95% CI) 6.47 [3.81, 11.00]
1.3 Latin America 1 1659 Odds Ratio (Random, 95% CI) 4.28 [3.21, 5.71]
1.4 American Indians/Islands 1 1542 Odds Ratio (Random, 95% CI) 3.12 [2.31, 4.21]
2 T2DM incidence (IFG6.1) 15 36866 Odds Ratio (Random, 95% CI) 6.60 [4.18, 10.43]
2.1 Asia/Middle East 7 28921 Odds Ratio (Random, 95% CI) 5.18 [2.32, 11.53]
2.2 Australia/Europe/North
America
7 6334 Odds Ratio (Random, 95% CI) 8.69 [4.95, 15.24]
2.3 Latin America 1 1611 Odds Ratio (Random, 95% CI) 3.73 [2.18, 6.38]
3 T2DM incidence (IGT) 20 21552 Odds Ratio (Random, 95% CI) 4.61 [3.76, 5.64]
3.1 Asia/Middle East 6 8643 Odds Ratio (Random, 95% CI) 3.74 [2.83, 4.94]
3.2 Australia/Europe/North
America
11 9165 Odds Ratio (Random, 95% CI) 5.20 [3.62, 7.45]
3.3 Latin America 2 3478 Odds Ratio (Random, 95% CI) 4.94 [3.15, 7.76]
3.4 American Indians/Islands 1 266 Odds Ratio (Random, 95% CI) 3.60 [1.40, 9.26]
4 T2DM incidence (IFG + IGT) 9 9656 Odds Ratio (Random, 95% CI) 13.14 [7.41, 23.30]
4.1 Asia/Middle East 3 4202 Odds Ratio (Random, 95% CI) 6.99 [3.09, 15.83]
4.2 Australia/Europe/North
America
6 5454 Odds Ratio (Random, 95% CI) 20.95 [12.40, 35.40]
5 T2DM incidence (HbA1c5.7) 3 3468 Odds Ratio (Random, 95% CI) 4.43 [2.20, 8.88]
5.1 Asia/Middle East 1 1137 Odds Ratio (Random, 95% CI) 4.54 [2.65, 7.78]
5.2 Europe/North America 2 2331 Odds Ratio (Random, 95% CI) 4.38 [1.36, 14.15]
6 T2DM incidence (HbA1c6.0) 3 18317 Odds Ratio (Random, 95% CI) 12.79 [4.56, 35.85]
6.1 Asia/Middle East 1 11866 Odds Ratio (Random, 95% CI) 23.20 [18.70, 28.78]
6.2 Australia/Europe/North
America
1 5735 Odds Ratio (Random, 95% CI) 15.60 [6.90, 35.27]
6.3 American Indians/Islands 1 716 Odds Ratio (Random, 95% CI) 5.89 [4.23, 8.20]
7 T2DM incidence (HbA1c5.7 +
IFG5.6)
2 14006 Odds Ratio (Random, 95% CI) 35.91 [20.43, 63.12]
7.1 Australia/Europe/North
America
1 1294 Odds Ratio (Random, 95% CI) 26.20 [16.30, 42.11]
7.2 Asia/Middle East 1 12712 Odds Ratio (Random, 95% CI) 46.70 [33.60, 64.91]
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Analysis 1.1. Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 1
T2DM incidence (IFG5.6).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 1 Hazard ratio as the effect measure for the development of T2DM
Outcome: 1 T2DM incidence (IFG5.6)
Study or subgroup
Intermediate
hypergly-
caemia IFG5.6 log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Asia/Middle East
Heianza 2012 (1) 1680 4149 1.8213 (0.1803) 13.4 % 6.18 [ 4.34, 8.80 ]
Kim 2005 (2) 276 2009 1.5623 (0.5573) 8.6 % 4.77 [ 1.60, 14.22 ]
Janghorbani 2015 (3) 230 627 2.0015 (0.3537) 11.3 % 7.40 [ 3.70, 14.80 ]
Han 2017 (4) 199 5633 1.2837 (0.1206) 14.0 % 3.61 [ 2.85, 4.57 ]
Subtotal (95% CI) 2385 12418 47.2 % 5.07 [ 3.41, 7.53 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 8.41, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 8.04 (P < 0.00001)
2 Australia/Europe/North America
Yeboah 2011 (5) 940 6215 2.3514 (0.1139) 14.0 % 10.50 [ 8.40, 13.13 ]
Forouhi 2007 (6) 633 407 1.0647 (0.4094) 10.5 % 2.90 [ 1.30, 6.47 ]
Warren 2017 (7) 4112 6215 0.8154 (0.0423) 14.3 % 2.26 [ 2.08, 2.46 ]
Subtotal (95% CI) 5685 12837 38.9 % 4.15 [ 1.24, 13.87 ]
Heterogeneity: Tau2 = 1.08; Chi2 = 159.84, df = 2 (P<0.00001); I2 =99%
Test for overall effect: Z = 2.31 (P = 0.021)
3 American Indians/Islands
Wang 2011 (8) 947 595 0.8671 (0.1285) 13.9 % 2.38 [ 1.85, 3.06 ]
Subtotal (95% CI) 947 595 13.9 % 2.38 [ 1.85, 3.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.75 (P < 0.00001)
Total (95% CI) 9017 25850 100.0 % 4.32 [ 2.61, 7.12 ]
Heterogeneity: Tau2 = 0.45; Chi2 = 193.41, df = 7 (P<0.00001); I2 =96%
Test for overall effect: Z = 5.72 (P < 0.00001)
Test for subgroup differences: Chi2 = 10.26, df = 2 (P = 0.01), I2 =81%
0.1 0.2 0.5 1 2 5 10
Normoglycaemia IFG5.6
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(1) 5 years follow-up
(2) 5 years follow-up
(3) 7 years follow-up
(4) 12 years follow-up
(5) 8 years follow-up
(6) 10 years follow-up
(7) 22 years follow-up
(8) 4 years follow-up
Analysis 1.2. Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 2
T2DM incidence (IFG6.1).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 1 Hazard ratio as the effect measure for the development of T2DM
Outcome: 2 T2DM incidence (IFG6.1)
Study or subgroup IFG6.1 Normoglycaemia log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Asia/Middle East
Heianza 2012 (1) 380 4149 2.4336 (0.175) 11.0 % 11.40 [ 8.09, 16.06 ]
Kim 2005 (2) 276 2009 3.543 (0.5323) 7.1 % 34.57 [ 12.18, 98.13 ]
Li 2003 (3) 42 435 1.7544 (0.3017) 9.7 % 5.78 [ 3.20, 10.44 ]
Nakagami 2016 (4) 134 1528 3.5522 (0.2929) 9.8 % 34.89 [ 19.65, 61.95 ]
Liu 2016 (5) 222 1635 0.6881 (0.1905) 10.8 % 1.99 [ 1.37, 2.89 ]
Subtotal (95% CI) 1054 9756 48.5 % 10.55 [ 3.61, 30.81 ]
Heterogeneity: Tau2 = 1.40; Chi2 = 90.70, df = 4 (P<0.00001); I2 =96%
Test for overall effect: Z = 4.31 (P = 0.000017)
2 Australia/Europe/North America
Lyssenko 2005 (6) 211 1503 0.8329 (0.2533) 10.2 % 2.30 [ 1.40, 3.78 ]
Forouhi 2007 (7) 257 407 1.4816 (0.4285) 8.3 % 4.40 [ 1.90, 10.19 ]
Bonora 2011 (8) 55 710 1.763 (0.3013) 9.7 % 5.83 [ 3.23, 10.52 ]
Warren 2017 (9) 1213 6215 1.0473 (0.0468) 11.7 % 2.85 [ 2.60, 3.12 ]
0.01 0.1 1 10 100
Normoglycaemia IFG6.1
(Continued . . . )
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(. . . Continued)
Study or subgroup IFG6.1 Normoglycaemia log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 1736 8835 39.9 % 3.30 [ 2.32, 4.67 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 7.29, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 6.69 (P < 0.00001)
3 Latin America
Leiva 2014 (10) 28 66 0.7227 (0.0803) 11.6 % 2.06 [ 1.76, 2.41 ]
Subtotal (95% CI) 28 66 11.6 % 2.06 [ 1.76, 2.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.00 (P < 0.00001)
Total (95% CI) 2818 18657 100.0 % 5.47 [ 3.50, 8.54 ]
Heterogeneity: Tau2 = 0.44; Chi2 = 188.70, df = 9 (P<0.00001); I2 =95%
Test for overall effect: Z = 7.48 (P < 0.00001)
Test for subgroup differences: Chi2 = 13.70, df = 2 (P = 0.00), I2 =85%
0.01 0.1 1 10 100
Normoglycaemia IFG6.1
(1) 5 years follow-up
(2) 5 years follow-up
(3) 5 years follow-up
(4) 5 years follow-up
(5) 11 years follow-up
(6) 6 years follow-up; isolated IFG6.1 ; univariate analysis
(7) 10 years follow-up
(8) 15 years follow-up
(9) 22 years follow-up
(10) 6 years follow-up
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Analysis 1.3. Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 3
T2DM incidence (IGT).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 1 Hazard ratio as the effect measure for the development of T2DM
Outcome: 3 T2DM incidence (IGT)
Study or subgroup IGT Normoglycaemia log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Asia/Middle East
Li 2003 (1) 118 435 1.0784 (0.2475) 18.7 % 2.94 [ 1.81, 4.78 ]
Janghorbani 2015 (2) 150 627 2.2407 (0.3429) 15.6 % 9.40 [ 4.80, 18.41 ]
Han 2017 (3) 1512 5633 1.4012 (0.0585) 23.7 % 4.06 [ 3.62, 4.55 ]
Subtotal (95% CI) 1780 6695 58.0 % 4.48 [ 2.81, 7.15 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 7.68, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 6.30 (P < 0.00001)
2 Australia/Europe/North America
Lyssenko 2005 (4) 221 1429 1.2528 (0.2606) 18.3 % 3.50 [ 2.10, 5.83 ]
Warren 2017 (5) 2009 4442 0.7227 (0.0576) 23.7 % 2.06 [ 1.84, 2.31 ]
Subtotal (95% CI) 2230 5871 42.0 % 2.53 [ 1.52, 4.19 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 3.95, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 3.59 (P = 0.00033)
Total (95% CI) 4010 12566 100.0 % 3.61 [ 2.31, 5.64 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 80.52, df = 4 (P<0.00001); I2 =95%
Test for overall effect: Z = 5.63 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.67, df = 1 (P = 0.10), I2 =62%
0.01 0.1 1 10 100
Normoglycaemia IGT
(1) 5 years follow-up; isolated IGT
(2) 7 years follow-up
(3) 12 years follow-up; isolated IGT
(4) 6 years follow-up
(5) 16 years follow-up
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Analysis 1.4. Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 4
T2DM incidence (IFG + IGT).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 1 Hazard ratio as the effect measure for the development of T2DM
Outcome: 4 T2DM incidence (IFG + IGT)
Study or subgroup IFG+IGT Normoglycaemia log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Asia/Middle East
Li 2003 (1) 49 435 1.8197 (0.3019) 17.9 % 6.17 [ 3.41, 11.15 ]
Janghorbani 2015 (2) 214 627 3.1135 (0.304) 17.9 % 22.50 [ 12.40, 40.83 ]
Han 2017 (3) 198 5633 2.1054 (0.0969) 22.9 % 8.21 [ 6.79, 9.93 ]
Subtotal (95% CI) 461 6695 58.7 % 10.20 [ 5.45, 19.09 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 11.42, df = 2 (P = 0.003); I2 =82%
Test for overall effect: Z = 7.26 (P < 0.00001)
2 Australia/Europe/North America
Lyssenko 2005 (4) 221 1429 1.335 (0.2562) 19.2 % 3.80 [ 2.30, 6.28 ]
Subtotal (95% CI) 221 1429 19.2 % 3.80 [ 2.30, 6.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.21 (P < 0.00001)
3 American Indians/Islands
Wang 2011 (5) 356 595 1.4012 (0.1459) 22.0 % 4.06 [ 3.05, 5.40 ]
Subtotal (95% CI) 356 595 22.0 % 4.06 [ 3.05, 5.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.60 (P < 0.00001)
Total (95% CI) 1038 8719 100.0 % 6.90 [ 4.15, 11.45 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 37.03, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 7.46 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.47, df = 2 (P = 0.02), I2 =73%
0.02 0.1 1 10 50
Normoglycaemia IFG+IGT
(1) 5 years follow-up
(2) 7 years follow-up
(3) 12 years follow-up
(4) 6 years follow-up
(5) 4 years follow-up
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Analysis 1.5. Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 5
T2DM incidence (HbA1c5.7).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 1 Hazard ratio as the effect measure for the development of T2DM
Outcome: 5 T2DM incidence (HbA1c5.7)
Study or subgroup HbA1c5.7 Normoglycaemia log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Asia
Bae 2011 (1) 1791 7932 1.8718 (0.2875) 24.2 % 6.50 [ 3.70, 11.42 ]
Heianza 2012 (2) 822 4149 1.8764 (0.2776) 24.5 % 6.53 [ 3.79, 11.25 ]
Nakagami 2016 (3) 583 1528 2.2742 (0.3433) 22.7 % 9.72 [ 4.96, 19.05 ]
Subtotal (95% CI) 3196 13609 71.4 % 7.21 [ 5.14, 10.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.01, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 11.44 (P < 0.00001)
2 Australia/Europe/North America
Warren 2017 (4) 2027 6215 0.9969 (0.0453) 28.6 % 2.71 [ 2.48, 2.96 ]
Subtotal (95% CI) 2027 6215 28.6 % 2.71 [ 2.48, 2.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 22.01 (P < 0.00001)
Total (95% CI) 5223 19824 100.0 % 5.55 [ 2.77, 11.12 ]
Heterogeneity: Tau2 = 0.44; Chi2 = 31.07, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 4.83 (P < 0.00001)
Test for subgroup differences: Chi2 = 30.06, df = 1 (P = 0.00), I2 =97%
0.05 0.2 1 5 20
Normoglycaemia HbA1c5.7
(1) 4 years follow-up
(2) 5 years follow-up
(3) 5 years follow-up
(4) 22 years follow-up
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Analysis 1.6. Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 6
T2DM incidence (HbA1c6.0).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 1 Hazard ratio as the effect measure for the development of T2DM
Outcome: 6 T2DM incidence (HbA1c6.0)
Study or subgroup HbA1c6.0 Normoglycaemia log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Asia/Middle East
Bae 2011 (1) 412 7932 3.7209 (0.2623) 14.7 % 41.30 [ 24.70, 69.06 ]
Heianza 2012 (2) 203 4149 2.0042 (0.3592) 14.2 % 7.42 [ 3.67, 15.00 ]
Nakagami 2016 (3) 156 1528 4.1457 (0.3169) 14.4 % 63.16 [ 33.94, 117.54 ]
Han 2017 (4) 1306 2715 1.454 (0.293) 14.6 % 4.28 [ 2.41, 7.60 ]
Han 2017 (5) 1415 2918 1.3987 (0.5568) 13.0 % 4.05 [ 1.36, 12.06 ]
Subtotal (95% CI) 3492 19242 70.9 % 13.12 [ 4.10, 41.96 ]
Heterogeneity: Tau2 = 1.62; Chi2 = 62.70, df = 4 (P<0.00001); I2 =94%
Test for overall effect: Z = 4.34 (P = 0.000014)
2 Australia/Europe/North America
Bonora 2011 (6) 70 710 2.2762 (0.428) 13.8 % 9.74 [ 4.21, 22.53 ]
Warren 2017 (7) 970 6215 1.1378 (0.0534) 15.2 % 3.12 [ 2.81, 3.46 ]
Subtotal (95% CI) 1040 6925 29.1 % 5.09 [ 1.69, 15.37 ]
Heterogeneity: Tau2 = 0.55; Chi2 = 6.97, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 2.89 (P = 0.0039)
Total (95% CI) 4532 26167 100.0 % 10.10 [ 3.59, 28.43 ]
Heterogeneity: Tau2 = 1.83; Chi2 = 183.45, df = 6 (P<0.00001); I2 =97%
Test for overall effect: Z = 4.38 (P = 0.000012)
Test for subgroup differences: Chi2 = 1.34, df = 1 (P = 0.25), I2 =25%
0.002 0.1 1 10 500
Normoglycaemia HbA1c6.0
(1) 4 years follow-up
(2) 5 years follow-up
(3) 5 years follow-up
(4) 12 years follow-up; HR for male participants
(5) 12 years follow-up; HR for female participants
(6) 15 years follow-up
(7) 22 years follow-up
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Analysis 1.7. Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 7
T2DM incidence (HbA1c + IFG).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 1 Hazard ratio as the effect measure for the development of T2DM
Outcome: 7 T2DM incidence (HbA1c + IFG)
Study or subgroup HbA1c+IFG Normoglycaemia log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 HbA1c5.7 + IFG5.6
Heianza 2012 (1) 410 4149 3.4812 (0.1764) 100.0 % 32.50 [ 23.00, 45.92 ]
Subtotal (95% CI) 410 4149 100.0 % 32.50 [ 23.00, 45.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 19.73 (P < 0.00001)
2 HbA1c5.7 + IFG6.1
Heianza 2012 (2) 159 5198 3.635 (0.1526) 100.0 % 37.90 [ 28.10, 51.12 ]
Subtotal (95% CI) 159 5198 100.0 % 37.90 [ 28.10, 51.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 23.82 (P < 0.00001)
3 HbA1c6.0 + IFG5.6
Heianza 2012 (3) 135 4493 3.9834 (0.1711) 100.0 % 53.70 [ 38.40, 75.09 ]
Subtotal (95% CI) 135 4493 100.0 % 53.70 [ 38.40, 75.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 23.28 (P < 0.00001)
4 HbA1c6.0 + IFG6.1
Heianza 2012 (4) 72 5730 3.957 (0.1657) 100.0 % 52.30 [ 37.80, 72.37 ]
Subtotal (95% CI) 72 5730 100.0 % 52.30 [ 37.80, 72.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 23.88 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.29, df = 3 (P = 0.10), I2 =52%
0.005 0.1 1 10 200
Normoglycaemia HbA1c+IFG
(1) 5 years follow-up
(2) 5 years follow-up
(3) 5 years follow-up
(4) 5 years follow-up
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Analysis 2.1. Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 1
T2DM incidence (IFG5.6).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 2 Odds ratio as the effect measure for the development of T2DM
Outcome: 1 T2DM incidence (IFG5.6)
Study or subgroup
Intermediate
hypergly-
caemia IFG5.6 log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Asia/Middle East
Song 2015 (1) 167 1092 1.4516 (0.527) 3.7 % 4.27 [ 1.52, 12.00 ]
Song 2015 (2) 154 666 2.0149 (0.51) 3.8 % 7.50 [ 2.76, 20.38 ]
Jeong 2010 (3) 495 792 1.7334 (0.2541) 4.5 % 5.66 [ 3.44, 9.31 ]
Liu 2008 (4) 169 470 1.5041 (0.4137) 4.1 % 4.50 [ 2.00, 10.12 ]
Latifi 2016 (5) 124 394 0.0392 (0.02) 4.8 % 1.04 [ 1.00, 1.08 ]
Wang 2007 (6) 261 400 0.9969 (0.3262) 4.3 % 2.71 [ 1.43, 5.14 ]
Sadeghi 2015 (7) 373 2607 1.1939 (0.2162) 4.6 % 3.30 [ 2.16, 5.04 ]
Liu 2017 (8) 3607 15003 1.3002 (0.0699) 4.8 % 3.67 [ 3.20, 4.21 ]
Aekplakorn 2006 (9) 223 2444 0.8796 (0.1546) 4.7 % 2.41 [ 1.78, 3.26 ]
Derakhshan 2016 (10) 523 3611 1.0986 (0.1356) 4.7 % 3.00 [ 2.30, 3.91 ]
Bergman 2016 (11) 263 739 0.1044 (0.1933) 4.7 % 1.11 [ 0.76, 1.62 ]
Subtotal (95% CI) 6359 28218 48.8 % 2.94 [ 1.77, 4.86 ]
Heterogeneity: Tau2 = 0.65; Chi2 = 467.30, df = 10 (P<0.00001); I2 =98%
Test for overall effect: Z = 4.19 (P = 0.000029)
2 Australia/Europe/North America
Levitzky 2008 (12) 460 0 2.5416 (0.2295) 4.6 % 12.70 [ 8.10, 19.91 ]
Levitzky 2008 (13) 313 0 3.1046 (0.2753) 4.5 % 22.30 [ 13.00, 38.25 ]
Soriguer 2008 (14) 56 1806 1.6677 (0.3441) 4.3 % 5.30 [ 2.70, 10.40 ]
Valdes 2008 (15) 114 510 1.361 (0.4546) 4.0 % 3.90 [ 1.60, 9.51 ]
Lipska 2013 (16) 189 1690 1.2528 (0.3117) 4.4 % 3.50 [ 1.90, 6.45 ]
Admiraal 2014 (17) 111 354 1.8083 (0.3454) 4.3 % 6.10 [ 3.10, 12.00 ]
Cugati 2007 (18) 229 1512 2.9513 (0.2557) 4.5 % 19.13 [ 11.59, 31.58 ]
De Abreu 2015 (19) 187 342 1.7492 (0.5758) 3.6 % 5.75 [ 1.86, 17.77 ]
Filippatos 2016 (20) 279 1206 1.2326 (0.2336) 4.6 % 3.43 [ 2.17, 5.42 ]
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(. . . Continued)
Study or subgroup
Intermediate
hypergly-
caemia IFG5.6 log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Vaccaro 1999 (21) 11 500 0.1823 (0.7073) 3.1 % 1.20 [ 0.30, 4.80 ]
Subtotal (95% CI) 1949 7920 41.7 % 6.47 [ 3.81, 11.00 ]
Heterogeneity: Tau2 = 0.59; Chi2 = 61.74, df = 9 (P<0.00001); I2 =85%
Test for overall effect: Z = 6.90 (P < 0.00001)
3 Latin America
Ferrannini 2009 (22) 65 1594 1.454 (0.1468) 4.7 % 4.28 [ 3.21, 5.71 ]
Subtotal (95% CI) 65 1594 4.7 % 4.28 [ 3.21, 5.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.90 (P < 0.00001)
4 American Indians/Islands
Wang 2011 (23) 947 595 1.1378 (0.1534) 4.7 % 3.12 [ 2.31, 4.21 ]
Subtotal (95% CI) 947 595 4.7 % 3.12 [ 2.31, 4.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.42 (P < 0.00001)
Total (95% CI) 9320 38327 100.0 % 4.15 [ 2.75, 6.28 ]
Heterogeneity: Tau2 = 0.92; Chi2 = 972.07, df = 22 (P<0.00001); I2 =98%
Test for overall effect: Z = 6.74 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.19, df = 3 (P = 0.07), I2 =58%
0.05 0.2 1 5 20
Normoglycaemia IFG5.6
334Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(1) 4 years follow-up; female participants
(2) 4 years follow-up; male participants
(3) 5 years follow-up; unclear whether IFG or IGT cohort
(4) 5 years follow-up
(5) 5 years follow-up
(6) 5 years follow-up
(7) 7 years follow-up; isolated IFG5.6
(8) 8 years follow-up
(9) 12 years follow-up
(10) 12 years follow-up; unclear if IFG5.6 or IFG6.1
(11) 24 years follow-up; isolated IFG5.6
(12) 4 years follow-up; male IFG cohort, total numbers from IFG6.1 cohort
(13) 4 years follow-up; female IFG cohort, total numbers from IFG6.1 cohort
(14) 6 years follow-up; univariate analysis
(15) 6 years follow-up
(16) 7 years follow-up
(17) 10 years follow-up
(18) 10 years follow-up
(19) 10 years follow-up
(20) 10 years follow-up
(21) 12 years follow-up; upper confidence limit in publication: 10.2
(22) 7 years follow-up; univariate analysis
(23) 4 years follow-up; univariate analysis
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Analysis 2.2. Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 2
T2DM incidence (IFG6.1).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 2 Odds ratio as the effect measure for the development of T2DM
Outcome: 2 T2DM incidence (IFG6.1)
Study or subgroup IFG6.1 Normoglycaemia log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Asia/Middle East
Chen 2003 (1) 156 444 1.4816 (0.4285) 5.6 % 4.40 [ 1.90, 10.19 ]
Sato 2009 (2) 794 4147 3.1144 (0.122) 6.8 % 22.52 [ 17.73, 28.60 ]
Wang 2007 (3) 112 400 0.5878 (0.3207) 6.2 % 1.80 [ 0.96, 3.37 ]
Kim 2016a (4) 1433 10763 3.0493 (0.1163) 6.8 % 21.10 [ 16.80, 26.50 ]
Nakanishi 2004 (5) 246 5500 0.27 (0.4813) 5.4 % 1.31 [ 0.51, 3.36 ]
Derakhshan 2016 (6) 523 3611 1.411 (0.1767) 6.7 % 4.10 [ 2.90, 5.80 ]
Bergman 2016 (7) 53 739 1.2326 (0.3068) 6.2 % 3.43 [ 1.88, 6.26 ]
Subtotal (95% CI) 3317 25604 43.8 % 5.18 [ 2.32, 11.53 ]
Heterogeneity: Tau2 = 1.08; Chi2 = 165.39, df = 6 (P<0.00001); I2 =96%
Test for overall effect: Z = 4.02 (P = 0.000057)
2 Australia/Europe/North America
Levitzky 2008 (8) 313 0 3.2696 (0.2108) 6.6 % 26.30 [ 17.40, 39.76 ]
Levitzky 2008 (9) 460 0 2.5572 (0.1669) 6.7 % 12.90 [ 9.30, 17.89 ]
Valdes 2008 (10) 52 510 2.4932 (0.4935) 5.3 % 12.10 [ 4.60, 31.83 ]
Rijkelijkhuizen 2007 (11) 149 1125 2.3026 (0.2522) 6.4 % 10.00 [ 6.10, 16.39 ]
Lipska 2013 (12) 100 1690 2.4336 (0.2416) 6.5 % 11.40 [ 7.10, 18.30 ]
Rathmann 2009 (13) 71 649 1.5476 (0.3873) 5.8 % 4.70 [ 2.20, 10.04 ]
Cederberg 2010 (14) 40 410 0.8629 (0.2368) 6.5 % 2.37 [ 1.49, 3.77 ]
Bonora 2011 (15) 55 710 1.7405 (0.3627) 6.0 % 5.70 [ 2.80, 11.60 ]
Subtotal (95% CI) 1240 5094 49.9 % 8.69 [ 4.95, 15.24 ]
Heterogeneity: Tau2 = 0.57; Chi2 = 66.97, df = 7 (P<0.00001); I2 =90%
Test for overall effect: Z = 7.54 (P < 0.00001)
3 Latin America
Ferrannini 2009 (16) 17 1594 1.3164 (0.274) 6.4 % 3.73 [ 2.18, 6.38 ]
Subtotal (95% CI) 17 1594 6.4 % 3.73 [ 2.18, 6.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.80 (P < 0.00001)
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Normoglycaemia IFG6.1
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(. . . Continued)
Study or subgroup IFG6.1 Normoglycaemia log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 4574 32292 100.0 % 6.60 [ 4.18, 10.43 ]
Heterogeneity: Tau2 = 0.78; Chi2 = 251.23, df = 15 (P<0.00001); I2 =94%
Test for overall effect: Z = 8.09 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.57, df = 2 (P = 0.10), I2 =56%
0.002 0.1 1 10 500
Normoglycaemia IFG6.1
(1) 3 years follow-up
(2) 4 years follow-up
(3) 5 years follow-up
(4) 5 years follow-up
(5) 7 years follow-up
(6) 12 years follow-up, unclear if IFG5.6 or IFG6.1
(7) 24 years follow-up
(8) 4 years follow-up; female IFG cohort
(9) 4 years follow-up; male IFG cohort
(10) 6 years follow-up
(11) 6 years follow-up
(12) 7 years follow-up
(13) 7 years follow-up
(14) 10 years follow-up
(15) 15 years follow-up
(16) 7 years follow-up
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Analysis 2.3. Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 3
T2DM incidence (IGT).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 2 Odds ratio as the effect measure for the development of T2DM
Outcome: 3 T2DM incidence (IGT)
Study or subgroup IGT Normoglycaemia log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Asia/Middle East
Wang 2007 (1) 126 400 1.1474 (0.3456) 4.3 % 3.15 [ 1.60, 6.20 ]
Jeong 2010 (2) 495 792 1.7934 (0.3168) 4.6 % 6.01 [ 3.23, 11.18 ]
Li 2003 (3) 118 435 1.0784 (0.2475) 5.6 % 2.94 [ 1.81, 4.78 ]
Sadeghi 2015 (4) 373 2607 0.9243 (0.1919) 6.4 % 2.52 [ 1.73, 3.67 ]
Aekplakorn 2006 (5) 0 2444 1.4725 (0.1254) 7.3 % 4.36 [ 3.41, 5.57 ]
Bergman 2016 (6) 114 739 1.7299 (0.3683) 4.0 % 5.64 [ 2.74, 11.61 ]
Subtotal (95% CI) 1226 7417 32.2 % 3.74 [ 2.83, 4.94 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 10.39, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 9.30 (P < 0.00001)
2 Australia/Europe/North America
Mykka¨nen 1993 (7) 203 689 2.2875 (0.2412) 5.7 % 9.85 [ 6.14, 15.80 ]
Stengard 1992 (8) 234 216 1.1314 (0.4842) 2.9 % 3.10 [ 1.20, 8.01 ]
Hanley 2005 (9) 274 603 1.6901 (0.2088) 6.1 % 5.42 [ 3.60, 8.16 ]
Soriguer 2008 (10) 54 1806 1.4586 (0.3906) 3.8 % 4.30 [ 2.00, 9.25 ]
Valdes 2008 (11) 88 510 1.9021 (0.3461) 4.3 % 6.70 [ 3.40, 13.20 ]
Rijkelijkhuizen 2007 (12) 111 1125 2.3888 (0.3046) 4.8 % 10.90 [ 6.00, 19.80 ]
Rathmann 2009 (13) 120 649 2.1748 (0.2884) 5.0 % 8.80 [ 5.00, 15.49 ]
Zethelius 2004 (14) 201 466 0.7793 (0.2151) 6.0 % 2.18 [ 1.43, 3.32 ]
Bonora 2011 (15) 53 710 1.361 (0.4546) 3.2 % 3.90 [ 1.60, 9.51 ]
Cederberg 2010 (16) 103 410 1.0647 (0.2157) 6.0 % 2.90 [ 1.90, 4.43 ]
Vaccaro 1999 (17) 40 500 1.8245 (0.4241) 3.4 % 6.20 [ 2.70, 14.24 ]
Subtotal (95% CI) 1481 7684 51.2 % 5.20 [ 3.62, 7.45 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 42.09, df = 10 (P<0.00001); I2 =76%
Test for overall effect: Z = 8.95 (P < 0.00001)
3 Latin America
Ferrannini 2009 (18) 179 1594 1.3888 (0.128) 7.3 % 4.01 [ 3.12, 5.15 ]
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(. . . Continued)
Study or subgroup IGT Normoglycaemia log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Lorenzo 2003 (19) 202 1503 1.8516 (0.1923) 6.4 % 6.37 [ 4.37, 9.29 ]
Subtotal (95% CI) 381 3097 13.6 % 4.94 [ 3.15, 7.76 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 4.01, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 6.94 (P < 0.00001)
4 American Indians/Islands
Dowse 1991 (20) 51 215 1.2809 (0.4819) 2.9 % 3.60 [ 1.40, 9.26 ]
Subtotal (95% CI) 51 215 2.9 % 3.60 [ 1.40, 9.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0079)
Total (95% CI) 3139 18413 100.0 % 4.61 [ 3.76, 5.64 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 61.78, df = 19 (P<0.00001); I2 =69%
Test for overall effect: Z = 14.78 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.51, df = 3 (P = 0.47), I2 =0.0%
0.02 0.1 1 10 50
Normoglycaemia IGT
(1) 5 years follow-up
(2) 5 years follow-up; unclear whether IFG or IGT cohort
(3) 5 years follow-up; isolated IGT
(4) 7 years follow-up; univariate analysis
(5) 12 years follow-up; number of participants with IGT not reported, univariate analysis
(6) 24 years follow-up
(7) 4 years follow-up; univariate analysis
(8) 5 years follow-up
(9) 5 years follow-up
(10) 6 years follow-up
(11) 6 years follow-up; univariate analysis
(12) 6 years follow-up; isolated IGT
(13) 7 years follow-up; univariate analysis
(14) 7 years follow-up
(15) 10 years follow-up; univariate analysis
(16) 10 years follow-up
(17) 12 years follow-up; isolated IGT
(18) 7 years follow-up; univariate analysis
(19) 8 years follow-up
(20) 5 years follow-up
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Analysis 2.4. Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 4
T2DM incidence (IFG + IGT).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 2 Odds ratio as the effect measure for the development of T2DM
Outcome: 4 T2DM incidence (IFG + IGT)
Study or subgroup IFG+IGT Normoglycaemia log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Asia/Middle East
Wang 2007 (1) 26 187 1.9615 (0.5212) 9.3 % 7.11 [ 2.56, 19.75 ]
Wang 2007 (2) 36 171 2.3253 (0.4999) 9.6 % 10.23 [ 3.84, 27.25 ]
Sadeghi 2015 (3) 373 2607 2.5337 (0.2722) 11.9 % 12.60 [ 7.39, 21.48 ]
Bergman 2016 (4) 63 739 1.026 (0.2966) 11.7 % 2.79 [ 1.56, 4.99 ]
Subtotal (95% CI) 498 3704 42.5 % 6.99 [ 3.09, 15.83 ]
Heterogeneity: Tau2 = 0.54; Chi2 = 14.83, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 4.66 (P < 0.00001)
2 Australia/Europe/North America
Soriguer 2008 (5) 28 1806 2.2192 (0.3881) 10.8 % 9.20 [ 4.30, 19.69 ]
Valdes 2008 (6) 20 510 3.8199 (0.5408) 9.1 % 45.60 [ 15.80, 131.61 ]
Rijkelijkhuizen 2007 (7) 31 1125 3.6763 (0.4302) 10.3 % 39.50 [ 17.00, 91.79 ]
Rathmann 2009 (8) 47 649 3.054 (0.3634) 11.0 % 21.20 [ 10.40, 43.22 ]
Bonora 2011 (9) 19 710 3.0204 (0.5063) 9.5 % 20.50 [ 7.60, 55.30 ]
Vaccaro 1999 (10) 9 500 2.3321 (0.7876) 6.8 % 10.30 [ 2.20, 48.22 ]
Subtotal (95% CI) 154 5300 57.5 % 20.95 [ 12.40, 35.40 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 9.54, df = 5 (P = 0.09); I2 =48%
Test for overall effect: Z = 11.37 (P < 0.00001)
Total (95% CI) 652 9004 100.0 % 13.14 [ 7.41, 23.30 ]
Heterogeneity: Tau2 = 0.64; Chi2 = 43.02, df = 9 (P<0.00001); I2 =79%
Test for overall effect: Z = 8.81 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.91, df = 1 (P = 0.03), I2 =80%
0.005 0.1 1 10 200
Normoglycaemia IFG+IGT
340Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(1) 5 years follow-up; female participants (IFG6.1+IGT); IFG5.6+IGT: 4.67 (1.87-11.62)
(2) 5 years follow-up; male participants (IFG6.1+IGT); IFG5.6+IGT: 9.81 (3.5-27.21)
(3) 7 years follow-up
(4) 24 years follow-up; IFG5.6+IGT (IFG6.1 + IGT: 3.85 (1.73-8.54))
(5) 6 years follow-up
(6) 6 years follow-up; univariate analysis
(7) 6 years follow-up
(8) 7 years follow-up; univariate analysis
(9) 10 years follow-up; IFG6.1+IGT, univariate analysis
(10) 12 years follow-up; univariate analysis
Analysis 2.5. Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 5
T2DM incidence (HbA1c5.7).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 2 Odds ratio as the effect measure for the development of T2DM
Outcome: 5 T2DM incidence (HbA1c5.7)
Study or subgroup HbA1c5.7 Normoglycaemia log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Asia/Middle East
Man 2017 (1) 675 462 1.5129 (0.2747) 32.7 % 4.54 [ 2.65, 7.78 ]
Subtotal (95% CI) 675 462 32.7 % 4.54 [ 2.65, 7.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.51 (P < 0.00001)
2 Europe/North America
Lipska 2013 (2) 207 1690 2.0794 (0.2606) 33.3 % 8.00 [ 4.80, 13.33 ]
Cederberg 2010 (3) 24 410 0.8838 (0.244) 34.1 % 2.42 [ 1.50, 3.90 ]
Subtotal (95% CI) 231 2100 67.3 % 4.38 [ 1.36, 14.15 ]
Heterogeneity: Tau2 = 0.65; Chi2 = 11.22, df = 1 (P = 0.00081); I2 =91%
Test for overall effect: Z = 2.47 (P = 0.013)
Total (95% CI) 906 2562 100.0 % 4.43 [ 2.20, 8.88 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 11.26, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 4.18 (P = 0.000029)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
0.01 0.1 1 10 100
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(1) 6 years follow-up
(2) 7 years follow-up; isolated HbA1c5.7
(3) 10 years follow-up
Analysis 2.6. Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 6
T2DM incidence (HbA1c6.0).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 2 Odds ratio as the effect measure for the development of T2DM
Outcome: 6 T2DM incidence (HbA1c6.0)
Study or subgroup HbA1c6.0 Normoglycaemia log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Asia/Middle East
Kim 2016a (1) 1103 10763 3.1442 (0.11) 35.6 % 23.20 [ 18.70, 28.78 ]
Subtotal (95% CI) 1103 10763 35.6 % 23.20 [ 18.70, 28.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 28.58 (P < 0.00001)
2 Australia/Europe/North America
Chamnan 2011 (2) 370 5365 2.7473 (0.4162) 29.5 % 15.60 [ 6.90, 35.27 ]
Subtotal (95% CI) 370 5365 29.5 % 15.60 [ 6.90, 35.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.60 (P < 0.00001)
3 American Indians/Islands
Wang 2011 (3) 121 595 1.7733 (0.1689) 34.9 % 5.89 [ 4.23, 8.20 ]
Subtotal (95% CI) 121 595 34.9 % 5.89 [ 4.23, 8.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.50 (P < 0.00001)
Total (95% CI) 1594 16723 100.0 % 12.79 [ 4.56, 35.85 ]
Heterogeneity: Tau2 = 0.76; Chi2 = 46.26, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 4.85 (P < 0.00001)
Test for subgroup differences: Chi2 = 46.26, df = 2 (P = 0.00), I2 =96%
0.01 0.1 1 10 100
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(1) 5 years follow-up
(2) 3 years follow-up
(3) 4 years follow-up
Analysis 2.7. Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 7
T2DM incidence (HbA1c5.7 + IFG5.6).
Review: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Comparison: 2 Odds ratio as the effect measure for the development of T2DM
Outcome: 7 T2DM incidence (HbA1c5.7 + IFG5.6)
Study or subgroup HbA1c5.7+IFG5.6 Normoglycaemia log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Australia/Europe/North America
Lipska 2013 (1) 169 1125 3.2658 (0.2421) 45.5 % 26.20 [ 16.30, 42.11 ]
Subtotal (95% CI) 169 1125 45.5 % 26.20 [ 16.30, 42.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 13.49 (P < 0.00001)
2 Asia/Middle East
Kim 2016a (2) 1951 10761 3.8437 (0.168) 54.5 % 46.70 [ 33.60, 64.91 ]
Subtotal (95% CI) 1951 10761 54.5 % 46.70 [ 33.60, 64.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 22.88 (P < 0.00001)
Total (95% CI) 2120 11886 100.0 % 35.91 [ 20.43, 63.12 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 3.85, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 12.44 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.85, df = 1 (P = 0.05), I2 =74%
0.005 0.1 1 10 200
Normoglycaemia HbA1c5.7+IFG5.6
(1) 7 years follow-up
(2) 5 years follow-up
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A D D I T I O N A L T A B L E S
Table 1. Overview: overall prognosis of people with intermediate hyperglycaemia and regression from intermediate hypergly-
caemia to normoglycaemia
Follow-up
time (years)
% (95% CI) cumulative T2DM incidence
[no of studies; no of participants with IH]
% (95%CI) regression
from IH to normogly-
caemia
[no of studies; no of
participants with IH]
IFG5.6 IFG6.1 IGT IFG + IGT HbA1c5.7 HbA1c6.0
1 - - 13 (5-23)
[3; 671]
29 (23-36)
[1; 207]
- - 59 (54-64)
[2; 375]
2 2 (1-2)
[1; 1335]
11 (8-14)
[2; 549]
16 (9-26)
[9; 1998]
- - - 46 (36-55)
[9; 2852]
3 17 (6-32)
[3; 1091]
9 (2-20)
[3; 927]
22 (18-27)
[3; 417]
34 (28-41)
[1; 209]
- 7 (5-10)
[1; 370]
41 (24-59)
[7; 1356]
4 17 (13-22)
[3; 800]
30 (17-44)
[2; 1567]
22 (12-34)
[5; 1042]
- 14 (7-23)
[3; 5352]
44 (40-48)
[2; 627]
33 (26-40)
[3; 807]
5 18 (10-27)
[7; 3530]
26 (19-33)
[11; 3837]
39 (25-53)
[12; 3444]
50 (37-63)
[5; 478]
25 (18-32)
[4; 3524]
38 (26-51)
[3; 1462]
34 (27-42)
[9; 2603]
6 22 (15-31)
[4; 738]
37 (31-43)
[5; 279]
29 (25-34)
[7; 775]
58 (48-67)
[4; 106]
17 (14-20)
[1; 675]
- 23 (3-53)
[5; 1328]
7 18 (8-30)
[5; 980]
15 (0-45)
[4; 434]
19 (13-26)
[5; 835]
32 (20-45)
[4; 753]
21 (16-27)
[1; 207]
- 41 (37-45)
[4; 679]
8 34 (27-40)
[2; 1887]
48 (31-66)
[1;29]
43 (37-49)
[4; 1021]
52 (47-57)
[1; 356]
- - 39 (33-44)
[2; 328]
9 38 (10-70)
[3; 1356]
- 53 (45-60)
[1; 163]
84 (74-91)
[1; 69]
- - 17 (14-22)
[1; 299]
10 23 (14-33)
[6; 1542]
29 (17-43)
[6; 537]
26 (17-37)
[6; 443]
30 (17-44)
[2; 49]
31 (29-33)
[2; 2854]
- 42 (22-63)
[7; 894]
11 - 38 (33-43)
[1; 402]
46 (43-49)
[1; 1253]
- - - 28 (17-39)
[2; 736]
12 31 (19-34)
[3; 433]
31 (28-33)
[1; 1382]
41 (38-43)
[2; 1552]
70 (63-76)
[2; 207]
- - -
15 - - - - - 29 (19-40)
[1; 70]
-
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Table 1. Overview: overall prognosis of people with intermediate hyperglycaemia and regression from intermediate hypergly-
caemia to normoglycaemia (Continued)
20 - - 60 (5-68)
[1; 114]
- - - -
CI: confidence interval; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 (threshold 5.7% or 6.0%); IFG5.6/6.1: impaired fasting
glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG + IGT: both IFG and IGT; IH: intermediate
hyperglycaemia; T2DM: type 2 diabetes mellitus
Table 2. Overview: intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for the development of type 2
diabetes
Ratio (95% CI)
95% prediction intervala,b
[no of studies; no of participants with IH/no of participants with normoglycaemia]
Hazard ratio
Region IFG5.6 cohort IFG6.1 cohort IGT cohort IFG + IGT
cohort
HbA1c5.7 co-
hort
HbA1c6.0 co-
hort
HbA1c5.7 +
IFG5.6 cohort
Asia/Middle
East
5.07 (3.41-7.
53)
1.07-24.02
[4; 2385/12,
837]
10.55 (3.61-
30.81)
NAb
[5; 1054/
9756]
4.48 (2.81-7.
15)
NAb
[3; 1780/
6695]
10.20 (5.45-
19.09)
NAb
[3; 461/6695]
7.21 (5.14-
10.11)
0.81-64.52
[3; 3196/13,
609]
13.12 (4.10-
41.96)
NAb
[4; 3492/19,
242]
32.50 (23.00-
45.92)c
NAa
[1; 410/4149]
Australia/
Europe/North
America
4.15 (1.24-
13.87)
NAb
[3; 5685/12,
837]
3.30 (2.32-4.
67)
0.84-12.99
[4; 1736/
8835]
2.53 (1.52-4.
19)
NAa
[2; 2230/
5871]
3.80 (2.30-6.
28)
NAa
[1; 221/1429]
2.71 (2.48-2.
96)
NAa
[1: 2027/
6215]
5.09 (1.69-
15.37)
NAa
[2; 1040/
6925]
-
Latin America - 2.06 (1.76-2.
41)
NAb
[1; 28/66]
- - - - -
American In-
dians/Islands
2.38 (1.85-3.
06)
NAa
[1; 947/595]
- - 4.06 (3.05-5.
40)
NAa
[1; 356/595]
- - -
Overall 4.32 (2.61-7.
12)
0.75-25.01
[8; 9017/25,
850]
5.47 (3.50-8.
54)
1.09-27.56
[9; 2818/18,
591]
3.61 (2.31-5.
64)
0.69-18.97
[5; 4010/12,
566]
6.90 (4.15-
11.45)
1.06-44.95
[5; 1038/
8719]
5.55 (2.77-
11.12)
0.23-141.18
[4; 5223/19,
824]
10.10 (3.59-
28.43)
NAb
[6; 4532/26,
167]
32.50 (23.00-
45.92)
NAa
[1; 410/4149]
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Table 2. Overview: intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for the development of type 2
diabetes (Continued)
Incidence rate ratio
Region IFG5.6 cohort IFG6.1 cohort IGT cohort IFG + IGT
cohort
HbA1c5.7 co-
hort
HbA1c6.0 co-
hort
HbA1c5.7 +
IFG5.6 cohort
Asia/Middle
East
5.23 (3.77-7.
25)
1.72-15.89
[6; 15,661/
145,597]
3.62 (1.67-7.
83)
NAa
[2; 1677/36,
334]
3.93 (3.03-5.
10)
1.71-9.02
[5; 14,809/73,
128]
11.20 (5.59-
22.43)
NAb
[4; 3166/69,
463]
6.62 (4.18-
10.49)
NAa
[1; 1965/
19961]
- 40.72 (29.30-
56.61)
NAa
[1; 1641/19,
961]
Australia/
Europe/North
America
4.96 (3.25-7.
57)
0.32-77.24
[3; 6322/
8062]
8.55 (6.37-
11.48)
4.37-16.73
[4; 3438/20,
246]
5.93 (4.11-8.
57)
2.38-14.81
[5; 2572/22,
329]
13.92 (9.99-
19.40)
6.71-28.85
[4; 699/18,
966]
- - -
Latin America - - - - - - -
American In-
dians/Islands
2.74 (1.88-3.
99)
NAa
[1; 2374/
1613]
- 4.46 (3.12-6.
38)
NAa
[2; 1087/
2952]
5.18 (3.42-7.
83)
NAa
[1; 605/1613]
- - -
Overall 4.81 (3.67-6.
30)
1.95-11.83
[10; 24,357/
155,272]
6.82 (4.53-
10.25)
2.03-22.87
[6; 5115/56,
580]
4.48 (3.69-5.
44)
2.60-7.70
[12; 18,468/
98,409]
10.94 (7.22-
16.58)
2.58-46.46
[9; 4470/90,
072]
6.62 (4.18-
10.5)
NAa
[1; 1965/
19961]
- 40.72 (29.30-
56.61)
NAa
[1; 1641/19,
961]
Odds ratio
IFG5.6 cohort IFG6.1 cohort IGT cohort IFG + IGT
cohort
HbA1c5.7 co-
hort
HbA1c6.0 co-
hort
HbA1c5.7 +
IFG5.6 cohort
Asia/Middle
East
2.94 (1.77-4.
86)
0.43-19.93
[10; 6359/28,
218]
5.18 (2.32-
11.53)
0.29-91.37
[7; 3317/25,
604]
3.74 (2.83-4.
94)
1.70-8.21
[6; 1226/
7417]
6.99 (3.09-
15.83)
NAb
[3; 498/3704]
4.54 (2.65-7.
78)
NAa
[1; 675/462]
23.20 (18.70-
28.78)
NAa
[1; 1103/10,
763]
46.70 (33.60-
64.91)
NAa
[1; 1951/10,
761]
Australia/
Europe/North
America
6.47 (3.81-
11.00)
0.99-42.32
[9; 1949/
7920]
8.69 (4.95-
15.24)
1.20-62.69
[7; 1240/
5094]
5.20 (3.62-7.
45)
1.50-18.09
[11; 1481/
7684]
20.95 (12.40-
35.40)
4.93-89.05
[6; 154/5300]
4.38 (1.36-
14.15)
NAa
[2; 231/2100]
15.60 (6.90-
35.27)
NAa
[1; 370/5365]
26.20 (16.30-
41.11)
NAa
[1; 169/1125]
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Table 2. Overview: intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for the development of type 2
diabetes (Continued)
Latin America 4.28 (3.21-5.
71)
NAa
[1; 65/1594]
3.73 (2.18-6.
38)
NAa
[1; 17/1594]
4.94 (3.15-7.
76)
NAa
[2; 381/3097]
- - - -
American In-
dians/Islands
3.12 (2.31-4.
21)
NAa
[1; 947/595]
- 3.60 (1.40-9.
26)
NAa
[1; 51/215]
- - 5.89 (4.23-8.
20)
NAa
[1; 121/595]
-
Overall 4.15 (2.75-6.
28)
0.54-32.00
[21; 9320/38,
327]
6.60 (4.18-
10.43)
0.93-46.82
[15; 4574/32,
292]
4.61 (3.76-5.
64)
2.10-10.13
[20; 3139/18,
413]
13.14 (7.41-
23.30)
1.84-93.66
[9; 652/9004]
4.43 (2.20-8.
88)
NAb
[3; 906/2562]
12.8 [4.56-
35.9]
NAb
[3; 1594/16,
723]
35.91 (20.43-
63.12)
NAa
[2; 2120/11,
886]
CI: confidence interval; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 (threshold 5.7% or 6.0%); HbA1c5.7 + IFG5.6: both
HbA1c5.7 and IFG5.6; IFG5.6/6.1: impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance;
IFG + IGT: both IFG and IGT; IH: intermediate hyperglycaemia; NA: not applicable; T2DM: type 2 diabetes mellitus; NR: not
reported
aWith fewer than 3 studies a prediction interval could not be calculated
bCalculation of the 95% prediction interval did not provide a meaningful estimate
cCombination of HbA1c6.0 plus IFG5.6 at baseline showed a hazard ratio for T2DM development of 53.7 (95% CI 38.4-75.1)
A P P E N D I C E S
Appendix 1. Glossary of terms
Abbreviation Explanation
ADA American Diabetes Association
ALAT Alanine aminotransferase
ASAT Aspartate transaminase
BG Blood glucose
BMI Body mass index
BW Body weight
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(Continued)
CI Confidence interval
FG Fasting glucose
FBG Fasting blood glucose
FINDRISC Finnish Diabetes Risk Score
FPG Fasting plasma glucose
G6PD Glucose-6-P-dehydrogenase test
HbA1c Glycosylated haemoglobin A1c
HbA1c5.7 Intermediate hyperglycaemia with HbA1c level 5.7%-6.4% at baseline (HbA1c 5.7% threshold)
HbA1c6.0 Intermediate hyperglycaemia with HbA1c level 6.0%-6.4% at baseline (HbA1c 6.0% threshold)
h-CRP High-sensitivity C-reactive protein
HOMA-B(eta) Homeostatic model assessment beta-cell function
HOMA-IR Homeostatic model assessment for insulin resistance
HR Hazard ratio
ICTRP International Clinical Trials Registry Platform
IEC International Expert Committee
IFG Impaired fasting glucose
IFG5.6 Intermediate hyperglycaemiawith impaired fasting plasma glucose level 5.6-6.9mmol/L at baseline (IFG5.6mmol/
L threshold)
IFG6.1 Intermediate hyperglycaemiawith impaired fasting plasma glucose level 6.1-6.9mmol/L at baseline (IFG6.1mmol/
L threshold)
IFG/IGT Combination of both IFG and IGT
i-IFG Isolated IFG
IGT Impaired glucose tolerance (intermediate hyperglycaemia defined by IGT: plasma glucose 7.8-11.1 mmol/L 2 hours
after a 75 g OGTT at baseline)
i-IGT Isolated IGT
IQR Interquartile range
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(Continued)
IRR Incidence rate ratio
JDS Japanese Diabetes Society
M Men
NCEP National cholesterol education program
NDDG National Diabetes Data Group
NGSP National Glycohemoglobin Standardization Program
NGT Normal glucose tolerance
OGTT Oral glucose tolerance test
OR Odds ratio
PG Postload glucose
QUIPS Quality In Prognosis Studies tool
ROC Receiver operating characteristics
RR Risk ratio, relative risk
SD Standard deviation
SE Standard error
T2DM Type 2 diabetes mellitus
W Women
WHO World Health Organization
γ -GT Gamma-glutamyl transferase/transpeptidase
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Appendix 2. Search strategies
Search strategy overview
Tier 1: prediabetes as predictor for CVD, mortality, stroke, cancer, micro/macrovascular complications
(
1. Population block (prediabetes AND prognosis filter)
OR
2. Prediabetes risk factors / diagnostic criteria block ((IFG, IGT, HbA1c) ADJ6 prognosis terms)
)
AND
3. Outcomes block (diabetes complications, micro/macrovascular, mortality)
Tier 2: prediabetes as predictor for diabetes incidence
(
1. Population block (prediabetes AND prognosis filter)
OR
2. Prediabetes risk factors / diagnostic criteria block ((IFG, IGT, HbA1c) ADJ6 prognosis terms)
)
AND
3. Outcomes block (diabetes incidence)
MEDLINE (Ovid SP)
Whole strategy (combining tier 1: ’prediabetes’ as predictor for cardiovascular disease, mortality, stroke, cancer, micro/macrovascular
complications and tier 2: ’prediabetes’ as predictor for diabetes incidence)
1. Prediabetic state/
2. (prediabet* or pre diabet*).tw.
3. intermediate hyperglyc?emi*.tw.
4. or/1-3
5. incidence.sh. or exp mortality/ or follow-up studies.sh. or prognos*.tw. or predict*.tw. or course*.tw. [Wilczynski 2004: MEDLINE
prognosis filter sensitivity maximizing]
6. prognosis/ or diagnosed.tw. or cohort*.mp. or predictor*.tw. or death.tw. or exp models, statistical/ [Wilczynski 2004: MEDLINE
prognosis filter best balance]
7. or/5-6
8. 4 and 7 [population block (prediabetes + prognosis filter)]
9. ((impaired fasting adj2 glucose) or IFG or (impaired adj FPG)).tw
10. (impaired glucose tolerance or IGT).tw.
11. (“HbA(1c)” or HbA1 or HbA1c or “HbA 1c” or ((glycosylated or glycated) adj h?emoglobin)).tw
12. or/9-11
13. (predict* or associa* or prognos*).tw.
14. ((prognostic or predict*) adj2 model?).tw.
15. predictive value?.tw.
16. (risk adj (predict* or factor? or score)).tw.
17. or/13-16
18. (((impaired fasting adj2 glucose) or IFG or “impaired FPG” or impaired glucose tolerance or IGT or “HbA(1c)” or HbA1 or
HbA1c or “HbA 1c” or ((glycosylated or glycated) adj h?emoglobin)) adj3 (predict* or associa* or prognos* or ((prognostic or predict*)
adj2 model?) or predictive value? or (risk adj (predict* or factor? or score)))).tw. [12 adj3 17 // risk factor block]
19. 8 or 18 [block 1 or block 2]
20. complication?.tw.
21. mortality.tw.
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22. (CHD or CVD).tw.
23. (coronary adj2 disease).tw.
24. (coronar* adj (event? or syndrome?)).tw.
25. (heart adj (failure or disease? or attack? or infarct*)).tw
26. (myocardial adj (infarct* or isch?emi*)).tw.
27. cardiac failure.tw.
28. angina.tw.
29. revasculari*.tw.
30. (stroke or strokes).tw.
31. cerebrovascular.tw.
32. ((brain* or cerebr*) adj (infarct* or isch?emi*)).tw.
33. apoplexy.tw.
34. ((vascular or peripheral arter*) adj disease?).tw.
35. cardiovascular.tw.
36. (neuropath* or polyneuropath*).tw.
37. (retinopath* or maculopath*).tw.
38. (nephropath* or nephrotic or proteinuri* or albuminuri*).tw
39. ((kidney or renal) adj (disease? or failure or transplant*)).tw
40. ((chronic or endstage or end stage) adj (renal or kidney)).tw
41. (CRD or CRF or CKF or CRF or CKD or ESKD or ESKF or ESRD or ESRF).tw
42. (microvascular or macrovascular or ((micro or macro) adj vascular)).tw
43. (cancer or carcino* or neoplas* or tumo?r?).tw.
44. (amputation? or ulcer* or foot or feet or wound*).tw.
45. or/20-44 [tier 1 strategy outcomes block]
46. 19 and 45
47. ((diabet* or type 2 or type II or T2D*) adj4 (progress* or inciden* or conversion or develop* or future)).tw. [tier 2 strategy outcomes
block]
48. 19 and 47
49. 46 or 48
50. exp animals/ not humans/
51. 49 not 50
52. (gestational or PCOS).tw.
53. 51 not 52
54. (comment or letter or editorial).pt.
55. 53 not 54
56. remove duplicates from 55
Embase (Ovid SP)
Whole strategy (combining tier 1: ’prediabetes’ as predictor for cardiovascular disease, mortality, stroke, cancer, micro/macrovascular
complications and tier 2: ’prediabetes’ as predictor for diabetes incidence)
1. (prediabet* or pre diabet*).tw.
2. intermediate hyperglyc?emi*.tw.
3. or/1-2
4. exp disease course or risk*.mp. or diagnos*.mp. or follow-up.mp. or ep.fs. or outcome.tw. [Wilczynski 2005: Embase prognosis filter
sensitivity maximizing]
5. follow-up.mp. or prognos*.tw. or ep.fs. [Wilczynski 2005: Embase prognosis filter best balance]
6. or/4-5
7. 3 and 6 [population block (prediabetes + prognosis filter)]
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8. ((impaired fasting adj2 glucose) or IFG or (impaired adj FPG)).tw
9. (impaired glucose tolerance or IGT).tw.
10. (“HbA(1c)” or HbA1 or HbA1c or “HbA 1c” or ((glycosylated or glycated) adj h?emoglobin)).tw
11. or/8-10
12. (predict* or associa* or prognos*).tw.
13. ((prognostic or predict*) adj2 model?).tw.
14. predictive value?.tw.
15. (risk adj (predict* or factor? or score)).tw.
16. or/12-15
17. (((impaired fasting adj2 glucose) or IFG or “impaired FPG” or impaired glucose tolerance or IGT or “HbA(1c)” or HbA1 or
HbA1c or “HbA 1c” or ((glycosylated or glycated) adj h?emoglobin)) adj3 (predict* or associa* or prognos* or ((prognostic or predict*)
adj2 model?) or predictive value? or (risk adj (predict* or factor? or score)))).tw. [12 adj3 17 // risk factor block]
18. 7 or 17 [block 1 or block 2]
19. complication?.tw.
20. mortality.tw.
21. (CHD or CVD).tw.
22. (coronary adj2 disease).tw.
23. (coronar* adj (event? or syndrome?)).tw.
24. (heart adj (failure or disease? or attack? or infarct*)).tw
25. (myocardial adj (infarct* or isch?emi*)).tw.
26. cardiac failure.tw.
27. angina.tw.
28. revasculari*.tw.
29. (stroke or strokes).tw.
30. cerebrovascular.tw.
31. ((brain* or cerebr*) adj (infarct* or isch?emi*)).tw.
32. apoplexy.tw.
33. ((vascular or peripheral arter*) adj disease?).tw.
34. cardiovascular.tw.
35. (neuropath* or polyneuropath*).tw.
36. (retinopath* or maculopath*).tw.
37. (nephropath* or nephrotic or proteinuri* or albuminuri*).tw
38. ((kidney or renal) adj (disease? or failure or transplant*)).tw
39. ((chronic or endstage or end stage) adj (renal or kidney)).tw
40. (CRD or CRF or CKF or CRF or CKD or ESKD or ESKF or ESRD or ESRF).tw
41. (microvascular or macrovascular or ((micro or macro) adj vascular)).tw
42. (cancer or carcino* or neoplas* or tumo?r?).tw.
43. (amputation? or ulcer* or foot or feet or wound*).tw.
44. or/19-43 [tier 1 strategy outcomes block]
45. 18 and 44
46. ((diabet* or type 2 or type II or T2D*) adj4 (progress* or inciden* or conversion or develop* or future)).tw. [tier 2 strategy outcomes
block]
47. 18 and 46
48. 45 or 47
[49-53: TSC Portal filter for exclusion of animal references]
49. exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
50. human/ or normal human/ or human cell/
51. 49 and 50
52. 49 not 51
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53. 48 not 52
54. (gestational or PCOS).tw.
55. 53 not 54
56. (comment or letter or editorial or conference).pt.
57. 55 not 56
58. remove duplicates from 57
ClinicalTrials.gov (Expert search)
( prediabetes OR prediabetic OR “pre diabetes” OR “pre diabetic” OR “intermediate hyperglycemia” OR “intermediate hypergly-
caemia”OR “intermediate hyperglycemic”OR “intermediate hyperglycaemic”OR “impaired glucose tolerance”OR “impaired fasting
glucose” ) AND ( complication OR complications OR mortality OR CHD OR CVD OR coronary OR heart OR myocardial OR
infarct OR infarction OR infarcts OR infarctions OR ischemia OR ischemic OR ischaemia OR ischaemic OR failure OR angina OR
revascularization OR revascularisation OR revascularizations OR revascularisations OR stroke OR strokes OR cerebrovascular OR
apoplexy OR vascular or peripheral OR cardiovascular OR neuropathy OR neuropathies OR polyneuropathy OR polyneuropathies
OR retinopathy OR retinopathies OR maculopathy OR maculopathies OR nephropathy OR nephropathies OR nephrotic OR
proteinuria OR proteinuric OR albuminuria OR kidney OR renal OR CRD OR CRF OR CKF OR CRF OR CKD OR ESKD
OR ESKF OR ESRD OR ESRF OR microvascular OR macrovascular OR “micro vascular” OR “macro vascular” OR cancer OR
carcinoma OR neoplasmOR neoplasms OR tumor OR tumors OR tumour OR tumours OR amputation OR amputations OR ulcer
OR foot OR feet OR wounds OR ( diabetes OR diabetic OR “type 2” OR “type II” OR T2D OR T2DM ) AND ( progress OR
progression OR progressed OR incident OR incidence OR conversion OR developed OR development OR future ) ) [OUTCOME]
ICTRP Search Portal (Standard search)
prediabet* AND prognos* OR
prediabet* AND predict* OR
prediabet* AND inciden* OR
prediabet* AND mortality OR
prediabet* AND prevent* OR
prediabet* AND progress* OR
prediabet* AND develop* OR
pre diabet* AND prognos* OR
pre diabet* AND predict* OR
pre diabet* AND inciden* OR
pre diabet* AND mortality OR
pre diabet* AND prevent* OR
pre diabet* AND progress* OR
pre diabet* AND develop* OR
impaired glucose tolerance AND prognos* OR
impaired glucose tolerance AND predict* OR
impaired glucose tolerance AND inciden* OR
impaired glucose tolerance AND mortality OR
impaired glucose tolerance AND prevent* OR
impaired glucose tolerance AND progress* OR
impaired glucose tolerance AND develop* OR
impaired fasting glucose AND prognos* OR
impaired fasting glucose AND predict* OR
impaired fasting glucose AND inciden* OR
impaired fasting glucose AND mortality OR
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impaired fasting glucose AND prevent* OR
impaired fasting glucose AND progress* OR
impaired fasting glucose AND develop* OR
HbA* AND prognos* OR
HbA* AND predict* OR
HbA* AND inciden* OR
HbA* AND mortality OR
HbA* AND prevent* OR
HbA* AND progress* OR
HbA* AND develop*
Seed publications (for PubMed’s ’similar articles’-algorithm)
24355200[PMID] OR 16873795[PMID] OR 9705020[PMID] OR 25906786[PMID] OR 9363520[PMID] OR
21278140[PMID] OR 21676480[PMID] OR 21300382[PMID] OR 10862313[PMID] OR 18689695[PMID] OR
27596059[PMID] OR 12397006[PMID] OR 18673544[PMID] OR 21307378[PMID] OR 15220202[PMID] OR
22647753[PMID] OR 28258520[PMID] OR 10663216[PMID] OR 20573752[PMID] OR 20622160[PMID] OR
9300248[PMID] OR 2060716[PMID] OR 27459384[PMID] OR 12757990[PMID] OR 10414941[PMID] OR
21335372[PMID] OR 9653617[PMID] OR 20073428[PMID] OR 17309402[PMID] OR 17315136[PMID] OR
14025561[PMID] OR 10466767[PMID] OR 26273669[PMID] OR 28698884[PMID] OR 11311100[PMID] OR
14710970[PMID] OR 27933333[PMID] OR 27543801[PMID] OR 2035513[PMID] OR 12062857[PMID] OR
11978676[PMID] OR 11679461[PMID] OR 19224196[PMID] OR 14693710[PMID] OR 28278309[PMID] OR
17257284[PMID] OR 7859632[PMID] OR 2689122[PMID] OR 10937506[PMID] OR 27515749[PMID] OR
20484131[PMID] OR 26675051[PMID] OR 8866565[PMID] OR 17032347[PMID] OR 11686540[PMID] OR
26606421[PMID] OR 18282630[PMID] OR 8635647[PMID] OR 9243105[PMID] OR 8886564[PMID] OR 7589843[PMID]
OR 9028719[PMID] OR 2407581[PMID] OR 28751960[PMID] OR 2912042[PMID] OR 28043048[PMID] OR
11916954[PMID] OR 16344402[PMID] OR 19531260[PMID] OR 19414206[PMID] OR 1216390[PMID] OR
22456865[PMID] OR 22510023[PMID] OR 22955996[PMID] OR 21705064[PMID] OR 21212932[PMID] OR
28768835[PMID] OR 9162608[PMID] OR 17000944[PMID] OR 25814432[PMID] OR 9406673[PMID] OR
11110508[PMID] OR 27740930[PMID] OR 24843430[PMID] OR 16518992[PMID] OR 18486512[PMID] OR
29133894[PMID] OR 29380232[PMID] OR 8894485[PMID] OR 28951335[PMID] OR 5226858[PMID] OR
27368062[PMID] OR 16100444[PMID] OR 15223223[PMID] OR 18452257[PMID] OR 27085081[PMID] OR
25245975[PMID] OR 6706044[PMID] OR 20827664[PMID] OR 20536946[PMID] OR 11606173[PMID] OR
10587859[PMID] OR 14967156[PMID] OR 7782724[PMID] OR 9754834[PMID] OR 11079739[PMID] OR
28004008[PMID] OR 17320447[PMID] OR 11772900[PMID] OR 2260546[PMID] OR 26885316[PMID] OR
25215305[PMID] OR 29074816[PMID] OR 18206734[PMID] OR 12590020[PMID] OR 26575606[PMID] OR
22640983[PMID] OR 24135387[PMID] OR 26840038[PMID] OR 24992623[PMID] OR 18485514[PMID] OR
27749572[PMID] OR 14578254[PMID] OR 15616025[PMID] OR 7748921[PMID] OR 17989310[PMID] OR
28371687[PMID] OR 8112189[PMID] OR 12610034[PMID] OR 12765960[PMID] OR 11784224[PMID] OR
9829346[PMID] OR 6702817[PMID] OR 3516770[PMID] OR 18697630[PMID] OR 11437858[PMID] OR 8612442[PMID]
OR 8070301[PMID] OR 8454106[PMID] OR 9203444[PMID] OR 12519316[PMID] OR 19414203[PMID] OR
8335178[PMID]OR1892482[PMID]OR2261821[PMID]OR27515716[PMID]OR15036828[PMID]OR15983331[PMID]
OR 8875091[PMID] OR 8720611[PMID] OR 3751746[PMID] OR 20508383[PMID] OR 17914548[PMID] OR
7497867[PMID] OR 16600415[PMID] OR 23283714[PMID] OR 21738002[PMID] OR 8922541[PMID] OR
25624343[PMID] OR 7481176[PMID] OR 12414877[PMID] OR 11106838[PMID] OR 3527626[PMID] OR
17143605[PMID] OR 18060659[PMID] OR 12627316[PMID] OR 20002472[PMID] OR 17259503[PMID] OR
11068083[PMID] OR 29018885[PMID] OR 3054559[PMID] OR 25350916[PMID] OR 21107436[PMID] OR
7075915[PMID] OR 19131461[PMID] OR 17536075[PMID] OR 18316395[PMID] OR 2752891[PMID] OR
20855549[PMID] OR 20200384[PMID] OR 23497506[PMID] OR 24083174[PMID] OR 10097917[PMID] OR
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9405904[PMID] OR 3542644[PMID] OR 20978739[PMID] OR 15189364[PMID] OR 25962707[PMID] OR
27239315[PMID] OR 18226046[PMID] OR 12777437[PMID] OR 12582008[PMID] OR 8314414[PMID] OR
8482427[PMID] OR 6507426[PMID] OR 18535192[PMID] OR 10333940[PMID] OR 16990660[PMID] OR
19046200[PMID] OR 10812323[PMID] OR 10480514[PMID] OR 17536076[PMID] OR 18249214[PMID] OR
20934897[PMID] OR 28632742[PMID] OR 27810987[PMID] OR 18405128[PMID] OR 8680609[PMID] OR
20578203[PMID] OR 16720024[PMID] OR 15451912[PMID] OR 15533586[PMID] OR 21270194[PMID] OR
10333943[PMID] OR 27863979[PMID] OR 11781759[PMID] OR 15175438[PMID] OR 15793193[PMID] OR
11194248[PMID] OR 26913636[PMID] OR 7712700[PMID] OR 14578234[PMID] OR 21718910[PMID] OR
15161800[PMID]
Appendix 3. QUIPS tool signalling questions
Study ID
Signalling question Authors’ judgement for ’yes’
Study participation: yes/noa /unclearb/NAc
a. Adequate participation in the study by eligible people NA: usually participants with information on glycaemic status
and follow-up data providing information on development of type
2 diabetes are selected from a greater study cohort (e.g. study
evaluating several cardiovascular risk factors)
b. Description of the source population or population of interest Source population for cohort with intermediate hyperglycaemia
is clearly described
c. Description of the baseline study sample Number of people with intermediate hyperglycaemia at baseline
is clearly described
d. Adequate description of the sampling frame and recruitment Way of establishing the source population, selection criteria and
key characteristics of the source population clearly described
e. Adequate description of the period and place of recruitment Time period andplace of recruitment for both baseline and follow-
up examinations are clearly described
f. Adequate description of inclusion and exclusion criteria Definiton of people with normoglycaemia, intermediate hyper-
glycaemia or diabetes mellitus and description of other inclusion
and exclusion criteria
Study participation: risk of bias rating (high/low/unclear) High: most items are answered with ’no’; Low: all items answered
with ’yes’; Unclear: most items are answered with ’unclear’
Note: potentially a single item may introduce a high risk of bias,
depending on study specifics
Study attrition: yes/no/unclear/NA
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a. Adequate response rate for study participants NA: usually participants with information on glycaemic status
and follow-up data providing information on development of type
2 diabetes are selected from a greater study cohort (e.g. study
evaluating several cardiovascular risk factors)
b. Attempts to collect information on participants who dropped
out described
Attempts to collect information on participants who dropped out
are described (e.g. telephone contact, mail, registers)
c. Reasons for loss to follow-up provided Reasons on participants who dropped out are available (e.g. de-
ceased participants between baseline and follow-up, participants
moving to another location)
d. Adequate description of participants lost to follow-up Key characteristics of participants lost to follow-up are described
(age, sex, glucose status at baseline, body mass index)
e. No important differences between participants who completed
the study and those who did not
Study authors described differences between participants com-
pleting the study and those who did not as not important or in-
formation provided to judge the differences
Study attrition: risk of bias rating (high/low/unclear) High: most items are answered with ’no’; Low: all items answered
with ’yes’; Unclear: most items are answered with ’unclear’
Note: potentially a single item may introduce a high risk of bias,
depending on study specifics
Glycaemic status measurement: yes/no/unclear/NA
a. Clear definition or description provided Measurements for glycaemic status are provided (e.g. IFG, IGT,
elevated HbA1c)
b. Adequately valid and reliable method of measurement Ideally measurements for glycaemic status are repeated to ensure
diagnosis, single measurements are accepted as well; technique for
glucose measurement or HbA1c measurement described
c. Continuous variables reported or appropriate cut points used Standard categories for intermediate hyperglycaemia (FPG 5.6-6.
9 mmol/L (IFG5.6), FPG 6.1-6.9 mmol/L (IFG6.1), 2-h PG 7.8
to < 11.0 mmol/L (IGT), HbA1c 6.0-6.4% (HbA1c6.0), HbA1c
5.7-6.4% (HbA1c5.7))
d. Same method and setting of measurement used in all study
participants
Measurements of glycaemic status are the same for all study par-
ticipants
e. Adequate proportion of the study sample had complete data NA: usually participants with information on glycaemic status
and follow-up data providing information on development of type
2 diabetes are selected from a greater study cohort (e.g. study
evaluating several cardiovascular risk factors)
f. Appropriate methods of imputation were used for missing data NA:missing laboratory measurements for glycaemic status cannot
be reliably imputed
356Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Glycaemic status measurement: risk of bias rating (high/low/
unclear)
High: most items are answered with ’no’; Low: all items answered
with ’yes’; Unclear: most items are answered with ’unclear’
Note: potentially a single item may introduce a high risk of bias,
depending on study specifics
Outcome measurement: yes/no/unclear
a. Clear definition of the outcome provided Measurement of type 2 diabetes mellitus has to be defined
b. Use of adequately valid and reliable method of outcome mea-
surement
Measurement of type 2 diabetes mellitus: a glucose (FPG, PG)
or HbA1c measurement has to be a part of the diagnosis (self-
reported diabetes alone will not be accepted)
c. Use of same method and setting of outcome measurement in
all study participants
Measurements of type 2 diabetes mellitus are the same for all study
participants
Outcome measurement: risk of bias rating (high/low/unclear) High: most items are answered with ’no’; Low: all items answered
with ’yes’; Unclear: most items are answered with ’unclear’
Note: potentially a single item may introduce a high risk of bias,
depending on study specifics
Study confounding: yes/no/unclear
a. Measurement of all important confounders Important confounders are: age, sex, family history of diabetes,
’ethnicity’, body mass index, blood pressure and hypertension,
smoking and drinking status, socioeconomic status, comedica-
tions and comorbidities, physical activity
b. Provision of clear definitions of the important confounders
measured
Measurement of confounders has to be clearly described
c. Adequately valid and reliable measurement of all important
confounders
Measurement of confounders is valid and reliable
d. Use of same method and setting of confounding measurement
in all study participants
Measurements of confounders are the same for all study partici-
pants
e. Appropriate imputation methods used for missing confounders
(if applicable)
Strategy to impute missing confounder data is described
f. Important potential confounders were accounted for in the
study design
Methods section of the publication describes strategy to account
for confounders
g. Important potential confounders were accounted for in the
analysis
Important confounders are accounted for in multivariable logistic
regression and Cox proportional hazards models
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Study confounding measurement: risk of bias rating (high/
low/unclear)
High: most items are answered with ’no’; Low: all items answered
with ’yes’; Unclear: most items are answered with ’unclear’
Note: potentially a single item may introduce a high risk of bias,
depending on study specifics
Statistical analysis and reporting: yes/no/unclear/NA
a. Sufficient presentation of data to assess the adequacy of the
analytic strategy
Mean ormedian values, including confidence intervals or standard
errors or standard deviations
b. Strategy for model building is appropriate and based on a con-
ceptual framework or model
NA: we do not anticipate conceptual frameworks or explicitmodel
building strategies for this type of research question (focusing on
one prognostic factor only)
c. Statistical model is adequate for the study design Mainly incidence rates, uni- and multivariate logistic regression,
Cox proportional hazard model
d. No selective reporting of results NA: development of type 2 diabetes mellitus and potentially re-
gression to normoglycaemia from intermediate hyperglycaemia
are the only outcomes; if missing the study will be excluded
Statistical analysis and reporting: risk of bias rating (high/
low/unclear)
High: most items are answered with ’no’; Low: all items answered
with ’yes’; Unclear: most items are answered with ’unclear’
Note: potentially a single item may introduce a high risk of bias,
depending on study specifics
aNo: no or no relevant information to answer the signalling question
bUnclear: not enough information to answer signalling question with yes or no
cNA (not applicable): signalling question not appropriate for this type of prognostic review
FPG: fasting plasma glucose;HbA1c: glycosylated haemoglobin A1c; IFG: impaired fasting glucose; IGT: impaired glucose tolerance;
PG: postload glucose (after an oral glucose tolerance test)
Appendix 4. Major cohort studies
Cohort study acronym Full study name
ADDITION Anglo-Danish-Dutch study of Intensive Treatment in People with Screen Detected Diabetes in Primary
Care (Rasmussen 2008)
- Ansung-Ansan Cohort Study (part of the Korean Genome and Epidemiology Study (KoGES)) - (Han
2017)
Asturias Asturias Study (Valdes 2008)
358Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
ARIC Atherosclerosis Risk in Communities study (Warren 2017)
ATTICA Province of Attica, Greece Study (Filippatos 2016)
AusDiab Australian Diabetes, Obesity and Lifestyle Study (Magliano 2008)
BLSA Baltimore Longitudinal Study of Aging (Meigs 2003)
BLSA Beijing Longitudinal Study on Aging (Liu 2016)
- Beijing Project as part of the National Diabetes Survey (Wang 2007)
BMES Blue Mountains Eye Study (Cugati 2007)
- Botnia Study (Lyssenko 2005)
- Bruneck Study (Bonora 2011)
CUPS-19 Chennai Urban Population Study-19 (Mohan 2008)
CURES Chennai Urban Rural Epidemiology Study (Anjana 2015)
ChinaMUCA China Multicenter Collaborative Study of Cardiovascular Epidemiology (Liu 2017)
CODAM Cohort on Diabetes and Atherosclerosis Maastricht (Den Biggelaar 2016)
DESIR Data from an Epidemiological Study on the Insulin Resistance Syndrome (Gautier 2010)
- Ely Study (Forouhi 2007)
EPIC-Norfolk cohort European Prospective Investigation of Cancer Norfolk cohort (Chamnan 2011)
- Finnish Cohorts of the Seven Countries Study (Stengard 1992)
None Framingham Heart Study (Levitzky 2008)
GOS Geelong Osteoporosis Study (De Abreu 2015)
Health ABC Health, Aging, and Body Composition Study (Lipska 2013)
- Hoorn Study (Rijkelijkhuizen 2007)
None Hong Kong Cardiovascular Risk Factor Prevalence Study (Wat 2001)
IRAS Insulin Resistance Atherosclerosis Study (Hanley 2005)
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ICS Isfahan Cohort Study (baseline survey of the Isfahan Healthy Heart Program) (Sadeghi 2015)
IDPS Isfahan Diabetes Prevention Study (Janghorbani 2015)
Israel GOH Study Israel Study of Glucose Intolerance, Obesity and Hypertension (Bergman 2016)
ILSA Italian Longitudinal Study on Aging (Motta 2010)
- Japanese American Community Diabetes Study (McNeely 2003)
JPHC Study Japanese Public-Health Center-based prospective (Diabetes) Study (Noda 2010)
- Kansai Healthcare Study (Sato 2009)
- Kinmen Study (Li 2003)
KORA S4/F4 Kooperative Gesundheitsfroschung in der Region Augsburg (Rathmann 2009)
KoGES Korean Genome Epidemiology Study-Kangwha Study (Song 2015)
- Kurihashi Lifestyle Cohort Study (Nakagami 2016)
- Mexico City Diabetes Study (Ferrannini 2009)
MESA Multi-Ethnic Study of Atherosclerosis (Yeboah 2011)
- Nauru Study (Dowse 1991)
- Paris Prospective Study (Charles 1997)
- Pima Indian Study (Gila River Indian Community) (Wheelock 2016)
- Pizarra study (Soriguer 2008)
PIFRECV Programa de Investigación de Factores de Riesgo de Enfermedad Cardiovascular (Leiva 2014)
- Rotterdam study (Ligthart 2016)
SALSA Sacramento Area Latino Study on Aging (Garcia 2016)
SAHS San Antonio Heart Study (Lorenzo 2003)
- San Luis Valley Diabetes Study (Marshall 1994)
- Singapore Impaired Glucose Tolerance Follow-up Study (Wong 2003)
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SIMES Singapore Malay Eye Study (Man 2017)
SDPP Stockholm Diabetes Prevention Programme (Alvarsson 2009a)
SHS Strong Heart Study (Wang 2011)
- Study within the WHO-assisted National Diabetes Programme (Schranz 1989)
SUNSET/HELIUS Surinamese in the Netherlands: study on health and ethnicity/Healthy life in an urban setting (Admiraal
2014)
TLGS Tehran Lipid and Glucose Study (Derakhshan 2016)
TOPICS Toranomon Hospital Health Management Center Study (Heianza 2012)
- Yonchon study (Shin 1997)
- Zanjan Healthy Heart Study (Sharifi 2013)
Appendix 5. Definition of normoglycaemia, intermediate hyperglycaemia and incident type 2
diabetes
Study ID Normogly-
caemia
(mmol/L or
%)
Intermedi-
ate hypergly-
caemia
(mmol/L or
%)
Incident type
2 diabetes
(mmol/L or
%)
OGTT mea-
surement
(glucose
load)
OGTT at
baseline
OGTT at fol-
low-up
Notes
Admiraal
2014
- IFG: FPG5.7-
6.9
FPG ≥ 7.0;
HbA1c ≥ 6.5;
self-reported
diabetes
- - - -
Aekplakorn
2006
- IFG: FPG ≥
5.6 to < 7.0;
IGT: 2-h PG
≥ 7.8 to < 11.
1
FPG ≥ 7.0; 2-
h PG≥ 11; di-
agnosis and/or
receipt of anti-
hypergly-
caemic medi-
cation
75 g Yes No -
Ammari
1998
- IGT: 2-h PG
7.8 to < 11.1
(WHO 1985)
2-h PG≥ 11.1
(WHO 1985)
75 g Yes Yes -
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Anjana 2015 FPG < 5.6 and
2-h PG < 7.8
i-IGT: 2-h PG
7.8-11.0 and
FPG > 5.6; i-
IFG: FPG 5.
6-6.9 and 2-h
PG < 7.8; pre-
diabetes: FPG
5.6-6.9 or 2-
h PG 7.8-11.
0 (i-IGT or i-
IFG or IFG/
IGT)
FPG ≥ 7.0; 2-
h PG ≥ 11.1;
diagnosed; an-
tihypergly-
caemic medi-
cation
75 g Yes Unclear -
Bae 2011 - HbA1c 5.7-6.
4, HbA1c 6.0-
6.4
FPG ≥ 7.0;
HbA1c ≥ 6.5;
history of di-
abetes; antihy-
perglycaemic
medication
None None None -
Baena-Diez
2011
FPG < 6.1 IFG: 6.1-6.9 FPG ≥
7.0 (measured
twice)
- - - -
Bai 1999 - IGT: 7.8 to
< 11.1 (WHO
1985)
2-h PG≥ 11.1
(WHO 1985)
75 g Yes Yes -
Bergman
2016
FPG < 5.6 +
and no antihy-
pergly-
caemic medi-
cation and 2-
h BG < 7.8 (if
available)
FPF 5.6-
7.8 (7.7?); 2-h
BG 7.8-11.0
FPG ≥ 7.8, 2-
h BG ≥ 11.1;
self-reported
100 g Yes Unclear -
Bonora 2011 - HbA1: 6.0-6.
49; IFG: not
defined, prob-
ably FPG 5.6-
6.9
FPG ≥ 7.0;
HbA1c ≥ 6.5;
diabetes treat-
ment
75 g Yes Unclear -
Cederberg
2010
- IFG: 6.1-6.9,
2-h PG < 7.
8; IGT: FPG
> 7.0, 2-h PG
7.8 to < 11.1
(WHO 2009)
; elevated
2-h PG: ≥ 11.
1, confirmed
by 2 OGTTs
- - - Diabetes inci-
dence
and IFG/IGT
not exactly de-
fined
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HbA1c: 5.7-6.
4
Chamnan
2011
- HbA1c 6.0-6.
4
HbA1c ≥ 6.5;
reported
physician-
diagnosed di-
abetes or dia-
betes medica-
tions; antihy-
pergly-
caemic med-
ication; diag-
nosis through
registers
- - - -
Charles 1997 - IGT: 2-h PG
≥ 7.8 to <
11.1 (WHO
1985)
2-h PG≥ 11.1
(WHO 1985)
; physician
diagnosed dia-
betes
75 g Yes Yes 2nd and 4th
examination
Chen 2003 FPG < 6.1 IFG: FPG6.1-
7.0
FPG ≥ 7.0 - - - -
Chen 2017 FPG < 5.6 and
2-h PG < 7.8
IFG: FPG5.6-
6.9 + 2-h PG
≤ 7.8; IGT:
FPG<5.6 + 2-
h PG 7.8-11.
0; IFG/IGT:
FPG 5.6-6.9 +
2-h PG 7.8-
11.0
FPG ≥ 7.0; 2-
h PG ≥ 11.
1; previously
diagnosed dia-
betes
75 g Yes Unclear -
Coronado-
Malagon
2009
ADA 2007 ADA 2007
(IFG/IGT: 5.
6-6.9/7.8 to <
11.1)
ADA 2007 (≥
7.0/≥ 11.1)
- - - -
Cugati 2007 - IFG: FPG5.6-
6.9 (originally
FPG ≥ 6.1 to
< 7.0)
FPG ≥ 7.0;
self-
reported dia-
betes history;
antihypergly-
caemic medi-
cation
- - - -
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De Abreu
2015
- IFG: 5.5-6.9 FPG ≥ 7.0;
self-reported;
antihypergly-
caemic medi-
cation
- - - -
Den
Biggelaar
2016
FPG < 6.1 and
2-h PG < 7.8
FPG 6.1-6.9;
2-h PG 7.8-
11.1
FPG ≥ 7.0; 2-
h PG ≥ 11.1
75 g Yes Unclear -
Derakhshan
2016
FPG ≤ 5.55
and 2-h PG ≤
7.77
5.55 ≤FPG <
7.0; 7.77 ≤ 2-
h PG ≤ 11.1;
no antihyper-
glycaemic
medication
FPG ≥ 7.0; 2-
h PG ≥ 11.1;
antihypergly-
caemic medi-
cation
82.5 g Yes Unclear Glu-
cose monohy-
drate solution,
equivalent
to 75 g anhy-
drous glucose
Dowse 1991 FPG and 2-h
PG < 7.8
IGT: FPG < 7.
8 and 2-h PG
≥ 7.8 to < 11.
1
2-h PG≥ 11.1
(WHO 1985)
; FPG ≥ 7.8
75 g Yes Yes -
Ferrannini
2009
- IFG: FPG6.1-
6.9; IGT: FPG
< 7.0 and 2-
h PG 7.8-11.
1; i-IFG6.1/i-
IFG5.6:
2-h PG < 7.8
and FPG 6.1-
6.9/5.6-6.1; i-
IGT/i-
IGT6.1/i-
IGT5.6
FPG ≥ 7.0; 2-
h PG ≥ 11.1
75 g Yes Yes -
Filippatos
2016
- IFG5.6: FBG
5.6-6.9
FBG > 6.9;
antihypergly-
caemic medi-
cation
None None None -
Forouhi 2007 FPG < 5.6 IFG6.1: FPG
6.1-6.9 (FPG
< 7.0 and 2-h
PG < 11.1)
(all) IFG5.6:
FPG 5.6-6.9
FPG ≥ 7.0; 2-
h PG ≥ 11.
1; doctor diag-
nosis or treat-
ment for dia-
betes
75 g Yes Yes -
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Garcia 2016 - Prediabetes:
FBG 5.6-6.9
FPG ≥ 7.0;
self-reported;
antihypergly-
caemic medi-
cation; di-
abetes comed-
ication of
death
- - - -
Gautier 2010 - IFG: FPG5.6-
6.9
FPG
≥ 7.0; treat-
ment for dia-
betes (at one
of the 3-yearly
examinations)
- - - -
Gomez-
Arbelaez
2015
- IFG: ≥ 5.6 to
< 7.0; IGT: ≥
7.8 to < 11.1;
HbA1c ≥ 5.7
to ≤ 6.4
FPG ≥ 7.0;
OGTT ≥ 11.
1;HbA1c≥ 6.
5
OGTT Yes Yes OGTTs
fromhospital’s
database
Guerrero-
Romero 2006
FPG < 6.1 and
2-h PG < 7.8
IGT: 2-h PG
≥ 7.8 to < 11.
1
2-h PG: ≥ 11.
1
OGTT Yes Yes OGTT:
as baseline and
each year dur-
ing the 5-year
follow-up
Han 2017 FPG < 5.6 and
2-h PG < 7.8
IFG: FPG5.6-
6.9 and no di-
agnosis of dia-
betes
IGT: 2-h PG
7.8 to < 11.1
i-IFG5.6: IFG
without IGT
i-IGT: IGT
without IFG
IGT, IGT:
IFG + IGT
’Prediabetes’:
IFG or IGT
FPG ≥ 7.0; 2-
h PG ≥ 11.
1;HbA1c≥ 6.
5; current an-
tihypergly-
caemic treat-
ment
75 g Yes Yes OGTT was
performed ev-
ery 2 years
Hanley 2005 - IFG,IGT
(WHO 1999)
Unclear 75 g Yes No -
Heianza
2012
Absence
of IFG or ele-
vated HbA1c
IFG: FPG5.6-
6.9
or FPG 6.1-6.
FPG
≥ 7.0; HbA1c
≥ 6.5%; self-
- - - -
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9; HbA1c 5.7-
6.4 or 6.0-6.4;
IFG/HbA1c =
’prediabetes’
reported clini-
cian-diag-
nosed diabetes
Inoue 1996 - IGT: ≥ 7.8 to
< 11.1 (pre-
sumed WHO
1985)
IGT: ≥ 11.1
(presumed
WHO 1985)
75 g Yes Yes OGGT was
performed ev-
ery year
Janghorbani
2015
FPG < 5.6 and
2-h PG < 7.8
i-IGT: FPG <
5.6 and 2-h
PG 7.8-11.1;
i-IFG: 5.6-6.9
and 2-h PG <
7.8; IFG/IGT:
5.6-6.9 and 2-
h PG 7.8-11.1
FPG ≥ 11.1;
antihypergly-
caemic medi-
cation; 2nd
FPG ≥ 7.0; 2-
h PG ≥ 11.1
75 g Yes Yes -
Jaru-
ratanasirikul
2016
FPG < 5.6 i-IGT: FPG <
5.6 and 2-h
PG 7.8 to <
11.1
FPG > 7.0; 2-
h PG ≥ 11.1
1.75 g/kg
(maximum 75
g) glucose so-
lution
Yes No -
Jeong 2010 - IFG: FPG ≥
5.6 to < 7.0;
IGT: 2-h PG
≥ 7.8 to <
11.1: ’predia-
betes’: IFG or
IGT
FPG ≥ 7.0; 2-
h PG ≥ 11.1
75 g Yes Yes -
Jiamjaras-
rangsi
2008a
- IFG: FPG ≥
5.6 to < 7.0
FPG ≥ 7.0 - - - -
Kim 2005 FPG < 5.0 IFG6.1: FPG
6.1 to < 7.
0 (group 4, =
276)
IFG5.6: FPG
5.6 to < 6.1
FPG ≥ 7.0;
antihypergly-
caemic treat-
ment
- - - -
Kim 2008 - IFG5.6: FPG
5.
6-7.0; IFG6.1:
FPG 6.1-7.0
FPG ≥ 7.0 - - - -
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Kim 2014 - i-IFG: FPG 5.
6-6.9 and 2-
h PG < 7.
8; i-IGT: 2-
h PG 7.8-11.
1 and FPG <
5.6; IFG/IGT:
combined glu-
cose intoler-
ance; HbA1c:
5.7-6.4
FPG ≥ 7.0; 2-
h PG ≥ 11.1;
HbA1c ≥ 6.5
75 g Yes Unclear -
Kim 2016a - FPG 5.6-6.9;
HbA1c 5.7-6.
4
FPG ≥ 7.0;
HbA1c ≥ 6.5;
antihypergly-
caemic medi-
cations
- - - -
Kleber 2010 - IGT: 2-h PG >
7.7: IFG: FPG
≥ 5.5 (WHO
definition)
ADA 2000 1.75 g/kg body weight (maxi-
mum 75 g) flavoured glucose
Yes -
Kleber 2011 - IGT: not
reported (pre-
sumed 7.8-11.
1)
“ADA”
(2000 criteria,
2-h PG ≥ 11.
1)
1.
75 g/kg body
weight (max.
75 g)
Yes Yes
Ko 1999 WHO/
NDDG 1979
WHO/
NDDG 1979
WHO/
NDDG 1979
- Yes Yes -
Ko 2001 FPG < 6.1 IFG: FPG6.1-
6.9
FPG ≥ 7.0 75 g Yes Yes Annual
OGTTs
Larsson 2000 FPG < 5.3 and
2-h BG < 7.8
i-IFG: BG 5.
3-5.9 and 2-
h BG < 7.8;
i-IGT: FPG <
5.3 and 2-h
BG 7.8-11.0;
IFG/IGT: BG
5.3-5.9 and 2-
h BG 7.8-11.0
FPG ≥ 7.0; 2-
h PG ≥ 11.1
75 g Yes Yes NGT at base-
line vs follow-
up: FPG < 5.3
vs < 6.1; FPG
5.3: 15% con-
version fac-
tor as recom-
mendedby the
WHO
(blood glucose
> plasma glu-
cose)
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Latifi 2016 - 5.6 ≤ FPG <
7.0
FPG ≥ 7.0;
antihypergly-
caemic medi-
cation
- - - -
Lecomte
2007
FPG < 6.1; no
personal his-
tory of dia-
betes; no hy-
poglycaemic
treatment
IFG6.1: FPG
6.1-6.
9; no personal
history of di-
abetes; no hy-
poglycaemic
treatment
FPG ≥ 7.0;
personal
history of di-
abetes; hypo-
glycaemic
treatment
- - - -
Lee 2016 - HbA1c 5.7-6.
4
HbA1c ≥ 6.5 - - - -
Leiva 2014 - IFG: 5.6-7.0
(low range: 5.
6-6.1;
high range: 6.
1-6.9)
FPG ≥ 7.0
(2 cons. days),
HbA1c ≥ 6.5
- - - -
Levitzky
2008
- IFG5.6: FPG
5.
6-6.9; IFG6.1:
FPG 6.1-6.9
FPG ≥ 7.0;
antihypergly-
caemic medi-
cation
- - - -
Li 2003 FPG < 6.1 and
2-h PG < 7.8
i-iFG:FPG 6.
1-7.0 and 2-h
PG < 7.8; i-
IGT: FPG < 6.
1
and 2-h PG 7.
8-11.1; IFG/
IGT: FPG 6.
1-7.0 and 2-h
PG 7.8-11.1
FPG ≥ 7.0; 2-
h PG ≥ 11.0;
antihypergly-
caemic medi-
cations
75 g Yes Yes -
Ligthart
2016
FBG ≤ 6.0 FBG>6.0 and
< 7.0; non-
fasting BG >
7.7 and < 11.1
FBG ≥ 7.
0; non-fasting
BG ≥ 11.1;
antihypergly-
caemic medi-
cation
- - - -
Lipska 2013 FPG < 5.6 and
HbA1c < 5.7
i-IFG: FPG 5.
6-6.9 and
HbA1c < 5.7;
i-HbA1c: 5.7-
Single HbA1c
≥ 6.5 (years
2,6,7); self-re-
port of physi-
- - - -
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6.4 and FPG >
5.6; IFG and
HbA1c: FPG
5.6-6.9
and HbA1c 5.
7-6.4
cian diagnosis
(annually)
; antihypergly-
caemic agent
(years 1,2,4,6,
7)
Liu 2008 - IFG 5.6-6.9 FPG ≥ 7.0; 2-
h PG ≥ 11.0;
antihypergly-
caemic medi-
cation
- - - -
Liu 2014 WHO IFG; IGT
(WHO)
WHO 75 g Yes Unclear -
Liu 2016 - FPG 6.1-6.9 FPG ≥ 7.0;
self-reported;
antihypergly-
caemic medi-
cation
- - - -
Liu 2017 FPG 3.9-5.5 FG 5.6-6.9 FG ≥ 7.0; us-
ing insulin/
hypogly-
caemic agents;
self-reported
- - - -
Lorenzo
2003
- IFG: FPG 6.
1-6.9; IGT: 2-
h PG 7.8 to
< 11.1(WHO
1999)
FPG: ≥ 7.0;
2-h PHG: ≥
11.1 (WHO
1999/1985)
75 g Yes Yes -
Lyssenko
2005
FPG < 6.1 IFG: FPG
≥ 6.1; WHO
1999 criteria
WHO 1999
criteria
75 g Yes Yes -
Magliano
2008
FPG < 6.1 and
2-h PG < 7.8
IFG: FPG 6.
1-6.9 and 2-
h PG < 7.8;
IGT: FPG < 7.
0 and 2-h PG
≤ 7.8 to < 11.
1
FPG ≥ 7.0; 2-
h PG ≥ 11.
1; current an-
tihypergly-
caemic medi-
cation
75 g Yes Yes -
Man 2017 Not ’predia-
betes’, not dia-
betes
HbA1c 5.7-6.
4; no self-re-
ported
diabetes or an-
Random glu-
cose≥ 11.1 or
HbA1c > 6.4;
- - - -
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tihypergly-
caemic medi-
cation
self-reported
history or an-
tihypergly-
caemic medi-
cation
Marshall
1994
- IGT: 2-h PG
≥ 7.8 to <
11.1 (WHO
1985)
2-h PG≥ 11.1
(WHO 1985)
75 g Yes Yes -
McNeely
2003
- IFG: FPG ≥
6.1 to < 7.0;
IGT: 2-h PG
≥ 7.8 to < 11.
1
FPG ≥ 7.0; 2-
h PG ≥ 11.1;
antihypergly-
caemic medi-
cation
prescribed by a
physician
75 g Yes Yes -
Meigs 2003 FPG < 6.1 and
2-h PG ≤ 7.8
IFG: FPG 6.
1-6.9 and 2-
h PG ≤ 7.
8; IGT: FPG
< 6.1 and 2-
h PG 7.8-11.
0; IFG/IGT
FPG ≥ 7.0; 2-
h PG ≥ 11.1
(IFG-IGT
person: di-
abetes defined
by OGTT)
Before
07/1977: 1.75
g glucose/
kg BW, aver-
age 143
g; from 07/
1977: 40 g/
kg body sur-
face area, aver-
age 78 g (men)
and 68 g
(women)
Yes Yes Serial OGTTs
over subse-
quent biennial
examinations
Mohan 2008 - IFG: FPG ≥
6.1 to < 7;
IGT: 2-h PG
≥ 7.8 to < 11.
1
FPG ≥ 7; 2-h
PG ≥ 11.1
75 g Yes Yes -
Motala 2003 Both FPG and
2-h PG < 7.8
(WHO 1985)
IGT: FPG < 7.
8 and 2-h PG
7.8 to < 11.1
(WHO 1985)
FPG ≥ 7.8; 2-
h PG ≥ 11.1
(WHO 1985)
75 g glucose
monohydrate
dissolved in
250 mL of wa-
ter (modified
OGTT)
Yes Yes -
Motta 2010 FPG < 6.1 IFG: 6.1 to <
7.0
FPG ≥ 7.0 - Yes -
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Mykkänen
1993
FPG and 2-h
PG < 7.8
IGT: FPG <
7.8 and 2-h
PG 7.8-11.1
(WHO 1985)
FPG ≥ 7.8; 2-
h PG ≥ 11.1
(WHO 1985)
75 g Yes Yes -
Nakagami
2016
- HbA1c 5.7-6.
4, FPG 5.5-6.
9
FPG ≥ 7.0,
HbA1c ≥ 6.5;
physician di-
agnosis of dia-
betes
- - - -
Nakanishi
2004
FPG < 6.1 IFG: FPG6.1-
6.9
FPG ≥ 7.0;
antihypergly-
caemic medi-
cation
- - - -
Noda 2010 - Taken from ta-
ble 2: FPG lev-
els: IFG 5.6
and 6.1
FPG
≥ 7.0; HbA1c
≥ 6.1%; self-
reported
- - - -
Park 2006 - IFG: FPG ≥
5.6
FPG ≥ 7.0 - - - -
Peterson
2017
FPG < 6.1 and
2-h PG < 7.8
IGT: FPG < 7.
0 and 2-h PG
≥ 7.8 to < 11.
1
FPG ≥ 7.0; 2-
h PG ≥ 11.1
- Yes Yes 2 standardised
OGTT at
baseline with
about 1 week’s
interval to ver-
ify glucose sta-
tus
Qian 2012 FPG < 6.1 and
2-h PG < 7.8
i-IFG: 6.1-6.9
and 2-h PG
< 7.8; i-IGT:
< 6.1 and 2-
h PG 7.8-11.
0; IFG/IGT:
6.1-6.9 and 2-
h PG 7.8-11.0
FPG ≥ 7.0; 2-
h PG ≥ 11.1
75 g Yes Unclear -
Rajala 2000 2-h PG < 7.8 IGT: 2-h PG
7.8 to < 11.1
2-h PG ≥ 11.
1; 2x FPG ≥
6.7
75 g Yes Yes New cases
identified
by OGTTs in
1994 and
1996-8
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Ramachan-
dran
1986
- IGT: 7.8-11.0
(presumed
NDDG1979)
2-h PG > 11.0
(presumed
NDDG1979)
75 g Yes Yes -
Rasmussen
2008
- IFG (i-IFG):
FBG 5.6 to <
6.1 and 2-h
BG<7.8; IGT
(i-IGT): FBG
< 6.1 and 2-
h BG 7.8 to
< 11.1; IFG/
IGT
FBG ≥ 6.1 or
2-h BG ≥ 11.
1
75 g Yes Unclear -
Rathmann
2009
WHO 1999 IFG: FPG 6.
1-6.9; IGT: 2-
h PG 7.8 to
< 11.1; ’predi-
abetes’: i-IFG,
i-IGT and
IFG/IGT
FPG ≥ 7.0; 2-
h PG ≥ 11.1;
val-
idated physi-
cian diagnosis
75 g Yes Yes -
Rijkeli-
jkhuizen
2007
ADA 1997/
2003
IFG5.6: FPG
5.
6-7.0; IFG6.1:
FPG 6.1-7.0;
IGT: 2-h PG
7.8 to < 11.1
FPG ≥ 7.0; 2-
h PG: ≥ 11.1
75 g Yes Yes -
Sadeghi 2015 - IFG: FPG ≥
5.5 and < 7.
0; IGT: 2-h
OGTT ≥ 7.8
and < 11.1
FPG > 7.0; 2-
h OGTT >
11.1;
IFG/IGT; an-
tihypergly-
caemic medi-
cation
- Yes Yes -
Sasaki 1982 FPG < 7.8 and
2-h PG < 7.8
(WHO 1980)
IGT: FPG <
7.8 and 2-h
PG 7.8-11.1
(WHO 1980)
FPG ≥ 7.8 or
2-h PG≥ 11.1
(WHO 1980)
50 g Yes Yes -
Sato 2009 - (Table
1): IFG: FPG
group 6.1-6.9;
HbA1c-
group: 6.0-6.4
FPG ≥ 7.0;
antihypergly-
caemic medi-
cation
- - - -
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Schranz 1989 - IGT: 2-h PG
≥ 7.8 to <
11.1 (WHO
1985)
2-h PG≥ 11.1
(WHO 1985)
OGTT Yes Yes -
Sharifi 2013 - FPG 5.6-7.0 FPG
> 7.0 (2 mea-
surements)
; diabetes diag-
nosis based on
documents
OGTT Yes (twice) - -
Shin 1997 - As-
sumed WHO
1985 criteria
“WHO cri-
teria”; antihy-
perglycaemic
medication
75 g Yes Yes -
Söderberg
2004
- IFG: FPG ≥
6.1 to < 7.0
and 2-h PG <
7.8; IGT: FPG
< 7.0 and 2-h
PG ≥ 7.8 to <
11.1
FPG ≥ 7.0; 2-
h PG ≥ 11.1
75 g Yes Yes -
Song 2015 - IFG: FPG5.6-
6.9
FPG ≥ 7.0;
HbA1c ≥ 6.5;
antihypergly-
caemic medi-
cation
- - - -
Song 2016a - IFG: FG 5.6-
6.9; IGT: 2-h
G 7.8-11.0
FG ≥ 7.0; 2-
h G ≥ 11.0;
HbA1c ≥ 6.5;
self-reported
75 g Yes Yes 100 g steamed
bread at fol-
low-up
Soriguer
2008
BG < 5.6 and
2-h BG < 7.8
IFG: BG 5.
6-6.1 and 2-
h BG < 7.8;
IGT: BG < 5.
6 and 2-h BG
7.8-11.1
BG > 6.1 or 2-
h BG > 11.1
75 g Yes Yes -
Stengard
1992
- IGT: 2-h PG
7.8-11.1
2-h PG≥ 11.1
(WHO 1985)
; antihypergly-
caemic medi-
cations
75 g Yes Yes -
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Toshihiro
2008
FPG < 6.1 and
2-h PG < 7.8
IFG: FPG 6.
1-6.9 and 2-
h PG < 7.8;
IGT: FPG < 7.
0 and 2-h PG
7.8-11.1
FPG ≥ 7.0; 2-
h PG > 11.
1; non-fasting
PG > 11.1
75 g Yes Yes Annual
OGTT dur-
ing the obser-
vation period
(3.2 years)
Vaccaro 1999 FPG < 5.6; 2-
h PG < 6.7; 2-
h PG < 6.7
IFG: FPG5.6-
6.0; IGT: 2-h
PG 6.7-9.9
FPG> 6.1; an-
tihypergly-
caemic medi-
cations; 2-h
PG ≥ 10.0
75 g Yes No Retro-
spective classi-
fication; note
thresholds
(whole blood)
Valdes 2008 FPG < 5.6 IFG5.6: 5.6-6.
1; IFG6.1: 6.1-
6.9
FPG ≥ 7.0; 2-
h PG ≥ 11.
1; clinical di-
abetes diagno-
sis; antihyper-
gly-
caemic medi-
cation, diet
75 g Yes Yes -
Vijayakumar
2017
- FG 5.6-6.9; 2-
h PG 7.8-11.
9; HbA1c 5.7-
6.4
FPG ≥ 7.0; 2-
h PG ≥ 11.1;
previous clini-
cal diagnosis
75 g Yes Yes HbA1c
new method =
−0.1916 + (0.
9829
× HbA1c old
method)
Viswanathan
2007
FPG and 2-h
PG < 6.1 and
< 7.8
IGT: 2-h PG
7.8 to < 11.1
Not defined,
presumably by
OGTT
75 g Yes Yes All partic-
ipants under-
went a second
OGTT
to confirm the
diagno-
sis in order to
be included in
the study; fol-
low-up: a re-
minder letter
was sent ev-
ery 6 months
to participants
to undergo an
OGTT
Wang 2007 - IFG: FPG6.1-
6.9; IGT: 2-h
PG 7.8-11.0
FPG ≥ 7.0; 2-
h PG ≥ 11.1
75 g Yes Unclear -
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Wang 2011 FPG < 5.6;
HbA1c < 6.
0; no FPG/
HbA1c
IFG: 5.6 to <
7.0; HbA1c 6.
0 to < 6.5
Diabetes sta-
tus: FPG ≥ 7.
0; antihyper-
glycaemic
medication;
HbA1c ≥ 6.5,
antihypergly-
caemic medi-
cation; FPG/
HbA1c: ≥ 6.
5 or FPG ≥
7.0 or antihy-
perglycaemic
medication
- - - -
Warren 2017 - FPG 5.6-6.9
(ADA); FG 6.
1-6.9 (WHO)
; 2-h 7.8-11.0
(ADA);
HbA1c 5.7-6.
4 (ADA); 6.0-
6.4 (IEC)
Self-report of
physician di-
agno-
sis; antihyper-
glycaemic
medication re-
ported during
a study visit
or annual tele-
phone call
75 g Yes (visit 4) Unclear -
Wat 2001 FPG and 2-h
PG < 7.8
IGT: FPG < 7.
8 and 2-h PG
7.8 to < 11.1
FPG ≥ 7.8; 2-
h PG ≥ 11.1
75 g Yes Yes -
Weiss 2005 FPG < 5.6 and
2-h PG < 7.8
IGT: FPG < 5.
6 and 2-h PG
7.8-11.1
FPG ≥ 7.0; 2-
h PG > 11.1;
presenta-
tion of hyper-
glycaemia
(more than
2 random glu-
cose measure-
ments > 11.
1), glucosuria,
polydipsia,
and polyuria
1.75 g/kg
body weight
flavoured glu-
cose orally (up
to a maximum
of 75 g)
Yes Yes OGTT was
repeated every
18-24 months
Wheelock
2016
- IGT: 2-h PG
≥ 7.8 to < 11.
1
FPG ≥ 7.0; 2-
h PG ≥ 11.1;
previous diag-
nosis
75 g Yes Unclear Modified
OGTT
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Wong 2003 - IGT: 2-h PG
≥ 7.8 to < 11.
1
FPG ≥ 7.0; 2-
h PG ≥ 11.1;
physician
diagnosed dia-
betes
75 g Yes Yes -
Yeboah 2011 FPG < 5.6 IFG: FPG5.6-
6.9
FPG>6.9; an-
tihypergly-
caemic medi-
cation
during exami-
nations 2,3, 4
- - - -
Zethelius
2004
- IGT: 2-h PG
7.8 to < 11.1
FPG ≥ 7.0;
antihypergly-
caemic medi-
cations
75 g Yes No -
BG: blood glucose;BW: bodyweight;FPG: fasting plasma glucose;HbA1c: glycosylated haemoglobin A1c; i-IFG: (isolated) impaired
fasting glucose; i-IGT: (isolated) impaired glucose tolerance; IFG/IGT: both impaired fasting glucose and impaired glucose tolerance;
NDDG: National Diabetes Data Group; NGT: normal glucose tolerance; OGTT: oral glucose tolerance test; PG: postload glucose;
WHO: World Health Organization
Appendix 6. Number of participants with and without intermediate hyperglycaemia at baseline
Study ID N partic-
ipants with/
without IH
Definitions of IH at baseline
’Prediabetes’
a
(%)
Elevated
HbA1c
(%)
IFG
(%)
IGT
(%)
IFG/HbA1c
(%)
IFG/IGT
(%)
Admiraal
2014
IFG5.6 total:
111/456
- - IFG5.6:
Total 24.3
South-Asian
Surinamese
34.4
African Suri-
namese 21.1
“Ethnic
Dutch” 22.7
- - -
Aekplakorn
2006
IFG5.6: 223/
2667
- - IFG5.6: 8.4 - - -
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Ammari
1998
IGT: 68 - - - 100 - -
Anjana 2015 ’Predi-
abetes’ (i-IFG,
i-IGTor both)
: 299/1376
21.7 - i-IFG5.6: 4.9 i-IGT: 11.8 - 5.0
Bae 2011 HbA1c5.7 :
1791/9723;
HbA1c6.0 :
412/1791
- HbA1c5.7 : 18.
4 HbA1c6.0:
4.2
- - - -
Baena-Diez
2011
IFG6.1: 115 - - IFG6.1: 100 - - -
Bai 1999 IGT: 252/696 - - - 36.2 - -
Bergman
2016
IGT: 68/853 - - - 8 - -
Bonora 2011 HbA1c6.0 : 70/
842
- 8.3 - - - -
Cederberg
2010
IFG6.1: 40/
553
IGT: 103/553
IFG/IGT: 15/
553
- - IFG6.1: 7.2 18.7 - 2.7
Chamnan
2011
HbA1c6.0 :
370/5735
- HbA1c6.0: 6.5 - - - -
Charles 1997 IGT:
418/4089; i-
IFG6.1: 476/
5042
- - i-IFG6.1: 9.4 10.2 - -
Chen 2003 IFG6.1: 156/
600
- - IFG6.1: 26 - - -
Chen 2017 i-IFG5.6: 329/
1347
i-IGT: 192/
1347
IFG/IGT:
209/1347
- - i-IFG5.6: 24.4 i-IGT: 14.2 15.5 -
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Coronado-
Malagon
2009
’Prediabetes’:
217/656
33.1 - - - - -
Cugati 2007 IFG5.6: 244/
2123
- - IFG5.6: 11.5 - - -
De Abreu
2015
IFG5.6: 187/
1167
- - IFG5.6: 16 - - -
Den
Biggelaar
2016
IFG6.1 and/or
IGT: 122/476
25.6 - - - - -
Derakhshan
2016
IFG5.6 and/or
IGT: 523/
8231
IFG5.6 and/or
IGT: 6.4
- - - - -
Dowse 1991 IGT: 105/
1201
- - - 8.7 - -
Ferrannini
2009
i-IFG5.6: 65/
1941
i-IFG6.1: 17/
1941
IGT: 179/
1941
i-IGT
(IFG5.6): 57/
1941
i-IGT
(IFG6.1): 29/
1941
- - i-IFG5.6: 3.3
i-IFG6.1: 0.9
IGT: 9.2
i-IGT5.6: 2.9
i-IGT6.1: 1.5
- -
Filippatos
2016
IFG5.6: 279/
1485
- - IFG5.6: 18.8 - - -
Forouhi 2007 IFG6.1: 257/
1040
IFG5.6: 633/
1040
- - IFG5.6: 60.9
IFG6.1: 24.7
- - -
Garcia 2016 IFG5.6: 310/
1777
- - IFG5.5: 17.5 - - -
Gautier 2010 IFG5.6: 979 - - IFG5.6: 100 - - -
Gomez-
Arbelaez
2015
’Prediabetes’:
186/772
24.1 - - - - -
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(Men: 61/
772, women:
125/772)
Guerrero-
Romero 2006
IGT: 75/375 - - - 20 - -
Han 2017 i-IFG5.6: 199/
7542
i-IGT: 1512/
7542
IFG/IGT:
198/7542
- - i-IFG5.6: 2.6 i-IGT: 20.0 - 2.6
Hanley 2005 IGT: 274/882 - - - 31.6 - -
Heianza
2012
IFG5.6: 1680/
6241
IFG6.1: 380/
6241
HbA1c5.7 :
822/6241
HbA1c6.0:
203/6241
IFG5.6/
HbA1c5.7 :
2092/6241
- HbA1c5.7 : 13.
2
HbA1c6.0: 3.3
IFG5.6: 26.9
IFG6.1: 6.1
- 33.5 -
Inoue 1996 IGT: 37 - - - 100 - -
Janghorbani
2015
i-IFG5.6: 304/
1530
i-IGT: 198/
1530
IFG/IGT:
268/1530
- - i-IFG5.6: 19.9 i-IGT: 12.9 - 17.5
Jaru-
ratanasirikul
2016
i-IGT: 27/177 - - - i-IGT: 15.3 - -
Jeong 2010 IFG5.6: 16%
IGT: 5.3%
- - IFG5.6: 16 5.3 - -
Jiamjaras-
rangsi
2008a
IFG5.6: 320/
2370
- - IFG5.6: 13.5 - - -
Kim 2005 IFG6.1: 276/
2964
- - IFG6.1: 9.3 - - -
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Kim 2008 IFG total:
1829/7211
IFG5.6: 1335/
7211
IFG6.1: 494/
7211
- - IFG total: 25.
4
IFG5.6: 18.5
IFG6.1: 6.9
- - -
Kim 2014 i-IFG5.6: 158/
406
i-IGT: 65/406
IFG/IGT:
119/406
i-HbA1c5.7 :
64/406
- i-HbA1c5.7 :
15.8
i-IFG5.6: 38.9 i-IGT: 16 - 29.3
Kim 2016a IFG5.6: 3544/
17971
HbA1c5.7 :
1713/17971
IFG5.6/
HbA1c5.7 :
1951/17971
- HbA1c5.7 : 9.5 IFG5.6: 19.7 - 10.9 -
Kleber 2010 IGT: 79 - - - 100 - -
Kleber 2011 IGT: 119 - - - 100 - -
Ko 1999 IGT: 123 - - - 100 - -
Ko 2001 IFG6.1: 55/
319
- - IFG6.1: 17.2 - - -
Larsson 2000 i-IFG6.1: 42/
265
i-IGT: 66/265
IFG/IGT: 30/
265
- - i-IFG6.1: 15.8 i-IGT: 24.9 - 11.3
Latifi 2016 IFG5.6: 124/
593
- - IFG5.6: 20.9 - - -
Lecomte
2007
IFG6.1: 743 - - IFG6.1: 100 - - -
Lee 2016 HbA1c5.7 :
3497
- HbA1c5.7 :
100
- - - -
Leiva 2014 IFG6.1: 28/94 - - IFG6.1: 29.8 - - -
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Levitzky
2008
Not reported - - - - - -
Li 2003 i-IFG6.1: 42/
644
i-IGT: 118/
644
IFG/IGT: 49/
644
- - i-IFG6.1: 6.5 i-IGT: 18.3 - 7.6
Ligthart
2016
IFG6.1: 1382/
10,050
- - IFG6.1: 13.8 - - -
Lipska 2013 IFG5.6: 189/
1690
i-HbA1c5.7 :
207/1690
IFG/HbA1c:
169/1690
- i-HbA1c: 12.2 IFG5.6: 11.2 - 10.0 -
Liu 2008 IFG5.6: 169/
1844
- - IFG5.6: 9.2 - - -
Liu 2014 ’Prediabetes’
(IFG or IGT):
450/2271
19.8 - - - - -
Liu 2016 IFG6.1: 222/
1857
- - IFG6.1: 12.0 - - -
Liu 2017 IFG5.6: 3607/
18610
- - IFG5.6: 19.4 - - -
Lorenzo
2003
IFG6.1: 29/
1734
IGT: 202/
1734
- - IFG6.1: 1.7 11.6 - -
Lyssenko
2005
i-IFG6.1: 263/
2115
i-IGT: 250/
2115
IFG/IGT:
173/2115
- - i-IFG6.1: 12.4 i-IGT: 11.8 - 8.2
Magliano
2008
Not reported - - - - - -
Man 2017 HbA1c5.7 :
675/1137
- HbA1c5.7 : 59.
4
- - - -
381Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Marshall
1994
IGT: 123 - - - 100 - -
McNeely
2003
5-6 years:
IFG6.1: 30/
465
IGT: 178/465
10 years:
IFG6.1: 28/
412
IGT: 157/412
- - 5-6 years:
IFG6.1: 6.5
10 years:
IFG6.1: 6.8
5-6 years:
38.3
10 years:
38.1
- -
Meigs 2003 i-IFG5.6: 126/
753
i-IGT
(IFG5.6): 115/
753
IFG5.6/IGT:
103/753
i-IFG6.1: 20/
753
i-IGT
(IFG6.1): 218/
753
IFG6.1/IGT:
27/753
- - i-IFG5.6: 16.7
i-IFG6.1: 2.7
i-IGT5.6: 15.3
i-IGT6.1: 29
- IFG5.6/IGT:
13.7
IFG6.1/IGT:
3.6
Mohan 2008 IGT: 37/513 - - - 7.2 - -
Motala 2003 IGT: 35/563 - - - 6.2 - -
Motta 2010 IFG6.1: 295/
2603
- - IFG6.1: 11.3 - - -
Mykkänen
1993
IGT: 203/892 - - - 22.8 - -
Nakagami
2016
IFG5.6: 467/
2267
IFG6.1: 134/
2267
HbA1c5.7 :
583/2267
HbA1c6.0 :
156/2267
- HbA1c5.7 : 25.
7
HbA1c6.0: 6.9
IFG5.6: 20.6
IFG6.1: 5.9
- - -
Nakanishi
2004
IFG6.1: 246/
5588
- - IFG6.1: 4.4 - - -
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Noda 2010 IGF5.6: 558/
2207
IFG6.1: 153/
2207
- - IFG5.6: 25.3
IFG6.1: 6.9
- - -
Park 2006 IFG5.6: 321/
5296
- - IFG5.6: 6.1 - - -
Peterson
2017
IGT: 29/74 - - - 39.2 - -
Qian 2012 i-IFG6.1: 46/
1042
i-IGT: 120/
1042
IFG/IGT: 33/
1042
- - i-IFG6.1: 4.4 i-IGT:11.5 - 3.2
Rajala 2000 IGT: 100 - - - 100 - -
Ramachan-
dran
1986
IGT: 107 - - - 100 - -
Rasmussen
2008
i-IFG5.6: 607/
1510
i-IGT 903/
1510
- - i-IFG5.6: 40.2 i-IGT: 59.8 - -
Rathmann
2009
i-IFG6.1: 71/
887
i-IGT: 120/
887
IFG/IGT: 47/
887
- - i-IFG6.1: 8 i-IGT: 13.5 - 5.3
Rijkeli-
jkhuizen
2007
IFG5.6: 488/
1428
IFG6.1: 149/
1428
- - IFG5.6: 34.2
IFG6.1: 10.4
- - -
Sadeghi 2015 ’Predia-
betes’ (IFG5.6
and/or IGT):
373/2980
12.5 - - - - -
Sasaki 1982 IGT: 13/207 - - - 6.3 - -
Sato 2009 Unclear - - - - - -
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Schranz 1989 IGT: 75/2128 - - - 3.5 - -
Sharifi 2013 IFG5.6: 123 - - IFG5.6: 100 - - -
Shin 1997 IGT: 153/
1193
- - - 12.8 - -
Söderberg
2004
i-IFG6.1:
87-98: 402/
6690
87-92: 149/
3193
92-98: 253/
3437
IGT:
87-98: 1253/
6690
87-92: 600/
3193
92-98: 662/
3437
- - i-IFG6.1:
87-98: 6
87-92: 4.7
92-98: 7.4
87-98: 18.
9 87-92: 18.8
92-98: 19.3
- -
Song 2015 IFG5.6: 321/
2467
- - IFG5.6: 13 - - -
Song 2016a ’Prediabetes’:
344
100 - - - - -
Soriguer
2008
IFG5.6: 56/
714
IGT: 54/714
IFG/IGT: 28/
714
- - IFG5.5: 7.8 7.6 - 3.9
Stengard
1992
IGT: 234/637 - - - 36.7 - -
Toshihiro
2008
IFG6.1: 14/
128
IFG and/or
IGT: 114/128
IFG and/or
IGT: 89.1
- IFG6.1: 10.9 - - -
Vaccaro 1999 i-IFG5.6: 36/
1141
i-IGT:
861141
IFG/IGT: 11/
1141
- - i-IFG5.6: 3.1 i-IGT: 7.5 - 1.0
384Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Valdes 2008 IFG5.6: 114/
630
IFG6.1: 52/
630
IGT: 50/630
- - IFG5.6: 18.1
IFG6.1: 8.3
7.9 - -
Vijayakumar
2017
IFG5.6 adults:
423/2005
IFG5.6
children: 193/
2095
HbA1c5.7
adults: 168/
2005
HbA1c5.7
children: 62/
2095
IGT adults:
347/2005
IGT children:
170/2095
IFG/IGT
adults: 169/
2005
IFG/
IGT children:
53/2095
- HbA1c5.7
adults: 8.4
HbA1c5.7
children: 3.0
IFG5.6 adults:
21.1
IFG5.6
children: 9.2
Adults: 17.3
Children: 8.1
- IFG/IGT
adults: 8.4
IFG/IGT
children: 2.5
Viswanathan
2007
IGT: 619/
1659
- - - 37.3 - -
Wang 2007 IGT: 141/541 - - - 26 - -
Wang 2011 i-IGT total:
135/10
i-IGT men:
29/447
i-IGT
women: 106/
635
- - - i-IGT total:
12.5
i-IGT men: 6.
5
i-IGT
women: 16.7
- -
Warren 2017 IFG5.6: 4112/
10844
IFG6.1: 1213/
10844
IGT: 2009/
7194
HbA1c5.7 :
2027/10844
- HbA1c5.7 : 19
HbA1c6.0: 9
IFG5.6: 38
IFG6.1: 11
28 - -
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HbA1c6.0 :
970/10844
Wat 2001 IGT: 322 - - - 100 - -
Weiss 2005 i-IGT
(IFG5.6): 33/
117
- - - i-IGT: 28.2 - -
Wheelock
2016
IGT: 169/
5532
- - - 3.1 - -
Wong 2003 IGT: 291 - - - 100 - -
Yeboah 2011 IFG5.6: 940/
6753
- - IFG5.6: 13.9 - - -
Zethelius
2004
IGT: 201/667 - - - 30.1 - -
aTerm ’prediabetes’ as used by study authors (usually defined by various combinations of glycaemic status measurements, e.g. IFG
and/or IGT)
FG: fasting glucose; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0: HbA1c threshold 5.7% or
6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively);HbA1c/IFG: both HbA1c and IFG; i-: isolated;IFG 5.6/6.1:
impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT;
PG: postload glucose;IH: intermediate hyperglycaemia; T2DM: type 2 diabetes mellitus
Appendix 7. Follow-up time and type of outcome measurement of the development of type 2
diabetes
Study ID Length of follow-up Time-points of mea-
surements
Outcomemeasurement
of the development of
T2DM
Notes
Admiraal 2014 10 years Baseline, follow-up Incidence, odds ratio Data for total popu-
lation/South-Asian Suri-
namese/African Suri-
namese/“Ethnic Dutch”
Aekplakorn 2006 12 years Baseline, follow-up Incidence, odds ratio -
Ammari 1998 2 years Baseline, follow-up Incidence -
Anjana 2015 Median 9.1 years (IQR
2.6)
Baseline, follow-up Incidence, incidence rate -
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Bae 2011 4 years (mean 47.2
months)
Baseline, follow-up (par-
tially annually/biannu-
ally)
Incidence, incidence
rate, hazard ratio
-
Baena-Diez 2011 10 years Baseline, follow-up Incidence -
Bai 1999 1 year Baseline, follow-up Incidence -
Bergman 2016 24 years Baseline, follow-up Incidence, odds ratio Also adjusted for fast-
ing blood glucose; 100 g
OGTT
Bonora 2011 15 years Baseline, follow-up (5,
10, 15 years)
Incidence, incidence
rate, hazard ratio
HbA1c category used: 6.
0% to 6.49%
Cederberg 2010 Mean 9.7 years (SD 0.7) Baseline, follow-up Incidence, risk ratio Total incident cases =
mixture of isolated and
combined intermediate
glycaemic conditions
Chamnan 2011 Median 3 years Baseline, follow-up Incidence, odds ratio Data for HbA1c 6.0%
to 6.4% group, focus
on clinically and/or bio-
chemically diagnosed di-
abetes
Charles 1997 2 years Baseline, follow-up (5
annual clinical examina-
tions)
Incidence -
Chen 2003 3 years Baseline, follow-up Incidence, odds ratio Also adjusted for
apolipoprotein B
Chen 2017 3 years Baseline, follow-up Incidence -
Coronado-Malagon
2009
1 and 2 years Baseline, follow-up Incidence, relative risk Results are given for year
1/year 2 of follow-up
Cugati 2007 10 years Baseline, follow-up (5
and 10 years)
Incidence, odds ratio Odds-ratio, age-and sex-
adjusted
De Abreu 2015 10 years Baseline, follow-up Incidence, incidence
rate, odds ratio
Age-standard-
ised incidence rate; addi-
tional co-
variates: metabolic syn-
drome, fasting glucose at
baseline
387Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Den Biggelaar 2016 7 years Baseline, follow-up Incidence -
Derakhshan 2016 Median 11.7 years (IQR
8.4-13.2)
Baseline, follow-up Incidence rate, hazard
ratio
-
Dowse 1991 Approx. 5 years Baseline, follow-up Incidence, incidence
rate, odds ratio
Incidence rates
for the periods 1975/76-
1982 and 1982-1987
Ferrannini 2009 7 years Baseline, follow-up Incidence, relative risk -
Filippatos 2016 10 years Baseline, follow-up (in-
termediate 5 -year fol-
low-up)
Incidence, odds ratio -
Forouhi 2007 10 years Baseline, follow-up Incidence, incidence
rate, hazard ratio
Cumulative incidence
increased across increas-
ing age groups and was
higher in men than in
women
Garcia 2016 Approx. 9 years Baseline, follow-up (ev-
ery 12-15 months, max.
6 follow-ups)
Incidence -
Gautier 2010 9 years Baseline, follow-up (3-
yearly examinations)
Incidence -
Gomez-Arbelaez 2015 Approx. 2 years Baseline, follow-up Incidence, incidence rate Rate was given in terms
of per 100 person-years
(recalculated to 1000
person-years)
Guerrero-Romero
2006
5 years Baseline, follow-up Incidence, incidence rate -
Han 2017 12 years Baseline, follow-up
(biannually)
Incidence, incidence
rate, hazard ratio
-
Hanley 2005 Average 5.2 years (range
4.5-6.6)
Baseline, follow-up Incidence, odds ratio -
Heianza 2012 Median 5 years Baseline, follow-up (an-
nual follow-ups)
Incidence, incidence
rate, hazard ratio
Adjusted odds ratios:
mean age and sex-ad-
justed
Inoue 1996 2.5 years Baseline, follow-up Incidence -
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Janghorbani 2015 Mean 6.8 years (SD 1.7) Baseline,
follow-up (OGTT at 3-
year intervals)
Incidence, incidence
rate, hazard ratio
Date for cohort without
hypertension
Jaruratanasirikul 2016 3-6 years Baseline, follow-up Incidence -
Jeong 2010 5 years Baseline, follow-up Odds ratio Also adjusted for ALAT,
ASAT, γ -GT, h-CRP
Jiamjarasrangsi 2008a Mean 2.6 years (SD 0.
97)
Baseline, follow-up (an-
nual follow-ups, 1-4
years)
Incidence -
Kim 2005 5 years Baseline, follow-up Incidence, hazard ratio -
Kim 2008 2 years Baseline, follow-up Incidence -
Kim 2014 Median 46 months Baseline, follow-up (ev-
ery 3-6 months, up to 9
years)
Incidence 81 par-
ticipants were diagnosed
with diabetes with a con-
version rate of 20% (81/
406); conversion rates
are given within predi-
abetes groups (e.g. 24/
158 i-IFG converters =
15.2%)
Kim 2016a Mean 5.2 years (range 3.
1-6.7)
Baseline, follow-up Incidence, odds ratio -
Kleber 2010 1 year Baseline, follow-up Incidence -
Kleber 2011 Mean 3.9 years (SD 0.6) Baseline, follow-up Incidence -
Ko 1999 Mean 1.4 years (range 0.
9-7.6)
Baseline, follow-up (an-
nual OGTTs)
Incidence -
Ko 2001 Median 1.7 years Baseline, follow-up (an-
nual OGTTs)
Incidence -
Larsson 2000 Mean 10 years (SD 1
year 10 months)
Baseline, follow-up Incidence -
Latifi 2016 Median 5 years Baseline, follow-up Incidence, incidence
rate, odds ratio
-
Lecomte 2007 5 years Baseline, follow-up Incidence -
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Lee 2016 Mean 3.7 years (SD 2.3) Baseline, follow-up Incidence -
Leiva 2014 6 years Baseline, follow-up Incidence, hazard ratio -
Levitzky 2008 4 years Baseline, follow-up (ap-
prox. 4-year intervals)
Incidence, odds ratio -
Li 2003 5 years Baseline, follow-up (ex-
amination every 2 years)
Incidence, incidence
rate, hazard ratio
Incidence rates for 5-
year cumulative inci-
dence; further adjust-
ments for HOMA-IR
and HOMA beta-cell
Ligthart 2016 14.7 years Baseline, follow-up
(blood glucose measures
approx. every 4 years)
Incidence rate -
Lipska 2013 7 years Baseline (year 4), follow-
up (years 5,6,7)
Incidence, odds ratio IFG6.1: sensitivity anal-
ysis, analysis for ’ethnic-
ity’, sex analysis
Liu 2008 5 years Baseline, follow-up Incidence, incidence
rate, relative risk
-
Liu 2014 3 years Baseline, follow-up Incidence, incidence rate No exact definition of
’prediabetes’ and dia-
betes incidence
Liu 2016 Median 10.9 years (IQR
8.0-15.3)
Baseline, follow-up Hazard ratio Subdistribution hazard
ratios; also adjusted for
self-rated health
Liu 2017 7.8 years Baseline, follow-up Odds ratio -
Lorenzo 2003 7-8 years Baseline, follow-up Incidence, odds ratio Also adjusted for NCEP
metabolic syndrome def-
inition, fasting insulin
Lyssenko 2005 Median 6 years (range 2-
12)
Baseline, follow-up (ev-
ery 2-3 years)
Incidence, hazard ratio 1372 persons 1 visit, 392
persons 2 visits, 219 per-
sons 3 visits, 132 persons
4 visits
Magliano 2008 5 years Baseline, follow-up Incidence, incidence
rate, odds ratio
5-year cu-
mulative incidence rate
was standardised to the
1998 Australian popula-
tion (age and sex-specific
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incidence rates)
Man 2017 6 years Baseline, follow-up Incidence, incidence
rate, risk ratio
Male: female, age stan-
dardised rate
Marshall 1994 Mean 22.6 months
(range 11-40)
Baseline, follow-up Incidence -
McNeely 2003 10 years Baseline, follow-up (5-6
years and 10 years)
Incidence -
Meigs 2003 5 years, 10 years Baseline, follow-up (3
to 10 biennial examina-
tions)
Incidence, incidence rate -
Mohan 2008 Mean 8 years (SD 1.3) Baseline, follow-up Incidence, incidence rate -
Motala 2003 10 years Baseline, follow-up Incidence -
Motta 2010 3 years Baseline, follow-up Incidence -
Mykkänen 1993 Mean 3.5 years (42
months (SD 4))
Baseline, follow-up Incidence, odds ratio -
Nakagami 2016 5 years Baseline, follow-up Incidence, hazard ratio -
Nakanishi 2004 7 years Baseline, follow-up (an-
nual health examina-
tions)
Incidence, incidence
rate, relative risk
Also adjusted for all
other components of the
metabolic syndrome at
study entry
Noda 2010 5 years Baseline, follow-up Incidence -
Park 2006 Mean 4.1 years Baseline, follow-up (an-
nual examinations)
Incidence, incidence rate -
Peterson 2017 10 years Baseline, follow-up Incidence -
Qian 2012 5 years Baseline, follow-up Incidence -
Rajala 2000 4.6 years (1.9-6.4) Baseline, follow-up (in-
cluding a separate co-
hort)
Incidence, incidence rate -
Ramachandran 1986 Reverters: 3.3 years (SD
2)
Converters: 5.1 years
(SD 3.5)
Baseline, follow-up (“pe-
riodically”)
Incidence All individuals were ad-
vised a calorie-restricted
high carbohydrate high-
fibre diet
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Rasmussen 2008 3.5 years
i-IFG5.6: median 2.5
years
i-IGT: median 2.1 years
Baseline, follow-up Incidence, incidence rate -
Rathmann 2009 7 years Baseline, follow-up Incidence, incidence
rate, odds ratio
-
Rijkelijkhuizen 2007 Mean 6.4 years Baseline, follow-up Incidence, incidence rate -
Sadeghi 2015 7 years Baseline, follow-up
(biannual)
Incidence, incidence rate -
Sasaki 1982 7 years Baseline, follow-up Incidence,odds ratio -
Sato 2009 4 years Baseline, follow-up Odds ratio -
Schranz 1989 6 years Baseline, follow-up Incidence -
Sharifi 2013 7 years Baseline, follow-up Incidence -
Shin 1997 2 years Baseline, follow-up Incidence -
Söderberg 2004 11 years Baseline, follow-up Incidence, incidence rate Incidence rates are given
for periods 1987-1992
and 1992-1998, strati-
fied by men:women
Song 2015 Median 3.97 years Baseline, follow-up Incidence, relative risk Also adjusted for glucose
Song 2016a Mean 10.8 years (range
10.5-12)
Baseline, follow-up (ad-
ditional follow-up 2014)
Incidence -
Soriguer 2008 Mean 6 years Baseline, follow-up Incidence, incidence
rate, relative risk
-
Stengard 1992 5 years Baseline, follow-up Incidence, odds ratio -
Toshihiro 2008 Mean 3.2 years (SD 0.1) Baseline, follow-up (an-
nual OGTT)
Incidence -
Vaccaro 1999 11.5 years Baseline, follow-up Incidence, odds ratio Odds ratios probably un-
adjusted
Valdes 2008 Mean 6.3 years (5.9-6.8) Baseline, follow-up Incidence, incidence
rate, odds ratio
Also adjusted for 2-h PG
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Vijayakumar 2017 Adults median 4.6 years
(IQR 2.8-7.9 )
Children: median 5.2
years (IQR 2.7-9.6)
Baseline, follow-up (ex-
aminations every 2 years)
Incidence, incidence rate Data for adults/children;
incidence rate taken
from figure 2 (boys:men;
girls:women)
Viswanathan 2007 Median 5 years Baseline, follow-up (re-
minder to undergo an
OGTT every 6 months)
Incidence, odds ratio Also adjusted for FPG
and 2-h PG
Wang 2007 5 years Baseline, follow-up Incidence, risk ratio -
Wang 2011 4 years Baseline, follow-up Odds ratio Unclear
which confounders were
used in the multivariate
model
Warren 2017 Cohort 1 (visit 2): 22
years
Cohort 2 (visit 4): 16
years
Baseline, follow-up (3
visits every 3 years, 5th
visit 2011-13)
Hazard ratio Data for IFG5.6, IFG6.1,
HbA1c5.7 , HbA1c6.0,
IGT (cohort 2 only)
Wat 2001 2 years Baseline, follow-up Incidence -
Weiss 2005 Mean 20.4 months (SD
10.3)
Baseline, follow-up
(biannual)
Incidence -
Wheelock 2016 Median 12.4 years (IQR
6.0-22.9)
Baseline, follow-up (ap-
prox. annual intervals for
repeated OGTTs)
Incidence Non-overweight partici-
pants with IGT cohort
and overweight partici-
pants with IGT group
Wong 2003 8 years Baseline, follow-up Incidence Odds ratios from Tai
2004
Yeboah 2011 7.5 years Baseline, follow-up (3
examinations)
Incidence, hazard ratio -
Zethelius 2004 7 years Baseline, follow-up Odds ratio Also adjusted for (split)
proinsulin, intact insulin
ALAT: alanine aminotransferase; ASAT: aspartate transaminase; FG: fasting glucose; FPG: fasting plasma glucose; h-CRP: high-
sensitivity C-reactive protein; HOMA-beta: homeostatic model assessment of beta-cell function; HOMA-IR: homeostatic model
assessment of insulin resistance; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 : HbA1c threshold 5.7% or 6.0% (usually
reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i-: isolated; IFG5.6/6.1: impaired
fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; IQR:
interquartile range; NCEP: national cholesterol education program; OGTT: oral glucose tolerance test; PG: postload glucose; SD:
standard deviation; T2DM: type 2 diabetes mellitus; γ -GT: gamma-glutamyl transferase/transpeptidase
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Appendix 8. Baseline characteristics (I)
Study ID Setting N participants in origi-
nal cohort
(several phases of the
cohort study)
N study sample
(several phases of the
cohort study)
Notes
Admiraal 2014 Amsterdam, The
Netherlands
2975 456 Baseline data for to-
tal cohort included in
the analyses (N = 456)/
South-Asian Surinamese
(N = 90)/African Suri-
namese (N = 190)/“eth-
nic Dutch” (N = 176)
Aekplakorn 2006 Bangkok, Thailand 3499/3245 2667 Baseline data for cohort
becoming diabetic (N =
361)
Ammari 1998 Jordan Unclear 121/68-200/144 (con-
trols)
Few baseline data re-
ported for study popula-
tion (N = 212)
Anjana 2015 Chennai, India 26,001 3589/2207 Baseline data for cohort
becoming diabetic at fol-
low-up (N = 176)
Bae 2011 South Korea 10,959 9723 Baseline data for the total
cohort (N = 9723)
Baena-Diez 2011 Barcelona, Spain 2248 168 Baseline data for predia-
betic cohort (N = 115)
Bai 1999 Chennai, India 4885/1082 1082/696 Baseline data for the IGT
cohort (N = 252)
Bergman 2016 Israel 1970 1037 Baseline data for IGTco-
hort (N = 24)
Bonora 2011 Bruneck (South Tyrol),
Italy
1000 936 No baseline data (except
white participants aged >
40 years, N = 919)
Cederberg 2010 Finland 593 553/499 Baseline data for the co-
hort (total N = 553, men
N = 223, women N =
330)
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Chamnan 2011 Norfolk (East Anglia),
UK
77,630/25,639 6372/5735 Baseline data for
HbA1c6.0−6.4 cohort (N
= 370)
Charles 1997 Paris, France Unclear 7540 (2nd clinical exam-
ination)/4089
Baseline data for individ-
uals with IGT convert-
ing to T2DM (N = 32)
Chen 2003 Penghu, Taiwan 1601 1306/600 Baseline data for cohort
converting to T2DM (N
= 26)
Chen 2017 China 8845 1374 Baseline data for i-IFG/i-
IGTand IFG/IGT across
age groups < 40 years +
> 60 years (data indicate
range across groups) (i-
IFG < 40 years N = 51
and > 60 years N = 278;
i-IGT < 40 years N = 41
and > 60 years N = 151;
IFG/IGT: < 40 years N
= 34 and > 60 years N =
175)
Coronado-Malagon
2009
Mexico 820 656 Baseline characteristics
for the prediabetic co-
hort (N = 217)
Cugati 2007 Australia, Blue Moun-
tains region
4433/3654 2335 (5 years)/1952 (10
years)/2123 complete
data (10 years)
Baseline data for people
without diabetes (N =
3437)
De Abreu 2015 Australia Unclear 1167/395 (IFG5.6) Baseline data for IFG co-
hort at baseline (N =
187)
Den Biggelaar 2016 The Netherlands 574/491 476 Baseline data for predia-
betic group (N = 122)
Derakhshan 2016 Tehran, Iran 12808 8231 Baseline data for predia-
betes group with normal
blood pressure
Dowse 1991 Nauru, Micronesia 1497/1201 830 (1982/1987-includ-
ing 143 nondiabetic per-
son from 1975/76)
No baseline data pro-
vided
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Ferrannini 2009 Mexico 3505 2282/1963 Baseline characteristics:
range across different
definitions of predia-
betes
Filippatos 2016 Attica, Greece 4056/3042/1875 1485 Baseline data for IFG5.6
cohort (N = 343)
Forouhi 2007 Ely (Cambridgeshire),
UK
1571/1122 (phase 1)/
912 (phase 2)
683 (phase 3) Baseline data for IFG6.1
cohort (N = 257)
Garcia 2016 Sacramento (CA), USA 1789 1777 Baseline data for predia-
betic cohort (N = 310)
Gautier 2010 France 3817 979 No baseline data
Gomez-Arbelaez 2015 Columbia 2012 772 Baseline data for the total
cohort (N = 772)
Guerrero-Romero
2006
Durango, Mexico Unclear 375 Baseline data for IGT
cohort at baseline pro-
gressing to T2DM (N =
20); all individuals were
counselled on the impor-
tance of diet and physical
exercise (standard care
for the whole cohort)
Han 2017 Ansung-Ansan, South
Korea
10,030 7542 Baseline data for i-IFG,
i-IGT and IFG/IGT co-
hort
Hanley 2005 USA 1625 822 Baseline data for dia-
betic cohort at follow-
up (N = 131); par-
ticipants were recruited
from 2 population-based
studies: the San Anto-
nio Heart Study and the
San Luis Valley diabetes
study
Heianza 2012 Japan 32057 6636/6241 Baseline data for total co-
hort (N = 6241)
Inoue 1996 Gunma (Gyeonggi),
Japan
Unclear Unclear Baseline data for the IGT
cohort (N = 37)
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Janghorbani 2015 Isfahan, Iran 3370 1489 Baseline data for i-IFG,
i-IGT and IFG/IGT co-
hort at baseline (N =
770); first-degree rela-
tives of people with
T2DM
Jaruratanasirikul 2016 Thailand 181 177 (157) Baseline data for IGTco-
hort (N = 27)
Jeong 2010 Dalseong County, South
Korea
1806/1599 1474 1287 participants were
re-evaluated in 2008 and
187 new participants
“added to the study”;
baseline data for partici-
pants with incident dia-
betes (N = 135)
Jiamjarasrangsi 2008a Bangkok, Thailand 3989 3243/2370 Baseline data for total co-
hort becoming diabetic
at follow-up (N = 48)
Kim 2005 Seoul, South Korea 20,203/15,936 2964 Baseline data for FPG
group 4 (6.1-7.0) with
baseline and follow-up
(N = 276)
Kim 2008 Incheon, South Korea 7510 7211 Baseline data for IFG5.6/
IFG6.1 cohort (N =
1335/494)
Kim 2014 Seoul, South Korea 418 418 Baseline data for i-IFG
(N = 158)/i-IGT (N =
65)/IFG/IGT (N = 119)
/i-HbA1c (N = 64); total
(N = 406)
Kim 2016a Seoul, South Korea 19,356 17,971 2 baseline data cohorts:
prediabetes by FPG only
and HbA1c only (N =
3544 and N = 1713)
Kleber 2010 Germany 79 79 Baseline data for IGTco-
hort (N = 79)
Kleber 2011 Germany 128 128 Baseline data for IFG co-
hort (N = 128)
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Ko 1999 Hong Kong 123 123 Baseline data for the IGT
cohort (N = 123)
Ko 2001 Hong Kong 657 319 Baseline data for IFG co-
hort (N = 55)
Larsson 2000 Sweden 1843 265 Baseline data for i-IGT
(N = 66)/i-IFG (N =
42)/IFG/IGT (N = 30)
; 265 follow-up par-
ticipants were randomly
sampled from each glu-
cose tolerance group of
the original cohort and
invited for follow-up
Latifi 2016 Ahvaz (Khuzestan), Iran 12,514/6640 Unclear/593 Baseline for prediabetic
cohort becoming dia-
betic at follow-up
Lecomte 2007 France 56,650 4532 Baseline data for IFG co-
hort attending both ex-
aminations (N = 743)
Lee 2016 South Korea 6246 5528 Baseline data for the total
cohort (N = 3497)
Leiva 2014 Chile 1007 177 Most baseline data for
cohort becoming dia-
betic at follow-up (N =
94 with IFG)
Levitzky 2008 Framingham (MA),
USA
Unclear 3634 Baseline data for individ-
uals on first exam, free of
cardiovascular disease (N
= 4058)
Li 2003 Kinmen, Taiwan Unclear 644 Baseline data for i-IGT
(N = 118)/i-IFG (N =
42)/IFG/IGT (N = 49)
Ligthart 2016 Rotterdam, The Nether-
lands
14,926/11,740 11,740/10,050 Baseline data for predia-
betic cohort (N = 1382)
Lipska 2013 USA 3075 1690 Baseline data for i-IFG
(N = 189)/i-HbA1c5.7
(N = 207)/IFG/HbA1c
(N = 169)
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Liu 2008 Jiang Su province, China 6400/5888 1844 Baseline data for non-di-
abetic participants (N =
1844); M (N = 788)/W
(N = 1056)
Liu 2014 Shanghai, China 4556 3174 Baseline data for the pre-
diabetic cohort convert-
ing to T2DM (N = 78)
Liu 2016 Beijing, China 2101 1857 Baseline data for partici-
pants without diabetes at
baseline (N = 1857)
Liu 2017 China 27,020 23,626/18,610 Baseline data for IFG co-
hort at baseline (N =
3607)
Lorenzo 2003 San Antonio (TX), USA 2941/2569 1734 Baseline data for cohort
converting to T2DM (N
= 195)
Lyssenko 2005 Finland Unclear 2115 Baseline data for IFG-
IGT individuals who
converted to T2DM (N
= 86)
Magliano 2008 Australia 20,347/11,247 6537 Baseline data for cohort
becoming diabetic at fol-
low-up (N = 224)
Man 2017 Singapore 3280 1279/1137 Baseline data for inci-
dent diabetes cohort (N
= 127)
Marshall 1994 Colorado, USA 1321 173/134 Baseline data
for IGT cohort convert-
ing to T2DM (N = 20)
McNeely 2003 Seattle (WA), USA 518 465 (5 years)/412 (10
years)
Baseline data for cohort
converting to T2DM at
5-6 years (N = 50) and
10 years (N = 74)
Meigs 2003 Baltimore (MD) and
Washington, D.C., USA
Unclear 815/753 Baseline data for the
IFG-IGT cohort (N =
265); follow-up time: at
least 6 years 77%, at least
10 years 44%, at least
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16 years 16%, at least 20
years 4.5%
Mohan 2008 Chennai, India 1061 513 Baseline data for cohort
becoming diabetic at fol-
low-up (N = 64)
Motala 2003 Durban (KwaZulu-Na-
tal), South Africa
2479 563 Baseline data for respon-
ders (both baseline and
follow-up examination)
(N = 563)
Motta 2010 Italy 2603 2603 No baseline data pro-
vided
Mykkänen 1993 Kuopio (Northern Savo-
nia), Finland
1300 1054/892 Baseline data for cohort
developing T2DM (N =
69)
Nakagami 2016 Japan 6012 2770/2267 Baseline data for cohort
converting to T2DM (N
= 99)
Nakanishi 2004 Japan Unclear/6812 5746 Baseline characteristics
for IFGcohort (N=246)
Noda 2010 Japan 22387 2207 Baseline characteristics
for the total cohort (N =
2207)
Park 2006 South Korea 6305 5557 Baseline data for in-
cident diabetic partici-
pants with IFG at base-
line (N = 40)
Peterson 2017 Sweden 119 87/74/29 Baseline data for IGTco-
hort (N = 29)
Qian 2012 Shanghai, China 1869 1042 Baseline data for cohort
progressing to T2DM
(N = 377)
Rajala 2000 Oulo (NorthOstroboth-
nia), Finland
1008/768 183 (1st)/193 (2nd,
other group)
Few baseline data for
IGT cohort (N = 171)
Ramachandran 1986 Madras, India Unclear 107 Baseline data for the dia-
betic cohort at follow-up
(N = 39)
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Rasmussen 2008 Denmark 1821 1510/1002 Baseline data for IFG (N
= 607)/IGT cohort (N =
903)
Rathmann 2009 Augsburg (Bavaria),
Germany
2656 1202 Baseline data for total co-
hort (follow-up partici-
pants, age-group 55-74
years, N = 887)
Rijkelijkhuizen 2007 The Netherlands 2484/1513 1428 Baseline data for IFG6.1
(N = 149)/IFG5.6 (N =
488)
Sadeghi 2015 Isfahan, Iran 6323 2980 Baseline data for predi-
abetic cohort becoming
diabetic at follow-up (N
= 131)
Sasaki 1982 Osaka, Japan 507 207 Baseline data for the IGT
cohort (N = 13)
Sato 2009 Japan 12,647 9116/6804 Baseline data for cohort
becoming diabetic at fol-
low-up (N = 659)
Schranz 1989 Malta 2128 1422 Baseline data for diabetic
cohort at follow-up (N =
166)
Sharifi 2013 Zanjan, Iran 2941 395 Baseline data for active
participants (N = 123)
Shin 1997 Yonchon County, South
Korea
2520/2293 2248/1193 Baseline data for in-
dividuals converting to
T2DM (N = 67)
Söderberg 2004 Mauritius 5083/6616/6291 Unclear Baseline data for cohort
1987-1998 (N = 2631)
, 10 years follow-up; 3
cohorts 1987-1992 (N =
3680), 1992-1998 (N =
4178), 1987-1998 (N =
2631)
Song 2015 South Korea 4899 2079 Baseline data for predi-
abetic cohort (men N =
154; women N = 167;
total N = 321)
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Song 2016a Shanghai, China 2132 778/526 Baseline data for predia-
betic cohort (N = 334)
Soriguer 2008 Pizarra (Andalusia),
Spain
1051 824 Baseline data for final
sample of follow-up (N
= 714)
Stengard 1992 Finland 1711 716/637 Baseline data
for IGT cohort convert-
ing to T2DM (N = 17)
Toshihiro 2008 Japan 732 128 Baseline data for cohort
becoming diabetic at fol-
low-up (N = 36); partic-
ipants with IFG and/or
IGT were given advice
about lifestyle modifica-
tions once or twice a year
Vaccaro 1999 Naples, Italy 1285/1245 1141/560 Baseline data for total co-
hort (follow-up exami-
nation N = 560)
Valdes 2008 Spain 1626/1034 943/630 Baseline data
for IFG5.6−6.1 (N = 114)
/IFG6.1−6.9 (N = 52)
Vijayakumar 2017 Phoenix (AZ), USA Unclear 2095 (10-19 years)/
2005 (20-39 years)
Baseline data for adults/
children with HbA1c 5.
7%-6.4% (children N =
62, adults N = 168)
Viswanathan 2007 India (probably Chen-
nai)
4084 1659 Baseline data for IGT
group (N = 619); partic-
ipants were given advice
on preventive measures
such as dietary modifica-
tions and regular exercise
Wang 2007 Beijing, China 20,682/1566 902 Baseline data for cohort
with incident diabetes
and no coronary heart
disease (N = 67)
Wang 2011 Arizona/North/South
Dakota/Oklahoma,
USA
Unclear 2849/1670 (2nd exam) No baseline data
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Warren 2017 USA, 4 communities 15,792 Cohort 1, N =
10844: 1990-1992 (FG,
HbA1c) as baseline
Cohort 2, N
= 7194: 1996-1998 (FG,
2-h glucose) as baseline
2 different
baseline cohorts; 4 pre-
diabetes definitions (visit
2: IFG5.6−6.9 N = 4112;
HbA1c5.7−6.4 N = 2027;
visit 4: IFG5.6−6.9 N =
2142; IGT N = 2009)
Wat 2001 Hong Kong 2900 434/322 Baseline data for IGTco-
hort (N = 322)
Weiss 2005 Conneticut, USA 129 117 Baseline data for IGTco-
hort (N = 33)
Wheelock 2016 Arizona, USA Unclear 5532 Baseline data for the full
cohort (N = 5532); pre-
diabetic cohort = non-
overweight (N = 37) +
IGT group and over-
weight + IGT group (N
= 132); 5-11 years/12-19
years
Wong 2003 Singapore 3568 469/291 Baseline data for IGT
group (N = 291)
Yeboah 2011 USA 6814 6814/6753 Baseline data for IFG co-
hort (N = 940)
Zethelius 2004 Uppsala, Sweden 2322/1221/1010 840/667 Baseline data for cohort
converting to T2DM (N
= 26)
FG: fasting glucose; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0: HbA1c threshold 5.7% or
6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively);HbA1c/IFG: both HbA1c and IFG; i-: isolated; IFG5.6/6.1:
impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT;
PG: postload glucose; T2DM: type 2 diabetes mellitus
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Appendix 9. Baseline characteristics (II)
Study ID Sex, %
women
Age (SD),
years
’Eth-
nicity’, %
white
’Ethnic-
ity’,
%
Arabian/
Asian/
(Pima) In-
dians
’Ethnic-
ity’,
%
Hispanic
’Ethnic-
ity’,
%
Black
Family
history of
diabetes,
%
BMI (SD)
,
kg/m2
Notes
Admiraal
2014
59
57
68
51
45
44
44
47
39 20 - 42 55
77
59
38
26.4
25.7
27.4
25.6
Total
cohort
South-
Asian Suri-
namese
African
Suri-
namese
“Ethnic
Dutch”
(the
Nether-
lands)
Aek-
plakorn
2006
19 43.6 (5.0) - 100 - - 53 24.8 (3.2) -
Ammari
1998
- 63% > 40 - 100 - - 99 - -
Anjana
2015
61 47 (13.1) - 100 - - 47 25.8 (4.3) -
Bae 2011 25 44.7 (5.4) - 100 - - - 23.8 (2.8) -
Baena-
Diez 2011
52 61.2 (11.
8)
- - 100 - 26 - -
Bai 1999 35 Mainly 40-
60+
- 100 - - - - -
Bergman
2016
38 50.5 (8.3) 42 29 - 47 - Men: 26.5
(3.8)
Women:
26.8 (5.2)
-
Bonora
2011
- - 100 - - - - - -
404Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Cederberg
2010
- - 100 - - - - Men: 27.6
(3.5)
Women:
27.9 (4.5)
-
Chamnan
2011
54 62.4 (8.2) 100 - - - 14 26.6 (4.0) -
Charles
1997
0 48.8 (1.8) 100 - - - - 27 (4) -
Chen
2003
49 59.6 - 100 - - 21 25.7 (3.1) -
Chen
2017
54-58 40-67 - 100 - - 9-37 23.8-24.8 -
Coron-
ado-
Malagon
2009
10 47.9 (8.6) - - 100 - - 26.8 (3.0) -
Cugati
2007
57 67.4 100 - - - 19 26 -
De Abreu
2015
100 53.8 (IQR
44.0-64.4)
Mostly
white Aus-
tralians
- - - - 27.7 (IQR
24.3-31.4)
-
Den
Biggelaar
2016
39 60.8 (IQR
55.3-64.9)
100 - - - - 28.0 (IQR
26.5-31.2)
-
Der-
akhshan
2016
56 42.8 (11.
7)
- 100 - - - 26.9 (4.1) -
Dowse
1991
- - - 100 - - - - -
Ferran-
nini
2009
52-70 47-50 - - 100 - 27-45 29.1-30.5 -
Filippatos
2016
35 46.4 (12.
4)
100 - - - 22 27.4 (4.7) -
Forouhi
2007
44 55.5 (7.9) 100 - - - - 27.8 (4.6) -
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Garcia
2016
- 69.8 (6.9) - - 49 - - 31.1 (5.6) -
Gautier
2010
31 30-64 100 - - - - - -
Gomez-
Arbelaez
2015
70 58 (12) - - 100 - - 27.4 (4.6) -
Guerrero-
Romero
2006
- 38 - - 100 - - 32.9 (5.6) -
Han 2017 28
60
33
50.4 (8.3)
53.1 (8.9)
52.4 (8.7)
- 100
100
100
- - 15
12
15
25.5 (3.4)
24.9 (3.2)
25.4 (3.2)
i-IFG5.6
i-IGT
IFG/IGT
Hanley
2005
60 56.2 (7.9) 38 - 36 26 - - -
Heianza
2012
25 49.9 (8.7) - 100 - - - 22.8 (2.8) -
Inoue
1996
- - - 100 - - - 23.2 -
Janghor-
bani
2015
- 44.4
42.9
44.1
- 100 - - 100 29.2
29.0
30.0
i-IFG
i-IGT
IFG/IGT
Jaru-
ratanasirikul
2016
37 12.4 (2.3) - 100 - - - 35.3 (5.8)
BMI SDS:
3.66 (0.
86)
-
Jeong
2010
- 61 (9) - 100 - - 7 24.6 (3.2) -
Jiamjaras-
rangsi
2008a
67 49.5 (12) - 100 - - 15 26.9 (0.6) -
Kim 2005 15 50.7 (7.2) - 100 - - 9 24.6 (2.2) -
Kim 2008 7
5
41
43
- 100 - - 9
8
24
25
IFG5.6
IFG6.1
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Kim 2014 49
57
48
56
60.2 (11.
3)
63.0 (11.
0)
59.1 (10.
1)
59.3 (10.
1)
- 100 - - 29
14
22
16
24.7 (3.0)
23.2 (3.5)
25.1 (3.3)
24.9 (4.7)
i-IFG
i-IGT
IFG/IGT
i-HbA1c
Kim
2016a
24
47
49.5
51.2
- 100 - - 22
22
24.4
23.9
IFG
HbA1c
Kleber
2010
51 13.1 (2.1) 100 - - - - 31.8 (6.3)
BMI SDS:
2.56 (0.
62)
-
Kleber
2011
53 13.5 (2.1) 100 - - - - 31.7 (6.1) -
Ko 1999 88 22-26 - 100 - - - - -
Ko 2001 84 37.4 (9.3) - 100 - - 38 25.9 (4.0) -
Larsson
2000
100 66 (2.3) 100 - - - - 24.6
26.2
26.7
i-IGT
i-IFG
IFG/IGT
(age at fol-
low-up)
Latifi
2016
38 46.6 (12.
5)
- 100 - - 80 - -
Lecomte
2007
0 44.5 (7.5) 100 - - - 3 26.4 (3.6) -
Lee 2016 33 46.1 (8.5) - 100 - - 24 24.8 (3.1) -
Leiva
2014
57 25-80 - - 100 - - 33.1 (4.3) -
Levitzky
2008
53 Women:
48
Men: 49
Mainly
white
- - - - Men: 27.3
(3.9)
Women:
25.6 (5.4)
-
Li 2003 57
36
53
56.1
48.4
58.9
- 100 - - - 24.8
23.8
25.5
i-IGT
i-IFG
IFG/IGT
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Ligthart
2016
51 66.6 (9.4) 92 - - - - 27.9 (4.2) -
Lipska
2013
33
60
47
76.6
76.7
76.6
82
36
60
- - - - 27.9
27.9
29.0
i-IFG
i-HbA1c
IFG +
HbA1c
Liu 2008 57 Men: 52
Women:
50
- 100 - - Men: 6
Women: 8
- -
Liu 2014 48 68.6 (6.7) - 100 - - - 23.5 (3.0) -
Liu 2016 - Men: 70
Women:
69
- 100 - - - - -
Liu 2017 50 50.9 (9.7) - 100 - - - 24.2 (3.6) -
Lorenzo
2003
61 47.7 (0.8) 19 - 81 - 46 31.3 -
Lyssenko
2005
50 52 (11) 100 - - - 100 - -
Magliano
2008
49 55.8 (12.
0)
85 - - - 31 Men: 29.3
(0.4)
Women:
29.7 (0.6)
-
Man 2017 57 54.4 (9.7) - 100 - - 39 28.5 (5.3) -
Marshall
1994
75 58.6 40 - 60 - 53 29.2 -
McNeely
2003
52
41
58.9
57.5
100 - - 60
62
24.9
25.1
5-6 years
follow-up
10 years
follow-up
Meigs
2003
28 61.8 (14) 95 - - - 29 ≥ 25: 60% -
Mohan
2008
- 43 (14) - 100 - - 28 24.4 (4.4) -
Motala
2003
60 36.4 (13.
9)
- 100 - - 45 22.6 (6.0) -
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Motta
2010
- 65-84 100 - - - - - -
Mykkänen
1993
57 68.6 100 - - - 29 29 -
Nakagami
2016
27 53 (7) - 100 - - 19 24.6 (3.5) -
Nakanishi
2004
0 49 (5.8) - 100 - - 16 24.6 (3.0) -
Noda
2010
63 Men: 62.4
Women:
61.5
- 100 - - - Men: 24.1
(3.0)
Women:
24.2 (3.2)
-
Park 2006 0 36.4 (3.9) - 100 - - - 24.8 (3.0) -
Peterson
2017
48 61.4 (0.8) 100 - - - - 26.9 (5.4) -
Qian
2012
- 60 (13) - 100 - - - 24.9 (3.7) -
Rajala
2000
58 - 100 - - - - - -
Ra-
machan-
dran
1986
31 48 - 100 - - 49 25.2 -
Ras-
mussen
2008
43
56
59.9
61.2
100 - - - - 29.1
29.6
IFG
IGT
Rath-
mann
2009
49 63.2 (5.4) 100 - - - 23 28.1 (4.0) -
Rijkeli-
jkhuizen
2007
46
53
62.5
61.5
100 - - - - 27.6
27.0
IFG6.1
IFG5.6
Sadeghi
2015
59 51.3 (9.8) - 100 - - 20 29.4 (4.5) -
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Sasaki
1982
54 57.4 - 100 - - - - -
Sato 2009 0 48.6 (4.2) - 100 - - 20 24.7 (3.3) -
Schranz
1989
56 Women:
59.8
Men: 57.7
100 - - - - - -
Sharifi
2013
63 40 (14) - 100 - - - 27.5 (4) -
Shin 1997 34 59.6 - 100 - - 6 24.5 -
Söderberg
2004
56 41.2 - 70 - 30 - 23.9 -
Song
2015
52 56-57 - 100 - - Men: 10
Women:
22
Men: 25.2
(2.7)
Women:
25.8 (3.4)
-
Song
2016a
63 57.2 (10.
0)
- 100 - - - - -
Soriguer
2008
65 45.0 (13.
4)
100 - - - 58 28.3 (5.2) -
Stengard
1992
0 70.8 (4.8) 100 - - - - 26.1 (4.2) -
Toshihiro
2008
0 50.5 (5.8) - 100 - - - 24.9 (3.3) -
Vaccaro
1999
23 44.1 (4.0) 100 - - - - 26.9 (4.4) -
Valdes
2008
- 54.8
56.7
100 - - - - 28.2
29.8
IFG5.6
IFG6.1
Vijayaku-
mar
2017
97
79
29.9
14
- 100 - - - 39.1
32.0
Adults
Children
Viswanathan
2007
39 42.4 (9.8) - 100 - - - - -
Wang
2007
46 47.9 (10.
7)
- 100 - - - 25.2 (3.5) -
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Wang
2011
- - - 100 - - - - -
Warren
2017
48 57.6 (5.7) - - - 25 25 28.9 (5.2) Data
for cohort
1 (IFG5.6)
Wat 2001 57 51 100 - - - 25.6 -
Weiss
2005
73 12.5 (2.7) 45 39 12 - - 36.6 (8.7)
BMI z
score: 2.42
(0.41)
-
Wheelock
2016
53 11.4 (3.6) 100 100 - - - Percentile:
87.6
-
Wong
2003
53 43.8 - 100 - - 28 25.2 -
Yeboah
2011
44 64.2 (9.8) 31 15 25 30 - 30.1 (5.7) -
Zethelius
2004
0 77 100 - - - - 26.7 (3.2) -
BMI: body mass index; FG: fasting glucose; FPG: fasting plasma glucose; i-HbA1c: (isolated) glycosylated haemoglobin A1c;
HbA1c5.7/6.0: HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively);HbA1c/IFG: both
HbA1c and IFG; i-: isolated; IFG5.6/6.1: impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose
tolerance; IFG/IGT: both IFG and IGT; IQR: interquartile range; SD: standard deviation; SDS: standard deviation score
Appendix 10. Baseline characteristics (III)
Study ID Mean
(SD)/
median
(IQR)
/range sys-
tolic BP,
mmHg
Mean
(SD)/
median
(IQR)
/range di-
astolic BP
(SD),
mmHg
Smoking:
cur-
rent and/
or past, %
Medica-
tions, %
Comor-
bidities,
%
Mean
(SD)/
median
(IQR)/
range
FPG,
mmol/L
Mean
(SD)/
median
(IQR)
/range 2-
h glucose,
mmol/L
Mean
(SD)/
median
(IQR)/
range
HbA1c,
%
Notes
Admiraal
2014
- - 38
26
41
- Hyperten-
sion:
26
5.2
5.3
5.2
- - Total
cohort
411Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
41 26
32
19
5.3 South-
Asian Suri-
namese
African
Suri-
namese
“Ethnic
Dutch”
Aek-
plakorn
2006
- - 42 - Hyperten-
sion: 33
- - - -
Ammari
1998
- - - - Hyperten-
sion: 47
- - - -
Anjana
2015
129 (21) 78 (11) 13 - - 5.2 (0.6) 8.7 (1.4) 6.2 (0.7) -
Bae 2011 113 (14) 76 (10) - - - 5.3 (0.5) - 5.4 (0.3) -
Baena-
Diez 2011
- - 33 - Hyperc-
holestero-
laemia:
38 Hyper-
triglyceri-
daemia: 15
Hyperten-
sion: 55
- - - -
Bai 1999 - - - - - - - - -
Bergman
2016
128 (16) 84 (10) 38 - - 5.2 (0.5) 8.6 (1.0) - -
Bonora
2011
- - - - - - - - -
Cederberg
2010
Men: 142
Women:
142
Men: 80
Women:
79
Men: 18
Women:
15
- - Men: 5.0
Women: 5.
0
Men: 6.8
Women: 7.
0
- -
Chamnan
2011
139 (17) 84 (11) 15 BP lower-
ing: 21
Corticos-
teroids: 4
- - - - -
Charles
1997
- - - - - 6.6 (0.8) 9.3 (0.9) - -
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Chen
2003
- - 38 - Hyperten-
sion: 46
- - - -
Chen
2017
- - 12-24 - Hyperten-
sion: 28-
55
5.1-6.1 5.9-9.2 - Range
for i-IFG,
i-IGT and
IFG/IGT
co-
horts sepa-
rated by <
40
years and >
60 years
Coron-
ado-
Malagon
2009
- - - - - 5.9 (0.3) - - -
Cugati
2007
146 83 - - - 5 - - -
De Abreu
2015
128 (IQR
114-140)
79 (IQR
72-86)
13 - Hyperten-
sion: 43
5.3 (IQR
5.0-5.8)
- - -
Den
Biggelaar
2016
141 (IQR
132-155)
83 (IQR
78-92)
18 - - 6.0 (IQR
5.5-6.3)
8.8 (IQR
7.8-9.9)
5.8 (IQR
5.6-6.1)
-
Der-
akhshan
2016
- - 26 - - - - - -
Dowse
1991
- - - - - - - - -
Ferran-
nini
2009
118-128 71-78 - - - 4.9-6.4 6.7-9.5 - Range for
i-IFG5.6, i-
IFG6.1, i-
IGT,
IGT5.6
and
IGT6.1 co-
horts
Filippatos
2016
127 (17) 82 (10) 62 - Hyperten-
sion: 36
Hyperc-
holestero-
5.9 (0.3) - - -
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laemia: 54
Forouhi
2007
136 (16) 82 (10) 52 - - - - - -
Garcia
2016
- - 58 - - - - - -
Gautier
2010
- - - - - - - - -
Gomez-
Arbelaez
2015
- - - - - 5.2 (0.7) 6.0 (1.8) 6.5 (1.3) -
Guerrero-
Romero
2006
- - - - Dyslipi-
daemia: 41
Hyperten-
sion: 24
6.4 (0.6) - - -
Han 2017 120 (17)
119 (18)
124 (18)
78 (12)
76 (12)
80 (11)
64
34
59
- Hyperten-
sion:
28
27
36
5.9 (0.3)
4.8 (0.4)
5.9 (0.3)
6.1 (1.2)
8.9 (0.9)
9.3 (0.9)
5.5 (0.4)
5.5 (0.4)
5.7 (0.4)
i-IFG5.6
i-IGT
IFG/IGT
Hanley
2005
132 (20) 79 (10) - BP lower-
ing: 38
Lipid low-
ering: 7
- 5.9 (0.7) 8.5 (1.7) - -
Heianza
2012
125 (16) 76 (11) - - - 5.3 (0.5) 5.3 (0.3) -
Inoue
1996
142 (9) 73 (7) - - - - - - -
Janghor-
bani
2015
116-117 76-77 - - Hyperten-
sion: 20-
23
5.1-61 5.9-9.2 5.1-5.3 Range
for i-IFG,
i-IGT and
IFG/IGT
cohorts
Jaru-
ratanasirikul
2016
124 (15) 77 (9) - - - - - - -
Jeong
2010
139 (21) 87 (12) 43 - - - - 5.7 (0.5) -
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Jiamjaras-
rangsi
2008a
- - 4 - - - - - -
Kim 2005 - - - - - 6.4 (0.2) - - -
Kim 2008 128/132 80/83 - - - 5.8/6.4 - - -
Kim 2014 127-129 78 20-31 - - - - - Range for
i-IFG, i-
IGT, IFG/
IGT and i-
HbA1c co-
horts
Kim
2016a
116-120 72-75 24-25 - - 5.1-5.9 - 5.3-5.8 Range for
IFG and
HbA1c co-
horts
Kleber
2010
120 (16) 73 (13) - - - 5.1 (1.1) 8.5 5.6 (0.7) -
Kleber
2011
120 (14) 73 (12) - - - 4.8 (0.4) 8.4 (0.6) - -
Ko 1999 - - - - - - - - -
Ko 2001 125 (21) 78 (10) 2 - - 6.5 (0.3) 9.1 (2.1) 6.2 (0.6) -
Larsson
2000
- - - - - 4.7/5.5/5.
5
8.6/6.8/8.
7
- -
Latifi
2016
- - - - Hyperten-
sion: 40
- - - -
Lecomte
2007
135 (13) 81 (10) 23 - Hyperten-
sion: 48
6.4 (0.2) - - -
Lee 2016 125 (15) 81 (11) 20 - Hyperten-
sion: 22
- - 5.9 (0.2) -
Leiva
2014
134 (16) 77 (10) - - - - - - -
Levitzky
2008
Women:
122
Men: 127
- Women:
29
Men: 28
Antihyper-
tensives:
Women:
14
Men: 16
Hyperten-
sion:
Women:
26
Men: 35
- - - -
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Li 2003 136-138 85-87 - - - 5.4-6.4 6.8-9.1 - Range
for i-IFG,
i-IGT and
IFG/IGT
cohorts
Ligthart
2016
145 (21) 81 (12) 50 BP lower-
ing: 33
Lipid low-
ering: 18
Stroke: 3
CHD: 8
Hyperten-
sion: 64
- - - -
Lipska
2013
140-143 - 54-65 - - 5.1-6.1 - 5.3-5.9 Range
for i-IFG,
i-HbA1c
and IFG/
HbA1c co-
horts
Liu 2008 Men: 126
Women:
124
Men: 80
Women:
77
- - - Men: 5.3
Women: 5.
4
- - -
Liu 2014 132 (16) 82 (8) - - - 5.8 (0.8) 9.2 (1.2) - -
Liu 2016 - - - - - - - - -
Liu 2017 128 (21) 81 (11) 37 - - 5.9 (0.4) - - -
Lorenzo
2003
124 75 - - - 5.3 7.6 - -
Lyssenko
2005
140 85 (11) - - - 6.3 (IQR
5.8-6.6)
8.3 (1.6) 5.7 (0.4) -
Magliano
2008
- - 48 - - 6 8 5.5 -
Man 2017 145 (20) 80 (12) 13 - Hyperten-
sion: 74
- - - -
Marshall
1994
- - - - - 6.1 9.5 - -
McNeely
2003
139
137
80
80
- - - 5.5
5.6
9.0
8.8
- 5-6 years
follow-up
10 years
follow-up
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Meigs
2003
- - - - - - - - -
Mohan
2008
127 (19) 81 (11) - - - 4.5 (0.6) - - -
Motala
2003
119 (19) 78 (13) - - - 4.6 (1.8) 6.2 (3.8) - -
Motta
2010
- - - - - - - - -
Mykkänen
1993
159 84 1 Antihyper-
tensives:
24
Hyperten-
sion: 47
6.2 8.4 - -
Nakagami
2016
134 (18) 82 (12) 35 - - 6.0 (0.6) - 6.0 (0.3) -
Nakanishi
2004
133 (16) 81 (11) 53 - Dyslipi-
daemia: 40
Protein-
uria: 5
Hyperten-
sion: 35
6.4 (0.2) - - -
Noda
2010
- - - - - Men: 5.4
Women: 5.
2
- Men: 5.0
Women: 5.
1
-
Park 2006 - - - - - 6.0 (0.3) - - -
Peterson
2017
- 75 (11) - - - - - 5.5 (0.4) -
Qian
2012
126 (21) 81 (12) - - - 5.2 (0.7) 6.1 (1.5) - -
Rajala
2000
- - - - Hyperten-
sion: 49
- - - -
Ra-
machan-
dran
1986
- - - - - - - - -
Ras-
mussen
2008
140-142 - - - - - - - Range for
IFG and
IGT
cohorts
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Rath-
mann
2009
133 (19) 80 (10) 49 Lipid low-
ering: 11
Hyperten-
sion: 49
5.5 (0.5) 6.3 (1.7) 5.6 (0.4) -
Rijkeli-
jkhuizen
2007
139-145 84-85 - - - - - - Range for
IFG5.6 and
IFG6.1 co-
horts
Sadeghi
2015
127 (21) 81 (11) 14 - - 5.7 (0.7) 8.4 (1.5) - -
Sasaki
1982
- - - - - 5.6 (0.9) 9.0 (0.9) - -
Sato 2009 - - 91 - - 6.0 (0.6) - 5.6 (0.6) -
Schranz
1989
- - - - - Women: 7.
2
Men: 6.2
Women:
10.8
Men: 9.7
- -
Sharifi
2013
130 (12) 79 (8) 5 - Hyper-
triglyceri-
daemia: 48
Hyperten-
sion: 25
- - - -
Shin 1997 130 84 - - - 6.1 6.7 - -
Söderberg
2004
125 77 27 - - 5.5 6.5 - -
Song
2015
123-127 76-80 2-27 - Dyslipi-
daemia:
64-66
Hyperten-
sion: 35-
44
- - 5.7-5.8 Ranges for
male
and female
cohorts
Song
2016a
134 (20) 85 (12) 23 - - 6.0 (0.4) 5.9 (1.6) - -
Soriguer
2008
- - - - - - - - -
Stengard
1992
156 88 - - Hyperten-
sion: 53
5.4 (1.1) 9.7 (0.8) - -
Toshihiro
2008
126 (12) 81 (10) 47 - - 6.1 (0.6) 8.8 (1.3) - -
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Vaccaro
1999
- - - - - 4.2 (0.8) 4.5 (1.7) - -
Valdes
2008
135-144 84-92 - - - 5.8-6.4 6.4-7.3 4.9-5.1 Ranges for
IFG5.6 and
IFG6.1 co-
horts
Vijayaku-
mar
2017
- - - - - A: 5.4/C:
5.2
A: 6.7/C:
6.5
A: 5.8/C:
5.7
-
Viswanathan
2007
- - - - - 6.1 (0.7) 8.9 (1.0) - -
Wang
2007
124 (19) 78 (11) 28 - Hyperten-
sion: 36
5.8 (0.9) 7.4 (1.7) - -
Wang
2011
- - - - - - - - -
Warren
2017
- - 22 - Hyperten-
sion: 38
6.0 (0.4) - 5.6 (0.4) Data
for cohort
1 (IFG5.6)
Wat 2001 126 78 - - - 5.4 8.9 - -
Weiss
2005
- - - - - 5.2 8.9 - -
Wheelock
2016
- - - - - - 5.4 (1.2) - -
Wong
2003
125 74 24 - - 5.7 8.9 - -
Yeboah
2011
132 (21) 74 (11) 50 BP lower-
ing: 56
Lipid low-
ering
(statins):
17
- 6.0 (0.4) - - -
Zethelius
2004
- - - - - 5.7 (0.7) 7.9 (1.9) - -
2-h: 2-h measurement after an OGTT; BP: blood pressure; CHD: coronary heart disease; FG: fasting glucose; FPG: fasting plasma
glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0: HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4%
and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i-: isolated; IFG5.6/6.1: impaired fasting glucose (threshold 5.
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6 mmol/L or 6.1 mmol/L);IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; IQR: interquartile range; OGTT: oral
glucose tolerance test; SD: standard deviation
Appendix 11. Cumulative incidence as the measurement for the development of T2DM
Study ID
(years
of follow-
up)
Diabetes cumulative incidence
NGT co-
hort
IFG5.6 co-
hort
i-IFG5.6
cohort
IFG6.1 co-
hort
i-IFG6.1
cohort
IGT
cohort
i-IGT co-
hort
IFG/IGT
cohort
HbA1c
cohort
Admiraal
2014 (10)
Unclear/
354
Total
cohort: 51/
111 (45.
9%)
Asian
13/31 (41.
9%)
African
14/
40 (35%)
“Ethnic
Dutch” 3/
40 (7.5%)
- - - - - - -
Aek-
plakorn
2006 (12)
Unclear/
2444
65/223
(29.1%)
- - - - - - -
Ammari
1998 (2)
10/144 (6.
9%)
- - - - 10/68 (14.
7%)
- - -
Anjana
2015 (9.1)
209/1077
(19.4%)
- 32/67 (47.
8%)
- - - 86/163
(52.8%)
58/69 (84.
1%)
-
Bae 2011
(4)
228/7932
(2.9%)
- - - - - - - HbA1c5.7 :
373/1791
(20.8%)
HbA1c6.0:
187/412
(45.4%)
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Baena-
Diez 2011
(10)
0 (IFG co-
hort)
- - 33/115
(28.7%)
- - - - -
Bai 1999
(1)
1/444 (0.
2%)
- - - - 14/252 (5.
6%)
- - -
Bergman
2016 (20)
202/739
(27.3%)
- - - - 68/114
(59.6%)
- - -
Bonora
2011 (15)
29/710 (4.
1%)
- 10 years:
18/55 (32.
7%)
- - 10 years:
8/53 (15.
1%)
10 years:
9/19 (47.
4%)
HbA1c6.0:
20/70 (28.
6%)
Cederberg
2010 (9.7)
11/410 (2.
7%)
- - 15/40 (37.
8%)
6.3% 38/103
(37.1%)
23.4% - HbA1c5.7 :
9/24 (37.
5%)
Chamnan
2011 (3)
37/5365
(0.7%)
- - - - - - - HbA1c6.0:
26/370
(7%)
Charles
1997 (2)
27/3671
(0.7%)
- - - 3 years:
15/476 (3.
2%)
2 years:
32/418 (7.
7%)
- - -
Chen
2003 (3)
11/444 (2.
5%)
- - 15/156 (9.
6%)
- - - - -
Chen
2017 (3)
60/644 (9.
3%)
- 40/329
(12.2%)
- - - 45/192
(23.4%)
71/209
(34%)
-
Coronado-
Malagon
2009a (1,
2)
Year 1: 3/
439 (0.
7%)
Year 2: 3/
439 (0.
6%)
- - - - - - - -
Cugati
2007 (10)
108/1512
(7.1%)
69/229
(30%)
- - - - - - -
De Abreu
2015 (10)
11/342 (3.
2%)
21/187
(11.2%)
- - - - - - -
Den
Biggelaar
2016b (7)
17/294 (5.
8%)
- - - - - - - -
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Der-
akhshan
2016c (11.
7)
162/3611
(4.5%)
- - - - - - - -
Dowse
1991 (6.2)
14/215 (6.
5%)
- - - - 13/51 (25.
5%)
- - -
Ferran-
nini
2009 (7)
89/1594
(5.6%)
- 11/65 (16.
9%)
- 1/17 (5.
9%)
- 31/179
(17.3%)
3 years:
44/188
(23.4%)
- -
Filippatos
2016 (10)
120/1206
(10.0%)
71/279
(25.4%)
- - - - - - -
Forouhi
2007 (10)
8/407
(2%)
53/633 (8.
3%)
- 34/257
(24.7%)
- 4.4 years:
17/170
(10%)
- - -
Garcia
2016 (9)
132/881
(15.0%)
169/310
(54.5%)
- - - - - - -
Gautier
2010 (9)
0 (IFG co-
hort)
142/979
(14.5%)
- - - - - - -
Gomez-
Arbelaez
2015d (2)
Unclear/
586
- - - - - - - -
Guerrero-
Romero
2006 (5)
1/272 (0.
4%)
- - - - 20/67 (29.
9%)
- - -
Han 2017
(12)
657/5633
(11.7%)
- 81/199
(40.7%)
- - - 624/1512
(41.3%)
138/198
(69.7%)
10 years:
HbA1c5.7 :
881/2830
(31.1%)
Hanley
2005 (5.2)
5 years:
47/603 (7.
8%)
- - - - 88/274
(32.1%)
5 years:
101/303
(33.3%)
- - -
Heianza
2012 (5)
4.7 years:
34/4149
(0.8%)
262/1680
(15.6%)
- 155/380
(40.8%)
- - - - HbA1c5.7 :
184/822
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(22.4%)
HbA1c5.7
and
IFG5.6:
292/2092
(14%)
HbA1c6.0:
100/203
(49.3%)
HbA1c6.0
and
IFG5.6:
271/1748
(15.5%)
Inoue
1996 (2.5)
1/22 (4.
5%)
- - - - 5/37 (13.
5%)
- - -
Janghor-
bani
2015 (6.8)
14/627 (2.
2%)
- 23/230
(10%)
- - - 26/150
(17.3%)
78/214
(36.4%)
-
Jaru-
ratanasirikul
2016 (3-6)
12/108
(11.1%)
- - - - - 9/33 (27.
3%)
- -
Jeong
2010e (5)
228/792
(28.8%)
- - - - - - - -
Jiamjaras-
rangsi
2008a (2.
6)
15/2050
(0.7%)
33/320
(10.3%)
- - - - - - -
Kim 2005
(5)
Unclear/
2009
- - 15/276 (5.
5%)
- - - - -
Kim 2008
(2)
21/5382
(0.4%)
22/1335
(1.6%)
- 48/494 (9.
7%)
- - - - -
Kim 2014
(3.8)
0 (cohort
with inter-
medi-
ate hyper-
glycaemia)
- 24/158
(15.2%)
- - - 12/65 (18.
5%)
38/119
(31.9%)
i-
HbA1c5.7 :
7/64 (10.
9%)
Kim
2016a (5.
2)
43/10,763
(0.4%)
- - 357/1433
(24.9%)
- - - - HbA1c6.0:
322/1103
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(29.2%)
IFG5.6 and
HbA1c5.7 :
435/1951
(22.3%)
Kleber
2010 (1)
0 (IGT co-
hort)
- - - - 1/79 (1.
3%)
- - -
Kleber
2011 (3.9)
0 (IGT co-
hort)
- - - - 3/119 (2.
5%)
- - -
Ko 1999
(1.4)
0 (IGT co-
hort)
- - - - 29/123
(23.6%)
- - -
Ko 2001
(1.7)
13/264 (4.
9%)
- - 14/55 (25.
5%)
- - - - -
Larsson
2000 (10)
5/127 (3.
9%)
- - - 5/42 (11.
9%)
- 8/66 (12.
1%)
6/30 (20.
0%)
-
Latifi
2016 (5)
25/394 (6.
3%)
21/124
(16.9%)
- - - - - - -
Lecomte
2007 (5)
0 (IFG co-
hort)
- - 127/743
(17.1%)
- - - - -
Lee 2016
(3.7)
0 (cohort
with inter-
medi-
ate hyper-
glycaemia)
- - - - - - - HbA1c5.7 :
390/3497
(11.2%)
Leiva
2014 (6)
0 (IFG co-
hort)
- - 11/28 (39.
3%)
- - - - -
Levitzky
2008 (4)
0 (IFG co-
hort)
- - Women:
87/313
(27.8%)
Men: 92/
460 (20.
0%)
- - - - -
Li 2003
(5)
38/435 (8.
7%)
- - - 16/42 (38.
1%)
2 years:
23/131
(17.6%)
33/118
(28%)
20/49 (40.
8%)
-
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Ligthart
2016 (14.
7)
Unclear/
7462
- - 425/1382
(30.8%)
- - - - -
Lipska
2013 (7)
38/1690
(2.2%)
20/189
(10.6%)
- 48/100
(48%)
- - - - i-
HbA1c5.7 :
44/207
(21.3%)
IFG and
HbA1c5.7 :
81/169
(47.9%)
Liu 2008
(5)
9/470 (1.
9%)
18/169
(10.7%)
- - - - - - -
Liu 2014f
(3)
153/1821
(8.4%)
- - - - - - - -
Liu 2016
(10.9)
Unclear/
1635
- - - - - - - -
Liu 2017
(7.8)
Unclear/
15003
- - - - - - - -
Lorenzo
2003 (7-8)
Unclear/
1503
- - 14/29 (48.
3%)
- 88/202
(43.6%)
- - -
Lyssenko
2005g (6)
41/1429
(2.9%)
- - - - - - - -
Magliano
2008 (5)
58/4715
(1.2%)
- - 44/370
(11.9%)
- 122/757
(16.1%)
- - -
Man 2017
(6)
15/462 (3.
2%)
- - - - - - - HbA1c5.7 :
112/675
(16.6%)
Marshall
1994 (1.9)
0 (IGT co-
hort)
- - - - 20/123
(16.3%)
- - -
McNeely
2003 (10)
5-6 years:
5/277 (1.
8%)
10 years:
13/277 (4.
5%)
5-6 years:
27/125
(21.6%)
10 years:
39/103
(37.9%)
- 5-6 years:
7/30 (23.
3%)
10 years:
18/28 (64.
3%)
- 5-6 years:
45/178
(25.3%)
10 years:
59/157
(37.6%)
- - -
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Meigs
2003 (5,
10)
6 (SD 5)
years:
55/488
(11.3%)
- - - 6 (SD 5)
years:
6/20 (30.
0%)
- 6 (SD 5)
years:
81/218
(37.1%)
6 (SD 5)
years:
15/27 (55.
6%)
-
Mohan
2008 (8)
64/476
(13.4%)
- - - - 15/37 (40.
5%)
- - -
Motala
2003 (10)
36/482 (7.
5%)
- - - - 13/35 (37.
1%)
4 years:
16/72 (22.
2%)
- - -
Motta
2010 (3)
52/2018
(2.6%)
- - 50/295
(16.9%)
- - - - -
Mykkänen
1993 (3.5)
21/689 (3.
0%)
- - - - 48/203
(23.6%)
- - -
Nakagami
2016 (5)
1528 77/467
(16.5%)
- 50/134
(37.3)
- - - - HbA1c6.0:
58/156
(37.2%)
HbA1c5.7 :
87/583
(14.9%)
Nakanishi
2004 (7)
51/5500
(0.9%)
- - 5/246 (2.
0%)
- - - - -
Noda
2010 (5)
Total: 30/
1649 (1.
8%)
Men:
13/540 (2.
4%)
Women:
17/1109
(6.4%)
To-
tal: 37/405
(9.1%)
Men:
18/202 (8.
9%)
Women:
19/203 (9.
4%)
- To-
tal: 58/153
(37.9%)
Men:
25/79 (31.
6%)
Women:
33/74 (44.
6%)
- - - - -
Park 2006
(4.1)
116/4975
(2.3%)
40/321
(12.5%)
- - - - - - -
Peterson
2017 (10)
2/39 (5.
1%)
- - - - 6/29 (20.
7%)
- - -
Qian
2012 (5)
59/843 (7.
0%)
- - - 17/46
(37%)
- 49/120
(41%)
17/33
(51%)
-
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Rajala
2000 (4.6)
0 (IGT co-
hort)
- - - - 32/171
(18.7%)
2.1 years:
14/183 (7.
7%)
- - -
Ra-
machan-
dran
1986 (5.1)
0 IGT co-
hort)
- - - - 39/107
(36.4%)
- - -
Rasmussen
2008 (3.5)
(i-
IFG5.6: 2.
5, IGT: 2.
1 )
0
(IFG, IGT
cohort)
- 141/442
(32%)
- - 181/442
(41%)
1 year:
35/296
(11.8%)
1 year:
60/207
(29%)
-
Rath-
mann
2009 (7)
25/649 (3.
9%)
- - 12/71 (16.
9%)
- - 34/120
(28.3%)
22/47 (46.
8%)
-
Rijkeli-
jkhuizen
2007 (6.4)
51/1125
(4.5%)
101/488
(20.7%)
- 62/149
(41.6%)
35/106
(33%)
36/111
(32.4%)
2 years:
45/158
(28.5%)
27/80 (33.
8%)
20/31 (64.
5%)
-
Sadeghi
2015 (7)
141/2607
(5.4%)
- 134/373
(35.9%)
- - - 49/373
(13.1%)
65/373
(17.4%)
-
Sasaki
1982 (7)
7/161/4.
3%)
- - - - 5/13 (38.
5%)
- - -
Sato 2009
(4)
118/4147
(2.9%)
- - 334/794
(42.1%)
- - - - HbA1c6.0:
90/215
(41.9%)
Schranz
1989 (6)
54/1251
(4.3%)
- - - - 23/75 (30.
7%)
- - -
Sharifi
2013 (7)
0 (IFG co-
hort)
24/123
(19.5%)
- - - - - - -
Shin 1997
(2)
47/1040
(4.5%)
- - - - 20/153
(13.1%)
- - -
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Söderberg
2004 (11)
Unclear/
2522
- - 5 years:
32/148
(21.6%)
153/402
(38%)
575/1253
(45.9%)
5 years:
103/489
(21.1%)
5 years:
45/118
(38.1%)
-
Song
2015 (4)
74/1758
(4.2%)
- 68/321
(21.2%)
Men: 30/
154 (19.
5%)
Women:
38/167
(22.8%)
- - - - - -
Song
2016a
(10.8)
0 (cohort
with inter-
medi-
ate hyper-
glycaemia)
- - - - - - - -
Soriguer
2008 (6)
13/1806
(0.7%)
- 23/56 (41.
1%)
- - 14/54 (25.
9%)
- 14/28
(50%)
-
Stengard
1992 (5)
6/216 (2.
8%)
- - - - 17/234 (7.
3%)
- -
Toshihiro
2008 (3.2)
h
0 (co-
hort with
IFG and/
or IGT)
- - - - - - - -
Vaccaro
1999 (11.
5)
36/500 (7.
2%)
- 1/11 (9.
1%)
- - - 13/40 (32.
5%)
4/9 (44.
4%)
-
Valdes
2008 (6.3)
16/510 (3.
1%)
14/114
(12.3%)
7/32 (21.
9%)
19/52 (36.
5%)
- 21/88 (23.
9%)
9/68 (13.
2%)
12/20
(60%)
-
Vijayaku-
mar
2017
(adults: 4.
6,
children:
5.2)
Adults: 58/
1466 (3.9)
Children:
26/1795
(1.4%)
[estimated
from figure
2]
Adults:
222/424
(52.4%)
Children:
52/193
(26.9%)
- - - Adults:
196/347
(56.5%)
Children:
55/169
(32.5%)
- IFG5.6/
IGT:
Adults:
116/169
(68.7%)
Children:
26/53 (49.
1%)
HbA1c5.7 :
adults: 75/
168 (44.
6%)
HbA1c5.7:
chil-
dren: 18/
62 (29%)
Viswanathan
2007 (5)
Total: 154/
465 33.
1%)
- - - - Total: 416/
619 (67.
- - -
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M: 99/265
(37.4%)
W: 55/200
(27.5%)
2%)
M: 251/
391 (64.
2%)
W: 165/
228 (72.
4%)
Wang
2007 (5)
51/358
(14.2%)
- 53/261
(20%)
28/112
(25%)
- 126/141
(89.4%)
31/95 (32.
6%)
IFG5.6/
IGT: 54/
109 (49.
5%)
IFG6.1/
IGT:
36/52 (69.
2%)
-
Wang
2011 (7.8)
84/595
(14.1%)
Total:
345/947
(36.4%)
Men: 137/
418 (32.
8%)
Women:
208/529
(39.3%)
- - - Total:
233/491
(47.5%)
Men: 75/
154 (48.
7%):
Women:
158/337
(46.9%)
4 years:
Total 198/
532 (37.
2%)
- Total:
185/356
(52%%)
Men: 66/
125 (52.
8%)
Women:
119/231
(51.5%)
HbA1c6.0:
19/121
(15.7%)
Warren
2017 (co-
hort 1: 22,
cohort 2:
16)
22 years:
8322
16 years:
4772
- - - - - - - -
Wat 2001
(2)
4/333 (0.
1%)
- - - - 31/322 (9.
6%)
- - -
Weiss
2005 (1.7)
8/84 (9.
5%)
- - - - - 8/33 (24.
2%)
- -
Wheelock
2016 (4.3)
Unclear/
5363
- - 5 years:
31%
- Non-over-
weight:
5 years: 9/
37 (24%)
10 years:
11/37 (29.
- 5 years:
41.2%
-
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7%)
Over-
weight:
5 years: 49/
132 (37%)
10 years:
84/132
(63.6%)
Wong
2003 (8)
12/278 (4.
3%)
- - - - 102/291
(35.1%)
- - -
Yeboah
2011 (7.5)
Unclear/
4973
273/940
(29.0%)
- - - - - - -
Zethelius
2004 (7)
Unclear/
466
- - - - Not
reported/
201
- - -
aDevelopment of T2DM from ’prediabetes’ (not defined) at year 1: 11/217 (5.1%), at year 2: 16/217 (7.6%)
bDevelopment of T2DM from ’prediabetes’ (IFG6.1 and/or IGT): 46/122 (37.7%).
cDevelopment of T2DM from IFG5.6 and/or IGT: 11.7 years150/523 (28.7%); 2.3 years: 121/911 (13.3%).
dDevelopment of T2DM from IFG5.6 or IGT or HbA1c5.7 : 20/186 (10.8%).
eDevelopment of T2DM from IFG or IGT: not reported.
fDevelopment of T2DM from IFG or IGT: 78/450 (17.3%).
gDevelopment of T2DM from IFG or IGT:86/686 (12.5%).
hDevelopment of T2DM from IFG and/or IGT: 36/128 (28.1%).
FPG: fasting plasma glucose;HbA1c: glycosylated haemoglobinA1c;HbA1c5.7/6.0 :HbA1c threshold 5.7%or 6.0%(usually reflecting
5.7% to 6.4% and 6.0% to 6.4%, respectively);HbA1c/IFG: both HbA1c and IFG; i-: isolated; IFG5.6/6.1: impaired fasting glucose
(threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; NGT: normal glucose
tolerance; PG: postload glucose; SD: standard deviation; T2DM: type 2 diabetes mellitus
Appendix 12. Diabetes incidence (cases per 1000 person-years)
Study ID Rate (diabetes cases/1000 person-years (95% CI))
Follow-up
(years)
NGT co-
hort
’Predi-
abetes’ co-
hort
IFG6.1 co-
hort
IFG5.6 co-
hort
IGT
cohort
IFG/IGT
cohort
Elevated
HbA1c
cohort
Elevated
HbA1c/
IFG
cohort
Anjana
2015
9.1 22.2 (19.
4-25.4)
78.9 (68.
0-90.9)
- 61.0 (42.
1-85.0)
67.8 (54.
6-83.0)
133.
6 (103.1-
169.3)
- -
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Bae 2011 4 - - - - - - Per 100
person-
years:
HbA1c5.7 :
5.6
HbA1c6.0 :
14.0
-
Bonora
2011
15 10 years: 4.
3 (2.7-5.9)
- 10 years:
37.0 (20.
2-53.8)
- 10
years: 17.0
(5.3-28.7)
10 years:
49.2 (17.
9-80.5)
HbA1c6.0 :
25.8
-
De Abreu
2015
10 - - - 18.1 (10.
7-28.2)
- - - -
Der-
akhshan
2016
11.7 - 30.3 6.5 years:
69.4 (56.
0-86.1)
6.5 years:
39.5 (34.
4-45.4)
6.5 years:
41.6 (36.
1-47.9)
- - -
Dowse
1991
6.2 10.5 - - - 40.4 - - -
Forouhi
2007
10 2.4 (1.2-4.
8)
4 years: 2.
64 (1.23-
4.05)
- 17.5 (12.
5-24.5)
10.6 (8.1-
13.9)
(IFG5.6:
FPG 5.6-
6.9)
4 years: 22.
5 (20.4-
24.6)
- - -
Han 2017 12 12.3 IFG or
IGT: 58.0
- i-IFG5.6:
51.3
i-IGT: 53.
1
114.4 10 years:
HbA1c5.7 :
43.2
-
Heianza
2012
5 2.3 - 104 34.6 - - HbA1c5.7 :
51.0
HbA1c6.0 :
129.2
HbA1c5.7
and
IFG5.6: 30.
6
HbA1c6.0
and
IFG5.6: 34.
4
Janghor-
bani
2015
6.8 3.1 (1.5-4.
7)
2.3 years:
4.6 (1.28-
11.7)
- - 16.3 (10.
3-24.4)
2.3 years: i-
IFG5.6: 50.
7 (20.7-
102.0)
25.9 (17.
0-37.7)
2.3 years: i-
IGT: 99.7
(77.1-126.
0)
57.9 (46.
1-71.7)
- -
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Jiamjaras-
rangsi
2008a
2.6 - - - 31.5 (11.
4-86.8)
- - - -
Latifi
2016
5 21.9 - - 34.5 - - - -
Li 2003 5 18.8 - 93.7 - 60.7 117 - -
Ligthart
2016
14.7 - - 43.0 (39.
2-47.2)
- - - - -
Liu 2008 5 9 - - 22.5 - - - -
Magliano
2008
5 0.2 (0.2-0.
3)
(incidence
percent per
years)
- i-
IFG6.1: 2.6
(1.8-3.4)
(incidence
percent per
years)
- i-IGT: 3.5
(2.9-4.2)
(incidence
percent per
years)
- - -
Meigs
2003
5, 10 Per 100
person-
years (an-
nu-
alised rate)
: FPG ≥ 7.
0:
0.64 (0.
32-1.13)
2-h PG ≥
11.1:
2.77 (2.
01-3.71)
- - - - Per 100
person-
years (an-
nualised
rate):
IFG or
IGT
FPG ≥ 7.
0:
0.98 (0.
65-1.41)
2-h PG ≥
11.1:
4.61 (3.
77-5.56)
- -
Mohan
2008
8 17.5 - - - 64.8 - - -
Nakagami
2016
5 - - 1 - - - - -
Nakanishi
2004
7 1.5 - 3.3 - - - - -
Park 2006 4.1 5.7 - - 31.3 - - - -
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Rajala
2000
4.6 - - - - 41 (28-57) - - -
Ras-
mussen
2008
3.5
(i-
IFG5.6: 2.5
, IGT: 2.1 )
- - - i-IFG5.6:
11.8 (9.9-
13.8)
per 100
person-
years
17.0 (14.
9-19.1)
per 100
person-
years
(i-IGT: 11.
8 (9.7-13.
9)
27 (22.5-
31.7)
per 100
person-
years
- -
Rath-
mann
2009
7 - - i-IFG6.1:
24.2 (12.
5-42.3)
- i-IGT:
42.0 (29.
0-58.7)
77.9 (48.
8-117.9)
- -
Rijkeli-
jkhuizen
2007
6.4 7 - 66.5 (49.
9-83.0)
32.7 (26.
3-39.1)
i-IGT: 57.
9
112.2 - -
Sadeghi
2015
7 Total: 14.1
(12.5-15.
9)
Men: 12.8
(10.7-15.
3)
Women:
15.5 (13.
1-18.3)
- - Total: 48.4
(35.0-66.
7)
Men: 46.4
(28.9-74.
7)
Women:
50.1 (32.
3-77.7)
Total: 40.3
(30.2-53.
8)
Men: 41.4
(25.7-66.
6)
Women:
39.6 (27.
5-57.0)
Total: 137.
6 (103.7-
182.5)
Men: 129.
9 (83.0-
203.7)
Women:
143.1 (99.
4-205.9)
- -
Söderberg
2004
11 - - 87-92:
Men: 54.1
(48.0-60.
1)
Women:
35.1 (30.
3-40.0)
92-98:
Men: 60.5
(54.1-67.
0)
Women:
74-7 (67.
8-81.8)
- 87-92:
Men: 60.7
(54.3-67.
1)
Women:
47.9 (42.
2-53.6)
92-98:
Men: 119.
6 (110.6-
128.6)
Women:
81.0 (73.
6-88.4)
- - -
Soriguer
2008
6 7.2 (4.2-
12.4)
- - 38.1 (25.
3-57.3)
31.1 (18.
4-52.5)
66.0 (39.
1-111.5)
- -
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Valdes
2008
6.3 3.8 (2.1-6.
8)
for i-IGT
and IFG/
IGT:
5.0 (2.8-8)
- 58.0 (37-
90.9)
19.5 (11.
5-32.9)
37.9 (24.
7-58.1)
i-IGT: 21
(10.9-40.
4)
95.2 (54.
1-167.7)
- -
Vijayaku-
mar
2017
Adults: 4.6
Children:
5.2
- - - Boys: 22
Men: 70
Girls: 55
Women:
101
Boys: 38
Men: 94
Girls: 60
Women:
118
- Boys: 52
Men: 100
Girls: 100
Women:
118
-
Wang
2011
7.8 21.1 - - Total: 66.2
Men: 57.7
Women:
73.4
Total: 95.8
Men: 98.1
Women:
94.8
Total: 109
Men: 109
Women:
109
- -
CI: confidence interval; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0: HbA1c threshold 5.
7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i-: isolated;
IFG5.6/6.1: impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG
and IGT;NGT: normal glucose tolerance; T2DM: type 2 diabetes mellitus
Appendix 13. T2DM cases and person-time (for calculation incidence rate ratios)
Study ID Persons (cases) with diabetes with/without IH at baseline
Follow-up (years) Cases in IH group Person-years for
IH group
Cases in normogly-
caemic group
Person-
years for normo-
glycaemic group
Anjana 2015 9.1 i-IFG5.6: 32
i-IGT: 86
IFG/IGT: 58
i-IFG5.6: 525
i-IGT: 1269
IFG5.6/IGT: 434
209 9398
De Abreu 2015 10 IFG5.6: 21 IFG5.6: 1768 11 -
Bae 2011 4 HbA1c5.7 : 373
HbA1c6.0: 187
HbA1c5.7 : 6594
HbA1c6.0 : 1338
- -
Bonora 2011 10 IFG6.1: 18
IGT: 8
IFG/IGT: 9
IFG6.1: 486
IGT: 471
IFG/IGT: 183
29 6704
Derakhshan 2016 11.7 IFG5.6: 150 IFG5.6: 4950 162 39,901
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Dowse 1991 6.2 IGT: 13 IGT: 322 14 1339
Forouhi 2007 10 IFG6.1: 34
IFG5.6: 53
4.44 years:
IGT: 17
IFG6.1: 1943
IFG5.6: 5000
4.44 years:
IGT: 756
8
4.44 years:
9
3333
4.44 years:
3409
Guerrero-Romero
2006
5 IGT: 20 IGT: 343 1 1388
Han 2017 12 i-IFG5.6: 81
i-IGT: 624
IFG/IGT: 138
i-IFG5.6: 1579
i-IGT: 11,744
IFG/IGT: 1206
657 53,461
Heianza 2012 5 IFG5.6: 108
HbA1c5.7: 30
HbA1c5.7/IFG5.6:
154
IFG5.6: 5920
HbA1c5.7 : 1965
HbA1c5.7/IFG5.6:
1641
46 19,961
Janghorbani 2015 6.8 i-IFG5.6: 23
i-IGT: 26
IFG/IGT: 214
i-IFG5.6: 1409
i-IGT: 1005
IFG/IGT: 1347
14 4578
Li 2003 5 i-IFG6.1: 16
i-IGT: 33
IFG/IGT: 20
i-IFG6.1: 171
i-IGT: 544
IFG/IGT: 179
38 2026
Ligthart 2016 14.7 IFG6.1: 425 iFG6.1: 9884 - -
Meigs 2003 5, 10 IFG or IGT
T2DM measured
by:
FPG ≥ 7.0: 26
2-h PG≥ 11.1: 101
IFG or IGT
T2DM measured
by:
FPG ≥ 7.0: 2647
2-h PG ≥ 11.1:
2192
28 1539
Mohan 2008 8 IGT: 15 IGT: 247 64 3665
Nakanishi 2004 7 IFG6.1: 5 IFG6.1: 1506 51 34,308
Park 2006 4.1 IFG5.6: 40 IFG5.6: 1278 116 20,298
Rijkelijkhuizen
2007
6.4 i-IFG6.1: 35
i-IGT: 27
IFG/IGT: 20
i-IFG6.1: 681
i-IGT: 466
IFG/IGT: 178
51 7286
Soriguer 2008 6 IFG5.6: 23
IGT: 14
IFG/IGT: 14
IFG5.6: 604
IGT: 450
IFG/IGT: 212
13 1806
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Valdes 2008 6.3 IFG5.6: 14
IFG6.1: 19
i-IGT: 9
IFG/IGT: 12
IFG5.6: 718
IFG6.1:328
i-IGT: 429
IFG/IGT: 126
11
(16 for i-IGT and
IFG/IGT)
2923
(3200 for i-IGT and
IFG/IGT)
Wang 2011 7.8 IFG5.6: 137
IGT: 75
IFG/IGT: 66
IFG5.6: 2374
IGT: 765
IFG/IGT: 605
34 1613
FPG: fasting plasma glucose;HbA1c: glycosylated haemoglobinA1c;HbA1c5.7/6.0 :HbA1c threshold 5.7%or 6.0%(usually reflecting
5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i-: isolated; IFG5.6/6.1: impaired fasting
glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; IH: intermediate
hyperglycaemia;T2DM: type 2 diabetes mellitus
Appendix 14. Odds ratios and hazard ratios as the effect measures for the development of T2DM
Study ID Adjusted [unadjusted] ratios (95% CI) for the development of diabetes comparing IH with normoglycaemia at
baseline
Follow-up
(years)
IFG6.1 IFG5.6 IGT ’Predia-
betes’
IFG/IGT HbA1c HbA1c/
IFG
Ratio
Admiraal
2014
10 - Total
cohort:
6.1 (3.1-
12.1)
[5.7 (3.1-
10.5)]
South-
Asian Suri-
namese:
11.1 (3.0-
40.8)
[9.9 (2.9-
34.3)]
African
Suri-
namese:
5.1 (2.0-
13.3)
[6.2 (2.6-
14.9)]
“Ethnic
Dutch”:
- - - - - Odds ratio
436Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
2.2 (0.5-
10.2)
[2.1 (0.5-
9.3)]
Aek-
plakorn
2006
12 - [2.41 (1.
78-3.28)]
[4.36 (3.
41-5.57)]
- - - - Odds ratio
Bae 2011 4 - - - - - HbA1c5.7 :
6.5 (3.7-
10.2)
HbA1c6.0 :
41.3 (24.
7-69.2)
[com-
pared with
HbA1c <
5.0]
- Hazard ra-
tio
Bergman
2016
24 20 years: i-
IFG6.1: 3.
43 (1.88-
6.28)
20 years: i-
IFG5.6: 1.
11 (0.76-
1.61)
5.64 (2.
74-12.33)
20 years: 3.
03 (1.80-
5.09)
- IFG5.6
+ IGT: 2.
79 (1.56-
5.00)
IFG6.1
+ IGT: 3.
85 (1.73-
8.54)
- - Odds ratio
Bonora
2011
15 5.83 (3.
23-10.54)
10 years:
5.7 (2.8-
11.4)
[3.9 (1.56-
9.3)]
10 years:
[3.9 (1.6-
9.3)]
- 10 years:
[20.5 (7.6-
55.3)]
HbA1c6.0 :
9.74 (4.
21-22.56)
- Hazard ra-
tio,
odds ratio
(10 years)
Cederberg
2010
9.7 2.37 (1.
49-3.78)
[2.56 (1.
57-4.16)]
- 2.90 (1.
90-4.43)
[2.98 (1.
94-4.569]
- - HbA1c5.7 :
2.42 (1.
50-3.91)
[2.78 (1.
80-4.31)]
- Risk ratio
Chamnan
2011
3 - - - - - HbA1c6.0 :
15.6 (6.9-
35.7)
[15.5 (7.2-
33.3)]
- Odds ratio
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Chen
2003
3 4.4 (1.9-
10.6)
- - - - - - Odds ratio
Coron-
ado-
Malagon
2009
1, 2 - - - [At 1 year:
7.7 (2.1-
27.9)]
- - - Relative
risk
Cugati
2007
10 [19.
13 (11.59-
31.66)]
- - - - - - Odds ratio
De Abreu
2015
10 5.75 (1.
86-17.78)
- - - - - - Odds ratio
Der-
akhshan
2016
11.7 6.5 years:
4.1 (2.9-5.
6)
6.5 years:
3.0 (2.3-3.
9)
- IFG5.6
and/or
IGT:
4.98 (4.
08-6.07)
- - - Hazard ra-
tio, relative
risk (6.5
years)
Dowse
1991
6.2 - - [3.6 (1.4-
9.1)]
- - - - Odds ratio
Ferran-
nini
2009
7 [3.73 (2.
18-6.39)]
[4.28 (3.
21-5.71)]
[4.01 (3.
12-5.14)]
- - - - Relative
risk
Filippatos
2016
10 - 3.43 (2.
17-5.44)
- - - - - Odds ratio
Forouhi
2007
10 4.4 (1.9-
10.0)
2.9 (1.3-6.
3)
- - - - - Hazard ra-
tio
Han 2017 12 - i-
IFG5.6: 3.
61 (2.85-
4.57)
i-IGT: 4.
06 (3.62-
4.55)
- 8.21 (6.
79-9.94)
6 years:
HbA1c6.0 :
Men: 4.28
(2.41-7.
58)
Women: 4.
05 (1.36-
12.07)
- Hazard ra-
tio
Hanley
2005
5.2 - - 5.42 (3.
60-8.17)
- - - - Odds ratio
Heianza
2012
5 11.4 (8.
09-16.1)
6.18 (4.
34-8.80)
- - - HbA1c5.7 :
6.53 (3.
HbA1c5.7
+ IFG5.6:
Hazard ra-
tio
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79-9.64)
HbA1c6.0 :
7.42 (3.
67-15.0)
32.5 (23.
0-45.8)
HbA1c5.7
+ IFG6.1:
37.9 (28.
1-51.1)
HbA1c6.0
+ IFG5.6:
53.7 (38.
4-75.1)
HbA1c6.0
+ IFG6.1:
52.3 (37.
8-72.3)
Janghor-
bani
2015
6.8 - 7.4 (3.7-
14.8)
[8.2 (4.2-
16.0)]
9.4 (4.8-
18.6)
[10.0 (5.2-
19.1)]
- 22.5 (12.
4-41.0)
[26.7 (15.
1-47.2)]
- - Hazard ra-
tio
Jeong
2010
5 - 5.66 (3.
44-9.31)
6.01 (3.
23-11.2)
- - - - Odds ratio
Kim 2005 5 Total: 34.
57 (12.18-
98.10)
Men: 76.
02 (10.42-
544.51)
Women:
15.46 (4.
08-58.61)
Total: 4.77
(1.60-14.
15)
Men:
9.5 (1.25-
72.24)
Women: 1.
91 (0.45-
8.21)
- - - - - Hazard ra-
tio
Kim
2016a
5.2 21.1 (16.
8-26.3)
- - - - HbA1c6.0 :
23.2 (18.
7-28.7)
HbA1c5.7
+ IFG5.6:
46.7 (33.
5-64.9)
Odds ratio
Latifi
2016
5 - 1.04 (1.
00-1.07)
- - - - - Odds ratio
Leiva
2014
6 2.06 (1.
76-5.14)
- - - - - - Odds ratio
Levitzky
2008
4 Women:
26.3 (17.
4-39.8)
Men: 12.9
(9.3-18.1)
Women:
22.3 (13.
0-38.1)
Men: 12.7
(8.1-20.0)
- - - - - Odds ratio
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Li 2003 5 5.78 (3.
20-10.43)
- i-IGT: 2.
94 (1.81-
4.76)
- 6.17 (3.
41-11.15)
- - Hazard ra-
tio
Lipska
2013
7 11.4 (7.1-
18.4)
IFG5.6:
Total: 3.5
(1.9-6.3)
Men: 8.6
(3.4-21.9)
Women: 1.
5 (0.5-4.6)
White:
3.2 (1.5-6.
6)
Black:
4.6 (1.6-
13.3)
- - - i-
HbA1c5.7 :
Total: 8.0
(4.8-13.2)
Men: 24.2
(9.5-61.8)
Women: 4.
6 (2.4-8.7)
White:
10.2 (5.0-
20.8)
Black:
5.8 (2.9-
11.7)
HbA1c5.7
+ IFG5.6:
Total:
26.2 (16.
3-42.1)
Men:
51.1 (21.
2-123.2)
Women:
20.4 (10.
9-38.0)
White:
34.9 (19.
1-63.8)
Black:
14.9 (6.8-
32.6)
Odds ratio
Liu 2008 5 - 4.5 (2.0-
10.1)
- - - - - Risk ratio
Liu 2016 10.9 1.99 (1.
37-2.90)
[2.12 (1.
46-3.08)]
- - - - - - Hazard ra-
tio
Liu 2017 7.8 - 3.67 (3.
20-4.21)
[4.36 (3.
83-4.97)]
- - - - - Odds ratio
Lorenzo
2003
7-8 - - 6.37 (4.
37-9.28)
- - - - Odds ratio
Lyssenko
2005
6 [i-IFG6.1:
2.3 (1.4-3.
7)]
- [i-IGT: 3.5
(2.1-5.8)]
- [3.8 (2.3-
6.2)]
- - Hazard ra-
tio
Man 2017 6 - - - - 4.54 (2.
65-7.78)
- - Risk ratio
Mykkänen
1993
3.5 - - [9.85 (6.
14-15.8)]
- - - - Odds ratio
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Nakagami
2016
5 34.89 (19.
65-61.95)
[37.
85 (22.73-
63.05)]
- - - - HbA1c6.0 :
[63.
16 (33.94-
117.52)]
HbA1c5.7 :
8.77(4.47-
17.21)
[9.72(4.
96-19.05)]
- Hazard ra-
tio
Nakanishi
2004
7 1.31 (0.
51-3.34)
- - - - - - Risk ratio
Rath-
mann
2009
7 [4.7 (2.2-
10.0)]
- [8.8 (5.0-
15.6)]
- [21.2 (10.
4-43.3)]
- - Odds ratio
Rijkeli-
jkhuizen
2007
6.4 i-IFG6.1:
10.0 (6.1-
16.5)
- i-IGT: 10.
9 (6.0-19.
9)
- 39.5 (17.
0-92.1)
- - Odds ratio
Sadeghi
2015
7 - i-
IFG5.6: 3.
30 (2.16-
5.06)
i-IGT: 2.
52 (1.73-
3.69)
- 12.6 (7.
39-21.4)
- - Odds ratio
Sato 2009 4 22.52 (17.
73-28.60)
- - - - - Odds ratio
Song
2015
4 - Men: 7.50
(2.76-20.
33)
Women: 4.
27 (1.52-
12.00)
- - - - - Relative
risk
Soriguer
2008
6 - [5.3 (2.7-
10.4)]
4.3 (2.0-9.
2)
- 9.2 (4.3-
19.5)
- - Relative
risk
Stengard
1992
5 - - 3.1 (1.2-8.
2)
- - - - Odds ratio
Vaccaro
1999
11.5 [i-
IFG6.1: 1.
2 (0.3-10.
2)]
[i-IGT: 6.
2 (2.7-13.
8)]
- [10.3 (2.2-
46.8)]
- - Odds ratio
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Valdes
2008
6.3 12.1 (4.6-
31.7)
[11.5 (5.6-
23.6]
3.9 (1.6-9.
8)
[6.7 (3.4-
13.3)]
[i-IGT: 4.
7 (1.9-11.
7)]
- [45.6 (15.
8-131.4)]
- - Odds ratio
Viswanathan
2007
5 - - 1.57 - - - - Odds ratio
Wang
2007
5 2.71 (1.
43-5.16)
Men: 2.29
(0.95-5.
49)
Women: 1.
95 (0.83-
4.61)
1.80 (0.
96-3.40)
Men: 1.79
(0.70-4.
57)
Women: 2.
08 (0.93-
4.67)
3.15 (1.
60-6.19)
i-IGT
(IFG6.1):
Men: 7.33
(2.62-20.
51)
Women: 1.
65 (0.76-
3.
60) i-IGT
(IFG5.):
Men: 7.50
(1.62-34.
63)
Women: 2.
21 (0.77-
6.36)
- IGT/
IFG6.1:
Men: 10.
23 (3.84-
27.30)
Women: 7.
11 (2.56-
19.72)
IGT/
IFG5.6:
Men: 9.81
(3.5-27.
21)
Women: 4.
67 (1.87-
11.62)
- - Risk ratio,
odds ratio
Wang
2011
7, 8 - Total: 2.38
(1.85-3.
05)
[2.68 (2.
25-3.63]
Men: 2.10
(1.40-3.
15)
[2.78 (1.
91-4.04)]
Women: 2.
46 (1.78-
3.39)
[ 2.92 (2.
15-3.98]
4 years: [3.
12 (2.31-
4.22)]
Total: 3.47
(2.64-4.
55)
[4.11 (3.
20-5.27)]
Men: 3.82
(2.41-6.
04)
[4.72 (3.
15-7.09)]
Women: 3.
16 (2.26-
4.43)
[3.74 (2.
72-5.14)]
- Total: 4.06
(3.05-5.
40)
[4.68 (3.
62-6.07) ]
Men: 4.44
(2.75-7.
15)
[5.28 (3.
49-7.99)]
Women: 3.
80 (2.66-
5.42)
[4.30 (3.
09-5.99)]
4 years:
HbA1c6.0 :
5.89 (4.
23-8.19)
- Hazard ra-
tio,
odds ratio
(4 years)
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Warren
2017
Cohort 1:
22
Cohort 2:
16
Cohort 1:
2.85 (2.
60-3.12)
Black: 2.66
(2.26-3.
13)
White: 2.
86 (2.57-
3.19)
Cohort 2:
3.41 (3.
01-3.85)
Black: 3.16
(2.47-4.
06)
White: 3.
67 (3.18-
4.23)
Cohort 1:
2.26 (2.
08-2.45)
Black: 2.
05 (1.75-
2.40)
White: 2.
30 (2.10-
2.53)
Cohort 2:
2.70 (2.
43-3.00)
Black: 2.65
(2.11-3.
32)
White: 2.
87 (2.54-
3.23)
Cohort 2:
2.06 (1.
84-2.31)
Black: 2.55
(2.01-3.
22)
White: 1.
95 (1.71-
2.21)
- - Cohort 1:
HbA1c5.7 :
2.71 (2.
48-2.95)
Black: 2.24
(1.92-2.
61)
White: 2.
91 (2.63-
3.22)
HbA1c6.0 :
3.12 (2.
81-3.46)
Black: 2.60
(2.21-3.
05)
White: 3.
64 (3.20-
4.14)
6 years:
HbA1c6.0 :
9.24 (7.
20-11.86)
- Hazard ra-
tio
Yeboah
2011
7.5 - 10.5 (8.4-
13.1)
[13.2 (10.
7-16.2)]
- - - - - Hazard ra-
tio
Zethelius
2004
7 - - [2.18 (1.
43-3.34)]
- - - - Odds ratio
aUnreliable adjusted HbA1c6.0 interval in publication: 105.47 (29.30-101.86)
CI: confidence interval; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0: HbA1c threshold 5.
7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i-: isolated;
IFG5.6/6.1: impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG
and IGT; IH: intermediate hyperglycaemia; T2DM: type 2 diabetes mellitus
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Study ID Follow-up (years) Regression to normoglycaemia from IH at baseline
Ammari 1998 2 IGT: 27/68 (39.7%)
Anjana 2015 9.1 i-IFG5.6 or i-IGT: 52/299 (17.4%)
Baena-Diez 2011 10 IFG6.1: 57/115 (49.6%)
Bai 1999 1 IGT: 162/252 (64.3%)
Charles 1997 2 IGT: 273/418 (65.3%)
Chen 2003 3 IFG6.1: 129/156 (82.6%)
Coronado-Malagon 2009 1, 2 ’Prediabetes’: 76/217 (35%)
Cugati 2007 10 IFG5.6: 5 years: 94/229 (27.9%); 10 years: 15/229 (6.6%)
IFG6.1: 5 years: 34/50 (68%); 10 years: 2/50 (4%)
De Abreu 2015 10 IFG5.6: 104/187 (55.6%)
Dowse 1991 6.2 IGT: 20/51 (39%)
Ferrannini 2009 7 IGT: 73/170 (42.9%)
Forouhi 2007 10 IFG6.1: 143/257 (55.6%)
Guerrero-Romero 2006 5 IGT: 3/75 (4%)
Heianza 2012 5 IFG5.6: 383/1680 (22.8%)
IFG6.1: 101/380 (26.5%)
HbA1c5.7 : 263/822 (32%)
HbA1c6.0: 63/203 (31.0%)
HbA1c5.7/IFG5.6: 428/2092 (20.5%)
HbA1c6.0/IFG5.6: 392/1748 (22.4%)
Inoue 1996 2.5 IGT: 11/37 (29.7%)
Jiamjarasrangsi 2008a 2.6 IFG5.6: 197/320 (61.6%)
Kim 2008 2 IFG total: 908/1829 (49.6%)
IFG5.6: 747/1335 (56%)
IFG6.1: 161/494 (32.6%)
Kleber 2010 1 IGT: 52/79 (65.8%)
Kleber 2011 3.9 IGT: 96/119 (80.1%)
Ko 1999 1.4 IGT: 60/123 (48.8%)
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Ko 2001 1.7 IFG6.1: 17/55 (30.9%)
Larsson 2000 10 i-IFG6.1 : 27/42 (64.3%)
i-IGT: 36/66 (54.6%)
IFG/IGT: 17/30 (56.7%)
Latifi 2016 5 IFG5.6: 62/124 (50%)
Lecomte 2007 5 IFG6.1: 297/743 (44%)
Leiva 2014 6 IFG6.1: 0/28 (0%)
Li 2003 2 IGT: 22/131 (16.8%)
Liu 2014 3 IFG or IGT: 130/450 (28.9%)
Lyssenko 2005 6 IFG or IGT: 379/686 (55.2%)
Marshall 1994 1.9 IGT: 60/123 (48.8%)
Mohan 2008 8 IGT: 6/37 (16.2%)
Motala 2003 10 IGT: 16/35 (45.7%)
4 years: IGT: 28/72 (38.9%)
Mykkänen 1993 3.5 IGT: 72/203 (35.5%)
Peterson 2017 10 IGT: 8/29 (27.6%)
Qian 2012 5 i-IFG6.1 : 14/46 (30.4%)
i-IGT: 45/120 (37.5%)
IFG/IGT: 8/33 (24.2%)
Rajala 2000 4.6 IGT: 96/171 (56.1%)
(2.1 years) IGT: 115/183 (62.8%)
Ramachandran 1986 3.3 IGT: 34/107 (31.8%)
Rijkelijkhuizen 2007 6.4 IFG6.1: 28/149 (18.8%)
IFG5.6: 33/488 (6.8%)
(3 years) IGT: 35/158 (22.2%)
Sadeghi 2015 7 IFG5.6 and/or IGT: 148/373 (39.7%)
Sasaki 1982 7 IGT: 5/13 (38.5%)
Schranz 1989 6 IGT: 25/75 (33.3%)
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Sharifi 2013 7 IFG5.6: 53/123 (43.1%)
Söderberg 2004 11 i-IFG6.1 : 153/402 (38%)
IGT: 296/1253 (23.6%)
Song 2016a 10.8 Total: 75/334 (22.5%)
Men: 28/125 (22.4%)
Women: 47/209 (22.5%)
Stengard 1992 5 IGT: 79/234 (33.8%)
Toshihiro 2008 3.2 IFG and/or IGT: 39/128 (30.5%)
Wang 2011 4 IGT: 147/532 (27.6%)
Wat 2001 2 IGT: 174/322 (54%)
Weiss 2005 1.7 i-IGT: 15/33 (45.5%)
Wong 2003 8 IGT: 122/291 (41.9%)
HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 : HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0%
to 6.4%, respectively);HbA1c/IFG: both HbA1c and IFG;i-: isolated; IFG5.6/6.1: impaired fasting glucose (threshold 5.6 mmol/L or
6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; IH: intermediate hyperglycaemia; IQR: interquartile
range; SD: standard deviation
Appendix 16. Confounder adjustment (I)
Study ID Age Sex Body mass
index, waist
circumfer-
ence,
waist-to-hip
ratio
’Ethnicity’ Site Smoking sta-
tus
Drinking sta-
tus
Physical activ-
ity
Medications
Admiraal
2014
Yes Yes Yes No No No No No No
Aek-
plakorn
2006
No No No No No No No No No
Bae 2011 Yes Yes No No No No No No No
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Bergman
2016
Yes Yes Yes No No Yes No No No
Bonora
2011
Yes Yes Yes No No Yes Yes Yes No
Cederberg
2010
No Yes Yes No No Yes Yes Yes No
Chamnan
2011
Yes Yes Yes No No Yes No No Yes
Chen
2003
Yes Yes Yes No No No No No No
Coron-
ado-
Malagon
2009
No No No No No No No No No
Cugati
2007
Yes Yes No No No No No No No
De Abreu
2015
Yes No Yes No No Yes Yes Yes No
Der-
akhshan
2016
Yes Yes Yes No No Yes No Yes No
Dowse
1991
No No No No No No No No No
Ferran-
nini
2009
No No No No No No No No No
Filippatos
2016
Yes Yes No No No Yes No Yes No
Forouhi
2007
Yes Yes Yes No No Yes No Yes No
Han 2017 Yes Yes Yes No Yes Yes Yes Yes No
Hanley
2005
Yes Yes No Yes Yes No No No No
Heianza
2012
Yes Yes Yes No No Yes No No No
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Janghor-
bani
2015
Yes Yes Yes No No No No No No
Jeong
2010
No No Yes No No No No No No
Kim 2005 Yes Yes Yes No No No No No No
Kim
2016a
Yes Yes Yes No No Yes Yes Yes No
Latifi
2016
Yes No Yes Yes No No No No No
Leiva
2014
No No No No No Yes No No Yes
Levitzky
2008
Yes No Yes No No Yes No No No
Li 2003 Yes Yes Yes No No No No No No
Lipska
2013
Yes Yes No Yes Yes Yes No Yes No
Liu 2008 Yes Yes No No No Yes Yes No No
Liu 2016 Yes No Yes No No No No Yes No
Liu 2017 Yes No No No No Yes Yes Yes No
Lorenzo
2003
Yes Yes No No No No No No No
Lyssenko
2005
No No Yes No No No No No No
Man 2017 Yes Yes Yes No No Yes No No No
Mykkänen
1993
No No No No No No No No No
Nakagami
2016
Yes No Yes No No Yes Yes No No
Nakanishi
2004
Yes No No No No Yes Yes No No
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Rath-
mann
2009
Yes Yes No No Yes No No No No
Rijkeli-
jkhuizen
2007
Yes Yes No No No No No No No
Sadeghi
2015
Yes Yes Yes No No No No No No
Sato 2009 Yes NA Yes No No Yes Yes Yes No
Song
2015
Yes No Yes No No Yes Yes Yes No
Soriguer
2008
Yes Yes Yes No No No No No No
Stengard
1992
Yes No Yes No No No No No No
Vaccaro
1999
No No No No No No No No No
Valdes
2008
Yes Yes Yes No No No No No No
Viswanathan
2007
Yes No Yes No No No No No No
Wang
2007
Yes Yes No No No Yes No No No
Wang
2011
Yes Yes Yes No No Yes No No No
Warren
2017
Yes Yes Yes Yes No Yes Yes No Yes
Yeboah
2011
Yes Yes Yes Yes No No No Yes No
Zethelius
2004
Yes No Yes No No No No No No
’No’ denotes possible confounder but statistical analysis did not adjust for this covariate
’Yes’ indicates that statistical analysis adjusted for this confounder
NA: not applicable
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Study ID Cardio-
vascular
disease
Glomeru-
lar filtra-
tion
rate, albu-
minuria
Blood
pressure,
hyperten-
sion
Family
history
of
diabetes
Socioeco-
nomic
status
Region Depression Triglyc-
erides
Choles-
terol
Admiraal
2014
No No No No No No No No No
Aek-
plakorn
2006
No No No No No No No No No
Bae 2011 No No No No No No No No No
Bergman
2016
Yes No Yes No No No No Yes Yes
Bonora
2011
No No Yes Yes Yes No No Yes Yes
Cederberg
2010
No No No No No No No No No
Chamnan
2011
No No Yes Yes Yes No No Yes Yes
Chen
2003
No No No Yes No No No Yes No
Coron-
ado-
Malagon
2009
No No No No No No No No No
Cugati
2007
No No No No No No No No No
De Abreu
2015
No No Yes No No No No Yes Yes
Der-
akhshan
2016
No No No Yes Yes No No Yes Yes
Dowse
1991
No No No No No No No No No
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Ferran-
nini
2009
No No No No No No No No No
Filippatos
2016
No No Yes No No No No Yes Yes
Forouhi
2007
No No No Yes No No No No No
Han 2017 No No Yes Yes No Yes No Yes Yes
Hanley
2005
No No No No No No No No No
Heianza
2012
No No Yes Yes No No No Yes Yes
Janghor-
bani
2015
No No No No No No No Yes Yes
Jeong
2010
No No Yes No No No No Yes Yes
Kim 2005 No No Yes Yes No No No Yes Yes
Kim
2016a
No No Yes Yes No No No Yes Yes
Latifi
2016
No No Yes Yes No No No No No
Leiva
2014
No No No Yes No No No No No
Levitzky
2008
No No No No No No No No No
Li 2003 No No No No No No No No No
Lipska
2013
No No Yes No No No No No No
Liu 2008 No No No Yes No No No No No
Liu 2016 No No No No No No No No No
Liu 2017 No No No No Yes Yes No No No
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Lorenzo
2003
No No No Yes No No No No No
Lyssenko
2005
No No No No No No No No No
Man 2017 No No Yes Yes Yes No No No Yes
Mykkänen
1993
No No No No No No No No No
Nakagami
2016
No No Yes Yes No No No No Yes
Nakanishi
2004
No No No Yes No No No No No
Rath-
mann
2009
No No Yes No No No No No No
Rijkeli-
jkhuizen
2007
No No No No No No No No No
Sadeghi
2015
No No No Yes No No No No No
Sato 2009 No No No Yes No No No No No
Song
2015
No No Yes Yes No No No Yes No
Soriguer
2008
No No Yes Yes No No No Yes No
Stengard
1992
No No No No No No No No No
Vaccaro
1999
No No No No No No No No No
Valdes
2008
No No No No No No No Yes No
Viswanathan
2007
No No No Yes No No No No No
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Wang
2007
No No No Yes Yes No No No Yes
Wang
2011
No No Yes Yes No No No Yes Yes
Warren
2017
No Yes Yes Yes Yes No No Yes Yes
Yeboah
2011
No No No No Yes No No No No
Zethelius
2004
No No No No No No No No No
’No’ denotes possible confounder but statistical analysis did not adjust for this covariate
’Yes’ indicates that statistical analysis adjusted for this confounder
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This review is part of a series of reviews on predictors for the development of type 2 diabetes mellitus in people with intermediate
hyperglycaemia and interventions for the prevention or delay of type 2 diabetes mellitus and its associated complications in persons at
increased risk for the development of type 2 diabetes mellitus which is funded by the WHO
(Hemmingsen 2016a; Hemmingsen 2016b; Hemmingsen 2016c)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We changed the title of the protocol from ’Intermediate hyperglycaemia as a predictor for the development of type 2 diabetes: prognostic
factor exemplar review’ to ’Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia’ to fit the objectives
of the review. We also modified the objectives from “to assess whether intermediate hyperglycaemia is a predictor for the development
of type 2 diabetes mellitus (T2DM)” to objective 1 “to assess the overall prognosis of people with IH for the development of T2DM
and to assess how many people with IH revert back to normoglycaemia (regression), and objective 2 ”to assess the difference in T2DM
incidence in people with IH versus people with normoglycaemia“. Both changes reflect the fact that our review addresses two prognostic
questions at the same time. First, if people have intermediate hyperglycaemia at baseline, how many individuals develop type 2 diabetes
in the future? This research question investigates the cumulative incidence of type 2 diabetes over time and does not depend on a
comparison with a group with normoglycaemia at baseline; it is also important to note howmany people change back from intermediate
hyperglycaemia to normoglycaemia. The second prognostic question is, how does glycaemic status (intermediate hyperglycaemia
compared with normoglycaemia) at baseline affect the development of type 2 diabetes? In particular, we were interested in intermediate
hyperglycaemia, defined using impaired fasting glucose, impaired glucose tolerance and elevated glycosylated haemoglobin A1c and
combinations thereof.
We specified inclusion criteria in more detail to explain the difference between studies evaluating the overall prognosis of people
with intermediate hyperglycaemia and studies evaluating intermediate hyperglycaemia versus normoglycaemia as a prognostic factor
developing type 2 diabetes mellitus.
Regarding methods, we explained our exclusion criteria in more detail and deleted ’conference abstract’ as an exclusion criterion (we
moved one formerly excluded study, Misnikova 2011, to ’Studies awaiting classification’).
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